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Abstract 
Several studies have reported that the multifunctional enzyme tissue transglutaminase (TG2) play 
important roles in neurite outgrowth and modulation of neuronal cell survival. Recently, TG2 enzymatic 
activity has been shown to be regulated by protein kinases such as PKA and PKC, modulating through 
G-protein coupled receptors (GPCRs). However, the regulation of TG2 following stimulation of GPCRs 
coupled to PKC and PKA activation are not fully understood. In neuronal cells, the neurotrophic factors; 
pituitary adenylate cyclase activating polypeptide (PACAP) and nerve growth factor (NGF) promote the 
differentiation, maturation, neurite outgrowth and survival of neurons via their GPCR’s; the pituitary 
adenylate cyclase type 1 receptor (PAC1) and the tyrosine kinase receptor (TrKA) Including multiple 
protein kinase signalling pathways. As some of these kinase pathways are associated with modulation 
of intracellular TG2 activity, it is conceivable to hypothesised that PACAP and NGF directly regulates 
TG2 activity. If this was found to be the case, it sought to determine whether the PACAP and/or NGF-
induced neurite outgrowth and modulation of neuronal cell survival involved TG2. The main aims of 
this study were to investigate the molecular mechanisms underlying TG2 modulation by PACAP and 
NGF and its role in neurite outgrowth and neuroprotection in differentiating mouse N2a and human SH-
SY5Y neuroblastoma cells.  
In the first part, the regulation of TG2 transamidase activity by PACAP-27 and NGF in differentiating 
mouse N2a and human SH-SY5Y neuroblastoma cells was assessed. TG2 transamidase activity was 
determined using an amine incorporation and a peptide cross linking assay. In situ TG2 activity was 
assessed by visualising the incorporation of biotin-X-cadaverine using confocal microscopy. TG2 
phosphorylation was monitored via immunoprecipitation and Western blotting. In the second part of this 
study, the role of TG2 in PACAP-27 and NGF-induced cytoprotection was investigated by monitoring 
hypoxia-induced cell death and assessing MTT reduction, LDH release, and caspase-3 activity. The 
neurite outgrowth was assessed using high-throughput analysis of immunofluorescently stained cells. 
In differentiating N2a and SH-SY5Y cells, stimulation of PAC1 and TrKA receptor with PACAP-27 and 
NGF respectively, resulted in a time- and concentration- dependent activation of TG2 amine 
incorporation and protein crosslinking activity, which was abolished by TG2 inhibitors Z-DON and 
R283. Responses to PACAP-27 were attenuated mainly by pharmacological inhibition of protein kinase 
A (KT 5720 and Rp-cAMPs), MEK1/2 (PD 98059), PKB (Akt inhibitor XI) and by removal of 
extracellular Ca2+. Responses to NGF were abolished by MEK1/2 (PD 98059), PKB (Akt inhibitor XI) 
and PKC (Ro 31-8220). Immunoprecipitation technique showed that both PACAP-27 and NGF triggered 
the levels of TG2-associated phosphoserine and phosphothreonine, which were attenuated by inhibition 
of MEK1/2 and PKA for PACAP and MEK1/2, PKB, PKC and removal of extracellular Ca2+ for NGF. 
Fluorescence microscopy demonstrated that PACAP-27 and NGF induced in situ TG2 activity. TG2 
inhibition blocked PACAP-27- and NGF-induced attenuation of hypoxia-induced cell death and neurite 
outgrowth. Taken together, this study highlights for the first time the importance of TG2 in the cellular 
functions of PACAP and NGF in neuronal cells and provides initial characterisation of the molecular 
mechanisms possibly involved. 
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1 Introduction 
 Overview of the nervous system  
The nervous system is the body’s control system. The mammalian nervous system is 
anatomically divided into two main parts, namely the central (CNS) and peripheral nervous 
system (PNS). The CNS is the integrative and control centre, consisting of the brain and spinal 
cord. The PNS represents the communication lines between the CNS and the rest of the body, 
and it is composed of the cranial and spinal nerves. The brain receives/sends impulses from/to 
the spinal cord to integrate the sensory input and initiate properly coordinated motor output 
(Barres & Barde, 2000).  
Nerve tissue is composed of two common cell types, namely neuronal and glial cells. Neurons 
are the basic structural unit of the nervous system; they receive, process and respond to stimuli 
and transmit cellular signals to other neurons and/or effector cells via synaptic transmission. 
Upon differentiation, neurons produce axons and dendrites (Coleman 2012). Glial cells, 
including astrocytes, oligodendrocytes, glioblasts and microglia, are generally smaller than 
neuronal cells, and they lack axons; however, they perform complex processes extending from 
their cell bodies. They are not involved in signal transmission, but they mainly provide 
mechanical, structural, nutritional and defensive support to the neurons (Compston et al., 1997; 
Rice & Barone, 2000). The nervous system undergoes various series of sensitive and complex 
development processes, extending from early embryonic life to adolescence. These processes 
include neuronal cell proliferation, migration, differentiation, synapse formation, glial cell 
development and apoptosis (Barone et al., 2000). All these cellular processes are tightly 
coordinated and regulated by highly integrated cell signalling. Cell signalling is a complex 
communication system that transfers information from one molecule to another in the 
cytoplasm. It ordinarily occurs when a cell receives an external signal, leading to the initiation 
of a cascade to transfer cellular signals to obtain the proper intracellular process (Bezzi & 
Volterra, 2001). 
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Neuronal signalling is the receiving and transferring of signals from one neuron to another. The 
low-resistance gap junctions connecting neuronal cells can communicate rapidly and directly, 
either by passing rapid electrical currents or via diffusion of a low-mass second messenger, such 
as cyclic adenosine 3’, 5’-cyclic monophosphate (cAMP) or inositol 1,4,5-trisphosphate (IP3). 
This signalling system, known as electrical signal communication, forms mostly between 
neuroglia (Knight & Verkhratsky, 2010). Another type of communication is chemical 
communication, which occurs when one cell releases a specific chemical stimulus, such as a 
neurotransmitter, hormone or growth factor, which passes to the target cells. These have 
receptors able to translate the incoming signal into a suitable internal cell signalling pathway, 
thereby causing a change in internal neuronal cell process (Perron and Bixby, 1999). 
The development of the healthy mammalian brain requires a functional, coordinated neuronal 
cell signalling system. It has been suggested that the interruption of such a signalling system 
may cause damage or death of neuronal cells, resulting in different neurodegenerative diseases 
(Knight & Verkhratsky, 2010). Neurons have complex molecular and cellular biology systems. 
Their physiological function is only possible due to their sensitive and precise coordination of 
extracellular and intracellular signalling pathways. Since the current study has focused on the 
effects of neurotrophic factors on modulation of transglutaminase 2 mechanisms of cell survival 
and signalling pathways, a detailed discussion of such events would be worthwhile. 
1.1.1 Signalling mechanisms  
Cell signalling is the mechanism that occurs in response to an external stimulus, where a 
message is transmitted through a signal transduction cascade; this amplifies the message, 
resulting in internal signals performing the appropriate response in the desired effector (Uing & 
Farrow, 2000; Bezzi & Volterra, 2001). Most cell signals are chemical in nature, where the cells 
typically recognise the signals by their specific receptors. On activation, the receptor undergoes 
a conformational change, which provokes the synthesis of the second messenger(s) required to 
initiate the intracellular signalling pathways of interest (Uings & Farrow, 2000). A cell can 
receive various signals and produce multiple signal transduction pathways at one time, with 
many points of intersection. For example, a single second messenger or protein kinase could 
have different roles in one pathway.  
One of the most systematic intracellular signalling pathways is cAMP; discovered in 1957, it 
was the first second messenger to be identified (Murad, 2011). The cAMP transduction cascade 
begins when adenylyl cyclase (AC), a membrane-bound enzyme, is activated by Gs protein and 
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then stimulates the synthesis of cAMP; this activates the enzyme protein kinase A, which then 
phosphorylates various substrates. Each of these signal amplifications continues to initiate 
different cell responses, such as the regulation of gene expression, proliferation, survival and 
differentiation (Uings & Farrow, 2000). Another common pathway controlled by second 
messengers is the phospholipase C (PLC) pathway. This pathway is initiated by the hydrolysis 
of phosphatidylinositol 4,5-bisphosphate (PIP2) by PLC to produce two second messengers, 
namely diacylglycerol (DAG) and 1,4,5-inositol trisphosphate (IP3). IP3, stimulates the release 
of intracellular Ca2+, which also has a role as a second messenger. DAG and Ca2+ jointly regulate 
protein kinase C (PKC), which modulates via phosphorylation many cellular responses (Putney 
& Tomita, 2011).  
The intracellular responses to cell surface receptors are complicated and poorly understood. 
This complexity of cell signalling is related to the way in which different pathways intersect 
and integrate to control diverse cellular processes. This complication may develop because cells 
do not act in isolation, a specific signalling event in one cell could have impact on other adjacent 
cells. Also, the activation of one second messenger and/or protein kinase can regulate the 
activity of a second component, either positively or negatively. Some of these diversities are 
summarised in the subsections below. 
The mitogen-activated protein kinase (MAPK) pathway 
The mitogen-activated protein kinases (MAPKs) comprise a family of protein kinases that are 
considered the central elements in highly conserved intracellular signalling pathways. MAPKs 
are a specific class of ubiquitous serine/ threonine kinases that participate in the transduction of 
signals from the surface to the interior of the cell and regulate a variety of cellular process such 
as cell proliferation, cell differentiation, cell survival and stress response (Johnson & Lapadat, 
2002, Korhonen and Moilanen, 2014). The MAPK family mainly consists of extracellular 
signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal kinase 1/2/3 (JNK1/2/3) and p38 
MAPKs (p38 MAPK-α/β/γ/δ). Each protein kinase cascade consists of no less than three 
enzymes – MAPKKK, MAPKK and MAPK – that are activated in sequence (Figure 1.1; 
Johnson and Lapadat, 2002). Activated MAPKs stimulate the phosphorylation of protein 
substrates such as transcription factors, protein kinases and phosphatases. A substantial number 
of reports confirm the central role of MAPKs in neuronal development, neuronal cell survival 
and neuroprotection (Creedon et al., 1996; Collins et al., 2015). 
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Extracellular-signal-regulated kinases 1/2  
ERK1/2 was the first characterised MAPK cascade. The binding of a ligand, such as epidermal 
growth factor (EGF), insulin or platelet-derived growth factor (PDGF), to its receptor leads to 
signalling cascade that activate ERK1/2. This cascade starts with Ras (H-Ras, K-Ras and N-
Ras) which is converted from Ras-GDP to Ras-GTP. Ras-GTP then activates Raf (A-Raf, B-
Raf, C-Raf; examples of MAPKKK), which initiates the downstream phosphorylation of the 
kinase MEK1/2. MEK1/2 phosphorylates the Thr202 and Tyr204 in ERK1 and Thr185 and Tyr187 
in ERK2,  which results in activation of the ERK1/2 cascade as shown in Figure 1.1(Wortzel & 
Seger, 2011). The activated ERKs have widespread cytoplasmic and nuclear substrates, and 
translocate to the nucleus and activate transcription factors and gene expression to promote cell 
proliferation and differentiation ( Zhang et al., 2002; Roskoski 2012). It has been reported that 
in pheochromocytoma PC12 cells, transient activation of the Raf signal triggers cell 
proliferation; in contrast, a sustained activation leads to cell differentiation and results in cell 
cycle arrest ( Zhang et al., 2002). With regard to neuronal damage, activation of the ERK 
signalling cascade in myelinated Schwann cells has been shown to induce the specific 
inflammatory responses required for nerve repair (Napoli et al., 2012). 
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Figure 1.1 Schematic diagram of the general mitogen-activated protein kinase (MAPK) 
signalling pathways. 
The MAPK cascade consists three main signalling modules including the extracellular-signal 
regulated kinases (ERK1/2), the stress-activated protein kinases p38, and the JUN N-terminal 
kinases (JNK). Each pathway is initiated by Ras activation, which phosphorylates 
serine/threonine residues of MAPKKK, which subsequently phosphorylates 
tyrosine/threonine residues of a MAPKK. This leads to the activation of MAPK, which in turn 
activates other protein kinases involved in cellular responses. 
MLK, Mixed lineage kinase; Apoptosis signal-regulating kinase. 
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The p38 MAPK signalling pathway 
Evidence shows that the p38 MAPK signalling pathway plays a key role in neuronal process; 
such as differentiation, proliferation (Morooka & Nishida, 1998), and different 
neurodegenerative diseases (Corrêa & Eales, 2012). The p38 MAPK enzyme is activated by 
dual phosphorylation of the Thr180 and Tyr182 residues either by MAP kinase kinase 3 (MKK3) 
or MAP kinase kinase 6 (MKK6) (Cuenda & Rousseau, 2007).  The p38 MAPK family is 
composed of p38-α, p38-β, p38-γ and p38-δ isoforms, which are all phosphorylated by MKK6, 
while MKK3 can activate the α, γ and δ but not β isoforms. In neurons, p38 MAPK is activated 
in response to inflammatory cytokines (such as interleukin 1 [IL-1] and tumour necrosis factor 
α [TNF-α]) and cellular stress stimuli such as ultraviolet [UV] radiation, heat shock and osmotic 
shock (Corrêa & Eales, 2012). The wide range of stimuli integrating p38 MAPK signalling 
pathways provide the diversity of cellular responses and regulatory mechanisms (extensively 
reviewed in (Zarubin & Han, 2005; Cuenda & Rousseau, 2007). Previous in vitro studies have 
revealed that p38 MAPK is involved in the production and release of pro-inflammatory 
cytokines such as IL-6 and IL-8, which are involved in neuroinflammatory processes. 
Moreover, this activity is blocked by inhibition of p38 MAPK with SB203580 ( Li et al. 2003). 
On the other hand, a substantial body of evidence indicates that the p38 MAPK pathway is 
involved in neuronal cell differentiation. An important role of the p38 MAPK signalling 
pathway involves promoting adult neural differentiation by triggering neural transcription 
factors, such as neurogenin 1 (Oh et al., 2009). Other studies have suggested that nerve growth 
factor (NGF) induces PC12 cell differentiation, and it has been shown that the p38 MAPK 
pathway is activated by NGF in PC12 cells, whereas blocking of the p38 MAPK pathway leads 
to the inhibition of NGF-induced neurite outgrowth (Morooka & Nishida, 1998; Takeda & 
Ichiijo, 2002). 
The c-Jun N-terminal kinase (JNK) signalling pathway 
JNK, also called stress-activated protein kinase (SAPK), is composed of three members, namely 
JNK1, JNK2 and JNK3. Like p38 MAPK, JNK is usually activated by various types of external 
stress stimuli, MKK4 and MKK7 being its main activation factors. It has been shown that 
MKK4/7 is mediated by the up-stream kinases apoptosis signal-regulation kinases (ASKs; 
Derijard et al. 1994). Activation of the JNK downstream pathway results in the phosphorylation 
of several transcription factors to initiate programmed cell death or apoptosis (Dhanasekaran & 
Reddy, 2008). The precise mechanisms of JNK-mediated apoptosis and neuronal death remain 
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to be illustrated. There is strong evidence that the activation of JNKs leads to the 
phosphorylation of transcription factors that regulate the apoptotic process (Dhanasekaran and 
Reddy, 2008), thus leading to cell death, which develops in numerous neurodegenerative 
disorders (Bogoyevitch et al., 2004). The pharmacological inhibition of JNK has been shown to 
have a neuroprotective role in Alzheimer disease’ (AD) models and this could be therapeutically 
effective in the treatment of AD (Braithwaite et al., 2010). Furthermore, the knockdown of all 
three JNK isoforms provides substantial protection; however, the knockdown of only one or 
two JNK isoforms does not show any protective effect (Björkblom et al., 2008). To date 
evidence for the crucial role of JNK-dependent neuronal death has been mainly 
pharmacological; further investigation is needed to determine the therapeutic efficiency of JNK 
inhibition.   
The protein kinase B/Akt signalling pathway 
Protein kinase B (PKB)/Akt is one of the most widely studied and ubiquitously distributed 
kinase family, and it plays a major role in the nervous system. It is composed of three isoforms, 
namely PKBα/Akt1, PKBβ/Akt2 and PKBγ/Akt3. Extracellular signals trigger the PKB/Akt 
pathway via receptor tyrosine kinases (RTKs), activated monomeric G-protein Ras (Shaw & 
Cantley, 2006) or GPCRs (Katso et al., 2001). The PKB/Akt pathway has a key role in numerous 
cellular processes such as cell survival, differentiation, growth and metabolism (Brazil and 
Hemmings 2001; Dillon et al., 2007; Courtney et al., 2010). The activation of PKB is initiated 
with the up-stream activation of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI-3K). 
Activated PI-3K phosphorylates PIP2 (phosphatidylinositol 4,5-bisphosphate) to PIP3 
(phosphatidylinositol 3,4,5-triphosphate), leading to the activation of pyruvate dehydrogenase 
kinase 1 (PDK1). Activation of PDK1 leads to subsequent phosphorylation of PKB at Thr308, 
while the other required site Ser473 is phosphorylated either by PDK2, integrin-linked kinase 
ILK, mammalian target of rapamycin complex 2 (mTORC2) or DNA-dependent protein kinase 
(DNA-PK; Vanhaesebroeck and Alessi 2000; Vanhaesebroeck et al., 2012). However, this PI-
3K-dependent signalling cascade is regulated by the lipid phosphatase PTEN (phosphatase and 
tensin homologue) that dephosphorylates PIP3 to PIP2 thereby leading to the termination of the 
PKB/Akt pathway (Carracedo et al., 2008; Mendoza et al., 2011). Furthermore, PKB activity 
can also be modulated either by protein phosphatase 2A (PP2A) that dephosphorylates PKB at 
Thr308 or PH domain and leucine rich repeat protein phosphatases (PHLPP) that 
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dephosphorylate PKB at Ser473 (Bayascas & Alessi, 2005; Pozuelo-Rubio et al., 2010) Figure 
1.2 summarises the PKB/Akt pathway. 
It has been reported that PKB is essential for many neuronal biological and physiological 
processes, such as metabolism regulation, regulation of cell growth, survival, proliferation, 
development, neurogenesis and axon establishment (Crowder & Freeman, 1998). Evidence has 
shown that PKB participates in neuron protection, and it has been reported that treatment of 
neurons with NGF stimulates the activation of endogenous PKB, while the PI-3K inhibitors 
LY294002 and wortmannin block this activation (Crowder & Freeman, 1998). It has also been 
reported that the functional expression of PKB or PI-3K efficiently prevents neuronal cell death 
following NGF deprivation (Crowder & Freeman, 1998).   
 
 
 
 
 
Figure 1.2  Schematic representation of the key steps in the PKB/Akt 
signalling cascade. 
The pathway is mainly activated by both RTKs and GPCRs and initiated by RAS 
activation, which in turn activates PI3K. PI3-Kinase is activated and generates the 
second messenger PIP3, which activates the downstream PKB/Akt. PKB/Akt is 
important for cell growth, survival, and metabolism (Adapted from Courtney et 
al, 2010). 
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 Neurodegenerative disease  
Neurodegenerative diseases are either acute or chronic illnesses with high morbidity and 
mortality that are associated with the progressive dysfunction or death of nerve cells. Examples 
of neurodegenerative diseases include Huntington’s disease (HD), Alzheimer’s disease (AD), 
Parkinson’s disease and amyotrophic lateral sclerosis (ALS), and associated dysfunction such 
as stroke or cerebral hypoxia (Friedlander, 2003). Programmed neuronal cell death is one of the 
pathological characteristics shared by most neurodegenerative diseases (Gorman, 2008). 
According to the latest update of the World Health Organization (WHO) in January 2017, 
cerebral stroke has a mortality rate of 30%, and it has been the second leading cause of death 
globally in the last 15 years (World Health Organization, 2017). 
 Cerebral stroke 
Cerebral stroke occurs when there is interruption in the oxygen supply to the brain; this happens 
when an artery to the brain is blocked, resulting in a loss of the neurological function in the 
affected area (Ter Horst and Korf, 1997). As the brain has a high metabolic rate, it exhibits a 
high demand for ATP and low affinity for anaerobic energy production; neuronal cells consume 
a huge amount of oxygen and glucose, of which they require a steady supply. Thus, neuronal 
cells and brain tissue are extremely sensitive to oxygen deprivation; in such conditions, they 
can be rapidly damaged and die within 5 minutes (harp & Bernaudin, 2004; Tomaselli et al., 
2005; Zhang et al., 2006; Semenza, 2011).  
Oxygen deficiency in neuronal cells or tissue causes an impairment of neuronal functions 
known as cerebral hypoxia (Friedlander, 2003). Long-lasting cerebral hypoxia is associated 
with symptoms like memory loss, decreased motor coordination, poor judgement and 
inattentiveness, seizure and coma (Feriche et al., 2007). Currently, the available treatments 
involve helping to relieve the symptoms; however, an official neuroprotective strategy is 
lacking (Meloni, 2017). Therefore, it is important to characterise the molecular mechanisms and 
cellular pathways that lead to neuronal cell death after exposure to hypoxia, which is important 
for identifying selective and effective therapeutic approaches for cerebral stroke.  
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The pathophysiology of neuron death after hypoxia 
Primary energy failure develops immediately after the brain is exposed to hypoxia/ischaemia, 
where the levels of high-energy phosphates and ATP decrease. This deprivation is not easy to 
manage or cure. The second energy failure in the brain reaches its peak at 48 h after the hypoxia 
incident, after which time the brain restores the energy level to normal (Descloux et al., 2015). 
It has been shown that in response to ischaemia, adenosine, the final metabolic product of the 
ATP dephosphorylation, is produced during the energy failure induced by hypoxia/ischaemia; 
this occurs via different mechanisms and it plays a role as a powerful endogenous 
neuroprotectant. It decreases the neuronal metabolism process and works as a vasodilator and 
thus increases blood flow to the affected area (Tomaselli et al., 2005). 
The molecular neuronal response to hypoxia/ischaemia is either acute or chronic. Excitotoxicity 
is a neuronal adaptive mechanism that takes place during the early stage of the insult, and it 
mainly depends on the modulation of ion channels (Mahura, 2003). This results in ion 
haemostasis involving the accumulation of extracellular neurotransmitters, mainly glutamate, 
and over-activation of its receptor, N-Methyl-D-aspartate (NMDA); this leads to massive 
increase in Ca2+ influx (Mahura, 2003). Following this, cell damage occurs due to the formation 
of reactive oxygen and nitrogen species, membrane destruction, DNA damage and the activation 
of enzymes, such as neuronal nitric oxide synthase and xanthene and NADPH oxidase. These 
enzymes are involved in the production of reactive oxygen species (ROS).  
These elevated levels of ROS are toxic and their accumulation triggers a different cytotoxic 
cascade of events, such as membrane destruction, lipid peroxidation, DNA damage, 
inflammation activation and increased blood brain barrier (BBB) permeability (Descloux et al., 
2015). ROS lead to the excessive production of free radicals, such as oxygen free radicals (O2
-), 
which have a role as signalling molecules to activate inflammation and apoptosis (Durukan & 
Tatlisumak, 2007). It has been found that NMDA receptor antagonists, Ca2+ channel blockers 
and antioxidants can provide neuroprotection in experimental models of hypoxia/ischaemia; 
however, this could also lead to disruption of normal brain function (Mahura, 2003; Durukan & 
Tatlisumak, 2007; Pun et al., 2009). Understanding the different neuronal cell death 
mechanisms of apoptosis or necrosis cell death will help in the ultimate targeting of treatment 
approaches. 
Apoptosis is a programmed and delayed cell death that is essential for supporting physiological 
and pathological processes (Elmore, 2007). It is mainly triggered by either intrinsic or extrinsic 
intracellular signalling pathways, where the caspase precursor is the main mediator for 
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controlled apoptosis (Jin & El-Deiry, 2005). Necrosis is the passive, un-programmed cell death 
characterised by cell swelling followed by cell lysis; it is mainly triggered by ATP deprivation. 
Necrosis mainly occurs in areas that are severely affected and results in the production of 
excitotoxins, such as glutamate, cytokines and calcium. In addition, the mitochondria and nuclei 
swell, followed by the rupture of the cytoplasm and nuclear degeneration of the DNA. This is 
considered a rapid, irreversible process; therefore, treatment of neuronal cells undergoing 
necrotic death is a complex problem (Galluzzi & Kroemer, 2008). To determine which 
mechanism is responsible for neuronal cell death under specific conditions, it is important to 
understand the entire molecular pathway involved (Nikoletopoulou et al., 2013). Cells cultured 
under hypoxia condition is a widely used model to study the signalling pathway and the 
mechanisms underlying apoptosis induced-cell death process. 
 Apoptosis signalling pathways  
Apoptosis is the delayed cell death mechanism that usually occurs in areas that are not severely 
affected by hypoxia. It has been reported that apoptosis is the predominant mechanism of 
neuronal cell death in chronic neurodegenerative diseases (Yuan et al., 2003). In the intrinsic 
pathway of apoptosis, the B-cell lymphoma 2 (Bcl-2) family is involved in the permeabilisation 
of the mitochondrial membrane, which results in the release of apoptogenic factors, such as 
cytochrome c and apoptosis inducing factor (AIF). The release of cytochrome c leads to 
caspase-9 activation, which activates caspase-3, the executioner caspase; this, in turn, activates 
caspase-activated DNase (CAD), leading to DNA damage, and mediates neuronal cell death 
(Jin & El-Deiry, 2005). The release of AIF and endonuclease G from the permeabilised 
mitochondria results in mediation of the caspase-independent pathway. The extrinsic apoptosis 
pathway mediated by cell death signalling factors, such as TNF-α, leads to the activation of 
caspase-8 (Riedl & Shi, 2004). Activated caspase-8 turns on the activation of the effector 
caspase, caspase-3. Activated caspase-3 cleaves different cell death substrates, such as inhibitor 
of CAD (ICAD) and lamin, which in turn, induces apoptotic cell death as shown in Figure 1.3 
(Riedl & Shi, 2004). 
The apoptosis pathways that induce neuronal cell death after hypoxia insult exhibit remarkable 
potential as therapeutic targets for neuroprotection. A substantial body of research indicates that 
treatment with caspase inhibitors has a potential role in neuroprotection in adult cerebral 
ischaemia (Akpan & Troy, 2013) and neonatal hypoxia/ischaemia models (Feng et al., 2003; 
Carlsson et al. 2011; Chauvier et al. 2011). It has been found that pharmacologically pre-treating 
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mice with a broad or partially selective caspase 1 and 3 inhibitor leads to brain protection from 
ischaemic insult (Fink et al., 1998; Hara & Snyder, 2007). However, using caspase inhibition 
as a neuroprotection treatment approach will be affected by the severity of the 
hypoxia/ischaemia in the adult model (Li, 2000). One of the limitations of the caspase inhibitor 
efficiency as a neuroprotective agent is that they remain unspecific and until now, no caspase 
inhibitor has been tested in a clinical trial (Northington et al., 2011). 
 
 
 
 
 
Figure 1.3 Schematic representation of the key steps in the main apoptosis molecular 
pathways 
In the extrinsic pathway death ligands activate their receptors, resulting in the formation of a 
death-inducing signalling complex (DISC). This trigger the activation of caspase-8. The 
intrinsic pathway is initiated by cellular stress lead to mitochondrial dysfunction and release 
of cytochrome c into the cytoplasm, this process is promoted by pro-apoptotic factor such as 
Bax and prevented by anti-apoptotic factor Bcl-2. Then form the apoptosome; an activation 
complex with apoptotic-protein activation factor-1 (Apaf-1) and caspase 9. Caspase 8 and 9 
then activate downstream executioner caspases such as caspase-3 resulting in apoptotic cell 
death.  
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Signalling pathways involved in brain hypoxia/ischaemia  
Generally, activation of ERK1/2 and PKB promote cell survival, while activation JNK and p38 
MAPK promote cell death (Neary, 2005). Thus, in the brain, the MAPK pathways may be 
triggered after ischaemia induction (Lee et al., 2000; Sugawara et al., 2004). ERK signalling 
has been indicated to be involved in the neuroprotection process, either by alleviating apoptosis 
or mediating the compensation of the oxygen glucose deprivation process (Nozaki et al., 2001). 
The MAPKs’ neuroprotective roles seem to be complicated. Thus, additional studies are needed 
to illustrate the activated signal transduction upstream and downstream cascades in cerebral 
ischaemia and deﬁne the involved signalling pathways prior to pharmacological manipulation 
of the MAPK cascades in this context. The neuroprotective role of ERK1/2 has been well 
established. It has been shown that activation of the ERK1/2 pathway is involved in protection 
against glutamate-induced-excitotoxicity, ischaemia and brain-derived neurotrophic factor 
(BDNF)-induced reversal of DNA damage (Alessandrini et al., 1999; Hetman et al., 1999). Also 
it has been established that in both in vivo models of cerebral ischaemia and in vitro research, 
activation of the ERK1/2 pathway results in the inactivation of Bad due to its phosphorylation 
at the Ser112 site (Zhu et al., 2002). Protein kinase A (PKA), is one of the most widely studied 
in this context. Studies have shown that PKA has a role in regulating Bad activity and its 
phosphorylation, as intraventricular treatment with H89, a PKA inhibitor, in rodent focal 
cerebral ischaemia models showed decreased PKA activity and Bad-Bcl2 dimerisation and 
associated cell death (Kimura et al., 1998; Lizcano et al., 2000; Saito et al., 2003).  
Furthermore, the findings indicate that stimulating PI3-kinase and/or a downstream effector, the 
Akt kinase, could also play a central protection role against apoptosis in different cell types 
including neuronal cells (Crowder & Freeman, 1998). In 2003, Bijur and his group 
demonstrated the existence of previously unrecognised Akt signalling inside the mitochondria. 
It has also been clarified that Akt has a key attenuating role in the intrinsic apoptotic pathway 
in both the pre- and post-mitochondrial apoptotic cascades (Bijur & Jope, 2003). It has been 
found that in primary hippocampal neurons exposed to hypoxia Akt blocks Bax apoptosis 
regulation, conformational change and distribution to the mitochondrial membrane (Yamaguchi 
& Wang, 2001). In addition to the antiapoptotic capacity of cytosolic Akt, its mitochondrial 
antiapoptotic activity has been studied in human SH-SY5Y neuroblastoma cells treated with 
staurosporine, a powerful apoptosis inducer. It has been shown that constitutively active Akt in 
the mitochondria decreased the level of the released cytochrome c, along with attenuating 
subsequent consecutive activation of caspase-9 and caspase-3 (Mookherjee et al., 2007).  
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On the other hand, JNK and p38 MAPK stress kinases, are activated by different cellular 
stressors and is thought to have a central role participating in neuronal cell death. In an in vitro 
model of AD, cortical neurons treated with JNK inhibitors blocked intracellular JNK activity 
and protected against neuronal cell death and thus promoted cell survival (Bozyczko-Coyne et 
al., 2001). The pharmacological inhibition of JNK or p38 MAPK was also reported to protect 
neurons from cell death induced by lack of survival signal such as Akt or NGF (Kummer et al.,  
1997; Le-Niculescu et al., 1999; Harding et al., 2001). Similarly, Xia et al. (1995) observed that 
inhibition of JNK and p38 MAPK attenuated apoptosis in PC12 cells and they proposed that 
cell survival or cell death could be predicted by the balance between ERK and JNK/p38 MAPK. 
This cumulative evidence all suggests that the ERK1/2, Akt and PKA pathways promotes cell 
survival, whilst JNK and p38 MAPK, promote cell death signalling pathways after cerebral 
hypoxia/ischaemia.  
 Neurotrophic factors 
It has recently been found that neurotrophic factors contribute to protecting neuronal cells from 
cell death after cerebral ischaemia. Both NGF and pituitary adenylate cyclase activating 
polypeptide (PACAP) have neurotrophic effects, which have been extensively studied; they 
promote the differentiation, maturation, neurite outgrowth and survival of neurons in vivo and 
in vitro (Williams et al., 1986; Hatanaka et al., 1988; Takei et al., 2000; Yuhara et al., 2001). In 
addition, the intracellular transduction pathways involved in their neurotrophic effects are now 
well established; for a review, see Ravni et al. (2006). Several well established transduction 
pathways are involved in these effects  (Kaplan & Miller, 2000; Ravni et al., 2006), for example, 
in the PC12 cell line, PACAP prevented cell apoptosis by activating PKA signal cascade 
(Reglodi et al., 2004) whereas, NGF inhibited apoptosis through the PI-3K/Akt pathway 
(Shimoke & Chiba, 2001; Salinas et al., 2003; Wu & Wong, 2005). Interestingly, researchers 
have been studying the possible complementary role of PACAP and NGF. It has been found 
that their ability to block programmed cell death is a synergistic action of both PACAP and 
NGF in differentiated PC12 cells (Seaborn et al., 2014). Within this context, additional study 
elucidated that co-treatment with PACAP and NGF induced choline acetyltransferase (ChAT) 
enzymatic activity in cultured basal forebrain neurons (Yuhara et al., 2003). This suggests that 
they may have potential therapeutic value for AD, as this neurodegenerative condition is 
associated with dysfunction of the basal forebrain cholinergic system.  Based on previous 
observations and current data that the two trophic factors exerted similar effects particularly 
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neurite outgrowth and neuronal survival, it can be speculated that they may be protecting 
neuronal cell death via a similar modulator. Hence, this study aims to investigate the possible 
modulation of the multifunctional enzyme transglutaminase 2 by both neurotrophic factors 
separately, to induce neuronal cell outgrowth and survival. This will be further discussed in the 
upcoming sections. 
1.5.1 The pituitary adenylate cyclase activating polypeptide 
Overview, structure and function 
In 1989, the sequence of a novel regulatory peptide known as PACAP was first established to 
have adenylyl cyclase (AC) activity in pituitary cells (Miyata et al., 1989). PACAP exists as a 
27 or 38 amino acid C-terminal-amidated peptide (PACAP-27 and PACAP-38), and it is widely 
expressed in the brain, so it is also classified as a neuropeptide (Vaudry et al., 2009). Sequencing 
of PACAP has revealed that there is a high degree of sequence identity with vasoactive intestinal 
polypeptide (VIP), such that they are both classiﬁed as members of the VIP-secretin-growth 
hormone-releasing hormone GHRH glucagon family (Vaudry et al., 2009). In 1991, it was 
demonstrated that in the human brain, the mRNA binding sites of PACAP/VIP are mainly 
localised in the cortex, basal ganglia, hypothalamus, cerebellum and brainstem (Suda et al., 
1991). The highest level of expression is found in the hypothalamus. In 1992, Suda and his 
group further investigated the affinity in these sites in the human brain, reporting that they had 
10–20 times greater affinity to PACAP than VIP (Suda et al., 1992). It is well reported that the 
PAC1 receptor gene is primarily expressed in neurons, as well as glial cells, including astrocytes 
(Jaworski, 2000; Suzuki et al., 2003). The PAC1 receptor is also found in various peripheral 
tissues, mainly in the pituitary gland, adrenal medulla, lymphocytes and immune system (Table 
1.1). PACAP  is also present peripherally in the gastrointestinal tract, adrenal gland and testis 
(Ghatei et al., 1993; Shioda & Arimura, 1995). The PAC1 receptor has been found to be 
expressed in the brain areas implicated in the emotional control of behaviour and learning, such 
as the hypothalamus, amygdala, bed nucleus of the stria terminalis (BNST) and periaqueductal 
grey matter (Hammack et al., 2010). Studies using the isolated VIP receptor complex from rat 
liver membrane have shown an association with GTP regulatory protein, and further studies 
have suggested that the VIP-associated G-protein is Gαs (Couvineau et al., 1986). Studies have 
shown a direct correlation between VIP, PACAP and their receptors and Gαs subunits, 
confirming that VIP and PACAP interact with GPCRs to activate intracellular signalling 
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cascades (Dickson & Finlayson, 2009). Three PACAP–G-protein coupled receptor (GPCRs) 
have been characterised, namely the PAC1, VPAC1 and VPAC2 receptors; these all belong to 
the group II secretin receptor family (Table 1.1). They are further divided into two classes 
according to the aﬃnity for PACAP and VIP. Class I includes the PAC1 receptor, which is 
predominantly expressed in the CNS and speciﬁcally binds to PACAP with high aﬃnity. 
Meanwhile, class II includes the VPAC1 and VPAC2 receptors, which are abundant in various 
peripheral organs and have comparable aﬃnity to both VIP and PACAP (Dickson & Finlayson, 
2009; Harmar et al., 2012). PACAP is coupled primarily to Gs for adenylate cyclase activation, 
leading to the production of cAMP and subsequent activation of PKA. The PAC1 receptor also 
couples to Gq and activates PLC; this leads to increases in intracellular Ca2+ and the activation 
of PKC (Zhou et al., 200; May et al., 2010; Baxter et al., 2011). Stimulation of the PAC1 receptor 
results in a variety of intracellular transduction pathways. PAC1 receptor signalling regulates 
various cellular and physiological responses, such as cell survival and diﬀerentiation, as well as 
the release of neuroendocrine hormones and neurotransmitters/neurotrophic factors (McCulloch 
et al., 2001; Lutz et al., 2006; Blechman & Levkowitz, 2013). 
As agonists, PACAP-27 and PACAP-38 are 100-fold more potent than VIP to the PAC1 receptor 
(Harmar et al., 2012). It has been indicated that there is a limited number of the VIP and PAC 
receptor selective drugs available, both in terms of agonists and antagonists (Nicole et al., 2000). 
For example, maxadilan is a peptide isolated from the salivary gland of Lutzomyia longipalpis 
that has no significant homology with PACAP or VIP sequences and has been characterised as 
a potent selective agonist for the PAC1 receptor; however, due to its lack of availability, the use 
of this peptide is limited. In addition, in many studies, PACAP 6-38 has been implicated for use 
as a PAC1 receptor antagonist, but it also has affinity to antagonising the VAPC2 receptor 
(Dickinson et al., 1997). Further studies are required to identify and design more selective 
ligands for the PAC1 receptor by elucidating the mechanism of its activation. 
Cloning of the PAC1 receptor gene has shown that there are several variants produced from 
alternative splicing. The PAC1 receptor gene exhibits a high level of alternative splicing, and 
this accounts for the variation in its aﬃnity and selectivity, leading to the modulation of a variety 
of intracellular signal transduction cascades (Lelièvre et al., 1998). A splice variant denotes the 
existence of different amino acid sequences; if these are found in the extracellular loops or N-
terminus, it may result in altered ligand affinity and selectivity, whereas variance in the internal 
loops or C-terminus could affect the signal transduction pathways. In the PAC1 receptor, the 
splice variants include either the absence or presence of each of the alternative exons called 
‘hip’ and ‘hop’. Human PAC1 receptor shows four variants (null, SV-1, SV-2, SV-3) produced 
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from alternative splicing (Pisegna and Wanks 1996;  Lelièvre et al. 1998). Different splice 
variants exert different coupling affinities to G-protein and second messengers and their 
subsequent intracellular signal transduction in neuronal cells. For example, the PAC1-hip 
cassette type of splice variant results in eliminating the coupling to the PLC pathway and 
maintain the AC mediated signalling pathway (May et al. 2010). Alternative splicing of the 
PAC1 receptor also alters the ligand binding properties involved in the determination of receptor 
selectivity for either PACAP-27 or PACAP-38 peptide or its potencies. The diversity of PAC1 
receptor splice variants and the subsequent activated signalling pathways could account for the 
broad spectrum of physiological functions and biological responses triggered by this peptide. 
PACAP and its receptors appear to affect various biological and physiological functions, such 
as circadian rhythm regulation, reproduction, cognitive behaviour, neuromodulation, 
neuroprotection and neurite outgrowth (Waschek, 2002; Hashimoto et al., 2006; Laburthe et al., 
2007). In the nervous system, PACAP peptides act as neurohormones and neurotransmitters. In 
the hypothalamus, PACAP peptides act as neuromodulators to regulate the neurohormones, 
such as somatostatin and luteinising hormone (LH). Moreover, PACAP acts as a potent 
modulator of hypothalamic neurons, triggering the release of oxytocin and vasopressin via 
stimulation of the cAMP/PKA pathway (Lutz-Bucher et al., 1996).  
The roles of the PACAP and PAC1 receptor in cell survival, neuronal outgrowth and 
neuronal protection 
A substantial body of evidence indicates that PACAP has neurotrophic activities during 
development and protects the brain from damage associated with different types of injury. 
Moreover, the PAC1 receptor is known to be actively expressed during development and 
proliferation in the CNS (Monaghan et al., 2008; May et al., 2010). It has been found that, 
following neuronal injury, PACAP expression is increased and neuronal regeneration is 
promoted (Monaghan et al., 2008). Furthermore, it has also been indicated that PACAP-38 is 
effective even if it is administered several hours after cerebral ischaemia (Reglodi et al., 2000). 
In addition, PACAP-38 pre-treatment could reduce the infarct size induced by stroke (Reglodi 
et al. 2002). PAC1 receptor stimulation results in PLC activation, leading to PKC translocation 
and cellular Ca2+ inﬂux to facilitate neuronal cell proliferation (May et al., 2010). It has also 
been shown that PAC1 receptor activation protects neuronal cells against cytotoxicity from β-
amyloid aggregation, a key element in AD, as well as against glutamate-induced cell death ( Lee 
and Seo 2014). Recently, PACAP’s neuroprotective potential against hypoxia has been 
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demonstrated, as it reduces brain damage after ischaemia (Reglodi et al., 2000; Dejda et al., 
2005). PACAP has also been revealed to inhibit programmed cell death through the PAC1 
receptor in cultured cells induced to undergo apoptosis (Villalba et al., 1997). Indeed, the 
literature data indicate that PACAP neurotrophic activity is modulated via two different major 
pathways, involving either stimulation of the AC or PLC pathway (Vaudry et al., 2000). The 
mechanism underlying the neuroprotective activities of PAC1 receptor have been suggested 
mainly to involve activation of the AC, cAMP, PKA and MAPK pathways; this activation is 
required for deactivation of caspase-3, a key enzyme in apoptosis (Falluel-Morel et al., 2004; 
Baxter et al., 2011) and regulation of gene expression changes that promote differentiation of 
neurons. PACAP activation of PLC leads to the production of IP3/DAG and activation of PKC 
signalling pathways and results in deactivation of caspase-3 activity (Dejda et al., 2005; Vaudry 
et al., 2009; Harmar et al., 2012). It has been investigated that, in vitro, PACAP shows 
neuroprotective activity against apoptotic cell death induced by oxidative stress in cerebellar 
neurons via different mechanisms (Vaudry et al., 2000). One of the mechanisms is inhibition of 
the activation of JNK/stress-activating proteins (Ohnou et al., 2016). Another intracellular 
mechanism that is likely to be involved in the neuroprotective activities of PACAP is the PKA 
pathway, which regulates c-fos gene expression, thereby triggering Bcl-2 expression (Aubert et 
al., 2006; Botia et al., 2007). PACAP mainly regulates this Bcl-2 downstream activity by 
preventing the release of cytochrome c and inhibiting caspase-9 and the activation of caspase-3 
(Figure 1.4 summarises PACAP intracellular mechanisms involved in neurotrophic activities).  
As described above, previous studies have revealed that stimulation of the PAC1 receptor by 
PACAP peptides exerts neuroprotective activity, suggesting that this receptor could be of 
therapeutic interest for the treatment of hypoxia/ischaemia and stroke. Hence, it is necessary to 
investigate the signalling pathways involved, speciﬁcally those that may lead to the 
development of novel therapies for the treatment of such neuronal injury. 
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Figure 1.4  Schematic representation of the intracellular mechanisms involved in 
neurotrophic activities of PACAP on neuronal cells. 
Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma 2; caspase, cysteinyl- 
aspartate-cleaving protease; cFos, Finkel Biskis Jinkins osteosarcoma-related oncogene; 
cJun, jun oncogene; cytC, cytochrome c; DAG, diacylglycerol; Epac, exchange factor 
directly activated by cAMP; IP3, inositol 1,4,5-trisphosphate; G, guanine-nucleotide 
binding regulatory protein; p38, p38 mitogen-activated protein kinase; PAC1-R, 
PACAP-specific receptor; Raf, Raf proto-oncogene serine/threonine-protein kinase; 
Rap1, small GTPase of the RAS oncogene family; Ras, retrovirus-associated DNA 
sequences; Rit, Ras-like GTPase without CAAX 1; Shh, sonic hedgehog; Src, sarcoma 
viral oncogene homolog. Figure adapted from Vaudry (2000). 
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Affinity data from the IUPHAR Database (Sharman et al., 2011).
Table 1.1 Pharmacological characteristics and transduction mechanisms associated with PACAP receptors 
Receptor 
subtypes 
Ligand binding affinity 
Kd 
G-protein 
subunits 
Splice 
variants 
Transduction mechanisms Physiological distribution References 
 
 
Adenylyl 
Cyclase 
PLC Others 
PAC1 Agonist 
Maxadilan ~ 0.05 ƞM  
PACAP-38 ≈ PACAP-27 ≈ 
0.5 ƞM 
VIP> 500 mM 
Antagonist 
PACAP 6-38 
Gαs 
Gαq 
S 
Hop1 
Hop2 
Hip-Hop 
 
 
 
 
 
 
Stimulated 
cAMP 
production 
 
 
Stimulates IP 
turnover 
Stimulates 
calcium 
mobilization 
And PLD 
 
 
 
 
 
 
 
L-type channel 
 
CNS; olfactory bulb, hippocampus, 
cerebral, cerebellar, cingulate and 
entorhinal cortices, hypothalamic, 
amygdaloid, thalamic 
Peripheral organ: Pituitary, adrenal 
medulla and placenta 
Moro and Lerner, 1997; 
Dickson et al. 2006a; 
Robberecht et al. 1992b; 
Vaudry et al. 2009 
Hip  
- 
Vs 
 
 
Stimulates IP 
turnover 
TM4 - 
VAPC1 Agonist 
[Ala11,22,28] VIP 
[Ala2,8,9,11,19,22,24,25,27,28]-
VIP 0.7 ƞM 
PACAP-38 ≈ PACAP-27 ≈ 
VIP ≈ 1 ƞM 
Antagonist 
PG 97-269 
Gαs 
Gαq 
Gαi 
 
 
 
 
- 
 
Stimulated 
cAMP 
production 
 
Stimulated 
PLC 
 
Stimulates 
calcium 
mobilization 
And PLD 
 
Peripheral organ: Lung, intestine, 
pancreas and adrenal medulla, 
almost all human epithelial tissues. 
Moro and Lerner, 1997; 
Dickson et al. 2006a; 
Robberecht et al. 1992b; 
Vaudry et al. 2009 
VAPC2 Agonist 
Ro 25-1553 ≈ 1 ƞM 
Ro 25-1392 ≈ 5 ƞM 
Bay 55-9837 0.3 ƞM 
PACAP-38 ≈ PACAP-27≈ 
VIP≈ 1 ƞM 
Antagonist 
PG 99-465 
Gαs 
Gαq 
Gαi 
 
 
 
- 
 
Stimulated 
cAMP 
production 
 
 
- 
 
Stimulates 
calcium 
mobilization 
And PLD 
 
Peripheral organ: hippocampus, 
thalamus, pituitary, reproductive 
organ, spleen and adrenal cortex. 
 
Moro and Lerner, 1997; 
Dickson et al. 2006a; 
Robberecht et al. 1992b; 
Vaudry et al. 2009 
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1.5.2 Nerve growth factor (NGF) 
Overview, structure and function 
Nerve growth factor (NGF) was the first neurotrophin to be characterised. It was initially 
described by Levi-Montalcini after transplantation of a mouse malignant sarcoma into a chick 
embryo resulted in an increase in size and strength of the root dorsal ganglia and sympathetic 
ganglia; even the ganglia that did not directly innervate the tumour showed an obvious increase 
in size (Levi-Montalcini and Hamburger 1951). Further in vitro investigation in 1954 by the 
same group showed that a signalling protein, later known as NGF, significantly promoted 
neurite outgrowth of co-cultured sympathetic and dorsal root ganglia. In 1986, Levi-Montalcini 
was awarded a Nobel Prize for Physiology and Medicine for the first of many growth-regulating 
signal substances to be discovered and characterized. In the following decades, NGF was 
considered as one of the most interesting parameters, and it was implicated in several novel 
findings, especially in the nervous system, as a part of much neuroprotective research.  
Several other factors closely related to NGF have been established and classified as 
neurotrophins. Neurotrophins comprise a group of proteins known as neurotrophic factors that 
promote neuronal survival during development. These factors include NGF, BDNF, 
neurotrophin 3 (NT-3) and neurotrophin 4/5 (Cai et al., 2014). NGF is synthesised in the cortex, 
hippocampus and pituitary gland. NGF generally modulates a wide range of biological functions 
and signalling events in the nervous system; it regulates cell proliferation, differentiation and 
survival. Furthermore, NGF has been found to have a function in immune cells; inflammatory 
mediators induce the synthesis of NGF by different cells to elicit a pain response (Kawamoto 
and Matsuda 2004; Chao, Rajagopal, and Lee 2006). It has also been found that NGF induces 
B and T cell proliferation and IL-2 receptor expression on T-lymphocytes (Otten et al., 1989; 
Thorpe & Perez-Polo, 1987). Therapeutically, it is well documented that NGF is linked to pain 
treatment, and thus it is a potential target to discover a drug to treat chronic pain. Studies have 
led to the development of NGF inhibitors in the form of antibodies that have analgesic effects 
(Lane et al., 2010; Kumar & Mahal, 2012).  
In neurons, NGF regulates the expression of enzymes involved in the synthesis of 
neurotransmitters and neuropeptides, such as tyrosine hydroxylase (TH) and dopamine β-
hydroxylase. Furthermore, NGF has a crucial role in the function and survival of the neurons of 
the basal forebrain complex (BFC) area, which includes memory and motivations; its neurons 
are those mainly affected in AD (Allen & Dawbarn, 2006; Aloe et al., 2012). Thus, NGF has 
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been indicated to have a potentially protective role against neurodegenerative disorders 
affecting this area (Allen & Dawbarn, 2006). An NGF knockout mouse model has been used to 
demonstrate the neuronal survival role of NGF during development, and it shows a significant 
loss of sympathetic and sensory neurons (Crowley et al., 1994; Freund et al., 1994; Ruberti et 
al., 2000). A substantial body of evidence shows that in neurons that depend on NGF for 
survival, NGF is secreted from the target tissue innervated by the neurons activating a signal by 
which the axon terminals communicate with the cell bodies to exert survival (Korsching & 
Thoenen, 1983). This highlights the question of the possible mechanisms by which NGF 
generates signals that travel to the cell body over long distances to mediate cell survival. NGF 
has also shown to possess a strong anti-apoptotic effect, and in the absence of NGF neurons 
display various morphological changes and undergo apoptosis (Lomb et al., 2009). 
Neurotrophins, including NGF, develop their biological functions through different signalling 
pathways by binding to two classes of structurally unrelated receptor, with varying affinities; 
these are the tyrosine kinase receptor family Trk (TrkA, TrkB and TrkC) and the p75NTR, 
tumour necrosis factor receptor family (TNFR). p75NTR was the first NGF receptor cloned and 
it has equal binding affinity for all neurotrophins, including NGF (Chao et al. 1986). Trk family 
receptors are generally more selective for neurotrophin ligand binding; NGF exerts its biological 
effects mainly through TrkA, while  TrkB binds BDNF and NT4/5, and TrkC binds NT3 
(Reichardt, 2006). NGF binds to p75NTR non-selectively and with high-affinity (KD = 10
-9 M), 
leading to either apoptosis via the JNK/c-Jun signalling pathway or cell survival through the 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway, according to 
the cellular context (Bai et al., 2010; Verbeke et al., 2010). A substantial number of studies have 
suggested that p75NTR promotes apoptosis via the activation of downstream apoptotic 
signalling pathways, possibly through JNK/c-Jun (Bamji et al., 1998; Kenchappa et al., 2006) 
as shown in Figure 1.5. It has been found that in sympathetic neurons, treatment with 
neurotrophins that do not preferentially bind to TrkA, such as BDNF, pro-BDNF, pro-NGF and 
NT-4, modulates apoptosis (Bamji et al., 1998; Kenchappa et al., 2006; Deppmann et al., 2008).  
Furthermore, it has been shown that p75NTR-induced neuronal survival can be considered a 
NGF-dependent response. In contrast, in the absence of TrkA signalling, p75NTR modulates a 
cytotoxicity response in some cells (Casaccia-Bonnefil et al., 1996; María Frade et al., 1996; 
Van der Zee et al., 1996; Yeo et al., 1997). Although, positive results have been obtained from 
the use of NGF in the treatment of classical neurodegenerative diseases (Van der Zee et al., 
1996), to date, the specific molecular mechanisms implicated to these opposing responses of 
p75NTR are not yet fully understood. Although this receptor is expressed during neuron 
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development, it has been found that binding of NGF to this receptor in the absence of the co-
expression of TrkA mainly promotes apoptosis by activating the JNK signalling cascade (Aloe 
et al., 2012). A p75NTR disrupted mouse model exhibited a considerable delay in the apoptosis 
of sympathetic and sensory neurons during the normal period of developmental death (Bamji et 
al., 1998; Agerman et al., 2000). Further studies on the co-expression of both receptors find that 
this co-expression results in increasing NGF affinity to TrkA. It has been shown that, in the 
presence of p75NTR, lower concentrations of NGF are required for TrkA to induce neuronal 
survival (Horton et al., 1997). Figure 1.5 summarises the multiple intracellular signalling of 
NGF receptors. 
Tyrosine kinase receptor A (TrkA)  
TrkA is mainly expressed in the central and peripheral nervous system, it is member of 
transmembrane glycoprotein of tyrosine-kinase receptor family; it is the preferable, high-affinity 
NGF receptor known to activate signalling cascades that induce neuronal survival, neurite 
outgrowth and differentiation (Zhang et al. 2000; Reichardt, 2006). NGF exerts most of its 
biological and cell survival effetcs by binding selectively to TrkA with high affinity (K D = 10-11 
M; Hefti et al. 2006). Activation of TrkA by NGF results in the intracellular auto-phosphorylation 
of TrkA, causing activation of signalling cascades that include Ras/Raf/MEK/ERK1/2, PI -3K/Akt 
and PLC/PKC signalling pathways, which subsequently lead to the prevention of apoptosis 
(Hausott et al., 2009; Mendoza et al., 2011). Studies using a TrkA knockout mouse model have 
shown that it is crucial for promoting the survival of neurons that depend on NGF during 
development (Wyatt & Davies, 1993, 1995). Altogether, evidence suggests that NGF-induced 
neuronal cell survival and differentiation are mediated particularly through the high -affinity TrkA 
receptor; therefore, it is worthwhile to further investigate this protective role as a therapeutic target 
for neuronal hypoxia. As the current study has focused on the effects of neurotrophic factor NGF, 
on mechanisms of cell survival and signalling pathways a detailed discussion of such events would 
be worthwhile. 
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Figure 1.5  Schematic representation of the multiple intracellular signalling of NGF 
receptors. 
A; NGF binding to TrkA receptor activates PI3K/Akt, Ras/MAPK and PLCγ pathways 
mediates proliferation, differentiation and survival. B; NGF binding to the p75NTR 
receptor activate NF-κB and c-Jun N-terminal kinase (JNK), mediate opposing effects 
of survival and apoptosis respectively. PI3K, Phosphatidylinositol-3-kinase; MAPK, 
Mitogen activated protein kinase; PLCγ, Phospholipase Cγ; NF-κB, Nuclear factor-κB; 
JNK, c-Jun N-terminal kinase (Wang et al., 2014). 
 
The role of NGF in cell survival, neurite outgrowth and neuronal protection 
NGF signalling appears to play crucial neuroprotective roles in response to neurodegeneration 
associated with brain injury or diseases. Multiple experimental animal studies have illustrated 
NGF’s neuroprotective role in response to hypoxic/ischaemic brain injury, while a few studies 
have examined the protective mechanism in patients with the same severe incidents (Tanaka et 
al., 1994; Holtzman et al., 1996; Tabakman et al., 2004; Tabakman et al., 2005). One clinical 
study was conducted on two cases of children with hypoxic/ischaemic brain injury, and the 
researchers reported a remarkable improvement in their electroencephalograms (EEGs) after 
treatment with intraventricular NGF (Fantacci et al., 2013). As discussed earlier, most molecular 
characterisation studies of the pathways initiated by NGF and associated with cell survival and 
neuroprotection have been indicated to be through the TrkA receptor. Furthermore, NGF 
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signalling has been shown to be involved in various neuronal processes associated with survival, 
neuronal differentiation and axon growth (Bibel & Barde, 2000; Sofroniew et al., 2001). It is 
important to take into consideration that NGF signalling and the molecular events associated 
with neuronal protection have not yet been fully characterised. Thus, this thesis focusses on how 
the NGF signalling cascade may be implicated in the response to specific conditions. 
One of the NGF-activated pathways contributing to neuronal cell survival occurs through the 
activation MAPK signalling. This signalling pathway is initiated by the phosphorylation of Shc, 
leading to the activation of a membrane-associated monomeric G-protein, Ras; which promotes 
the activation of Raf. Raf, in turn, activates MAPKK (MEK1/2) and ERK1/2, which facilitate 
the phosphorylation of ribosomal S6 kinase (RSK), leading to activation of the cAMP response 
element binding (CREB) protein. This regulates the expression of different genes contributing 
to neuronal differentiation or neurite outgrowth (Bibel & Barde, 2000). 
In addition, the PI-3K/Akt pathway is especially important for neuronal survival induced by 
NGF, and it is the most studied pathway. Activated PI-3K phosphorylates PIP2 to PIP3, which 
then recruits Akt for activation. The activated Akt induces downstream targets that promote 
neuronal survival. For example, Akt phosphorylates pro-apoptotic proteins, such as forkhead 
box-O (FoxO) transcription factors and Bad; this leads to the inhibition of neuronal apoptosis 
by controlling the expression of genes involved in cell death (Brunet et al., 1999). Various 
studies examined the requirement of this pathway in NGF-inducing neuronal survival. It has 
been shown that the pharmacological inhibition of PI-3K using LY294002 leads to the partial 
blocking of NGF-induced neuronal survival (Atwal et al., 2000). It has been reported that, NGF-
activation of PKC via the PLCγ pathway results in the inhibition of gene expression associated 
with programmed cell death (Cabeza et al., 2012). Much of the research has focussed on how 
survival is promoted by the cooperation of PKC and PI-3K pathways in NGF-dependent neuron 
survival. It has been found that the PKC pathway induces inhibition in the expression of genes 
responsible for neuronal cell death, which takes place in conjunction with the PI-3K pathway 
(Pierchala et al., 2004; Lallemend et al., 2005).  
The implication NF-κB in NGF-dependent neuron survival has also been investigated. NF-κB 
is a nuclear transcription factor that regulates the expression of genes that play roles in cell 
survival. It has been found that NF-κB regulates NGF-induced neuronal survival during 
embryonic development through p75NTR (Hamanoue et al., 1999).    
These studies on NGF and those previously discussed on PACAP, have increased the interest 
in the study of a possible role for the multifunctional enzyme transglutaminase 2 (TG2) in 
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neuroprotection and neurite outgrowth signalling pathways induced by PACAP- and NGF. 
Therefore, it is worthwhile to discuss how TG2 could link in to such events. 
 
 Transglutaminases 
1.6.1 Family and physiological function 
Transglutaminases (TGs) are a family of ubiquitous and related enzymes that were first 
characterised in 1957, when they were isolated from guinea pig liver (Clarke et al., 1959). They 
possess the ability to catalyse calcium-dependent post-translational modification of proteins, 
and they were first described as TGs in 1959 by Clarke et al. (1959). Nine different genes 
encoding TG isozymes have been identified, and some of them have been studied at the protein 
level (Grenard et al., 2001). The precise biochemical activity of TGs was first established in 
blood plasma, where coagulation factor XIII was shown to have the ability to crosslink and 
stabilise fibrin during the coagulation cascade (Pisano et al., 1969). This brought up the concept 
that these enzymes can modify proteins and act as a biological glue. 
 In mammals, there are nine genes encoding isoforms of TGs; eight of the gene products are 
classified as catalytically active enzymes, named TG1–7 and Factor XIIIa and the ninth one is 
the catalytically inactive erythrocyte membrane protein band 4.2 (Griffin et al., 2002; Eckert et 
al., 2014). They are widely distributed among various tissues. All the isoforms shared the same 
amino acid sequence at the active site except band 4.2 (Eckert et al., 2014).  The characterisation 
of the TG family is summarised in Table 1.2. 
The protein structure of the TG family consists of four domains, including an NH2 terminal–β-
sandwich, and α/β catalytic core and two COOH-terminal β-barrel domains. The active site 
consists of a cysteine, histidine and aspartate residue and tryptophan, which stabilises the 
transition state. This generates a compact structure (GDP-bound form) in which the active site 
is enfolded; this is called the catalytically inactive state. Upon activation, in presence of calcium, 
the structure takes an extended form (GTP-bound), where the active site is exposed 
(Nurminskaya & Belkin, 2013; Eckert et al., 2014). The TG1 and FXIII isoforms have an 
additional NH2 terminal pro-peptide sequence that is cleaved in order to make them active 
(Iismaa et al., 2009). Active TGs crosslink proteins by catalysing an acyl transfer reaction 
between γ-carboxamides of glutamines and the ε-amino group of lysine residues, which results 
in different outcomes. Other TG activities include the incorporation of polyamines into proteins 
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and deamidation of proteins (Griffin et al., 2002; Iismaa et al., 2009).  TGs’ actions modulate 
different activities such as signal transduction, membrane stabilisation and protein 
polymerisation, and this could modulate a wide range of physiological functions. TG2 is the 
most widely expressed TG isoform, and it is found in most mammalian tissues (Fesus & 
Piacentini, 2002) and implicated in a wide range of cellular processes. In the mammalian CNS, 
TG2 is the most predominantly expressed isoform, but TG1 and 3 have also been identified (shii 
& Ui, 1994; Bailey et al., 2004; Bailey & Johnson, 2005). Consequently, most studies on the 
role of TG in neuronal cell function have focussed on TG2. As a ubiquitous and multifunctional 
protein, it would be anticipated to have a crucial physiological role. The TG2 cellular functions 
and significant roles in cell physiology are discussed in the following section.
 
 
 
 
 
  
 
 
 28 
 
Table 1.2 Members of transglutaminase family: classification and related information about molecular mass, cell or tissue localisation and biological function
Isoform 
name 
Alternative name Molecular weight 
KDa 
Tissue expression Main biological functions References 
Factor 
XIIIA 
Plasma transglutaminase 83  
 
Plasma, platelets, 
chondrocytes, astrocytes, 
macrophages, heart, eye 
and dendritic cells in the 
dermis 
Blood clotting, bone growth, 
ECM stabilization, wound 
healing 
Schroeder and kohler, 2013; 
Odii and Coussons, 2014; 
Eckert et al, 2014 
 
TG1 Keratinocyte transglutaminase, type 
1 TG 
90 Keratinocytes, 
cytosol, membrane and 
squamous epithelia 
keratinocytes Epidermal 
differentiation and cell 
envelope formation 
Yamanishi et al., 1992, Odii and 
Coussons, 2014; Eckert et al., 
2014 
TG2 Tissue transglutaminase, type 2 TG, 
Gαh, cytosolic transglutaminase, 
transglutaminase type II, liver TG, 
erythrocyte TG, endothelial TG 
78 Ubiquitous distribution in 
different tissues, 
membrane, cytosol, 
nucleus and extracellular 
cell - ECM adhesion, cell 
differentiation, matrix 
stabilisation, cell survival, 
apoptosis, signalling 
Collighan and Griffin, 2009; 
Eckert et al., 2014; 
Nurminskaya and Belkin, 2012; 
Odii and Coussons, 2014 
 
TG3 Epidermal transglutaminase, type 3 
TG, TGE 
77 Cytosol, hair follicle, 
brain, epidermis 
Keratinocyte differentiation, 
terminal differentiation of 
keratinocytes and hair follicle, 
GTPase activity 
Rose et al,2009; Odii and 
Coussons, 2014; Eckert et al., 
2014  
TG4 Prostatic transglutaminase, type 4 
TG, TGP 
77 Prostate gland, prostatic 
fluids and seminal plasma 
Prostate isoform, reproduction 
and fertility, semen coagulation 
in rodents 
Ablin et al., 2011; Odii and 
Coussons, 2014; Jiang et al., 
2013; Eckert et al., 2014 
TG5 Type 5 TG, TGX 81 Epithelial tissues Keratinocyte differentiation and 
cornified cell envelope 
assembly 
Thibaut et al., 2005; Odii and 
Coussons, 2014; Eckert et al., 
2014 
TG6 Type 6 TG, TGY 78 Skin epidermis Development and motor 
function 
Thomas et al, 2013; Odii and 
Coussons, 2014; Eckert et al., 
2014 
TG7 Type 7 TG, TGZ 81 Ubiquitous Not characterised Odii and Coussons, 2014; 
Eckert et al., 2014 
Band 4.2 Erythrocyte membrane protein band 
4.2 
72 Erythrocyte membranes, 
spleen, bone marrow, 
foetal liver 
Maintain membrane integrity Mouro-Chanteloup et al., 2003; 
Odii and Coussons, 2014; 
Eckert et al., 2014; Kalfa et al., 
2014 
Introduction  Chapter 1 
29 
 
 Tissue transglutaminase TG2 
1.7.1 The cellular and biological function of transglutaminase 2 (TG2) 
Tissue TG2 is a multifunctional enzyme that is found both intracellularly and extracellularly 
(Eckert et al., 2014). TG2 is the most abundant and widely distributed member of the TG family 
(Lorand & Graham, 2003). It is mainly cytosolic; however, its presence in the nucleus and other 
cell components has been documented (Griffin et al., 2002; Filiano et al., 2010). The wide range 
of TG2 protein substrates accounts for its various biological functions, such as cell adhesion 
and migration, growth and differentiation, survival and apoptosis and organisation of the 
extracellular matrix (ECM; Eckert et al., 2014; Odii and Coussons, 2014). TG2 catalyses the 
Ca2+ -dependent transamination of proteins involving the acyl transfer reaction between the γ-
carboxamide group of polypeptide-bound glutamine and the primary amino group of either a 
polypeptide-bound lysine or polyamine (Mhaouty-Kodja, 2004). Moreover, TG2 has Ca2+-
independent enzymatic and non-enzymatic functions (Eckert et al., 2014). The Ca2+-
independent enzymatic activities are the protein kinase function (Mishra et al., 2007), GTPase 
activity (Nanda et al., 2001), protein disulphide isomerase (PDI) activity (Hasegawa et al., 2003) 
and signal transduction G-protein (Gαh). The non-enzymatic functions include roles in cell 
adhesion and stabilisation of the ECM (Eckert et al., 2014). The TG2 structure is like that of the 
other TGs, containing in the four domains, as previously discussed (Figure 1.6). The TG2 N-
terminus contains a fibronectin binding site, which is involved in the cell adhesion processes 
(Hang et al., 2005); the catalytic domains, which are required for the transamidating activity 
with some residues involved in GTP/GDP-binding (Griffin et al., 2002; Ruan et al., 2008). β-
barrel-1, mainly contains the GTP/GDP binding site and β-barrel-2 is essential for PLCδ1 
activation via Gαh and signal transduction (Nurminskaya & Belkin, 2013).  
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Figure 1.6  Schematic diagram of TG2 protein domain and crystal structure 
Protein boundary of TG2 (A); the diagram shows the four TG2 structural domains N 
terminal, β-sandwich, catalytic core domain that contain essential (cys277, His335, 
Asp358) residues, β-barrel-1 and 2. Figure adapted from Lai and Greenberg (2012). The 
crystal structure of TG2 (B); shows compact form, GDP-bound TG2 (left) and extended 
form, exposed active site. Figure modified from Pinkas et al., (2007). 
GTPase and G protein function 
TG2’s ability to bind and hydrolyse GTP was first established in 1987 (Achyuthan & 
Greenberg, 1987). In 1994, the correlation between GTP hydrolysis activity and the function of 
GPCRs was first demonstrated (Nakaoka et al., 1994). This showed that when the high-
molecular-weight GTP-binding protein known as Gαh was co-isolated with the α1B adrenergic 
receptor, it was identical to the TG2 sequence from different species (Lee et al., 1989; Im et al., 
1993). Another shared functional ability between TG2 and Gαh is mediating signalling through 
different GPCRs, which results in the stimulation of PLCδ1 (Das et al., 1993). TG2/Gαh activity 
is independent of the transamidating activity (Achyuthan & Greenberg, 1987). A substantial 
number of studies focussing on functional comparisons between TG2 and Gαh have shown that 
Gαh displays similar activity to TG2, and this activity is inhibited by guanine nucleotides; it also 
binds with GTP at a 1:1 ratio and hydrolyses it to GDP (Achyuthan & Greenberg, 1987; 
Greenberg et al., 1991; Bergamini & Signorini, 1993). Together, these studies confirmed that 
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TG2 and Gαh exert the same cellular functions and pass on a receptor signal to the effector; this 
is described as TG2-GTPase activity.  
It has also been reported that TG2-GTPase activity regulates signalling pathways namely ERK 
and the regulatory kinase MEK in cardiomyocytes (Lee et al. 2003). Moreover, it triggers AC 
activity in neuroblastoma cells (Tucholski & Johnson, 2003), but inhibits AC activity in 
fibroblasts and endothelial cells (Gentile et al., 1997). In fibroblasts, it has been confirmed that 
via GTP-binding activity, TG2 promotes cell migration (Kang et al., 2004) and regulates cell-
cycle progression (Mian et al., 1995). Increasing evidence confirms that the GTPase activity of 
TG2 plays a definite role in shedding light on the possible kinase activity of TG2, which is 
discussed in the next section. 
Kinase activity 
In 2004, evidence was obtained for possible TG2 kinase activity, since it was indicated that in 
breast cancer cells, TG2 phosphorylates insulin-like growth factor-binding protein-3 (IGFBP-
3), thereby reducing its pro-apoptotic activity (Mishra & Murphy, 2004). Furthermore, 
researchers have reported that TG2 kinase activity is inhibited with increases in intracellular 
calcium (Mishra & Murphy, 2004). It has also been found that in embryonic fibroblasts, TG2 
kinase activity is stimulated by PKA and inhibited by increasing calcium levels (Mishra & 
Murphy, 2007). 
Protein kinases, such as PKA and PKC, have been shown to regulate the activity and expression 
of TG2. For example, PKA phosphorylates TG2 at serine216 which promotes the binding of the 
adaptor protein 14-3-3 (Mishra & Murphy, 2006). This results in the  modulation of  various 
TG2 activities, such as the activation of pro-survival factors, NF-κB and PKB/Akt, and 
downregulation of tumour suppressor phosphatase and tensin homologue PTEN (Wang et al., 
2012). The interaction between TG2 and 14-3-3 protein has been suggested to be an important 
regulator of TG2 kinase function. It has been also shown that TG2 serine212 is also  a potential 
phosphorylation site for  kinases such as PKC, RSK; ribosomal S6 kinase and CDK5; cyclin-
dependent-like kinase 5 (Rikova et al., 2007). This regulates the interaction of TG2 with Bcl-2, 
resulting in an attenuated pro-apoptotic function (Wang et al., 2012). It has also been reported 
that TG2 is involved in activation of various signalling pathways, such as ERK1/2, JNK1/2 and 
p38 MAPK (Singh et al., 2003), CREB (Tucholski & Johnson, 2002), and PLC (Nakaoka et al., 
1994). Further work would benefit from considering the role of TG2 kinase activity in these 
different pathways and the regulation among signalling events.  
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Protein disulphide isomerase activity 
Protein disulphide isomerase (PDI) is an enzyme member of the thioredoxin family in the 
endoplasmic reticulum (ER); it catalyses the formation, breakup and exchange of disulphide 
bonds within proteins to ensure correct protein folding (Hasegawa et al., 2003). It has been 
found that several PDIs exert transamidating activity involving Cys, His and Asp residues, 
which TG2 requires in order to initiate the primary amine incorporation into proteins (Blaskó 
et al., 2003). This finding suggests a possible PDI activity of TG2 in the cytosol, where TG2 is 
present in higher concentrations. Thus, the PDI function of TG2 was first reported when the 
inactive RNase A was folded into the active form by TG2. Furthermore, TG2 mediated PDI 
activity is independent of calcium/GTP and transamidating function (Hasegawa et al., 2003). It 
has been also found that the PDI activity of TG2 can control the ADP/ATP transportation 
mechanism in the mitochondria, as researchers have reported that there is low ATP production 
in TG2 knockout mouse cardiomyocytes and skeletal muscle, and they suggested that this 
reduction is due to a lack of TG2 mediated formation of disulphide bridges (Krasnikov et al., 
2005; Malorni et al., 2009). 
Protein scaffolding 
Another TG2 function is protein scaffolding. TG2 is mainly present in the cytosol; however, it 
can also be found in the ECM c and on the cell surface, where it can act as a scaffolding protein. 
This activity was shown in the interaction of TG2 with fibronectin (Gaudry et al., 1999) and β-
integrins (β1, β3 and β5; Akimov et al. 2000). This reaction leads to the stabilising and 
remodelling of the ECM and produces stronger cell adhesion, migration and differentiation due 
to the modulation of various signalling pathways (Akimov and Belkin 2001; Wang and Griffin 
2011). It has been well documented that the ability of TG2 to enhance cell attachment to the 
ECM has a supportive effect on cell survival; a lack of this supportive attachment leads to cell 
death. As cell surface TG2 has a role in enhancing the attachment to ECM, this promotes cell 
survival and protects cells from the death process (Aeschlimann and Paulsson 1991; Martinez 
et al. 1994; Belkin 2011). TG2 can also act as a scaffolding protein in the cytosol and nucleus. 
In the cytosol, it has been reported that TG2 scaffolding activity is required for NF-kB pathway 
activation (Lee et al. 2004). In the nucleus, the evidence on the existence of TG2 as scaffolding 
protein is well documented to be implicated in various types of transcriptional regulation (Ahn 
et al. 2008; Filiano et al. 2008; McConoughey et al. 2010; Jang et al. 2010). It has been shown 
that in cellular models of Huntington’s disease, nuclear TG2 can interact with cytochrome-c 
Introduction  Chapter 1 
33 
 
promoters and decrease their transcriptional activity (McConoughey et al., 2010). Later studies 
have suggested that the nuclear TG2 activity implicated in gene expression depended on its 
transamidation activity (Tatsukawa et al., 2009). Consequently, in the nucleus, TG2 could 
possibly act as scaffolding protein or transamidating enzyme, according to the physiological 
and pathological context. 
Transamidase activity 
The transamidating activity of TG2 was first identified in 1957. In this activity, TG2 catalyses 
a calcium-dependent post-translational modification (Sarkar et al., 1957). TG2 was initially 
considered a transamidating enzyme; however, further studies showed that under normal 
physiological condition, TG2 is not active in transamidation. The transamidating function of 
TG2 must be initiated by Ca2+ binding; the Ca2+ binding site in the TG2 structure is situated in 
the catalytic domain, and any mutation of one of the Ca2+ binding sites result in a reduction in 
the transamidating activity of TG2 (Király et al., 2009). GTP is also another modulator of this 
activity, GTP-bound form of TG2 is the catalytically inactive state. Under normal physiological 
conditions, the cytosolic has high GTP concentration and TG2 is in catalytically inactive 
(Klöock & Khosla, 2012). Inactive TG2 requires high concentration of Ca2+influx to activate, 
which may associate with physiological disruption conditions such as apoptosis and this 
activation is depend on the precise level of Ca2+ (Orrenius et al., 2003). Once TG2 is activated 
by binding to Ca2+, the catalytic domain (containing a cysteine residue) is exposed, leading to 
transfer of the acyl group between γ-carboxamide of the glutamines and the ε-amino group of 
lysine residue, as well as the formation of an ϵ-(γ-glutamyl) lysine isopeptide bond. The 
mechanism of this reaction consists of two main steps. First, the acyl acceptor substrate 
(glutamine containing) binds to the enzyme catalytic site and forms a thioester bond with the 
active cysteine site of TG2; this step is associated with the release of ammonia. Second, an 
amine donor binds to the enzyme by attacking the thioester intermediate bond and reforming 
the active site of the enzyme. If the amine donor group is a primary amine (free amine), the 
reaction will result in protein post-translational modification by amine incorporation. In 
contrast, if the involved group is peptide-bound lysine, the reaction outcome will be crosslinking 
of the two proteins. Furthermore, the reaction will result in deamidation if the group is a water 
molecule (Folk et al., 1983). For the purpose of this study, transamidation activity has been used 
to assess the TG2 activity. A simple summary illustrating the transamidation reaction catalysed 
by TG2 is shown in Figure 1.7.  
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The various outcomes of transamidating reactions have been found to be implicated in different 
biological and pathological processes. For example, it has been found that the transamidation 
function of TG2 is implicated in the activation of the small G-protein (Rac1) in pancreatic β-
cells by incorporating serotonin (5-HT) on glutamine residues of GTPase to form a glutamyl 
amide bond (Paulmann et al., 2009). In skin, TG2 transamidation activity is essential for the de 
novo formation of functional dermo-epidermal cohesion apparatus required for bone healing 
(Haroon et al. 1999; Mearns et al. 2002). In contrast, excessive TG2 crosslinking activity has 
been reported to be involved in pathological processes, such as wound healing or the fibrogenic 
reactions associated with different diseases (Aeschlimann and Thomazy 2000). The role of TG2 
in different diseases or disorders is discussed in the next section. 
 
 
Figure 1.7  TG2 Transamidation reaction 
A, Crosslinking reaction between γ-carboxamide group of a peptidyl glutamine and ε- 
amino group of a peptidyl lysine. B, Transamidation reaction between - γ carboxamide 
group of a peptidyl glutamine and a free amine. C, deamidation reaction between γ-
carboxamide group of glutamine and water molecule (Adapted from Eckert et al., 2014). 
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1.7.2 TG2’s role in diseases and disorders 
As discussed previously, TG2 is important in various intracellular signalling processes, where 
it is either involved in the modulation of cellular process or pathological conditions, such as 
coeliac disease, fibrosis, inflammation and neurodegenerative disease. TG2 can be activated 
under pathological conditions in response to immune signals, and it exerts potential cellular 
protective and stabilising roles. Although any abnormal activation, deactivation or increase in 
the cellular level of TG2 is associated with various pathological processes, it has been found 
that autoimmune inflammatory disorders, such as coeliac disease (Briani et al., 2008) liver 
cirrhosis and fibrosis (Elli et al., 2009) and rheumatoid arthritis (Picarelli et al., 2003), are 
associated with increased TG2 expression. Furthermore, TG2 has a potential role in 
neurodegenerative diseases, such as Parkinson’s disease (Andringa et al., 2004), AD and HD 
(Citron et al., 2001), thus making TG2 one of the most important therapeutic targets.  
Coeliac disease 
A substantial body of evidence suggests the possible role of TG2 in coeliac disease’s 
pathological process. The protein post-translational modification activity of TG2 results in the 
generation of autoantibodies, such as that produced in the autoimmune disorder of gluten-
sensitivity disease/coeliac disease (Siegel & Khosla, 2007; Ciccocioppo et al., 2010; Wanf & 
Griffin, 2011; Nurminskaya & Belkin, 2013). Coeliac disease is a chronic autoimmune disease 
caused by a permanent intolerance to ingesting wheat gluten or any related products; it is 
characterised by innate immune responses to this type of protein in the diet (Di Sabatino & 
Corazza, 2009). Increasing TG2 expression has been reported in jejunal biopsies from coeliac 
disease patients, suggesting that TG2 is implicated in this disease pathology (Bruce et al., 1985). 
In this process, TG2 is involved in the generation of deamidated gluten, thereby triggering 
inflammatory responses (Matysiak-Budnik et al., 2008). The immune complex is recognised by 
T cells, leading to the formation of autoantibody immunoglobulin A (IgA) against TG2 (Koning 
et al., 2005; Ciccocioppo et al., 2010). This is used as a diagnostic marker for this disease, 
revealing the role of TG2 in modulation of the immune responses in its pathogenesis.  
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Inflammation and tumour progression 
Various inflammatory diseases have been associated with either activation or deactivation of 
TG2. TG2 has been reported to promote inflammation through the activation of the NF-kB 
cascade, which is known to be a key switch for inflammation ( Lee et al. 2004). TG2 induces 
activation of the NF-kB cascade via enhancing crosslinking and the subsequent degradation of 
IkBα, its inhibitory subunit. This TG2 crosslinking activity leads to the dissociation of NF-kB 
and its translocation to the nucleus, which results in the  up-regulation of inflammatory genes, 
such as TNF-α, and promoting the expression of anti-apoptotic proteins, such as Bcl-xL ( Lee 
et al. 2004; Mann et al. 2006). Conflicting regulation mechanisms with regard to TG2 
expression in response to inflammation and injury have been reported, with its upregulation 
enhanced by cytokines, such as IL-1 and IL-6, that are secreted in response to inflammation 
(Suto et al., 1993; Johnson et al., 2001). In addition, it has been reported that the pro-
inflammatory cytokine transforming growth factor β1 (TGF-β1) enhances TG2 expression; 
sequentially, TG2 binds to the cell surface, activating the conversion of TGF-β1 to its 
biologically active form. This has been suggested to be a crucial stabilisation mechanism of 
inflammation (Quan et al., 2005).  
Tumour progression shows high similarity to the inflammatory responses; TG2 shows 
conflicting integration in tumour progression being either up- or down-regulated (Mehta & Han, 
2011). It has been reported that TG2 expression is down-regulated in primary tumours and 
tumour progression, while it is up-regulated in the metastatic stage of tumours that have 
developed resistance to chemotherapy (Kotsakis & Griffin, 2007). Increasing the TG2 at the 
metastatic stage reveals a possible role in stabilising the contact points of tumours to the ECM 
(Kong & Korthuis, 1997). It has been shown that increased TG2 expression in ovarian cancer 
promotes adhesion with fibronectin and cell migration (Satpathy et al., 2007). In this mode, 
TG2 could be implicated in the survival of cancer cells. In contrast, TG2’s enzymatic 
transamidation activity suggests that it has a role in promoting cancer cell death, as it has been 
shown to establish cell apoptosis in some cancer cell lines (Milakovic et al., 2004). These 
opposing functions of TG2 in cancer biology suggest that it could have both cell death and cell 
survival roles. 
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1.7.3 The cell death and cell survival roles of TG2 
In the past decade, a considerable number of studies have established the contradictory role of 
TG2 in promoting cell survival and apoptosis (Fesus & Szondy, 2005; Mehta et al., 2006; Verma 
& Mehta, 2007). TG2’s multifunctional, conformational change and localisation properties 
make it complex to identify the possible trigger to initiate this dual role. It has been found that 
TG2 modulates caspase-dependent cell death and is involved in another mechanism to control 
cell death that is independent of caspase (Fesus & Szondy, 2005). It has also been found that 
TG2 transamidation activity can both facilitate and inhibit apoptosis. However, TG2 has been 
shown to have an anti-apoptotic effect via its crosslinking activity (Fesus & Szondy, 2005; 
Sarang et al., 2005).  
TG2’s role in cell death and survival has been widely studied using neuronal models, as TG2 is 
the most predominant TG isoform expressed in the brain (Kim et al., 1999; Bailey et al., 2004). 
Moreover, it has been found to be up-regulated in the human brain associated with acute and 
chronic neurodegenerative diseases, suggesting a possible role in neuronal cell death or survival. 
It has been found that in a mouse model of Huntington’s disease TG2-/- knockout revealed a 
delay in motor dysfunction onset. Furthermore, prolonged survival of transgenic TG2-/- mice 
has been reported (Mastroberardino et al., 2002; Bailey & Johnson, 2005; Mishra et al., 2007).  
However, the reason that the TG2 knockout caused protection in the Huntington disease mouse 
model has not yet been established. In contrast, in the SH-SY5Y human neuroblastoma hypoxia 
model, TG2 binding to hypoxia inducible factor 1β (HIF1β) protected neuronal cells from 
hypoxia induced-cell death (Filiano et al., 2008).  
Several studies have reported that overexpression of TG2 under apoptotic conditions leads to 
more neuronal phenotypes in human neuroblastoma SH-SY5Y cells (Zhang et al., 1998). These 
data provide evidence that TG2 up-regulation is not necessarily associated with apoptosis; 
instead, it could lead to diﬀerentiation and axon outgrowth. Furthermore, the up-regulation of 
TG2 was found to suppress the apoptosis and cell death induced by Ca2+ overload via Bax 
suppression, decreased activation of caspase-3 and 9, decreased release of cytochrome C and 
inhibition of mitochondrial permeability transition pore (Cho et al., 2010). This revealed the 
protective and anti-apoptotic role of TG2 in diseases involving Ca2+ overload. Although TG2 
has long been known to be involved in the apoptosis process, a deﬁnitive answer to whether it 
is pro-apoptotic or anti-apoptotic has not yet been determined. Altogether, these studies suggest 
a role for TG2 in mediating the cellular response in pathological conditions, such as ischaemia 
and stroke. Thus, it is likely to be a target for pharmacological manipulation to alleviate 
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associated neuropathology. Several extensive reviews discuss the potential complicated role of 
TG2 in cell survival and cell death (Fesus & Szondy, 2005; Chhabra et al. 2009; Iismaa et al., 
2009; Caccamo et al., 2012).  
1.7.4 TG2’s neuroprotective role 
Although TG2 plays a role in various cellular processes, its neuroprotective function by 
regulating cell survival and death has been an area of especial interest. In the past decade, 
increasing evidence has suggested the potential role of TG2 in protecting and stabilising cells 
and tissue, especially in neuronal cells (Eckert et al., 2014). 
Ischaemia/stroke 
Inadequate oxygen and glucose levels in cerebral tissue as a consequence of stroke/ischaemia, 
induce various processes involving adaptive responses and apoptotic and excitotoxic cell death. 
They also initiate hypoxic signalling via HIFs ( Lee et al. 2000; Thornton et al. 2017). There is 
a growing awareness that TG2 is up-regulated in response to hypoxic/ischaemic stress 
(Tolentino et al., 2004). In addition, it has been documented that the TG2 activity and expression 
are increased in an animal model of cerebral ischaemia and stroke (Ientile et al., 2004; Tolentino 
et al., 2004). Therefore, it is reasonable to hypothesise a functional role of TG2 in response to 
ischaemic insult. Studies on cardiomyocytes from TG2-/- mice revealed that TG2 had a 
protective role against cardiac ischaemia (Szondy et al., 2006). In contrast, astrocytes of TG2-/- 
mice showed resistance to ischaemia and increased survival compared to wild-type mouse 
astrocytes (Colak & Johnson, 2012). These conflicting finding suggests that the TG2 cell 
survival function depends on the cell context. 
At the neuronal level, a considerable amount of evidence has been gathered concerning TG2’s 
role in hypoxia/ischaemia, and this has confirmed its neuroprotective functions. Neuronal 
selective TG2 over-expression in mice resulted in smaller infarct volumes compared to wild-
type mice after ischaemic stroke ( Filiano et al. 2010). The possible cellular protective 
mechanisms of TG2 were investigated previously by the same group in 2008, and it was shown 
that TG2 protected against oxygen and glucose deprivation (OGD)-induced cell death in the 
SH-SY5Y neuroblastoma cell line. This protective role of TG2 is due to its interaction with 
HIF1β and suppression of the HIF1 hypoxic response pathway ( Filiano et al. 2008). 
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Neuronal differentiation 
Considerable progress has been made in understanding the role of TG2 in neuronal 
differentiation. The first study conducted to identify this role was performed by Maccioni and 
Seeds (1986), who reported that TG2 activity increased 10-fold in association with neuronal 
outgrowth during neuroblastoma cell differentiation. In addition, a localisation study of TG2 in 
neuroblastoma cell lines showed that TG2 was predominantly found in the tips of neurites and 
the perinuclear area, suggesting a role in neurite outgrowth (Tucholski et al., 2001). These 
findings indicate that TG2 acts as a positive regulator of neuronal differentiation. Further 
research has demonstrated that inhibition of TG2 blocks neurite outgrowth and the expression 
of neuronal markers (Singh et al., 2003). It has also recently been found that the overexpression 
of active TG2 in neuroblastoma cell lines promotes neurite outgrowth (Tee et al., 2010). The 
possible underlying molecular mechanism has been studied, and it was found for the first time 
that the transamidation of RhoA by TG2 is required for activation of ERK1/2 and p38 MAPK 
pathways, which are involved in neuronal differentiation (Singh et al., 2003). It has been found 
that TG2 contributes to neuronal differentiation by facilitating AC, thereby activating the 
cAMP/CREB pathway, which plays a critical role in neuronal differentiation process 
( Tucholski and Johnson 2003). Various studies have found that TG2 most likely contributes to 
neuronal differentiation by enhancing AC activity; however, further studies are still required to 
identify the clear mechanism by which this occurs. Therefore, one of the research aims of the 
work presented in this thesis was to determine this possible underlying mechanism. 
 The use of In vitro mammalian cell models for the assessment 
of neuronal cell survival and neurite outgrowth 
Neuronal cell signalling is a complex molecular interaction that stimulates the surrounding cell 
components, resulting in the modulation and induction of various cellular processes and 
complicated intermolecular reactions. The capacity of in vitro model systems has changed the 
field of neurobiology and contributed to the understanding of most neuronal cell processes. 
Furthermore, it has produced a useful platform for characterising protein functionality and 
molecular processes associated with specific conditions to understand their pathogenesis and 
implement pharmacological assessments. The ethical issues and economic costs associated with 
animal experiments for neurological studies have encouraged researchers to rely more and more 
on in vitro cell cultures (Gordon et al., 2013). The disadvantages of in vitro cell cultures are that 
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they could show some physiological differences due to lack cell to cell interaction and partial 
manipulation of pharmacokinetic factors (Rice & Barone, 2000). However, this cell culture 
method also has numerous potential advantages, making it suitable for this project. This 
approach can grow cell cultures relatively easily, give unlimited numbers of homogenous cells 
and be easily maintained for long periods of time to conduct assessments with minimal time 
and much lower financial costs (Radio & Mundy, 2008; Flaskos, 2012). Furthermore, it is 
appropriate for assessing cellular, molecular and morphological alterations.  
1.8.1 The mouse N2a neuroblastoma cell line 
The mouse N2a neuroblastoma cell line was derived from the mouse C1300 neuroblastoma 
(Klebe and Ruddle, 1969). Due to its immediate response to stimuli to express signalling 
molecules and to serum deprivation to induce differentiation within a short time, it is broadly 
used to study neuronal differentiation, neurite outgrowth and signalling pathways. Serum 
withdrawal and the addition of retinoic acid (RA) is one method used to differentiate the cells 
into neurons and have them undergo several morphological changes. Upon differentiation, N2a 
cells show a neuron-like morphology, expressing various adrenergic and cholinergic neuronal 
markers (Sajithlal et al. 2002, Klebe and Ruddle, 1969). Furthermore, differentiated N2a cells 
can develop axon-like processes and dendrites and express important axon outgrowth associated 
proteins such as neurofilaments (NFs) and microtubules (MTs; Evangelopoulos et al., 2005; 
Tremblay et al. 2010). All these factors make N2a cells a suitable model for the purpose of this 
study on the screening of cell signalling and morphology alterations. However, appreciation of 
the pharmacological and functional differences between neurons and neuron-like cell lines is 
essential, including an understanding of species–specific differences in some cellular processes 
when compared to humans. Therefore, a human cell line has been also used in the current study, 
as discussed in the following section. 
1.8.2 Human SH-SY5Y neuroblastoma 
Human SH-SY5Y neuroblastoma cells have been cultured and used extensively in neurobiology 
research. They were derived by sub-cloning from the parental metastatic bone tumour cell line 
SK-N-SH, which was generated from bone marrow biopsy. Undifferentiated SH-SY5Y cells 
exhibit a large, flat, epithelial-like phenotype with several short outward extending processes. 
The differentiated cells are morphologically similar to primary neurons, exhibiting numerous 
neurite projections that connect to surrounding cells, as well as long branched processes. In 
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addition, they express various neuronal markers, such as axon growth-associated protein 43 
(GAP-43), NFs and MT-associated proteins (MAPs). SH-SY5Y cells are characterised by 
having a stable karyotype, and they can be differentiated into mature human neurons via 
different approaches, including the use of RA. The use of RA with serum removal induces SH-
SY5Y cells to differentiate into neurons with a dopaminergic phenotype (Presgraves et al., 
2004; Korecka et al., 2013). These differentiated SH-SY5Y neurons are similar to mature 
human neurons found in vivo and provide an appropriate model for understanding cellular 
processes, cell signalling and morphology.  
 Framework and aims of this study 
As discussed previously, the multifunctional enzyme TG2 has a strong relationship with 
hypoxic stress, and its protective role against cell death under ischaemia-like conditions and 
induction of neuronal outgrowth has been reported in the literature (Maccioni and Seeds 1986; 
Filiano et al. 2008; Filiano et al. 2010). It has also been shown that protein kinases, such as PKA 
and PKC, regulate the activity of TG2 via GPCRs to modulate cytoprotection (Almami et al., 
2014). However, not much is known about the GPCRs and signalling pathways involved. It is 
well established that neurotrophic factors, such as PACAP and NGF, stimulate via their 
receptors (PAC1 and TrKA, respectively) signalling pathways including ERK1/2, PKA, PKC 
and Akt, thereby inducing neuronal cell growth and survival. As some of these pathways are 
associated with the modulation of intracellular TG2 activity, it is conceivable that these 
neurotrophic factors directly regulate TG2 activity and induce neuroprotection. Understanding 
the pathways involved in hypoxia stress and the implications they may have for TG2 on 
activation of the PAC1 receptor by PACAP or the TrKA receptor by NGF, would provide a 
clear view as to how this enzyme may be involved in neuroprotection. Accordingly, the aims of 
this study were to investigate the modulation of TG2 by PACAP and NGF via their receptors 
to induce neuronal cell growth and survival. 
In this research, a series of studies is completed with the objective of characterising TG2’s 
ability to modulate neuronal outgrowth and survival via the kinase signalling cascade induced 
by neurotrophic factors (PACAP and NGF) in differentiating N2a mouse neuroblastoma and 
SH-SY5Y human neuroblastoma cells. To begin, the ability of these neurotrophic factors to 
induce TG2 transamidase activity through their receptors is characterised (chapter 4 and 5). 
Next, the neuroprotective potential of PACAP- and NGF-induced TG2 activity following 
exposure of N2a and SH-SY5Y cells to hypoxia is assessed (chapter 6). Finally, high-
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throughput approaches are applied to evaluate the role of PACAP- and NGF-induced TG2 
activity on different neurite outgrowth parameters, such as the average cell number, average 
neurite number, average and maximum neurite length, mean processes and branches per cell 
(chapter 6). 
 Aims of the thesis 
This study had the following experimental aims: 
1. To investigate the modulation of TG2 activity by PACAP via the PAC1 receptor; 
2. To investigate the modulation of TG2 activity by NGF via the TrkA receptor; 
3. To assess the neuroprotective and cell survival potential of PACAP- and NGF-induced 
TG2 activity; 
4. To apply high-throughput approaches to evaluate the involvement of TG2 in PACAP- 
and NGF-modulation of neuronal outgrowth. 
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2 Materials and Methods 
 Materials 
All reagents used in the laboratory were of the highest grade and purchased from Sigma-Aldrich 
Co Ltd (Gillingham, UK) unless otherwise specified.  
2.1.1 Cell culture reagents 
Dulbecco’s modified Eagle’s Medium (DMEM), glucose free DMEM, foetal bovine serum 
(FBS), L- glutamine (200 mM), penicillin (10,000 U/ml)/streptomycin (10,000 µg/ml) and 
trypsin (10 X) were purchased from BioWhittaker Lonza Group Ltd., UK. Phosphate buffered 
saline (PBS) was obtained from Life Technologies (Invitrogen, UK). All-trans retinoic acid was 
obtained from Sigma-Aldrich Co. Ltd (Gillingham, UK).  
2.1.2 Cell lines  
Murine N2a and human SH-SY5Y neuroblastoma cells were obtained from the European 
Collection of Animal Cell Cultures (Porton Down, Salisbury, UK).  
2.1.3 Kinase inhibitors  
Akt inhibitor XI (PKB/Akt, 100 nM; Hu et al., 2000), KT 5720 (PKA, 5 µM; Cabell et al., 
1993), Rp-cAMPs (PKA, 50 µM; Gjertsen et al., 1995) and Ro 31-8220 (PKC, 10 µM; Han et 
al., 2000) were obtained from Calbiochem (San Diego, CA). PD 98059 (MEK1/2, 50 µM; 
Dudley et al., 1995), SB 203580 (p38 MAPK; 20 μM; Davis et al., 2000), and SP 600 125 
(JNK1/2; 20 μM; Bennett et al.,2001) were purchased from Tocris Bioscience (Bristol, UK). 
All protein kinase inhibitors used in this study are listed in Table 2.1. 
 
Materials and Methods  Chapter 2 
44 
 
 
 
 
 
 
 
 
 
2.1.4 Chemical compounds and reagents 
 [Ala11,22,28] VIP, Bay 55-9837, PACAP-27, PACAP 6-38 were obtained from Tocris 
Bioscience (Bristol, UK). Nerve growth factor (NGF) was obtained from Merck Millipore 
(Watford, UK). Casein, N’,N’-dimethylcasein, IBMX (3-isobutyl-1-methylxanthine), IGEPAL, 
MTT (3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), paraformaldehyde, 
TritonTM X-100, Protease Inhibitor Cocktail (AEBSF – [4-(2-aminoethyl) benzenesulfonyl 
fluoride hydrochloride], aprotinin, bestatin hydrochloride, E-64 – [N-(trans-epoxysuccinyl)-L 
leucine 4-guanidinobutylamide], leupeptin hemisulfate salt, pepstatin A), Phosphatase Inhibitor 
Cocktails 2 (sodium orthovanadate, sodium molybdate, sodium tartrate and imidiazole) and 3 
(cantharidin, (–)-p-bromolevamisole oxalate, calyculin A), Ammonium persulphate (APS), 
ExtrAvidin-horseradish Peroxidase (HRP) and ExtrAvidin-FITC were obtained from Sigma-
Aldrich Co. Ltd. (Gillingham, UK). The TG2 inhibitors Z-DON (Z-DON-Val-Pro-Leu-OMe) 
and R283, together with purified guinea-pig liver TG2 were obtained from Zedira GmbH 
(Darmstadt, Germany). VectaShield® containing 4,6-diamidino- 2-phenylinole (DAPI) was 
from Vector Laboratories Inc (Peterborough, UK). Fluo-8/AM was purchased from Stratech 
Scientific Ltd (Newmarket, UK). Biotin-TVQQEL was purchased from Pepceuticals (Enderby, 
UK). Biotin cadaverine (N-(5 aminopentyl)biotinamide) and biotin-X-cadaverine (5-([(N-
(biotinoyl)amino)hexanoyl]amino) pentylamine) were purchased from Invitrogen, UK 
(Loughborough, UK). N,N,N’,N’- tetramethylethylenediamine (TEMED) was from (National 
Diagnostics, USA. 
 
Compound Concentration Target Supplier 
Akt inhibitor XI 1 μM Akt inhibitor  
 
Calbiochem (San Diego, CA) 
 
KT 5720 5 μM PKA inhibitor 
Rp-8-Cl-cAMPS 50 μM PKA inhibitor 
Ro-31-8220 10 μM PKC inhibitor 
PD 98059 50 μM MEK1/2 inhibitor  
 
Tocris Bioscience (Bristol, UK)  
  
SB 203580 30 μM p38 MAPK 
inhibitor 
SP 600 125 20 μM JNK1/2 inhibitor 
Table 2.1 Protein kinase inhibitor compounds used in this study  
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2.1.5 Antibodies 
 
 
 
 
Antibody Dilution 
Western blotting 
Dilution 
Immunocyto
-chemistry 
Molecular 
wt. kDa 
Supplier and 
catalogue 
number 
Monoclonal phospho-specific 
ERK1/2 (Thr202/Tyr204) 
1:1000 - 44-42 Sigma-Aldrich, 
UK, M8159 
Monoclonal anti-total ERK1/2  1:1000 - 44-42 New England 
Biolab, UK, 9107 
Polyclonal phospho-specific PKB  
(Ser473) 
1:1000 - 60 New England 
Biolab, UK, 9271 
Polyclonal anti-total PKB 
 
1:1000 - 60 New England 
Biolab, UK, 9272 
Polyclonal anti-total JNK 
 
1:1000 - 54-46 New England 
Biolab, UK, 9252 
Monoclonal phospho-specific JNK 
(Thr183/Tyr185) 
1:1000 - 54-46 New England 
Biolab, UK, 9251 
Monoclonal phospho-specific p38 
MAPK (Thr180/Tyr182) 
1:1000 - 43 New England 
Biolab, UK, 9216 
Polyclonal anti-total p38 MAPK 1:1000 - 43 New England 
Biolab, UK, 9212 
Monoclonal cleaved caspase-3 
 
1:500 - 19-17 New England 
Biolab, UK, 9661 
Monoclonal anti-TG2 1:1000 - 78 Thermo Scientific 
(CUB 7402) 
Polyclonal anti-TG1 
 
1:1000 - 90 Zedira GmbH 
A018 
Polyclonal anti-TG3 
 
1:1000 - 78 Zedira GmbH 
A015 
Monoclonal anti-α-tubulin 
clone B512 
1:2000 1:100 50 Sigma-Aldrich, 
UK, T6074 
Monoclonal anti-tyrosine  
Hydroxylase 
1:1000 1:200 60 Sigma-Aldrich, 
UK, T1299 
Polyclonal anti-choline 
acetyltransferase 
1:1000 1:200 82 Santa Cruz 
Biotechnology, 
SC20672 
Monoclonal anti-GAPDH 1:1000 - 36 Abcam, Uk, 
ab8245 
 
polyclonal anti-phosphoserine 
 
1:1000 
IP 
- - Abcam 
(Cambridge, UK) 
ab9332 
polyclonal anti-phosphothreonine 
 
1:1000 
IP 
- - Abcam 
(Cambridge, UK) 
ab9337 
 
Table 2.2 Monoclonal and polyclonal primary antibodies 
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 Methods 
2.2.1 Cell culture 
Maintenance of cells  
Mouse N2a cells and human SH-SY5Y cells were grown and maintained as a monolayer in 
DMEM, supplemented with 2 mM L-glutamine, 10% (v/v) FBS, penicillin (100 U/ml) and 
streptomycin (100 µg/ml). Cells were incubated at 37°C in a humidified atmosphere of 95% air 
/5% CO2. 
Sub-culture of cells 
Cells were passaged or sub-cultured when growth reached 70-80% confluence (i.e. every 3-4 
days). On reaching 80% confluence, the cell cultures were either used to seed monolayers on 
cell culture plates for assays, (for example; T75 flasks for Western blot analysis, chamber slides 
for immunofluorescence staining and high throughput screening of neurite outgrowth) or 
passaged to maintain the cell line. N2a cells were mechanically removed from the flask surface 
using a sterile Pasteur pipette to detach the cells by aspirating growth medium and squirting it 
out on the monolayer surface. In contrast, SH-SY5Y cells were passaged by removing the 
growth medium and washing cells with sterile phosphate buffered saline (PBS), then detached 
using trypsin (0.05 % w/v)/EDTA (0.02 % w/v) in PBS. Following trypsinisation, 10 ml of fully 
supplemented DMEM medium were added to the trypsinized cells. Then both suspended N2a 
and SH-SY5Y cells were harvested by centrifugation at 300 x g at room temperature for 5 min. 
The supernatant was discarded, and the cell pellet resuspended in 1 ml of growth medium and 
further sub-cultured (1:5 split ratio). Experiments were performed on passage numbers 8-20 for 
N2a and 18-25 for SH-SY5Y because later passages would be more susceptible to the effect of 
genetic drift. 
Antibody Dilution 
Western 
blotting 
Dilution 
Immunocyto-
chemistry 
Supplier and catalogue number 
Anti-mouse IgG-HRP 1:1000 - Sigma-Aldrich, UK (A4416) 
Anti-rabbit IgG-HRP 1:1000 - Sigma-Aldrich, UK (A0545) 
Anti-mouse-Alexa 568 - 1:500   Molecular Probes (Invitrogen, UK) (A-11031) 
Anti-rabbit-Alexa 568 - 1:500 Molecular Probes (Invitrogen, UK) (A10042) 
ExtrAvidin®-FITC - 1:200 Sigma-Aldrich, UK (E2761) 
 
Table 2.3 Secondary antibodies 
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Counting and plating cells for experimental analysis 
Cells were plated out for experimental analysis when they reached 70-80% confluence in the 
maintenance flasks. Initially, cells were passaged as described in the previous section and, after 
resuspending in 1 ml of the growth medium, automated cell counting carried on using a TC20 
automated cell counter (BioRad, Hemel Hempstead, UK). The device utilised prepared TC20 
Trypan blue dye (0.4% Trypan blue (w/v) in 0.81% (w/v) sodium chloride and 0.06% (w/v) 
potassium phosphate dibasic solution). Trypan blue is a vital stain that differentiates between 
live and dead cells (Wang, 2006). The principle of this dye is based on the blue acid dye 
chromophores which react and are taken up by the internal region of dead (non-viable) cells 
through a damaged membrane, whereas live (viable) cells do not take up this dye. A volume of 
10 μl of cell suspension was added to 10 μl of Trypan blue solution and left for 4 min to allow 
for cells to be exposed to the stain. A volume of 10 μl of this mixture was then loaded into a 
chamber of the counting slide. The slide was inserted into the slide slot of the TC20 cell counter 
and cell counting was automatically initiated as soon as the cell counter detected the presence 
of the slide and Trypan blue dye. Viable cell counts per ml were used to determine the volume 
necessary to seed the cells at a required cell density in growth medium. Cell density of 50,000 
cells/ml was used to plate out mouse N2a cells and 100,000 cells/ml was used for SH-SY5Y 
cells (Table 2.4). Flasks were then incubated at 37oC in a humidified atmosphere of 95% air/5% 
CO2 for 24 h to allow for cell recovery. 
 
 
Differentiation of cells 
Differentiation of N2a cells was induced by culturing cells in serum-free DMEM containing 1 
µM all-trans retinoic acid for 48 h, unless otherwise specified. Differentiation of SH-SY5Y 
cells was induced by culturing cells in serum-free DMEM containing 10 µM all-trans retinoic 
acid for 5 days. The addition of retinoic acid induced N2a and SH-SY5Y cells to develop the 
 
Cell culture dish/plate Loading volume Total cells number 
N2a SH-SY5Y 
T175 flask 50 ml/flask 2,5000,000 5,000,000 
T75 flask 40 ml/flask 2000,000 4,000,000 
T25 flask 10 ml/flask 500,000 1,000,000 
8 well slide 300 μl/well 15,000 30,000 
24 well plate 500 μl/well 25,000 50,000 
96 well plate 200 μl/well 10,000 20,000 
Table 2.4 Cell density for experiments with N2a and SH-SY5Y cells. 
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characteristic phenotype of differentiated neurons with neurite extensions (Tremblay et al., 
2010). 
Measurement of cell differentiation 
Coomassie Brilliant Blue staining  
Differentiation of N2a and SHSY-5Y cells was monitored for morphological change under a 
light microscope (mitotic cells were used as control) using Coomassie Brilliant Blue staining 
solution. Cells were cultured and differentiated as mentioned previously. The growth medium 
was aspirated, and the cells were washed with PBS three times. The cells were then fixed at -
20 °C with 90 % (v/v) methanol solution for 15 min. The methanol fixing solution was then 
removed and Coomassie blue staining solution ((0.1% (w/v) Coomassie brilliant blue G, 50 % 
(v/v) methanol, 10 % (v/v) acetic acid)) was added the cells for 10 min to stain the cells. Staining 
solution was aspirated, and stained cells were washed three times with deionised water and left 
to air dry at room temperature then examined with the aid of a light microscope. Five randomly 
selected fields were examined in each well. Cells showed neuronal-like phenotype and neurite 
extension by forming axon like process in N2a cells and showed consistently slender and longer 
bipolar morphology in SH-SY5Y cells (Biedler et al., 1973). 
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2.2.2  Experimental treatment procedure  
 
Figure 2.1  Flow diagram representing the cell culture, treatment and 
experimental process 
a) Neurotrophic factor (stimulus) treatment (PACAP-27 or NGF). N2a and SH-
SY5Y cells were exposed for 10 or 30 min, respectively, to PACAP-27 or to NGF 
for 1 h in both cell lines. b) TG2 inhibitors were applied for 1 h, and PAC1 receptor 
antagonist and protein kinase inhibitors for 30 min prior to neurotrophic factor 
(stimulus) treatment. 
 
2.2.3 Protein estimation assay 
Protein concentration in cell lysates was measured based on the Bicinchoninic acid (BCA) 
method of Smith et al. (1985) using a commercially available kit (Sigma-Aldrich Co Ltd, 
Gillingham, UK). Bovine serum albumin (BSA) was used as the protein standard. In brief, 
protein standards were prepared using dilutions of 1 mg/ml BSA to produce a linear standard 
curve. Standards (20 µl) and cell lysate samples (20 µl) were added to a 96-well flat-bottomed 
plate in triplicate. A volume of 200 μl of working BCA reagent (50 parts of reagent A to 1 part 
of reagent B) was added to each of the wells and the plate incubated at 37oC for 30 min. 
Absorbance was read at 570 nm using a standard 96-well plate reader. Protein content of 
samples was obtained by measuring them against the BSA standard curve. 
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2.2.4  Tissue transglutaminase activity assays 
Cell extraction for measurement of TG2 activity   
N2a and SH-SY5Y cells were grown in T75 tissue culture flasks and induced to differentiate as 
described in section 2.2.1. Following the treatments, cells were washed twice with ice cold PBS 
and then lysed with 500 μl of ice cold-lysis buffer (50 mM Tris-HCl pH 8.0, containing 0.5% 
(w/v) sodium deoxycholate, 0.1% (v/v) protease inhibitor cocktail and 1% (v/v) phosphatase 
inhibitor cocktails 2 and 3). The cells were incubated in the lysis buffer on ice for 30 min, 
scraped and clarified by centrifugation at 4°C for 10 min at 14000 x g. The supernatant was 
collected and stored at -80°C until assayed for TG transamidase activity. Protein levels were 
determined by BCA protein assay (section 2.2.3). Transglutaminase activity was subsequently 
monitored by two different transamidase assays; amine incorporation and peptide cross-linking.  
Biotin-labeled cadaverine incorporation assay  
The amine incorporating activity of TG2 was measured via biotin-cadaverine incorporation into 
N, N’-dimethylcasein. The assay was performed as per the method described by Slaughter et al. 
(1992) with the modifications of Lilley et al. (1998). Briefly, 96-well microtitre plates were 
coated overnight at 4°C with 250 μl of N′,N′-dimethylcasein (10 mg ml-1 in 100 mM Tris-HCl, 
pH 8.0). The plate was washed twice with distilled water and blocked with 250 μl of 3% (w/v) 
BSA in 100 mM Tris-HCl, pH 8.0 and incubated for 1 h at room temperature with gentle 
agitation. The plate was washed twice with distilled water before the application of 150 µl of 
either 6.67 mM calcium chloride (required for enzyme activity) or 13.3 mM EDTA (used to 
detect background TG activity) assay buffer containing 225 µM biotin cadaverine (a widely 
used substrate to monitor TG amine incorporating activity) and 2 mM 2-mercaptoethanol. The 
reaction was started by the addition of 50 μl of samples or positive control (50 ng/well of guinea-
pig liver TG2) and negative control (100 mM Tris-HCl, pH 8.0). After incubation for 1 h at 
37°C, plates were washed as before. Then, 200 μl of 100 mM Tris-HCl pH 8.0 containing 1% 
(w/v) BSA and ExtrAvidin®-HRP (1:5000 dilution) were added to each well and the plate 
incubated at 37°C for 45 min then washed as before. The plate was developed with 200 μl of 
freshly made developing buffer (7.5 µg ml-1 3,3’,5,5’-tetramethylbenzidine (TMB) and 
0.0005% (v/v) H2O2 in 100 mM sodium acetate buffer, pH 6.0) and incubated at room 
temperature for 15 min. The reaction was terminated by adding 50 μl of 5 M sulphuric acid and 
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the absorbance read at 450 nm. One unit of transglutaminase activity was defined as a change 
in absorbance at 450nm/1 h.  
Biotin-labeled peptide cross-linking assay   
The crosslinking activity of TG2 was measured via biotin-TVQQEL peptide incorporation into 
casein as described by Trigwell et al., (2004) with minor modifications. The 96-well microtitre 
plates were coated and incubated overnight at 4°C with casein at 1.0 mg ml-1 in 100 mM Tris-
HCl pH 8.0 (250 μl per well). The wells were washed twice with distilled water, before being 
blocked with 250 μl of 3% (w/v) BSA in 100 mM Tris-HCl, pH 8.0 and incubated for 1 h at 
room temperature with gentle agitation. The plate was washed twice with distilled water before 
the application of 150 µl of either 6.67 mM calcium chloride and or 13.3 mM EDTA assay 
buffer containing 5 μM biotin-TVQQEL and 2 mM 2-mercaptoethanol. The reaction was started 
by the addition of 50 μl of samples or positive control (50 ng/well of guinea-pig liver TG2) and 
negative control (100 mM Tris-HCl, pH 8.0) and allowed to proceed for 1 h at 37°C. Reaction 
development and termination were performed as described for biotin-cadaverine assays. One 
unit of TG2 activity was defined as a change in absorbance at 450nm/1 h. 
2.2.5 Visualisation of in situ TG2 transamidase activity  
N2a (15,000 cells/well) and SH-SY5Y (30,000 cells/well) cells were seeded on 8-well chamber 
slides and induced to differentiate as described in section 2.2.1. The the medium was then 
removed, and slides incubated for 6 h with 1 mM biotin-X-cadaverine (a cell permeable TG2 
substrate; Perry et al., 1995) in serum-free DMEM before experimentation. Then cells were 
treated as required, washed three times (five min per wash) with PBS, fixed with 3.7 % (w/v) 
paraformaldehyde and permeabilised with 0.1% (v/v) Triton-X100, both in PBS for 15 min at 
room temperature. After washing, cells were blocked with 3% (w/v) BSA in PBS for 1 h at 
room temperature. The transglutaminase mediated biotin-X-cadaverine labeled protein 
substrates were detected by FITC-conjugated ExtrAvidin® (Sigma-Aldrich) (1:200 v/v) in 
blocking buffer. The slides were incubated overnight at 4°C. The next day, cells were washed 
as before and nuclei counter-stained using DAPI in Vectashield mounting medium. The slides 
were sealed with coverslips and secured with clear nail varnish and stored at 4°C until required. 
Images were acquired using a Leica TCS SP5 II confocal microscope (Leica Microsystems, 
GmbH, Manheim, Germany) equipped with a 20x air objective. Optical sections were typically 
1–2 µm; the highest fluorescence intensity values were acquired and fluorescence intensity 
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relative to DAPI stain was quantified for each field of view. Image analysis and quantification 
were carried out using Leica LAS AF software from five fields of view per culture well.  
2.2.6 Visualisation of neuronal markers   
N2a (15,000 cells/well) and SH-SY5Y (30,000 cells/well) cells were seeded on 8-well chamber 
slides and induced to differentiate as described in section 2.2.1. The medium was then removed, 
and the cells washed three times (five min per wash) with PBS, fixed with 3.7 % (w/v) 
paraformaldehyde for 15 min at room temperature then washed three times with 300 μl/well of 
ice cold PBS (2 min/rinse). Then cells were permeabilised with 0.05% (v/v) Triton-X100 in 
PBS, for 15 min at room temperature. Following three further rinses with PBS, non-specific 
binding was prevented by blocking the fixed cells with 500 μl of BSA/PBS per well for 1 h at 
room temperature. Then, cells were incubated overnight at 4oC with rabbit anti-choline 
acetyltransferase antibody or mouse anti-tyrosine hydroxylase antibody all diluted 1:200 in 3% 
(w/v) BSA/PBS. Unbound primary antibody was then removed, and the cells washed three 
times for 5 min with PBS. Cells were then incubated for 2 h at room temperature with either 
goat anti-mouse or anti-rabbit FITC-conjugated immunoglobulin G (Abcam, Cambridge, UK) 
diluted 1:1000 in 3% (w/v) BSA/PBS. The chamber slide was subsequently washed three times 
for 5 min with PBS, air-dried and mounted with Vectashield mountant (Vector Laboratories 
Ltd, Peterborough, UK) containing DAPI counterstain for nuclei visualisation. Finally, slides 
were sealed using clear, colourless nail varnish and stained cells visualised using a Leica TCS 
SP5 II confocal microscope (Leica Microsystems, GmbH, Manheim, Germany) equipped with 
a 20x air objective. Optical sections were typically 1-2 µm; the highest fluorescence intensity 
values were acquired and fluorescence intensity relative to DAPI stain was quantified for each 
field of view. Image analysis and quantification were carried out using Leica LAS AF software.   
2.2.7 cAMP accumulation assay 
N2a (5,000 cells/well) and SH-SY5Y (10,000 cells/well) cells were plated in 96-well microtitre 
plates, with clear bottomed wells (Corning; Fisher Scientific, Loughborough, UK) and induced 
to differentiate as described in section 2.2.1. The medium was then removed, and the cell 
monolayer treated with the neurotrophic (100nM PACAP-27) in serum-free DMEM (50 
µl/well) in the presence of 20 mM MgCl2 and 500 µM 3-isobutyl-1-methylxanthine (IBMX).  
Following stimulation, cAMP levels within cells were determined using the cAMPGloTM Max 
Assay kit (Promega; Southampton, UK). Briefly, following cell treatment, 10 µl of cAMP 
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detection solution were added to all wells and incubated for 20 min at room temperature. After 
incubation, Kinase- Glo® reagent (50 µl/well) was added and incubated for 10 min at room 
temperature, following which luminescence levels across the plate were recorded using a plate-
reading FLUOstar Optima luminometer (BMG Labtech Ltd, UK,). Treatment with forskolin 
(10 µM) was used as a positive control and the luminescence values were converted to cAMP 
levels using a cAMP standard curve (0-100 nM), according to the manufacturer’s instructions. 
2.2.8 Measurement of intracellular calcium 
N2a (25,000 cells/well) and SH-SY5Y (50,000 cells/well) cells were plated in 24-well flat-
bottomed plates and induced to differentiate as described in section 2.2.1. Cells were loaded with 
Fluo-8 AM; a cell-permeable medium affinity green fluorescent calcium binding dye, diluted 
1:2000 in imaging buffer (134 mM NaCl, 6 mM KCl, 1.3 mM CaCl2, 1 mM MgCl2, 10 mM 
HEPES, and 10 mM glucose; pH 7.4) for 30 min before mounting on the stage of a Leica TCS 
SP5 II confocal microscope (Leica Microsystems, GmbH, Manheim, Germany) equipped with 
a 20x air objective. Cells were incubated at 37°C using a temperature controller and micro 
incubator (The Cube, Life Imaging Services, Basel, Switzerland) in the presence of imaging 
buffer (134 mM NaCl, 6 mM KCl, 1.3 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, and 10 mM 
glucose; pH 7.4). Using an excitation wavelength of 490 nm, emissions over 514 nm were 
recorded. Images were collected every 1.7 s for 10 min. Increases in intracellular Ca2+ were 
defined as F/F0 where F was the fluorescence at any given time, and F0 was the initial basal 
level of fluorescence. 
2.2.9 One dimensional polyacrylamide gel electrophoresis (SDS- PAGE) and 
Western blotting 
To examine the activation or the expression of the proteins of interest, SDS- PAGE and Western 
blotting were employed. 
Preparation of cell lysates for SDS-PAGE and Western blot analysis 
N2a and SH-SY5Y cells were grown in T75 tissue culture flasks and induced to differentiate as 
described in section 2.2.1. Following the treatments, serum free medium was carefully removed, 
and cells washed twice with PBS (room temperature). Cell monolayers were then subjected to 
500 μl of boiling sodium dodecyl sulphate buffer (0.5% w/v SDS in Tris buffered saline) after 
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which cells were removed by a scraper from the flask surface and collected in 1.5 ml 
Eppendorf™ tubes, boiled for 10 min and then allowed to cool to room temperature for 10-15 
min. The lysates were stored at -20°C until use. The amount of protein presentin each sample 
was then estimated by BCA assay (section 2.2.3).  
Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Once the protein concentration of the samples was determined, the desired amount of protein 
was diluted in a 3:1 ratio with 4x reducing Laemmli buffer (8 % w/v SDS, 40 % (v/v) glycerol, 
10 % (v/v) β-mercaptoethanol, 0.01 % (w/v) bromophenol blue, 250 mM Tris- HCl pH 6.8; 
Laemmli, (1970)) and boiled for 10 min at 95°C to denature the proteins. Based on the molecular 
weight of the investigated proteins, a 10% (w/v) acrylamide resolving gel was prepared for all 
experiments. The gels were prepared according to manufacturer’s instructions (Geneflow Ltd, 
Staffordshire, UK). The resolving gel is also called separating gel, which separates the proteins 
by size. A Bio-Rad mini-PROTEAN III™ electrophoresis chamber was used. Two glass plates 
with combs and spacers of 1.5 mm thickness were used. The 10% (w/v) acrylamide resolving 
gel mixture was prepared according to the required number of gels, as indicated in Table 2.5. 
Acrylamide polymerisation was initiated by the addition of the volumes indicated of 10 % (w/v) 
APS (Ammonium persulfate in deionised water) and TEMED (N,N,N’,N’-
tetramethylethylenediamine), after which the mixture was swirled gently. For each gel, about 8 
ml of resolving gel mixture was transferred into the glass cast to allow sufficient space for a 
stacking gel to be added later. Distilled water was carefully overlaid on the top layer of the 
freshly poured gel mixture to create a smooth interface and prevent any gel shrinkage. The gel 
mix was allowed to polymerise at room temperature for approximately 30 to 40 min. Once the 
resolving gel had polymerised, water was removed, the required amount of 4% (w/v) 
polyacrylamide stacking gel was prepared and polymerised by the adding of 10% APS and 
TEMED as indicated in Table 2.5. The stacking gel is used because it allows proteins entry and 
accumulation at its interface with the resolving gel. Immediately after the stacking gel was 
poured, a plastic comb was placed to form the sample wells. Following polymerisation, the gels 
were placed in the electrophoretic tank to which electrophoresis buffer (0.01 % (w/v) SDS, 2.5 
mM Tris, 19.2 mM glycine, pH 8.3) was added. The protein samples (15-20 µg/well) were 
loaded along with 5 μl of protein ladder (BioRad, Hemel Hempstead, UK, 1610374). 
Electrophoresis was conducted at 120 V through the stacking gel and then at 160 V through the 
resolving gel. 
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Western blotting 
Proteins were transferred to nitrocellulose membranes in a Bio-Rad Trans-Blot system. A set 
up of a wet transfer was performed, with the blotting cassettes set up as follows; pre-wet sponge 
- filter paper - gel- nitrocellulose membrane filter - filter paper – pre-wet sponge. The layers 
were then placed into a Western blotting cassette and closed gently to avoid air bubbles and 
placed in the transfer tank that contained chilled transfer buffer (25 mM Tris, 192 mM glycine 
pH 8.3 and 20% (v/v) MeOH). Proteins were transferred at 100 V for 1 h. After electrotransfer 
of the proteins, the nitrocellulose membrane was stained by Ponceau red stain (Sigma-Aldrich 
Co Ltd, Gillingham, UK) to confirm protein transfer from the gel. The membranes were washed 
with Tris-buffered saline (TBS) then blocked for 1 h at room temperature with 3% (w/v) 
skimmed milk powder in TBS containing 0.1% (v/v) Tween-20 with mild agitation.  Blocking 
is essential to prevent non-specific binding of the antibodies to the membrane in subsequent 
steps. Blots were then incubated overnight with gentle agitation at 4°C in blocking buffer 
containing one of the following primary antibodies (1:1000 unless otherwise stated): Phospho-
specific ERK1/2, phospho-specific JNK (1:500), phospho-specific p38 MAPK (1:500), 
phospho-specific PKB (1:500), cleaved active caspase-3 (1:200), Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), TG1, TG2, TG3, anti-phosphoserine or anti-phosphothreonine 
(Table 2.2). After incubation, the primary antibodies were removed, and blots washed three 
times for 5 min in TBS/Tween 20. After washing, blots were probed with the appropriate 
(1:1000) horseradish peroxidase (HRP)-conjugated secondary antibodies (New England 
Biolabs Ltd; Hitchin, UK) for 2 h at room temperature in blocking buffer (Table 2.3). Following 
 
Reagent 
Volume (for 2 gels) 
10% (w/v) acrylamide 
resolving gel  
4% (w/v) acrylamide 
stacking gel 
30% (w/v) acrylamide: bisacrylamide (37.5:1) 6.66 ml 1.3 ml 
Protogel® Resolving buffer 
(1.5 M Tris-HCl buffer pH 8.8, 0.4% (w/v) SDS) 
5 ml - 
Protogel® stacking buffer 
(0.5 M Tris-HCl buffer pH 6.8, 0.4% (w/v) SDS) 
- 2.5 ml 
deionised water 8.12 ml 6.1 
10 % (w/v) Ammonium persulfate (APS) solution 200 μl 50 μl 
TEMED 20 μl 10 μl 
 
Table 2.5 Preparation of SDS-PAGE gels 
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removal of the secondary antibody, blots were extensively washed as above and developed 
using the Enhanced Chemiluminescence Detection System (Uptima, Interchim, France). Images 
of the blots were captured by the LAS 4000 system and the bands were quantified by 
densitometry using Advanced Image Data Analysis software (AIDA) (Fuji; version 3.52). All 
band densities were measured and corrected for background, then normalised to band densities 
for internal control. Data are expressed as a percentage of the average value of the peak area 
compared to its corresponding control ± SEM. To confirm uniform protein loading in the gel 
primary antibodies specific to GAPDH were used.  
2.2.10 Immunoprecipitation analysis of TG2 phosphorylation 
Immunoprecipitation (IP) was used to monitor the phosphorylation status of TG2 under 
different conditions.  
Preparation of cell lysates 
Briefly, N2a and SH-SY5Y cells were grown in T175 tissue culture flasks and induced to 
differentiate as described in section 2.2.1. Following treatments, cells were washed twice with 
ice cold PBS. The cells were then scraped, collected in 5 ml of PBS and subjected to 
centrifugation at 300 x g at room temperature for 5 min. Cells were then washed by suspending 
the cell pellet in PBS followed by centrifugation at 300 x g at room temperature for 5 min to 
pellet cells. The supernatant was discarded and the cell pellet resuspended in 500 μl of ice cold 
lysis buffer (2 mM EDTA, 1.5 mM MgCl2, 10% (v/v) glycerol, 0.5% (v/v) IGEPAL, 0.1% (v/v) 
protease inhibitor cocktail (AEBSF–[4-(2-aminoethyl) benzenesulfonyl fluoride 
hydrochloride], aprotinin, bestatin hydrochloride, E-64 – [N-(trans-epoxysuccinyl)-L leucine 4-
guanidinobutylamide], leupeptin hemisulfate salt, pepstatin A), and 1% (v/v) phosphatase 
inhibitor cocktail 2 (sodium orthovanadate, sodium molybdate, sodium tartrate and imidiazole) 
and 3 (cantharidin, (–)-p-bromolevamisole oxalate, calyculin A). The cells were incubated with 
lysis buffer for 30 min and then clarified by centrifugation at 4°C for 10 min at 14000 x g. The 
supernatant was collected and transferred to a new Eppendorf tube for protein estimation and 
further analysis. 
Preparation of the Immune complex 
A total of 500 µg of protein (cell lysate) was incubated overnight at 4°C with 2 μg of anti-TG2 
monoclonal antibody (CUB 7402) or non-specific IgG using an Eppendorf tube revolver.  
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Precipitation of the Immune complex 
Immune complexes were precipitated using a Pierce™ Classic Magnetic IP/Co-IP kit (Thermo 
Scientific, Loughborough, UK). The eluted proteins were resolved by SDS-PAGE in a 10 % 
polyacrylamide gel and levels of TG2 bound phosphoserine and phosphothreonine assessed via 
Western blotting using anti-phosphoserine or anti-phosphothreonine antibodies. The blots were 
developed using the ECL detection system and quantified by densitometry, as described in 
section 2.2.6.  
2.2.11 Assessing the protection against hypoxia 
Stimulation of hypoxia 
Differentiating N2a and SH-SY5Y cells in glucose-free and serum-free DMEM (Gibco™, Life 
Technologies Ltd, Paisley, UK) were exposed to 8 h hypoxia (except for time interval 
experiments) using a hypoxic incubator (5% CO2/1% O2 at 37°C) in which O2 was replaced by 
N2. Normoxic incubation of cells at similar passage numbers were used as controls. Cells were 
treated as required in serum-free DMEM prior to it being replaced with glucose-free and serum-
free DMEM for the hypoxic/normoxic incubation. 
Cell viability assessment 
1. MTT reduction assay  
Cell viability was determined by measuring the activity of cellular dehydrogenases via MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide) reduction assay (Mosmann, 
1983). MTT is a tetrazolium dye that is converted to water-insoluble purple formazan on the 
reductive cleavage of its tetrazolium ring by the respiratory enzyme succinate dehydrogenase 
in active mitochondria and by other cellular dehydrogenases. The assay was used to assess cell 
viability after exposure to hypoxia under different pharmacological treatments. N2a (25,000 
cells/well) and SH-SY5Y (50,000 cells/well) cells were plated in 24-well flat-bottomed plates 
and induced to differentiate as described in section 2.2.1 Cells were exposed to hypoxia and 
required treatment and cell viability subsequently determined by incubating with 0.5 mg/ml 
MTT at 37 °C for 1 h prior to completion of periods of hypoxia. After completion of this final 
hour, the medium in each well was carefully aspirated, and replaced with 500 µl of DMSO. The 
plate was then gently agitated to ensure sufficient dissolution of the water-insoluble purple 
formazan crystals. After that, 200 μl of the resultant solution was transferred into a 96-well plate 
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and the absorbance of the solutions was read at 570 nm using a standard 96-well plate reader. 
The absorbance of the blank (DMSO) was subtracted from each sample absorbance reading and 
the viability of the cells is directly proportional to the basal MTT reduction, which determined 
by the absorbance of the solubilized formazan product at 570 nm. 
 
2. Lactate dehydrogenase (LDH) assay 
Cytotoxicity induced by hypoxia was also assessed by lactate dehydrogenase (LDH) release 
into the culture medium. The LDH assay was performed according to the manufacturer’s 
instructions using a CytoTox 96® non-radioactive cytotoxic assay kit (Promega, Southampton, 
UK). The assay is a colorimetric assay based on the measurement of LDH release from damaged 
tissue that catalyses the conversion of lactate to pyruvate via reduction of NAD+ to NADH. 
Then, the dehydrogenase enzyme diaphorase (present in the substrate mix in the kit) coupled 
with NADH results in the formation of a red formazan product tetrazolium salt (INT). Thus, the 
amount of LDH released is proportional to the red formazan product. N2a (5,000 cells/well) and 
SH-SY5Y (10,000 cells/well) cells were plated in 96-well flat-bottomed plates and induced to 
differentiate as described in section 2.2.1 Following exposure to hypoxia and required 
treatment, the plate was centrifuged (5 min, 300 x g) to allow cellular debris to be compacted 
to the bottom of the wells. A volume of 50 µl of the supernatant was then transferred to a new 
non-sterile 96 well plate and 50 µl of the reconstituted assay buffer (10 ml assay buffer added 
to one bottle of substrate mix, in kit) added to each sample well. The plate was then covered 
with foil and incubated at room temperature for 30 min using a mixer shaker. After that, a 
volume of 50 µl of assay stop solution (1 M acetic acid) was added to stop the reaction. The 
change in absorbance was monitored at 490 nm using a standard plate reader. 
 
3. Caspase-3 activation 
N2a and SH-SY5Y cells were grown in T75 tissue culture flasks and induced to differentiate as 
described in section 2.2.1. Where appropriate, treatments were performed in the respective 
medium, which was replaced with glucose-free and serum-free DMEM for the 8 h incubation 
under hypoxic conditions. Following incubations, cells were lysed and subjected to Western 
blotting to detect cleaved caspase-3 (Section 2.2.9). 
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2.2.12 High-throughput analysis 
The role of TG2 in neurite outgrowth involving PACAP and NGF in N2a and SH-SY5Y cells 
was further determined using the ImageXpress Micro Widefield High Content Analysis System 
(Molecular Devices, Wokingham, UK). This technique permits rapid assessment of the effects 
of a wide range of pharmacological treatments at different concentrations on multiple 
parameters of neurite outgrowth. The screening system integrates an inverted epifluorescence 
microscope combined with automated image acquisition and analysis software to quantify 
different subcellular measurements of neurite outgrowth such as cell count, neurite count, 
neurite length and cell body area (Smith and Eisenstein, 2005). 
Briefly, cells were seeded on 8-well Ibidi μ-slides: 15,000 cells/well for N2a and 30,000 
cells/well for SH-SY5Y and cultured for 24 h in fully supplemented DMEM. Where 
appropriate, cells were treated for 1 h with TG2 inhibitors Z-DON (150 μM) or R283 (200 μM) 
or for 30 min with the PAC1 receptor antagonist PACAP 6-38 (100nM). The medium containing 
the previous treatment was removed and replaced with fresh medium before the addition of 
either 100 nM PACAP-27 or 100 ng/ml NGF for 48 h. Following stimulation, cells were fixed 
with 3.7 % (w/v) paraformaldehyde for 15 min at room temperature then washed three times 
with 300 μl/well of ice cold PBS (2 min/rinse). Then cells were permeabilised with 0.05% (v/v) 
Triton-X100 in PBS, for 15 min at room temperature. After three further rinses with PBS, cells 
were blocked with 3% (w/v) BSA in PBS for 1 h at room temperature. Cells were then stained 
overnight at 4˚C with monoclonal primary antibodies to total α-tubulin (B512) diluted 1:1000 
in BSA/PBS after which primary antibody was removed and the monolayers washed 3 times 
for 2 min with TBS. This was followed by incubation with Alexa Fluor®488 goat anti-mouse 
IgG labelled secondary antibody diluted 1:500 in BSA/PBS for 2 h at room temperature. The 
slides were subsequently washed three times for 5 min with PBS and incubated for 1 min with 
Vectashield mountant (Vector Laboratories Ltd, Peterborough, UK) containing DAPI 
counterstain for nuclei visualisation.  Slides were preserved in PBS containing 0.01% (w/v) 
sodium azide as a preservative and stored at 4˚C prior to image acquisition and analysis. Neurite 
outgrowth was monitored using an ImageXpress® Micro Widefield High Content Screening 
(HCS) System (Molecular Devices, Wokingham, UK). Fluorescence images were acquired 
using a 10× objective lens in order to acquire all neurites in one field of view, thus enabling 
more reliable analysis of neurite outgrowth. The acquired images were then segmented by multi-
coloured tracing masks on neurites and cell bodies. Segmentation masks were generated using 
the MetaXpress imaging and analysis software (version 5.1.0.46; Molecular devices, USA), 
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where each neurite segment is given the same coloured mask as that of their parent neuronal 
cell bodies. The segmentation images were then analysed by the neurite outgrowth module 
integrated within the MetaXpress imaging and analysis software, to measure a number of 
morphological parameters including average number of cells/field, average cell body area/cell, 
neurite length/cell, mean processes/cell, mean branches/cell, percentage of cells with significant 
outgrowth and average intensity of staining within the positive cells. Particles from each image 
were identified as cells if valid nuclei width between 5 to 10 µm had been detected and cell 
body width ranged from 15 to 20 μm. Outgrowth was recorded as significant when minimum 
cell outgrowth was more than 10 μm (approximately half a cell body diameter in length). 
Analysis was performed on a total of four fields and at least 200 cells per well from four 
independent experiments.  
2.2.13 Statistical analysis 
All graphs and statistics (one-way ANOVA followed by Dunnet's multiple comparison test and 
two-way ANOVA for group comparison) were performed using GraphPad Prism® software 
(GraphPad Software, Inc., USA). All sets of data were based on a minimum of four separate 
experiments and expressed as mean ± standard error of the mean (SEM) and p values <0.05 
were considered statistically significant. 
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3 Characterisation of N2a and SH-SY5Y neuroblastoma 
cells 
 Introduction 
The mouse N2a and human SH-SY5Y neuroblastoma cell lines have been widely used as a 
suitable in vitro model to study cell signalling pathways, differentiation, neurite outgrowth and 
molecular mechanisms associated with neuronal apoptosis (Li et al., 2007; Kim et al., 2011; 
Sahu et al., 2013; Murillo et al., 2017; Pirou et al. 2017). N2a and SH-SY5Y cells can be induced 
to differentiate and develop into a more mature neuron-like phenotype following serum 
withdrawal and retinoic acid (RA) treatment (Pahlman et al., 1984; Mao et al., 2000; Sajithlal 
et al., 2002; Korecka et al., 2013). Differentiating N2a and SH-SY5Y cells were chosen as 
model systems in this study for assessing the possible molecular intervention of TG2 in 
neurotrophic factor-induced neurite outgrowth and cell survival function. 
N2a mouse neuroblastoma cells have a rapid and reproducible potential to differentiate within 
a few hours of serum withdrawal (Evangelopoulos et al., 2005). However, eﬀects may be 
observed that could be unique to the species due to lack of a human component, genetic drift or 
clonal/species-related eﬀects. Therefore, it is essential to use a more homogenous, consistent 
model of human neurological system to avoid these variations. To validate this research 
observations were also made in a human-species-related cell model, namely human SH-SY5Y 
neuroblastoma cells. SH-SY5Y cells were derived from a neuroblastoma patient’s bone marrow 
biopsy, and the cell line can be induced to differentiate into neuronal like phenotypes (Biedler 
et al., 1973). Differentiating SH-SY5Y cells have been widely used as a model for in vitro 
experiments requiring neuron-like cells (Ross et al., 1983). 
It is critical to ensure that the in vitro neuronal system used properly differentiates into neurons 
to generate data that represent the best possible approximation of what could happen in neurons 
in vivo. Several mechanisms exist for inducing cultured neuronal cells to differentiate in vitro; 
RA treatment is the most widespread, successful technique (Mao et al., 2000; Shipley et al., 
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2016). Inducing cells to differentiate using RA involves several processes, including the 
formation and extension of axonal processes and expression of neuron-specific enzymes (Adem 
et al., 1987; Mao et al., 2000; Tremblay et al., 2010). Furthermore, RA can drive N2a and SH-
SY5Y cells toward various mature neuronal phenotypes involving cholinergic, adrenergic and 
dopaminergic neurons (Zimmermann et al., 2004; Cheung et al., 2009; Lopes et al., 2010; 
Tremblay et al., 2010; Korecka et al., 2013). The specific neuronal phenotype induced in 
response to RA treatment in N2a and SH-SY5Y cells is still unclear. Thus, it was essential to 
characterise the molecular phenotype of differentiating N2a and SH-SY5Y cells as an initial 
step in this research. 
The first aim of the work in this chapter was to define the RA-induced differentiation of N2a 
and SH-SY5Y cells morphologically and biochemically. Prior to investigating the possible 
modulation of TG2 activity by the neurotrophic factors PACAP and NGF, it was also important 
to examine whether TG2 and other neuronally expressed TG isoforms (TG1 and TG3) were 
expressed in RA-induced differentiating N2a and SH-SY5Y cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characterisation of N2a and SH-SY5Y cells  Chapter 3 
63 
 
  Results 
3.2.1 Morphological characterisation of N2a and SH-SY5Y cells 
N2a and SH-SY5Y neuroblastoma cells were induced to differentiate into a more neuron-like 
phenotype by treatment with 1 µM and 10 µM RA, respectively, as described in section 2.2.1. 
After the required period of differentiation, the cells were stained with Coomassie Brilliant 
Blue, and cell morphology was assessed microscopically (section 2.2.1). As shown in Figure 
3.1, after 24 h under normal culture conditions, mitotic N2a cells grew as round neuroblasts. 
N2a cells responded to serum withdrawal and RA treatment (48 h). As shown in Figure 3.1B, 
the differentiating N2a cells underwent morphological changes by developing axon-like 
processes and dendrites. Undifferentiated SH-SY5Y cells were characterised by elongated cell 
bodies and short neurite-like processes, as shown in Figure 3.2. In contrast, differentiating SH-
SY5Y cells treated with 10 µM RA displayed extended long, branched processes (Figure 3.2). 
These changes in the morphological parameters of mouse and human neuroblastoma cells 
treated with RA combined with serum deprivation all suggest the differentiation into a neuron-
like phenotype in both cell lines. 
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Figure 3.1  Light microscopy examination of morphological differentiation of N2a 
cells. 
Images represent cellular morphologies viewed with the aid of an inverted light 
microscope. A) Mitotic N2a cells (24 h/DMEM 10% (v/v)-foetal bovine serum) grow as 
round neuroblasts. B) Differentiating N2a cells (48 h/1 μM RA serum-free DMEM) 
exhibit neurite extensions (red arrow). Images were visualised using a 20× objective lens. 
Scale bar = 100 μm. 
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Figure 3.2  Light microscopy examination of morphological differentiation of SH-
SY5Y cells. 
Images represent cellular morphologies viewed with the aid of an inverted light 
microscope. A) Mitotic SH-SY5Y cells (24 h/DMEM 10% (v/v) foetal bovine serum) 
show short branched processes. B) Differentiating SH-SY5Y cells (5 days/10 μM RA 
serum-free DMEM) display neurite extensions (arrow). Images were visualised using 
a 20× objective lens. Scale bar = 100 μm 
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3.2.2 Characterisation of the neuronal phenotypes of N2a and SH-SY5Y 
cells 
A substantial body of evidence indicates that the use of different methods to induce N2a and 
SH-SY5Y cell differentiation can select for specific neurotransmitter phenotypes, such as 
dopaminergic and cholinergic neurons (Pahlman et al., 1984; Xie et al., 2010). Thus, the 
characterisation of the specific neuronal phenotype induced on the induction of differentiation 
of N2a and SH-SY5Y by using RA should be considered when using these cells for in vitro 
studies. After exhibiting successful differentiation by RA into a more mature neuron-like 
morphological phenotype in the previous section, the next aim was to investigate RA’s effect 
on the specific neuronal phenotype markers, namely tyrosine hydroxylase (TH) for the 
dopaminergic and choline acetyl transferase (ChAT) for the cholinergic neuronal marker. 
Changes in the protein expression levels of these neuronal markers in mitotic and RA-
differentiating N2a and SH-SY5Y were assessed by Western-blot analysis. As shown in Figure 
3.3, the quantitative values showed a significant increase in the expression of the cholinergic 
neuronal marker ChAT in RA-differentiating N2a cells and the dopaminergic neuronal marker 
TH in differentiating SH-SY5Y cells compared with the mitotic cells. The data were confirmed 
by immunocytochemistry, whereby the changes in the fluorescence intensity of ChAT and TH 
were compared between mitotic and RA-differentiating N2a and SH-SY5Y cells, as shown in 
Figure 3.4. The observations illustrated a significant increase in the fluorescence intensity of 
ChAT in differentiating N2a cells and TH in differentiating SH-SY5Y cells compared with 
undifferentiated cells (Figure 3.4). These findings agree with the data revealed by Western blot 
analysis. 
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Figure 3.3  Expression of choline acetyltransferase and tyrosine hydroxylase in 
differentiating neuroblastoma cells. 
A) N2a and B) SH-SY5Y cells were differentiated with retinoic acid in serum-free 
medium. Expression levels of cholinergic and dopaminergic neuronal protein biomarkers 
were assessed by Western blot analysis using anti-choline acetyltransferase (ChAT) 
antibody (cholinergic neuronal marker) and anti-tyrosine hydroxylase (TH) antibody 
(dopaminergic and noradrenergic neuronal marker). Cell lysates were also analysed on 
separate blots for GAPDH expression to confirm equal protein loading. Quantified data 
are expressed as the ratio of the TG isoform to GAPDH and represent the mean ± SEM 
from three independent experiments.  **p < 0.01 versus control (mitotic) cells. 
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Figure 3.4  Immunocytochemical analysis of neuronal markers in differentiating 
neuroblastoma cells. 
A) N2a and B) SH-SY5Y cells were induced to differentiate with retinoic acid in 
serum-free medium. Immunocytochemistry was performed via fluorescence 
microscopy using anti-choline acetyltransferase (ChAT) antibody (cholinergic 
neuronal marker; green) and anti-tyrosine hydroxylase (TH) antibody (dopaminergic 
and noradrenergic neuronal marker; green) and DAPI counterstain for visualisation of 
nuclei (blue). Images presented are from one experiment and are representative of 
three assays. Quantified immunocytochemistry data represent the mean ± SEM. of 
fluorescence intensity relative to DAPI stain for five fields of view each from three 
independent experiments. ****p < 0.0001 versus mitotic cells. 
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3.2.3 Characterisation of TG expression patterns in N2a and SH-SY5Y cells 
To elucidate the expression patterns of the TG isoforms that are most susceptible to expression 
in neuronal cells (Kim et al., 1999; Condello et al., 2008), Western blot analysis was performed 
to compare the expression of TG isoforms in mitotic and RA-differentiating N2a and SH-SY5Y 
cells. TG1, TG2 and TG3 expression were detected in both mitotic and differentiating N2a cells 
(Figure 3.5). This suggests that not only TG2, but also TG1 and TG3 isoforms exist in 
differentiating N2a cells. In addition, the observations showed a significant increase in the 
expression of the three isoforms in N2a cells after RA-induced differentiation. In SH-SY5Y 
cells, Western blot analysis revealed that mitotic SH-SY5Y cells expressed comparable levels 
of TG1, TG2 and TG3, and only TG2 expression significantly increased following RA-induced 
differentiation (Figure 3.6). 
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Figure 3.5  TG isoform expression in differentiating N2a neuroblastoma cells. 
Protein expression of TG isoforms in mitotic and differentiating N2a cells. Cell lysates 
from mitotic (M) and differentiating (D) N2a cell lysates were analysed for TG1, TG2 
and TG3 expression by Western blotting using TG isoform-specific antibodies. Cell 
lysates were also analysed on separate blots for GAPDH expression to confirm equal 
protein loading, and 0.1 ng from purified enzymes was used as positive control. 
Quantified data are expressed as the ratio of TG isoform to GAPDH and represent the 
mean ± SEM from three independent experiments. **p < 0.01, ***p < 0.001 and ****p 
< 0.0001 versus control (mitotic) cells. 
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Figure 3.6  TG isoform expression in differentiating SH-SY5Y neuroblastoma cells. 
Protein expression of TG isoforms in mitotic and differentiating N2a cell lysates from 
mitotic (M) and differentiating (D) SH-SY5Y cell lysates were analysed for TG1, TG2 
and TG3 expression by Western blotting using TG isoform-specific antibodies. Cell 
lysates were also analysed on separate blots for GAPDH expression to confirm equal 
protein loading, and 0.1 ng from purified enzymes was used as positive control. 
Quantified data are expressed as the ratio of TG isoform to GAPDH and represent the 
mean ± SEM from three independent experiments. **p < 0.01, ***p < 0.001 and ****p 
< 0.0001 versus control (mitotic) cells. 
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  Discussion 
3.3.1 Assessment of the differentiating N2a- and SH-SY5Y neuron-like 
phenotype  
N2a and SH-SY5Y neuroblastoma cells have been widely used in neuroscience research, and 
they are accepted as reliable models for neuronal cells in their differentiating form. In some 
cases, undifferentiated cells are used; however, the assessment is complicated because of cell 
replication and division during the experimental processing. Hence, the first part of this study 
aimed to characterise and validate the effect of the most widely used differentiation agent all-
trans RA on cell morphology and neuronal markers. The current study showed the detailed 
characteristics of RA-differentiating N2a and SH-SY5Y cellular morphology, the 
immunocytochemistry and molecular expression of dopaminergic (e.g. TH) and cholinergic 
(e.g. ChAT) neuronal markers. The findings confirm that the N2a and SH-SY5Y neuroblastoma 
cells were induced to differentiate into well-established neuron-like phenotypes. 
Mouse N2a and human SH-SY5Y neuroblastoma cells can be induced to differentiate by 
different methods, such as using dibutyryl cyclic AMP (Kuramoto et al., 1981; Kume et al., 
2008; Tremblay et al., 2010) and all-trans RA (Pahlman et al., 1984; Manabe et al., 2005; 
Cheung et al., 2009). RA is an efficient differentiation factor; it was used in the current study to 
avoid potential problems with using dibutyryl cAMP when assessing functional responses 
mediated by the Gs-protein-coupled PAC1 receptor. Morphologically, N2a cells exhibited 
considerable long extending axon-like processes induced by RA and fully visible neurite 
extension was observed in the SH-SY5Y cells. These findings suggest similar processes to those 
exhibited in earlier work, whereby RA enhanced the differentiation of N2a and SH-SY5Y 
neuroblastoma cells into well-established neuron-like cells (Encinas et al., 2000; Wu et al., 
2009; Tremblay et al., 2010; Korecka et al., 2013).  
Previous studies have suggested that differentiation of N2a cells into different neuronal 
phenotypes depends on the method used (Manabe et al., 2005; Tremblay et al., 2010). For 
example, serum withdrawal in the presence of RA induces differentiation into cholinergic 
neurons, whereas dibutyryl cAMP promotes the development of dopaminergic neurons 
(Manabe et al., 2005; Tremblay et al., 2010). In the current study, the immunocytochemical 
staining indicated that the expression of the cholinergic neuronal marker, choline acetyl-
transferase (ChAT) increased markedly after 48 h, confirming that RA promotes differentiation 
of N2a cells into a cholinergic neuronal phenotype (Figure 3.4). Moreover, as shown in Figure 
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3.3, Western blot analysis demonstrated that differentiating N2a cells highly expressed ChAT 
protein and lacked expression of TH. These findings agree with many previous in vitro studies 
demonstrating that RA treatment enhances cholinergic characteristics in N2a cells (Berrard et 
al., 1993; Pedersen et al., 1995; Zeller and Strauss 1995; Hill and Robertson 1997; Kornyei et 
al., 1998; Malik et al., 2000; Personett et al., 2000; Chu et al., 2003). 
The effects of the differentiation process induced by RA in SH-SY5Y cells were similarly 
investigated. Using RA to induce neuron-like differentiation in human neuroblastoma SH-
SY5Y cells is a widely applied method (Kaplan et al., 1993; Kito et al., 1997); however, to date, 
there is no consensus in the profiling of the developed specific neuronal phenotype (Korecka et 
al., 2013). The observed increases in the immunocytochemical staining intensity and Western 
blot analysis of TH, together with the lack of a statistically significant effect on ChAT, revealed 
that RA induces differentiation of SH-SY5Y cells into the dopaminergic neuronal phenotype. 
These findings agree with a great majority of studies that aimed to characterise the neuronal 
phenotype of RA-differentiating SH-SY5Y. Tyrosine hydroxylase, the dopaminergic neuronal 
marker, has been previously demonstrated to be highly expressed in RA-differentiating SH-
SY5Y cells, suggesting the development of a dopaminergic neuronal phenotype (Presgraves et 
al. 2004; Cheung et al. 2009). Although the current study and others confirm that RA induced 
this cell line to differentiate into a dopaminergic neuron-like phenotype (Lopes et al., 2010), 
some studies claim that in SH-SY5Y cells RA enhances the cholinergic-specific neuronal 
phenotype (Adem et al., 1987; Zimmermann et al., 2004).  
3.3.2 Characterisation of TG expression patterns in differentiating 
neuroblastoma cells 
 The mouse and human differentiating neuroblastoma cell models employed in the current study 
are suitable for studying the molecular events associated with neuronal survival and neurite 
outgrowth (Li et al., 2007; Kim et al., 2011; Sahu et al., 2013; Pirou et al. 2017; Murillo et al. 
2017). To assess the role of TG2 in the neurotrophic activity of PACAP and NGF, it was 
necessary as an initial step in this research to investigate which TG isoform(s) are expressed in 
the differentiating neuroblastoma cells. In the current study, the expression patterns of TG1, 
TG2 and TG3 – the transglutaminase members predominantly expressed in neuronal tissue 
(Kim et al. 1999; Condello et al. 2008) – were assessed. The presented findings confirmed the 
differential nature of TG1, TG2 and TG3 expression in neuroblastoma cells. 
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Previously, the presence of TG activity in the nervous system was reported (Thomázy & Fésüs, 
1989; Reichelt & Poulsen, 1992; Facchiano et al., 1993; Johnson et al., 1997).  Most of these 
activities were attributed to the TG2 isoform, since TG2 is the enzyme member of the 
transglutaminase family that has been identified as the most abundant isoform expressed in the 
adult human brain (Thomázy & Fésüs, 1989). Although TG2 is the most abundant isoform that 
has been identified in neuronal tissue, the differential expression of other transglutaminase 
isoforms, namely TG1 and TG3, has also been reported (Facchiano et al., 1993; Kim et al., 
1999; Lesort et al. 2000; Condello et al., 2008). In the current study, Western blot analysis was 
performed to compare the expression of TG isoforms in mitotic and differentiating N2a cells. 
TG1, TG2 and TG3 expression increased significantly in N2a cells following differentiation for 
48 h with all-trans RA (Figure 3.5). These observations are in agreement with those of previous 
studies (Condello et al., 2008; Currò et al., 2009). Furthermore, the findings revealed that 
mitotic SH-SY5Y cells expressed comparable levels of TG1, TG2 and TG3, but only TG2 
expression significantly increased following RA-induced differentiation (Figure 3.6). Multiple 
studies have confirmed the expression of TG2 in SH-SY5Y cells (Tucholski et al., 2001; Singh 
et al., 2003; Joshi et al., 2006; Filiano et al., 2008); however, there is no evidence on relating 
TG1 and TG3 to this cell line. 
In conclusion, the results presented in this chapter indicate that N2a and SH-SY5Y cells 
differentiate into cholinergic and dopaminergic neuronal phenotypes, respectively, following 
treatment with RA. Furthermore, data presented confirms the expression of the TG2 isoform in 
both cell lines and its increase on cell differentiation. 
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4 Modulation of TG2 activity by PACAP in 
differentiating neuroblastoma cells 
 Introduction 
Pituitary adenylate cyclase–activating polypeptide (PACAP) is a neurotrophic factor that has 
neuroprotective activity arising through activation of the pituitary adenylate cyclase type 1 
receptor (PAC1). This receptor belongs to the glucagon/ secretin family of GPCR. Previous 
studies have shown that the PAC1 receptor is widely expressed in the brain (Vaudry et al., 2000; 
Jolivel et al., 2009) and modulates neurite outgrowth activity through signalling cascade 
initiated by PACAP (Deutsch and Sun, 1992; Kambe and Miyata 2012). In the central nervous 
system (CNS), activation of the PAC1 receptor stimulates Gs and Gq proteins, leading to 
activation of adenylyl cyclase/cAMP/PKA and phospholipase C/DAG/PKC signalling 
pathways, respectively (Dickson & Finlayson, 2009; Vaudry et al., 2009). Moreover, PACAP 
has long been known to activate PKA, ERK1/2 and p38 MAPK signalling cascades, which 
contribute to its neuroprotective eﬀect (Vaudry et al., 2009). However, very little is known about 
the specific signal transduction pathways that mediate this neuroprotective activity. It has been 
found previously that the multifunctional enzyme transglutaminase 2 (TG2) protects neuronal 
cells against cell death under ischaemia-like conditions (Filiano et al., 2008). Also, the activity 
of TG2 and other TG family members can be regulated by protein kinases. For example, it has 
been shown that protein kinases, such as PKA and PKC, regulate the activity of TG2 (Almami 
et al., 2014). Furthermore, phosphorylation of TG2 by protein kinase A (PKA) inhibits its 
transamidating activity but enhances its kinase activity (Mishra et al., 2007). The transamidating 
activity of TG1 (keratinocyte transglutaminase) is enhanced by phorbol ester-induced 
stimulation of PKC and ERK1/2 (Bollag et al., 2005). These findings suggest that the activity 
of TG can be regulated by signalling pathways associated with GPCRs. Indeed, examples 
include muscarinic receptor-mediated increases in TG2 activity in SH-SY5Y cells (Zhang et al., 
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1998), 5-HT2A receptor-mediated transamidation of Rac1 in the rat A1A1v cortical cell line (Dai 
et al., 2008) and β2-adrenoceptor and A1 adenosine receptor-mediated increases in TG2 
transamidase activity in rat H9c2 cardiomyoblasts (Vyas et al., 2016; Vyas et al., 2017). 
However, the regulation of intracellular TG2 following stimulation of GPCRs is not well 
understood. Since some of these protein kinase pathways are associated with PACAP-induced 
signalling cascades (PKA, PKC and ERK1/2) it is conceivable that the PAC1 receptor regulates 
TG activity. The majority of studies have focused on the regulation of TG by different protein 
kinases (Bollag et al., 2005; Mishra et al., 2007; Almami et al., 2014). However, little work has 
been done regarding molecular mechanisms implicit in this regulation.   
Therefore, the aims of the current study were to investigate the modulation of TG2 by PACAP 
via the PAC1 receptor and identify the possible signalling pathways involved using 
diﬀerentiated neuroblastoma cells. To achieve this aim, the effect of the highly selective PAC1 
receptor agonist PACAP-27 on modulation of TG2 activity was investigated using TG2 
transamidase activity assays and immunofluorescence visualisation. Also, the possible 
molecular mechanisms underlying this modulation has been investigated by assessing the 
protein kinases involved. 
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 Results 
4.2.1 Functional expression of PAC1 receptor in differentiating N2a and SH-
SY5Y cells 
The expression of PAC1 receptor in N2a and SH-SY5Y cells has been previously 
investigated (Lelièvre et al., 1998; Monaghan, MacKenzie, Plevin, & Lutz, 2008). In this study 
the functional expression of the PAC1 receptor was initially assessed and confirmed using 
a cAMP accumulation assay (section 2.2.8) and calcium imaging (section 2.2.9).  
PAC1 receptor mediated cAMP accumulation and calcium signalling 
cAMP accumulation assays measuring cellular levels of cAMP are dependent on the activity of 
adenylyl cyclase, which is regulated by GPCRs coupled to Gαs or Gαi/o protein (Milligan & 
Kostenis, 2006). Gαs positively stimulates the activity of adenylate cyclase, resulting in 
increased cellular cAMP. As shown in Figure 4.1, PACAP-27 induced a robust increase in 
cAMP accumulation in N2a cells (EC50 = 4.0 ± 1.3 nM; p[EC]50= 8.5 ± 0.2; n=3; Figure 
4.1 A) and SH-SY5Y cells (EC50 = 0.28 ± 0.25 nM; p[EC]50= 9.4 ± 0.7; n=3; Figure 4.1 
B). These findings confirm the activation of Gs protein signalling via the PAC1 receptor by 
PACAP-27 and confirm the functional expression of PAC1 receptor in differentiating N2a 
and SH-SY5Y cells. Further experiments were performed to assess whether the PAC 1 
receptor triggers intracellular Ca2+ responses in differentiating N2a and SH-SY5Y cells, 
which would be indicative of Gq protein coupling. Calcium imaging experiments revealed 
that PACAP-27 (100 nM) also triggered a robust increase in intracellular Ca2+ in differentiating 
N2a cells (Figure 4.2 A and B) that was abolished in the absence of extracellular Ca2+ (Figure 
4.2 C), ATP (10 μM) was added where indicated as a positive control. The findings suggesting 
that these responses were dependent upon extracellular Ca2+ influx. Similar responses were 
made in the differentiating SH-SY5Y cells (Figure 4.3).  Overall, these data indicate that the 
PAC1 receptor is functionally expressed in differentiating mouse N2a and human SH-SY5Y 
cells.  
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Figure 4.1  PACAP-27-induced cAMP accumulation in differentiating N2a and SH-
SY5Y cells. 
Differentiating N2a and SH-SY5Y cells were treated with the indicated concentrations 
of PACAP-27 for 10 min. Levels of cAMP were determined as described in section 2.2.7. 
The results represent the mean ± S.E.M. of three experiments each performed in 
triplicate. Forskolin (10 μM) stimulation was used as a positive control. *P<0.05, 
**P<0.01, ***P<0.001, and ****P<0.0001 versus control (unstimulated cells) response. 
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Figure 4.2  Effect of PACAP-27 on [Ca2+]i in differentiating N2a cells. 
(A) Confocal imaging snapshots of PACAP (100 nM) and ATP (10 µM)-induced Ca2+ 
responses in the presence of extracellular Ca2+ (1.3 mM). The panel letters (a-d) 
correspond to the time points shown in (B). (C) Ca2+ responses to PACAP were absent 
in experiments performed in nominally Ca2+-free buffer and 0.1 mM EGTA. In these 
experiments depletion of intracellular Ca2+ stores with thapsigargin (5 µM) was still 
evident. In (D) responses to PACAP-27 (100 nM) in the presence of extracellular Ca2+ 
and pre-treated with PAC1 receptor antagonist PACAP 6-38 (100 nM). ATP (10 μM) 
was added where indicated as a positive control. Similar results were obtained in three 
other experiments. 
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Figure 4.3  Effect of PACAP-27 on [Ca2+]i in differentiating SH-SY5Y cells. 
(A) Confocal imaging snapshots of PACAP (100 nM) and ATP (10 µM)-induced Ca2+ 
responses in the presence of extracellular Ca2+ (1.3 mM). The panel letters (a-d) 
correspond to the time points shown in (B). (C) Ca2+ responses to PACAP were absent 
in experiments performed in nominally Ca2+-free buffer and 0.1 mM EGTA. In these 
experiments depletion of intracellular Ca2+ stores with thapsigargin (5 µM) was still 
evident. In (D) responses to PACAP-27 (100 nM) in the presence of extracellular Ca2+ 
and pre-treated with PAC1 receptor antagonist PACAP 6-38 (100 nM). ATP (10 μM) was 
added where indicated as a positive control. Similar results were obtained in three other 
experiments. 
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4.2.2 Effect of PACAP-27 on TG2-mediated biotin cadaverine incorporation 
and protein cross-linking activity  
Initial experiments in this study investigated whether the PAC1 receptor agonist PACAP-27 
induced modulation of TG2-mediated amine incorporation and peptide cross-linking activity in 
differentiating N2a and SH-SY5Y neuroblastoma cells. Cells were treated with PACAP-27 (100 
nM) for varying periods of time and cell lysates subjected to the biotin cadaverine incorporation 
assay and biotin-labelled peptide (Biotin-TVQQEL) cross-linking assay (section 2.2.4). 
PACAP-27 treatment produced transient increases in TG2 catalysed biotin-cadaverine 
incorporation and protein cross-linking activity, peaking at 10 min in N2a cells (Figure 4.4 A 
and B) and 30 min in SH-SY5Y cells (Figure 4.5 A and B). Furthermore, various concentrations 
of PACAP-27 were tested for their ability to modulate TG2 activity. As shown in Figure 4.4 C 
and D, PACAP-27 stimulated concentration-dependent increases in biotin-cadaverine 
incorporation activity (EC50 = 0.08 ± 0.01 nM; p[EC50] = 10.1 ± 0.1; n=5) and protein cross-
linking activity (EC50 = 0.4 ± 0.2 nM; p[EC50] = 9.7 ± 0.2; n=6) in N2a cells. In SH-SY5Y 
cells (Figure 4.5 C and D) PACAP-27 also triggered concentration-dependent increases in both 
biotin-cadaverine incorporation activity (EC50 = 2.2 ± 1.0 nM; p[EC50] = 8.9 ± 0.4; n=3) and 
protein cross-linking activity (EC50 = 1.3 ± 0.5 nM; p[EC50] = 9.0 ± 0.2; n=3). Overall, these 
data indicate that PACAP-27 triggers a marked increase in TG2 biotin-cadaverine incorporation 
and protein cross-linking activity in neuroblastoma cells. 
Since PACAP-27 also acts as a VAPC1 and VAPC2 receptor agonist (Vaudry et al. 2009), 
testing of its selectivity for the PAC1 receptor in modulating TG2 activity in differentiating N2a 
and SH-SY5Y cell lines was required. The eﬀects of various concentrations of [Ala1,22,28]VIP 
(Ala-VIP; a potent and highly selective agonist for VPAC1 receptor) and Bay 55-9837 (a 
selective VPAC2 receptor agonist) on TG2 activity were assessed (Nicole et al., 2000, Dickson 
et al., 2006, Vaudry et al. 2009). As shown in Figure 4.6, no noticeable stimulation of TG2 
activity was shown with Ala-VIP or Bay 55-9837 in both differentiating neuroblastoma cell 
lines. Furthermore, those selective VAPC1 and VAPC2 receptor agonists had no significant 
effect on cAMP accumulation (Figure 4.7). Thus, it appears likely that this TG2 activity is 
mediated principally through the PAC1 receptor. 
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Figure 4.4  Effect of PACAP-27 on TG2 activity in N2a cells. 
Differentiating N2a cells were either incubated with 100 nM PACAP-27 for the 
indicated time periods or for 10 min with the indicated concentrations of PACAP-27. 
Cell lysates were then subjected to the biotin-cadaverine incorporation (A and C) or 
peptide cross-linking assay (B and D). Data points represent the mean TG speciﬁc 
activity ± S.E.M. from four (A and C), ﬁve (B) or six (D) independent experiments. *P 
< 0.05, **P <0.01, ***P < 0.001, and ****P < 0.0001 versus control response. 
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Figure 4.5  Effect of PACAP-27 on TG2 activity in SH-SY5Y cells. 
Differentiating SH-SY5Y cells were either incubated with 100 nM PACAP-27 for the 
indicated time periods or for 30 min with the indicated concentrations of PACAP-27. 
Cell lysates were then subjected to the biotin-cadaverine incorporation (A and C) or 
peptide cross-linking assay (B and D). Data points represent the mean TG specific 
activity ± S.E.M. from four (A and B) or three (C and D) independent experiments. 
*P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 versus control response. 
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Figure 4.6  Eﬀect of VAPC1 and VAPC2 agonist on TG2 activity in differentiating 
N2a and SH-SY5Y cells. 
Cells were treated with increasing concentrations of Ala-VIP (panels A-D) and Bay55-
9837 (panels E-H) for 10 min. Cell lysates were subjected to biotin cadaverine 
incorporation assay (A, C, E and G) or peptide crosslinking assay (B, D, F and H). 
PACAP-27 (100 nM, 10 min) stimulation was used as a positive control. Data points 
represent the mean of TG2-speciﬁc activity ±SEM from four to six independent 
experiments. **P<0.01 and ****P<0.0001 versus basal TG2 activity. 
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Figure 4.7 Eﬀect of VAPC1 and VAPC2 agonists on cAMP accumulation in 
differentiating N2a and SH-SY5Y cells. 
Cells were treated with increasing concentrations of Ala-VIP (panels A and C) and 
Bay55-9837 (panels B and D) for 10 min. Levels of cAMP were determined as described 
in (section 2.2.7). PACAP-27 (100 nM, 10 min) stimulation was used as a positive 
control. Data points represent the mean of TG2-speciﬁc activity ±SEM from four to six 
independent experiments. ****P<0.0001 versus basal TG2 activity. 
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4.2.3 Effect of PAC1 receptor antagonist and TG2 inhibitors on PACAP-27-
induced TG2 activity 
To determine whether the induced TG2 activity was via the PAC1 receptor, differentiating N2a and 
SH-SY5Y cells were treated for 30 min with PAC1 receptor selective antagonist PACAP 6-38 (100 
nM) prior to stimulation with 100 nM PACAP-27. PACAP 6-38 attenuated PACAP-27 induced 
TG2 biotin-cadaverine incorporation and protein crosslinking activity in differentiating N2a 
(Figure 4.8 A and B) and SH-SY5Y cells (Figure 4.9 A and B), confirming the involvement of the 
PAC1 receptor. 
To confirm that TG2 was responsible for PAC1 receptor-mediated transglutaminase activity in 
differentiating N2a and SH-SY5Y cells, two structurally different cell permeable TG2 specific 
inhibitors were tested; R283 (a small molecule; Freund et al., 1994) and Z-DON (peptide-based; 
Schaertl et al., 2010). Cells were pre-treated for 1 h with Z-DON (150 µM) or R283 (200 µM) prior 
to stimulation with PACAP-27 (100 nM) for 10 min (N2a) and 30 min (SH-SY5Y). Both inhibitors 
completely blocked PACAP-27-induced TG-mediated amine incorporation and peptide cross-
linking activity in both cell lines (Fig. 4.8 C and D and Fig. 4.9 C and D). It is important to note 
that, despite these TG2 inhibitors being cell-permeable, inhibition of cellular TG2 is only achieved 
at concentrations significantly above their IC50 value (Z-DON 150 nM and R283 1 μM) versus 
purified enzyme (Freund et al., 1994; Schaertl et al., 2010). Overall, these data indicate that TG2 
is the TG isoform activated by the PAC1 receptor. 
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Figure 4.8  Effect of the selective PAC1 receptor antagonist PACAP 6-38 and 
inhibitors of TG2 on PACAP-27 induced TG2 activity in differentiating N2a cells. 
Differentiated N2a cells were pre-treated for 1 h with the TG2 inhibitors Z-DON (150 
µM) and R283 (200 µM) or for 30 min with the selective PAC1 receptor antagonist 
PACAP 6-38 (100 nM) prior to 10 min stimulation with PACAP-27 (100 nM). Cell 
lysates were then subjected to the biotin-cadaverine incorporation (panels A and C) or 
protein cross-linking assay (panels B and D). Data points represent the mean TG specific 
activity ± S.E.M. from four independent experiments. *P<0.05, ***P<0.001, and 
****P<0.0001, (a) versus control and (b) versus 100 nM PACAP-27 alone.   
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Figure 4.9  Effect of the selective PAC1 receptor antagonist PACAP 6-38 and 
inhibitors of TG2 on PACAP-27 induced TG2 activity in differentiating SH-SY5Y 
cells. 
Differentiating SH-SY5Y cells were pre-treated for 1 h with the TG2 inhibitors Z-DON 
(150 µM) and R283 (200 µM) or for 30 min with the selective PAC1 receptor antagonist 
PACAP 6-38 (100 nM) prior to 30 min stimulation with PACAP-27 (100 nM). Cell 
lysates were then subjected to the biotin-cadaverine incorporation (panels A and C) or 
peptide cross-linking assay (panels B and D). Data points represent the mean TG 
specific activity ± S.E.M. from four independent experiments. **P<0.01 and 
***P<0.001, (a) versus control and (b) versus 100 nM PACAP-27 alone. 
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4.2.4 The effect of protein kinase inhibitors on PACAP-27 induced TG2 
activity 
PACAP-27-induced TG2 activity in differentiating N2a and SH-SY5Y cells may involve the 
modulation of pro-survival and/or other signalling pathways. Hence, in this section the role of 
protein kinases in PAC1 receptor-induced TG2 activity was determined.  
Effect of PACAP-27 on protein kinase activation 
Modulation of protein kinase activity following PAC1 receptor activation by PACAP-27 was 
assessed by Western blot analysis using phospho-specific antibodies that recognise 
phosphorylated motifs within activated ERK1/2 (pT202EpY204), p38 MAPK (pT180GpY182), JNK 
(pT183pPy185) and PKB (S473). PACAP-27 (100 nM) stimulated significant increases in ERK1/2 
and PKB phosphorylation in differentiating N2a (Figure 4.10 A and B) and SH-SY5Y cells 
(Figure 4.10 C and D). As expected PACAP-27-mediated increases in ERK1/2 and PKB 
phosphorylation were inhibited by PD 98059 (50 µM; MEK1/2 inhibitor) and Akt inhibitor XI 
(0.1, 1 µM and 10 µM; PKB inhibitor), respectively in both cell lines (Figure 4.10). 
Furthermore, PACAP-27 significantly increased JNK1/2 phosphorylation in differentiating N2a 
cells but no significant increase was observed in SH-SY5Y cells (Figure 4.11 A and C). Finally, 
p38 MAPK was significantly activated by PACAP-27 in differentiating SH-SY5Y cells but not 
in N2a cells (Figure 4.11 B and D). As depicted PACAP-27-mediated increases in JNK1/2 
phosphorylation were inhibited by SP 600125 (20 µM; JNK1/2 inhibitor; Figure 4.11 B) in N2a 
cells only while SB 203580 (20 µM; p38 MAPK inhibitor; Figure 4.11 D) reversed the 
activation of p38 MAPK induced by PACAP-27 in SH-SY5Y cells only.  
Role of PKA, PKC and Ca2+ in PACAP-27 induced ERK1/2 activation 
Since activation of ERK1/2 by phosphorylation is a major and central regulatory event in neurite 
outgrowth and cell survival in PC12 (Ravni et al., 2006), N2a (Biernat et al., 2002) and SHSY-
5Y cells (Monaghan et al., 2008) therefore it was of interest to examine the effect of other 
protein kinase inhibitors on PACAP-27 induced ERK1/2 phosphorylation. As it has been 
previously reported that PKA can activate ERK1/2 (Emery & Eiden, 2012; Clason et al., 2017), 
the effect of the PKA inhibitor KT 5720 (5 µM) on PACAP-27 induced ERK1/2 
phosphorylation was assessed. As shown in Figure 4.12 A and 4.13 A, PACAP-27–induced 
increases in ERK1/2 were attenuated by KT 5720 in both cell lines, suggesting an up-stream 
role of PKA in PACAP-27 induced ERK1/2 activation. PAC1 receptor-induced ERK1/2 is 
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dependent on Ca2+ influx and PLC/DAG/PKC (Vaudry et al., 2009) and hence the role of PKC 
and Ca2+ was determined. PACAP-27–induced increases in ERK1/2 were partially attenuated 
by Ro 31-8220 (10 µM; PKC inhibitor; Figure 4.12 B) in N2a and showed no significant effect 
in SH-SY5Y cells (Figure 4.13 B). Finally, removal of extracellular Ca2+ in both cell lines did 
not block PACAP-27 induced ERK1/2 activation (Figure 4.12 C and 4.13 C). 
In summary, these data have shown that PAC1 receptor activation by PACAP-27 in 
differentiating N2a and SH-SY5Y cells triggers robust increases in phosphorylation of ERK1/2, 
PKB, JNK1/2 (N2a cells only) and p38 MAPK (SH-SY5Y cells only) and that ERK1/2 
activation is PKA-dependent in both cell lines.  
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Figure 4.10  Effect of PACAP-27 on ERK1/2 and PKB phosphorylation in 
differentiating N2a and SH-SY5Y cells.   
Where indicated N2a and SH-SY5Y cells were pre-treated for 30 min with PD 98059 (50 
µM) or Akt inhibitor X1 (0.1 µM, 1 µM or 10 µM) prior to stimulation with PACAP-27 
(100 nM) for 10 min (N2a) and 30 min (SH-SY5Y). Cell lysates were analysed by 
Western blotting for activation of ERK1/2 (panels A and C) and PKB (panels B and D) 
using phospho-specific antibodies. Samples were subsequently analysed on separate 
blots using antibodies that recognize total ERK1/2 and PKB. Quantified data are 
expressed as the percentage of the value for control cells (=100%) in the absence of 
protein kinase inhibitor and represent the mean ± S.E.M. of four independent 
experiments. **P<0.01, ***P<0.001 and ****P<0.0001, (a) versus control and (b) versus 
100 nM PACAP-27. 
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Figure 4.11  Effect of PACAP-27 on JNK 1/2 and p38 MAPK phosphorylation in 
differentiating N2a and SH-SY5Y cells.   
Where indicated N2a and SH-SY5Y cells were pre-treated for 30 min with SP 600 125 
(20 µM) or SB 203580 (20 µM) prior to stimulation with PACAP-27 (100 nM) for 10 
min (N2a) and 30 min (SH-SY5Y). Cell lysates were analysed by Western blotting for 
activation of JNK1/2 (panels A and C) and p38 MAPK (panels B and D) using phospho-
specific antibodies. Samples were subsequently analysed on separate blots using 
antibodies that recognize total JNK1/2 and p38 MAPK. Quantified data are expressed 
as the percentage of the value for control cells (=100%) in the absence of protein kinase 
inhibitor and represent the mean  S.E.M. of four independent experiments. **P<0.01 
and ****P<0.0001, (a) versus control and (b) versus 100 nM PACAP-27. 
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Figure 4.12  Effect of protein kinase inhibitors (PKA and PKC) and role of 
extracellular Ca2+ on PACAP-27 induced ERK1/2 activation in differentiating 
N2a cells. 
Where indicated differentiating N2a cells were pre-treated for 30 min with (A) KT 
5720 (5 µM) or (B) Ro 318220 (10 µM) prior to stimulation with PACAP-27 (100 nM) 
for 10 min. (C) cells were stimulated for 10 min with PACAP-27 (100 nM) either in 
the presence (1.8 mM CaCl2) or absence of extracellular Ca2+ (nominally Ca2+-free 
Hanks/HEPES buffer containing 0.1 mM EGTA). Cell lysates were analysed by 
Western blotting for activation of ERK1/2 using a phospho-specific antibody. Samples 
were subsequently analysed on separate blots using an antibody that recognizes total 
ERK1/2. Quantified data are expressed as the percentage of the value for control cells 
(=100%) in the absence of protein kinase inhibitor or presence of extracellular Ca2+ 
and represent the mean  S.E.M. of four independent experiments. *P<0.05 and 
****P<0.0001, (a) versus control and (b) versus 100 nM PACAP-27. 
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Figure 4.13  Effect of protein kinase inhibitors (PKA and PKC) and role of 
extracellular Ca2+ on PACAP-27 induced ERK1/2 activation in differentiating 
SH-SY5Y cells. 
Where indicated differentiating SH-SY5Y cells were pre-treated for 30 min with (A) 
KT 5720 (5 µM) or (B) Ro 318220 (10 µM) prior to stimulation with PACAP-27 (100 
nM) for 30 min. (C) cells were stimulated for 30 min with PACAP-27 (100 nM) either 
in the presence (1.8 mM CaCl2) or absence of extracellular Ca2+ (nominally Ca2+ -free 
Hanks/HEPES buffer containing 0.1 mM EGTA). Cell lysates were analysed by 
Western blotting for activation of ERK1/2 using a phospho-specific antibody. Samples 
were subsequently analysed on separate blots using an antibody that recognizes total 
ERK1/2. Quantified data are expressed as the percentage of the value for control cells 
(=100%) in the absence of protein kinase inhibitor or presence of extracellular Ca2+ and 
represent the mean  S.E.M. of four independent experiments. **P<0.01and 
****P<0.0001, (a) versus control and (b) versus 100 nM PACAP-27. 
Modulation of TG2 activity by PACAP in neuroblastoma cells Chapter 4 
95 
 
Eﬀect of protein kinase inhibitors on PACAP-27-induced TG2 activity 
The role ERK1/2, PKA, PKB, PKC, p38 MAPK and JNK1/2 in PACAP-27-induced TG2 
activation was determined using pharmacological inhibitors of these protein kinases. Pre-
treatment with PD 98950, Akt inhibitor XI and PKA inhibitors (KT 5720; 5 µM or Rp-cAMPs; 
50 µM), completely abolished PACAP-27-induced amine incorporation and peptide cross-
linking activity, confirming the involvement of ERK1/2, PKB and PKA respectively, in 
PACAP-27-mediated TG2 responses in differentiating N2a and SH-SY5Y cells (Figure 4.14 
and 4.15). In N2a cells the JNK1/2 inhibitor SP 6000125 attenuated PACAP-27-induced peptide 
cross-linking activity (Figure 4.16 B) but was without effect on TG2-mediated amine 
incorporation (Figure 4.16 A). In SH-SY5Y cells SP 600125 had no significant effect either of 
the TG2 activities (Figure 4.16 C and D). The PKC inhibitor Ro 318220 blocked PACAP-27- 
induced TG2 activities in N2a cells but not in SH-SY5Y cells (Figure 4.16). Finally, the p38 
MAPK inhibitor SB 203580 showed no effect on PACAP-27-induced TG2 activation in either 
cell line (Figure 4.16).  
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Figure 4.14  Effect of protein kinase inhibitors (ERK1/2 and PKB) on PACAP-27-
induced TG2 activity in differentiating N2a and SH-SY5Y cells. 
Differentiating N2a and SH-SY5Y cells were pre-treated for 30 min with PD 98059 (50 µM) 
or Akt inhibitor XI (100 nM) prior to stimulation with PACAP-27 (100 nM) for 10 min 
(N2a) and 30 min (SH-SY5Y). Cell lysates subjected to biotin-cadaverine incorporation 
(panels A and C) or peptide cross-linking assay (panels B and D). Data points represent the 
mean ± S.E.M. TG specific activity from four independent experiments. ** P<0.01, 
***P<0.001 and **** P<0.0001, (a) versus control and (b) versus 100 nM PACAP-27 alone. 
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Figure 4.15  Effect of PKA inhibitors on PACAP-27-induced TG2 activity in 
differentiating N2a and SH-SY5Y cells. 
Differentiating N2a and SH-SY5Y cells were pre-treated for 30 min with KT 5720 (5 
µM) or Rp-3’,5’-cAMPs (50 µM) prior to stimulation with PACAP-27 (100 nM) for 10 
min (N2a) and 30 min (SH-SY5Y). Cell lysates subjected to biotin-cadaverine 
incorporation (panels A and C) or peptide cross-linking assay (panels B and D). Data 
points represent the mean ± S.E.M. TG specific activity from four independent 
experiments. *P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001, (a) versus control 
and (b) versus 100 nM PACAP-27 alone. 
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Figure 4.16  Effect of protein kinase inhibitors (PKC, JNK 1/2 and p38 MAPK) on 
PACAP-27-induced TG2 activity in differentiating N2a and SH-SY5Y cells. 
Differentiating N2a and SH-SY5Y cells were pre-treated for 30 min with Ro 31-8220 
(10 µM), SP 600 125 (20 µM) or SB 203580 (20 µM) prior to stimulation with PACAP-
27 (100 nM) for 10 min (N2a) and 30 min (SH-SY5Y). Cell lysates subjected to biotin-
cadaverine incorporation (panels A and C) or peptide cross-linking assay (panels B and 
D). Data points represent the mean ± S.E.M. TG specific activity from four independent 
experiments. *P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001, (a) versus control 
and (b) versus 100 nM PACAP-27 alone. 
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It was important to assess the effect of the compounds used in this study; PACAP-27, PACAP 
6-38, Ala-VIP, Bay55-9837 and protein kinase inhibitors on purified guinea pig liver TG2 
activity. TG2 amine incorporating and peptide crosslinking assays were carried out using 
purified guinea pig liver TG2 (50 ng/ well) after incubated with the indicated concentrations of 
the compounds for 30 min then, subjected to the biotin-cadaverine incorporation or peptide 
cross-linking assays. As shown in Figure 4.17 the compounds used in this study had no 
significant effect on purified guinea pig liver TG2 activity. Overall, these data suggest that the 
activating of PAC1 receptor with PACAP-27 stimulates TG2 activity in differentiating N2a and 
SH-SY5Y cells via a multi protein kinase-dependent pathway. 
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Figure 4.17  Effect of compounds used in this study on purified guinea pig liver TG2 
activity. 
TG2 amine incorporating (A) and peptide crosslinking (B) assays were carried out using 
purified guinea pig liver TG2 (50 ng/ well). Briefly, 50 ng of purified guinea pig liver 
TG2 was incubated with concentrations of the compounds as indicated for 30 min prior 
to 1 h incubation in presence of either 6.67 mM calcium chloride or 13.3 mM EDTA 
containing 225 μM biotin-cadaverine and 2mM 2-mercaptoethanol. Following 
incubation, the plates were processed as described in section 2.2.4 of chapter 2. Data 
points represent the mean ± S.E.M. TG2 specific activity from 4 independent experiments 
at basal level of purified guinea pig liver TG2 (control 100%). 
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4.2.5 The role of Ca2+ in PACAP-27 induced TG2 activity 
Since TG2 is a Ca2+-dependent enzyme, it was of interest to investigate the role of extracellular 
Ca2+ in TG2 activation. This was achieved by monitoring PACAP-27 induced TG2 activity in 
the absence of extracellular Ca2+ using nominally Ca2+-free Hanks/HEPES buffer containing 
0.1 mM EGTA. Removal of extracellular Ca2+ abolished PACAP-27-induced TG2 activation in 
differentiating N2a (Figure 4.18 A and B) and SH-SY5Y cells (Figure 4.18 C and D). In order 
to assess the role of intracellular Ca2+ in TG2 activities, differentiated cells were pre-treated 
with the Ca2+ chelator (BAPTA-AM, 50 µM) for 30 min in the absence of the extracellular Ca2+ 
prior to stimulation with PACAP-27 and measurement of TG2 activities. PACAP-27-induced 
TG2 activities were not further affected by Ca2+ chelating in the absence of extracellular Ca2+ 
(Figure 4.18). These observations suggest that PAC1 receptor-induced TG2 activation is 
dependent upon extracellular Ca2+. 
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Figure 4.18  The role of intracellular and extracellular Ca2+ in PACAP-27-induced 
TG2 activity in differentiating N2a and SH-SY5Y cells. 
Differentiating cells were treated with PACAP-27 for 10 min (N2a cells) and 30 min 
(SH-SY5Y cells) either in the presence (1.8 mM CaCl2) or absence of extracellular Ca2+ 
(nominally Ca2+-free Hanks/HEPES buffer containing 0.1 mM EGTA). Experiments 
were also performed using cells pre-incubated for 30 min with 50 µM BAPTA/AM and 
in the absence of extracellular Ca2+ (nominally Ca2+ -free Hanks/HEPES buffer 
containing 0.1 mM EGTA) to chelate intracellular Ca2+. Cell lysates were subjected to 
biotin-cadaverine incorporation assay (A and C) or peptide cross-linking assay (B and 
D). Data points represent the mean TG specific activity ± S.E.M. from four independent 
experiments. *P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001, (a) versus control in 
presence of extracellular Ca2+, (b) versus 100 nM PACAP-27 in presence of extracellular 
Ca2+. 
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4.2.6 Visualisation of in situ TG2 activity  
Since PACAP-27 was able to induce in vitro TG2 amine incorporation activity via a multi 
protein kinase dependent pathway, it was of interest to assess the capability of PACAP-27 to 
induce in situ TG2 activity using biotin-X-cadaverine, a cell penetrating primary amine, which 
enables the in situ visualisation of endogenous protein substrates of TG2, when combined with 
FITC-ExtrAvidin® (Lee et al., 1993). Differentiating cells were pre-incubated for 6 h with 
biotin-X-cadaverine prior to treatment with PACAP-27 (100 nM) for varying periods of time or 
various concentrations. After fixation and permeabilization, intracellular proteins with 
covalently attached biotin-X-cadaverine were visualised using FITC-ExtrAvidin® (section 
2.2.5). The data from these experiments revealed that PACAP-27 induced a time-dependent 
increases in in situ TG2 activity peaking at 10 min in N2a (Figure 4.19 A and C) and 30 min in 
SH-SY5Y cells (Figure 4.20 A and C). These observations are similar to the pattern of in vitro 
TG2 activity (section 4.2.3). Similarly, PACAP-27 induced a concentration-dependent increase 
in TG2 in situ incorporation of biotin-X-cadaverine into endogenous protein substrates in 
differentiating N2a (EC50= 6.7  3 nM; pEC50 = 8.3  0.2; n=3; Figure 4.19 B and D) and SH-
SY5Y (EC50= 0.82  0.5 nM; pEC50 = 9.4  0.4; n=3; Figure 4.20 B and D.) Finally, in situ 
responses to PACAP-27 were attenuated by the PAC1 receptor selective antagonist (PACAP 6-
38; 100 nM) and the TG2 inhibitors Z-DON (150 µM) and R283 (200 µM) in both cell lines 
(Figure 4.21 A and Figure 4.22 A) confirming that the induced activity was mediated by the 
PAC1 receptor and TG2 is the responsible TG isoform of the observed activity. Overall, these 
data indicate that PACAP-27 induces a marked increase in TG2 in situ activity that is comparable 
to the pattern of TG2 activation observed in vitro. 
The in situ responses to PACAP-27 were also significantly reversed by inhibitors of MEK1/2 
(PD 98059, 50 µM), PKB (Akt Inhibitor XI, 100 nM), PKA (KT 5720, 5 µM), PKC (Ro 31-
8220, 10 µM) and following removal of extracellular Ca2+ in N2a cells (Figure 4.21 B and C). 
Similarly, in SH-SY5Y cells, PACAP-27-mediated biotin-X-cadaverine incorporation into 
protein substrates was attenuated by PD 98059, Akt Inhibitor XI, KT 5720 but showed no 
significant inhibition with Ro 31-8220 or Ca2+ removal (Figure 4.22 B and C).      
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Figure 4.19  Effect of PACAP-27 on in situ TG2 activity in differentiating N2a cells. 
Cells were incubated with 1 mM biotin-X-cadaverine (BXC) for 6 h, after which they 
were incubated with (A, C) 100 nM PACAP-27 for 1, 5, 10, 20, 30 or 40 min or (B, D) 
the indicated concentrations of PACAP-27 for 10 min. TG2-mediated biotin-X-
cadaverine incorporation into intracellular proteins was visualized using FITC-conjugated 
ExtrAvidin® (green). Nuclei were stained with DAPI (blue) and viewed using a Leica 
TCS SP5 II confocal microscope (20x objective magnification). Images presented are 
from one experiment and representative of three. Quantified data represent the mean ± 
S.E.M. of fluorescence intensity relative to DAPI stain for five fields of view each from 
at least three independent experiments. **P<0.01, *** P<0.001 and ****P<0.0001 versus 
control response. 
Modulation of TG2 activity by PACAP in neuroblastoma cells Chapter 4 
105 
 
 
 
 
 
 
Figure 4.20  Effect of PACAP-27 on in situ TG2 activity in differentiating SH-SY5Y 
cells. 
Cells were incubated with 1 mM biotin-X-cadaverine (BXC) for 6 h, after which they were 
incubated with (A) 100 nM PACAP-27 for 5, 10, 20, 30, 40 or 60 min or (B) the indicated 
concentrations of PACAP-27 for 30 min. TG2-mediated biotin-X-cadaverine incorporation 
into intracellular proteins was visualized using FITC-conjugated ExtrAvidin® (green). 
Nuclei were stained with DAPI (blue) and viewed using a Leica TCS SP5 II confocal 
microscope (20x objective magnification). Images presented are from one experiment and 
representative of three. Quantified data represent the mean ± S.E.M. of fluorescence intensity 
relative to DAPI stain for five fields of view each from at least three independent 
experiments. **P<0.01, *** P<0.001 and ****P<0.0001 versus control response. 
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Figure 4.21  Effect of PAC1 receptor antagonist, TG2 inhibitors, protein kinase 
inhibitors and removal of extracellular Ca2+ on PACAP-27-induced in situ TG2 
activity in differentiating N2a cells. 
Cells were incubated with 1 mM biotin-X-cadaverine (BXC) for 6 h, after which they were 
incubated with (A) the PAC1 receptor antagonist PACAP6-38 (100 nM) for 30 min or for 1 
h with TG2 inhibitors Z-DON (150 µM) and R283 (200 µM),(B) PD 98059 (50 µM), Akt 
Inhibitor XI (100 nM) and KT 5720 (5 µM) for 30 min, or (C) Ro 31-8220 (10 µM) for 30 
min or in the absence of extracellular Ca2+ (nominally Ca2+-free Hanks/HEPES buffer 
containing 0.1 mM EGTA) or pre-incubated for 30 min with 50µM BAPTA/AM and in the 
absence of extracellular Ca2+ (nominally Ca2+-free Hanks/HEPES buffer containing 0.1 mM 
EGTA) prior to stimulation with PACAP-27 (100 nM) for 10 min. TG2-mediated biotin-X-
cadaverine incorporation into intracellular proteins was visualized using FITC-conjugated 
ExtrAvidin® (green). Nuclei were stained with DAPI (blue) and viewed using a Leica TCS 
SP5 II confocal microscope (20x objective magnification). Scale bar = 20 µm. Images 
presented are from one experiment and representative of three. Quantified data represent the 
mean ± S.E.M. of fluorescence intensity relative to DAPI stain for five fields of view each 
from at least three independent experiments. *P<0.05, **P<0.01 and ****P<0.0001 versus 
control response. 
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Figure 4.22  Effect of PAC1 receptor antagonist, TG2 inhibitors, protein kinase 
inhibitors and Ca2+ on PACAP-27-induced in situ TG2 activity in differentiating SH-
SY5Y cells. 
Cells were incubated with 1 mM biotin-X-cadaverine (BXC) for 6 h, after which they were 
incubated with (A) the PAC1 receptor antagonist PACAP6-38 (100 nM) for 30 min or for 1 
h with TG2 inhibitors Z-DON (150 µM) and R283 (200 µM), (B) PD 98059 (50 µM) and 
Akt Inhibitor XI (100 nM) for 30 min, or (C) Ro 31-8220 (10 µM) for 30 min or in the 
absence of extracellular Ca2+ (nominally Ca2+-free Hanks/HEPES buffer containing 0.1 mM 
EGTA) or pre-incubated for 30 min with 50µM BAPTA/AM and in the absence of 
extracellular Ca2+ (nominally Ca2+-free Hanks/HEPES buffer containing 0.1 mM EGTA) 
prior to stimulation with PACAP-27 (100 nM) for 30 min. TG2-mediated biotin-X-
cadaverine incorporation into intracellular proteins was visualized using FITC-conjugated 
ExtrAvidin® (green). Nuclei were stained with DAPI (blue) and viewed using a Leica TCS 
SP5 II confocal microscope (20x objective magnification). Scale bar = 20 µm. Images 
presented are from one experiment and representative of three. Quantified data represent 
the mean ± S.E.M. of fluorescence intensity relative to DAPI stain for five fields of view 
each from at least three independent experiments. *P<0.05, **P0.01, *** P0.001 and 
****P0.0001 versus control response. 
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4.2.7 Phosphorylation of TG2 following PAC1 receptor activation with 
PACAP-27 
The effect of PAC1 receptor activation on the phosphorylation status of TG2 was monitored via 
immunoprecipitation of TG2 followed by SDS-PAGE and Western blot analysis using anti-
phosphoserine and anti-phosphothreonine antibodies. PACAP-27 (100 nM) triggered a robust 
increase in the levels of TG2-bound phosphoserine and phosphothreonine in N2a (Figure 4.23 
and 4.25) and SH-SY5Y cells (Figure 4.24 and 4.26). Pre-treatment with PD 98059 (50 µM) 
and KT 5720 (5 µM) attenuated PACAP-27-mediated increases in TG2 phosphorylation in 
differentiating N2a (Figure 4.23) and SH-SY5Y cells (Figure 4.24). In contrast, Ro 318220 (10 
µM) had no significant effect in either cell line (Figure 4.25 and Figure 4.26). Finally, removal 
of extracellular Ca2+ partially attenuated PACAP-27-induced TG2 phosphorylation in N2a but 
had no significant effect in SH-SY5Y cells (Figure 4.25 and Figure 4.26). These data indicate 
that activation of the PAC1 receptor promotes robust increases in TG2 phosphorylation and this 
process is mainly ERK1/2 and PKA dependent. 
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Figure 4.23  Effect of the ERK1/2 inhibitor (PD 98059) and PKA inhibitor (KT 5720) 
on PACAP-27-induced phosphorylation of TG2 in differentiating N2a cells. 
Where indicated, differentiating N2a cells were pre-treated for 30 min with PD 98059 (50 
µM) or KT 5720 (5 µM) prior to stimulation with PACAP-27 (100 nM) for 10 min. 
Following stimulation with PACAP-27, cell lysates were subjected to 
immunoprecipitation using anti-TG2 monoclonal antibody as described in section 2.2.10. 
The resultant immunoprecipitated protein(s) were subjected to SDS-PAGE and Western 
blot analysis using anti-phosphoserine (panels A and C) and anti-phosphothreonine 
(panels B and D) antibodies. One tenth of the total input was applied to the first lane to 
show the presence of phosphorylated proteins prior to immunoprecipitation and negative 
controls with the immunoprecipitation performed with immunobeads only were included 
to demonstrate the specificity of the band shown. Quantified data for PACAP-induced 
increases in TG2-bound serine and threonine phosphorylation are expressed as a 
percentage of the TG2 phosphorylation observed in control cells (=100%). Levels of TG2 
are shown for comparison as internal loading control. Data points represent the mean ± 
S.E.M. from three independent experiments. ****P<0.0001 (a) versus control and (b) 
versus 100 nM PACAP-27 alone. 
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Figure 4.24  Effect of the ERK1/2 inhibitor (PD 98059) and PKA inhibitor (KT 
5720) on PACAP-27-induced phosphorylation of TG2 in differentiating SH-SY5Y 
cells. 
Where indicated, differentiating SH-SY5Y cells were pre-treated for 30 min with PD 
98059 (50 µM) or KT 5720 (5 µM) prior to stimulation with PACAP-27 (100 nM) for 30 
min. Following stimulation with PACAP-27, cell lysates were subjected to 
immunoprecipitation using anti-TG2 monoclonal antibody as described in section 2.2.10. 
The resultant immunoprecipitated protein(s) were subjected to SDS-PAGE and Western 
blot analysis using (A) anti-phosphoserine and (B) and anti-phosphothreonine antibodies. 
One tenth of the total input was applied to the first lane to show the presence of 
phosphorylated proteins prior to immunoprecipitation and negative controls with the 
immunoprecipitation performed with immunobeads only were included to demonstrate 
the specificity of the band shown. Quantified data for PACAP-induced increases in TG2-
bound serine and threonine phosphorylation are expressed as a percentage of the TG2 
phosphorylation observed in control cells (=100%). Levels of TG2 are shown for 
comparison as internal loading control. Data points represent the mean ± S.E.M. from 
three independent experiments.  ***P<0.001 and ****P<0.0001 (a) versus control and (b) 
versus 100 nM PACAP-27 alone. 
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Figure 4.25  Effect of the Ca2+ and PKC inhibitor (Ro 31-8220) on PACAP-27-
induced phosphorylation of TG2 in differentiating N2a cells. 
Where indicated, differentiating N2a cells were subjected to the absence of 
extracellular Ca2+ (nominally Ca2+-free Hanks/HEPES buffer containing 0.1 mM 
EGTA) or pre-treated for 30 min with Ro 31-8220 (10 µM) prior to stimulation with 
PACAP-27 (100 nM) for 10 min. Following stimulation with PACAP-27, cell lysates 
were subjected to immunoprecipitation using anti-TG2 monoclonal antibody as 
described in section 2.2.10. The resultant immunoprecipitated protein(s) were 
subjected to SDS-PAGE and Western blot analysis using anti-phosphoserine (panels 
A and C) and anti-phosphothreonine (panels B and D) antibodies. One tenth of the 
total input was applied to the first lane to show the presence of phosphorylated proteins 
prior to immunoprecipitation and negative controls with the immunoprecipitation 
performed with immunobeads only were included to demonstrate the specificity of the 
band shown. Quantified data for PACAP-induced increases in TG2-bound serine and 
threonine phosphorylation are expressed as a percentage of the TG2 phosphorylation 
observed in control cells (=100%). Levels of TG2 are shown for comparison 
as internal loading control.  Data points represent the mean  S.E.M. from three 
independent experiments. ****P0.0001 (a) versus control and (b) versus 100 nM 
PACAP-27 alone. 
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Figure 4.26  Effect of the Ca2+ and PKC inhibitor (Ro 31-8220) on PACAP-27-
induced phosphorylation of TG2 in differentiating SH-SY5Y cells. 
Where indicated, differentiating SH-SY5Y cells were subjected to the absence of 
extracellular Ca2+ (nominally Ca2+-free Hanks/HEPES buffer containing 0.1 mM 
EGTA) or pre-treated for 30 min with Ro 31-8220 (10 µM) prior to stimulation with 
PACAP-27 (100 nM) for 30 min. Following stimulation with PACAP-27, cell lysates 
were subjected to immunoprecipitation using anti-TG2 monoclonal antibody as 
described in section 2.2.10. The resultant immunoprecipitated protein(s) were 
subjected to SDS-PAGE and Western blot analysis using anti-phosphoserine (A) and 
anti-phosphothreonine (B) antibodies. One tenth of the total input was applied to the 
first lane to show the presence of phosphorylated proteins prior to immunoprecipitation 
and negative controls with the immunoprecipitation performed with immunobeads 
only were included to demonstrate the specificity of the band shown. Quantified data 
for PACAP-induced increases in TG2-bound serine and threonine phosphorylation are 
expressed as a percentage of the TG2 phosphorylation observed in control cells 
(=100%). Levels of TG2 are shown for comparison as internal loading control. Data 
points represent the mean ± S.E.M. from three independent experiments.  **P<0.01, 
***P<0.001 and ****P<0.0001 (a) versus control and (b) versus 100 nM PACAP-27 
alone. 
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 Discussion 
In this study, the modulation of TG2 activity by the neurotrophic factor PACAP-27 through 
PAC1 receptor was investigated in differentiating mouse (N2a) and human (SH-SY5Y) 
neuroblastoma cells and the molecular mechanisms underlying this modulation were 
determined. PAC1 receptor agonist; PACAP-27, TG2 inhibitors, PAC1 receptor antagonist and 
different protein kinase inhibitors were used to assess the in vitro and in situ TG2 activity and 
to investigate the pathways involved. The results provide evidence that PACAP-27 modulates 
TG2 activity in differentiating N2a and SHSY5Y cells occurs via a multi protein kinase 
dependent pathways. 
4.3.1 Modulation of TG2 transamidation activity by PACAP-27 
Functional expression of PAC1 receptors on differentiating N2a and SH-SY5Y 
Previous studies have been reported that the PAC1 receptor is expressed in mitotic N2a, and 
both mitotic and differentiating SH-SY5Y cells (Lelièvre et al., 1998; Lutz et al., 2006; Miura 
et al., 2013). Initially in the current study, functional expression of the PAC1 receptor was 
investigated in differentiating N2a and SH-SY5Y cells, first via measuring cAMP accumulation 
and mediating of Ca2+ signalling. Hence, this study has demonstrated functional expression of 
the PAC1 receptor in N2a and SH-SY5Y cells induced to differentiate with retinoic acid. The 
results revealed the potential ability of PACAP-27 to mediate robust activation of cAMP 
production (up to 60-fold of basal activity) with potencies of approximately 4 nM and 2.8 nM 
in differentiating N2a and SH-SY5Y cells respectively. Live calcium imaging enabled further 
characterisation of the functional expression of the PAC1 receptor in differentiating N2a and 
SH-SY5Y cells. Previous studies have shown that the PAC1 receptor promotes Ca
2+ 
mobilization from intracellular stores and Ca2+ influx via N-type calcium channels in rat 
cerebellar granule cells (Basille-Dugay et al., 2013). The data presented in the current work 
support these findings by showing that PACAP-27-triggered Ca2+ responses were abolished in 
the absence of extracellular Ca2+, which is indicative of extracellular Ca2+ influx as the 
intracellular stores were still intact. In order to confirm the involvement of PAC1 receptor in 
mediating these Ca2+ responses, the PAC1 receptor selective antagonist (PACAP 6-38) was 
used. As expected, PACAP-27 induced Ca2+ responses were attenuated by the PAC1 receptor 
antagonist in both cell lines, confirming the involvement of PAC1 receptor. Overall, these data 
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demonstrated the functional expression of the PAC1 receptor in differentiating N2a and SH-
SY5Y neuroblastoma cells. These findings are broadly comparable to those shown in another 
neuroblastoma cells model N1E 115, where PACAP-27 stimulates cAMP accumulation and 
increases [Ca2+]i through the PAC1 receptor (Chik et al., 1996). 
Modulation of TG2 transamidation activity by PACAP-27 
The neurotrophic factor PACAP mediates neurite outgrowth and neuroprotection; however, it 
is not known if these events involve PAC1 receptor-induced TG2 activation (Monaghan et al., 
2008; Manecka et al., 2013; Jóźwiak-Bębenista et al., 2015). It has been shown that TG2 is 
regulated by signaling pathways associated with GPCRs such as PKC and PKA in rat H9c2 
cardiomyoblasts (Almami et al., 2014) and further investigation has shown A1 adenosine 
receptor-mediated increases in TG2 transamidase activity in the same cell line (Vyas et al., 
2016). Hence, it was of interest to investigate whether PACAP could modulate TG2 
transamidase activity via the PAC1 receptor in neuroblastoma cell lines prior to assessing the 
possible neuroprotection role. 
TG2 can catalyse two types of transamidation, namely (i) intra-, and/or inter-molecular covalent 
cross-links between protein-bound glutamine and protein-bound lysine residues, and (ii) cross-
links between primary amines and protein-bound glutamine (Nurminskaya and Belkin, 2013). 
In the current study the PAC1 receptor agonist PACAP-27 triggered time- and concentration-
dependent increases in TG2-mediated biotin-cadaverine incorporation and peptide cross-linking 
activity in differentiating N2a and SH-SY5Y cells. The EC50 values for PACAP-27-mediated 
transglutaminase-catalysed amine incorporation (0.08 nM in N2a and 2.2 nM in SH-SY5Y) and 
protein cross-linking activity (0.4 nM in N2a and 1.3 nM in SH-SY5Y) are in-line with the 
affinity of PACAP-27 for the PAC1 receptor (Dickson et al., 2006; Dickson and Finlayson, 
2009; Harmar et al., 2012). Interestingly, the response was peaking at 10 min in N2a and 30 
min in SH-SY5Y cells, also the potency of PACAP-27 in N2a cells was significantly higher 
than in human SH-SY5Y neuroblastoma cells, suggesting that the N2a cells are more sensitive 
than SHSY5Y cells to this neuropeptide. These findings are similar to those reported in previous 
work on N2a and SH-SY5Y cells, indicated that mouse N2a cells are more sensitive than human 
SH-SY5Y neuroblastoma in cytotoxic assessment study (Li et al., 2007; Sahu et al., 2013). This 
could be attributed to species dependent differences in the sensitivity of the signalling cascades 
activated via the PAC1 receptor. 
The findings in this section were confirmed by using an immunocytochemistry-based assay that 
enabled fluorescence microscopy visualisation of in situ TG2 activity. Increases in in situ TG2 
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activity following PAC1 receptor stimulation with the PACAP-27 occurred in a time- and 
concentration- dependent manner. However, given the covalent nature of biotin-X-cadaverine 
incorporation into protein substrates, it was surprising to observe that in situ TG2 activity 
returned to basal levels after 40 min. Possible explanations for this include reversal of amine 
incorporation by TG itself (Stamnaes et al. 2008), targeting of modified proteins for degradation 
or their rapid removal from the cell. Previous studies have reported the rapid expulsion of 
biotinylated proteins from H9c2 cells following treatment with PMA or forskolin (Almami et 
al. 2014). It could be that the rapid expulsion of biotinylated proteins from neuroblastoma cells 
occurs via exosomes (Kalani et al. 2014). Since neuroblastoma cells secrete exosomes it will be 
interest to determine whether amine-labelled proteins can be detected in exosomes purified from 
cell culture supernatants obtained from these cells following PACAP-27 treatment (Chivet et 
al. 2014). 
Selectivity of PACAP-27 to PAC1 receptor in modulation of TG2 activity 
It is known that PACAP and its structurally related neuropeptide VIP act through the three 
GPCRs, namely PAC1, VAPC1 and VAPC2 receptors, with varying potencies (Monaghan et al., 
2008; Harmar et al., 2012). The naturally occur peptide PACAP has 100-fold greater potency 
than VIP for the PAC1 receptor (Lutz et al., 2006; Dickson and Finlayson 2009). The only 
available selective agonist for PAC1 receptor is maxadilan (Uchida et al., 1998), which was 
isolated from salivary gland of sand flies and is structurally unrelated to PACAP/VIP (Lerner 
et al., 1991). It is a 61-amino acid peptide with three disulfide-bonds but is rarely used as it is 
difficult to synthesize (Harmar et al., 2012).  A previous study aimed to develop PAC1 receptor 
selective agonists by designing PACAP analogues that were conformationally restricted for 
their receptor-selectivity position (Ramos-A`lvarez et al., 2015). However, the variety of PAC1 
receptor splice-variants and their diﬀerences in aﬃnities/potencies for PACAP-27/PACAP-38, 
as well as the high sequence identity (68%) between VIP and PACAP27, made the process 
particularly difficult (Ramos-A‘lvarez et al., 2015). Hence, in the current study it was necessary 
to examine the PAC1 receptor speciﬁcity for induction of TG2 activity. Experiments were 
performed with the VAPC1 and VAPC2 receptor-speciﬁc agonists Ala-VIP and Bay 55-9837, 
respectively. The data presented indicated that Ala-VIP and Bay 55-9837 had no significant 
effect on cAMP accumulation or TG2 transamidase activity. The findings confirm that the TG2 
responses obtained occur via the PAC1 receptor in differentiating N2a and SH-SY5Y. Further 
investigation used the PAC1 receptor antagonist PACAP 6-38 (Robberecht et al., 1992) which 
blocked PACAP-27-induced TG2 activity, confirming that the induced activity was via the 
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PAC1 receptor. It is important to note that PACAP 6-38 also displays high affinity for the 
VPAC2 receptor (Dickinson et al.,1997); however, since the VPAC2 agonist Bay 55-9837 did 
not trigger increased TG2 activity, it is likely that the effects of PACAP 6-38 are mediated 
entirely via the PAC1 receptor. Finally, PAC1 receptor-induced increases in TG2 activity were 
inhibited by R283 and Z-DON, structurally different TG2 inhibitors, confirming that the 
observed increases in TG activity were via TG2. It is important to note that the inhibition effect 
of these TG2 inhibitors on cellular TG2 is only achieved at a concentration significantly higher 
than their IC50 value versus purified enzyme (Freund et al., 1994; Schaertl et al., 2010). The 
observed increases in in situ TG2 responses induced by PACAP-27 were also reversed by the 
PAC1 receptor antagonist PACAP 6-38, confirming the role of the PAC1 receptor in the reported 
TG2 activity. Furthermore, the TG2 in situ PACAP-27-induced polyamine incorporation was 
sensitive to TG2 inhibitors Z-DON and R283, further confirming that TG2 is the TG isoform 
responsible for the observed activity. Since diﬀerentiating N2a and SH-SY5Y cells also express 
TG1 and TG3 isoforms (Chapter 3), it would be of interest to investigate if PACAP-27 also 
regulates the activity of these enzymes. It is difficult to establish an assay for discriminating 
between the different TG isoform activities; however  Hitomi et al. (2009)  have established a 
highly sensitive colorimetric assay using selective substrate peptides to some of the TG isoforms 
(Hitomi et al., 2009). It would be interesting in future work to use such substrates to determine 
whether the other TGs isoform are also regulated by PACAP-27 in neuroblastoma cells; such 
types of future testing paradigms could help to assess the possible differences in responses and 
sensitivity of TG1 and TG3 to PACAP-27 and the related alterations in cell signalling. However, 
in the current study, the improved understanding of function and role of TG2 in PACAP-27-
induced neurite outgrowth and cell survival suggests that TG2 represents a potential target. 
4.3.2 Role of protein kinases 
There is increasing evidence showing that TG2 activity can be modulated by different kinases 
such as ERK1/2 and PKC in different models (Bollag et al., 2005; Mishra et al., 2007; Almami 
et al., 2014). However, there is very little known about the role of protein kinases in modulating 
TG2 activity in differentiating mouse N2a and human SH-SY-5Y neuroblastoma cells. To 
determine whether various protein kinase signaling pathways were involved in PACAP-27-
induced TG2 activity, the current study investigated the effect different protein kinase inhibitors 
on PACAP-27 induced modulation of protein kinase phosphorylation and PACAP-27-induced 
TG2 activity. It was presumed that activation of the PAC1 receptor would induce activation of 
Modulation of TG2 activity by PACAP in neuroblastoma cells Chapter 4 
117 
 
ERK1/2, p38 MAPK (Monaghan et al., 2008), PKA (Dickson & Finlayson, 2009; Vaudry et al., 
2009), PKC (May et al., 2014), and PKB (May et al., 2010; Castorina et al., 2014) signalling 
pathways. In the current study it appears that PACAP-27-induced the activation of ERK1/2 and 
PKB in both neuroblastoma cell lines. However, the activation of p38 MAPK by PACAP-27 
was shown only in human neuroblastoma SH-SY5Y cells and the activation of JNK1/2 was 
shown in N2a cells only. These findings could be attributed to species dependent differences in 
the signalling cascades activated via the PAC1 receptor. These findings were also consistent 
with the observed reduction of PACAP-27-induced TG2-medaited amine incorporation and 
peptide crosslinking activity by pharmacological inhibition of the protein kinases. The MEK1/2 
(upstream activator of ERK1/2) inhibitor PD 98059 and Akt inhibitor XI significantly blocked 
PACAP-27-induced TG2 activity, suggesting a prominent role for ERK1/2 and PKB. While, 
SP 600125 (JNK1/2 inhibitor; Figure 4.16) and SB 203580 (p38 MAPK inhibitor; Figure 5B) 
had no significant effect on TG2 activity in either cell line.  
The phosphorylation of TG2 by PKA inhibits its transamidating activity but augments its kinase 
activity (Mishra et al. 2007). These contrasting effects on TG2 activity were obtained using 
histidine-tagged TG2 immobilized on nickel-agarose and incubated with the catalytic subunit 
of PKA. In the current study, the PKA inhibitors KT 5720 and Rp-cAMPs completely blocked 
PACAP-27-induced TG2 transamidating activity, which reflects PAC1 receptor signaling via 
cAMP/PKA. The PAC1 receptor also activates PLC/DAG/PKC (via Gq-protein coupling) 
signalling and hence the role of PKC was investigated. The broad-spectrum PKC inhibitor Ro 
318220 inhibited PACAP-27-induced TG2 activity, indicating that Gq-protein coupling is 
involved in PAC1 receptor-mediated TG2 activation in N2a cells. The observed response is in 
good agreement with that noted in H9c2 cells, where the A1 adenosine receptor-mediated 
activation of TG2, was also sensitive to ERK1/2 and PKC inhibition (Vyas et al., 2016). In 
transfected HEK293 cells, PAC1 receptor-induced ERK1/2 is dependent upon calcium influx 
and PLC/DAG/PKC (May et al., 2014) and hence the inhibition of PACAP-27-induced TG2 
activity by removal of extracellular Ca2+ and inhibition of PKC may reflect their up-stream 
role(s) in ERK1/2 activation. However, in the current study, PAC1 receptor-induced ERK1/2 
activation was found to be independent of Ca2+ influx in both cell lines and partially sensitive 
to PKC inhibition in N2a cells and PKC-independent in SH-SY5Y cells. Similarly, PKA can 
activate ERK1/2 (Stork and Schmitt, 2002) and therefore the effect of PKA inhibitors on PAC1 
receptor TG2 activation may also reflect the up-stream role of PKA in ERK1/2 activation. In 
guinea-pig cardiac neurons PAC1 receptor-induced ERK1/2 activation is PKA-independent 
(Clason et al., 2016). In the current study, PAC1 receptor-induced ERK1/2 signalling was shown 
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to be PKA-dependent in both neuroblastoma cell lines. Hence, PKA-mediated inhibition of TG2 
activation may indeed reflect the up-stream role of PKA in ERK1/2 activation.  
Role of protein kinases in PACAP-27-mediated in situ TG2 activation 
PACAP-27 induced in situ TG2 responses were also blocked by pharmacological inhibition of 
MEK1/2 (PD 98059), PKB (Akt inhibitor XI) and PKA (KT 5720) (figures 4.21 and 4.22), 
further confirming the role of these signalling pathways. The finding also demonstrates that the 
observed response was attenuated by PKC (Ro 31-8220) and removal of Ca2+ in N2a cells but 
not in SH-SY5Y cells. Overall these observations are comparable to PACAP-27-induced TG2 
activation observed in vitro. As previously discussed, the conflicting data as to whether PKC 
plays a role in PACAP-27-induced TG2 activity in differentiating N2a cells, suggests that PKC 
may regulate targets involved in TG2 activation other than the targets assessed in this study. 
Furthermore, the effective role of Ca2+ removal was observed only in mouse N2a cells. These 
finding suggest that, in differentiating N2a cells, PACAP-27 stimulates the PAC1 receptor to 
modulate TG2 activity either via Gs protein leading to activation of adenylyl 
cyclase/cAMP/PKA or through phospholipase C/DAG/PKC via Gq protein coupling-dependent 
signalling pathways.  In contrast, TG2 responses in human neuroblastoma SH-SY5Y cells are 
insensitive to either PKC inhibition or removal of Ca2+ and display higher sensitivity to PKA 
inhibition, suggesting that the ability of PAC1 receptor to induced TG2 activity is mainly via Gs 
protein dependent adenylyl cyclase/cAMP/PKA-signalling in human neuroblastoma cells. The 
effect of protein kinase inhibitors on PACAP-27-induced TG2 activation in summarized in 
Figure 4.27 and Table 4.1. 
Role of protein kinases in PACAP-27-mediated TG2 phosphorylation 
Since Vyas et al., (2016) showed that TG2 was phosphorylated following activation of the A1 
adenosine receptor in H9c2 cells (Vyas et al., 2016), it was of interest to examine the 
phosphorylation status of TG2 following activation of the PAC1 receptor with PACAP-27. The 
data presented in the current study demonstrate that TG2 is phosphorylated following PAC1 
receptor activation. Furthermore, PAC1 receptor-induced TG2 phosphorylation was attenuated 
by pharmacological inhibition of MEK1/2 and PKA in both neuroblastoma cell lines and by 
removal of extracellular Ca2+ in N2a cells only. It is not clear how the absence of extracellular 
Ca2+ blocks TG2 phosphorylation since the PAC1 receptor-induced ERK1/2 activation is 
independent of Ca2+ influx in N2a cells. One possible explanation is that changes in [Ca2+]i 
promote conformational changes in TG2 that facilitate its phosphorylation by protein kinase(s). 
Modulation of TG2 activity by PACAP in neuroblastoma cells Chapter 4 
119 
 
Alternatively, Ca2+ influx may play a role in augmenting PAC1 receptor-induced PLC/PKC 
signalling. However, the fact that the PKC inhibitor Ro 31-8220 did not block TG2 
phosphorylation, suggests that PKC may regulate other targets involved in TG2 activation. The 
next logical step would be to identify the specific site(s) of TG2-associated serine and threonine 
phosphorylation. In human cells, various TG2 phosphorylation sites have been identified 
namely Ser56, Ser60, Tyr219, Thr368, Tyr369, Ser419, Ser427, Ser538, Ser541 and Ser608 (Rikova et al., 
2007; Imami et al., 2008; Kettenbach et al., 2011; Bian et al., 2014). Previous studies have 
shown that TG2 is phosphorylated by PKA at Ser215 and Ser216 (Mishra and Murphy, 2006) and 
at an unknown site(s) by PTEN-induced putative kinase 1 (PINK1; Min et al., 2015). At present 
the precise role of PAC1 receptor-induced TG2 phosphorylation is not known. However, PKA-
mediated phosphorylation of TG2 enhances its interaction with the scaffolding protein 14-3-3 
and increases TG2 kinase activity, whereas PINK1-mediated phosphorylation of TG2 blocks its 
proteasomal degradation (Mishra and Murphy, 2006; Mishra et al., 2007; Min et al., 2015). It 
is also conceivable that TG2 phosphorylation sensitizes TG2 to low levels of intracellular 
[Ca2+]i or alters its subcellular location. Further work to determine the functional consequences 
of PAC1 receptor-induced TG2 phosphorylation would be of value.  
Role of Ca2+ in PACAP-27-mediated TG2 activation 
Previous studies have shown that PACAP-induced  increases in [Ca2+]i are blocked by the PAC1 
receptor antagonist PACAP 6–38 in human fetal chromaffin cells (Payet et al., 2003). In the 
current study, PACAP-27-triggered Ca2+ responses in neuroblastoma cell lines loaded with 
Fluo-8 AM were abolished in the absence of extracellular Ca2+, which is indicative of Ca2+ 
influx. The transamidating activity of TG2 is dependent upon Ca2+, which promotes the “open” 
form of TG2 and negates the inhibitory actions of the nucleotides GTP, GDP and ATP (Király 
et al., 2011). Previous studies have shown that release of Ca2+ from intracellular Ca2+ stores or 
influx of extracellular Ca2+ is linked to TG activation in response to GPCR stimulation (Zhang 
et al., 1998; Walther et al., 2003; Vyas et al., 2016). The data presented in the current work 
indicate that PAC1 receptor-induced TG2 transamidase activity is dependent upon extracellular 
Ca2+. Clearly, further studies are required to determine the mechanism(s) of PAC1 receptor-
induced Ca2+ influx in differentiating N2a and SH-SY5Y cells and its role in TG2 activation. It 
is interesting to note that changes in intracellular [Ca2+] required for TG2 transamidating activity 
are typically in the order 3-100 µM (Király et al., 2011). However, there is growing evidence 
that intracellular [Ca2+] can reach levels sufficient to activate TG2, for example in calcium 
microdomains that occur near the cell membrane following the opening of voltage gated Ca2+ 
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channels or near internal stores (Berridge, 2006; Király et al., 2011). Alternatively, the role of 
Ca2+ in PAC1 receptor-induced TG2 activation may require the sensitization of TG2 to low 
levels of intracellular [Ca2+]. For example, interaction of TG2 with protein binding partners 
and/or membrane lipids have been proposed to induce a conformational change that promotes 
activation at low levels of intracellular [Ca2+] (Király et al., 2011).  
 Conclusion 
From the results presented in this chapter, it can be concluded that exposure of differentiating 
mouse N2a and human SH-SY5Y neuroblastoma cells to the neurotrophic factor PACAP-27 
mediated activation of TG2 activity through the PAC1 receptor. The findings also demonstrate 
that this activity is sensitive to the inhibition of various protein kinases, suggesting that the 
stimulation of TG2 activity via the PAC1 receptor is associated with a multi-protein kinase 
dependent pathway. Overall the data describe a strong correlation between the signalling 
pathway trigger by neurotrophic factor PACAP-27 and TG2 activity that could be part of the 
neuronal survival and neurite outgrowth process. This principle could also be applicable to 
another neurotrophic factor e.g. nerve growth factor, which is investigated in the next chapter.  
 
Modulation of TG2 activity by PACAP in neuroblastoma cells Chapter 4 
121 
 
 
 
 
The results of range of treatments used in this study to investigate the role of PACAP-27 in 
modulating of TG2 activity. Differentiating neuroblastoma N2a or SH-SY5Y cells were 
treated with the compounds in the table, then cells were stimulated with PACAP-27 and the 
TG2 activity assessed by different approaches; in vitro amine incorporation and peptide 
crosslinking assays, visualisation of in situ amine incorporation activity, protein kinase 
activation by Western blotting (WB) and TG2 phosphorylation via immunoprecipitation 
(IP). ns= no significant change, nd= not determined, *P0.05, **P<0.01, ***P<0.001, and 
****P<0.0001.  
 
 
 
 
 
 
 
Treatment 
Assessment following PACAP-27 treatment 
Amine 
incorporation 
Peptide 
crosslinking 
 
In-situ 
 
IP 
 
WB 
N2a SH-SY5Y N2a SH-SY5Y N2a SH-SY5Y N2a SH-SY5Y N2a SH-SY5Y 
PACAP 6-38 
(100 nM; PAC1 receptor antagonist) 
 
**** 
 
*** 
 
*** 
 
*** 
 
**** 
 
**** 
 
nd 
 
nd 
 
nd 
 
nd 
Z-DON 
(150 μM; TG2 inhibitors) 
 
**** 
 
** 
 
**** 
 
** 
 
**** 
 
**** 
 
nd 
 
nd 
 
nd 
 
nd 
R283 
(200 μM; TG2 inhibitors) 
 
**** 
 
*** 
 
**** 
 
*** 
 
**** 
 
**** 
 
nd 
 
nd 
 
nd 
 
nd 
PD 98059 
(50 μM; MEK1/2 inhibitor) 
 
**** 
 
*** 
 
**** 
 
*** 
 
**** 
 
*** 
 
**** 
 
*** 
 
**** 
 
**** 
Akt inhibitor XI 
(0.1 μM; PKB inhibitor) 
 
*** 
 
** 
 
*** 
 
**** 
 
**** 
 
** 
 
nd 
 
nd 
 
**** 
 
**** 
 
KT 5720 
(5 μM; PKA inhibitors) 
 
**** 
 
*** 
 
**** 
 
*** 
 
**** 
 
**** 
 
**** 
 
*** 
 
****     
vs ERK1/2  
 
**                       
vs ERK1/2 
Rp-3’,5’-cAMPS 
(50 μM; PKA inhibitors) 
 
**** 
 
** 
 
**** 
 
** 
 
nd 
 
nd 
 
nd 
 
nd 
 
nd 
 
nd  
 
Ro 31-8220 
(10 μM; PKC inhibitor) 
 
**** 
 
ns 
 
**** 
 
ns 
 
* 
 
ns 
 
ns 
 
ns 
 
*                     
vs ERK1/2 
 
ns                 
vs ERK1/2 
Nominally Ca2+-free Hanks/HEPES 
buffer containing 0.1 mM EGTA 
 
**** 
 
* 
 
** 
 
** 
 
** 
 
ns 
 
*** 
 
ns 
 
ns                 
vs ERK1/2 
 
ns                 
vs ERK1/2 
50 μM BAPTA-AM in nominally 
Ca2+-free Hanks/HEPES buffer 
containing 0.1 mM EGTA 
 
**** 
 
** 
 
*** 
 
** 
 
** 
 
** 
 
nd 
 
nd 
 
nd 
 
nd  
 
SP 600125 
(20 μM; JNK1/2 inhibitor) 
 
ns 
 
ns 
 
* 
 
ns 
 
nd 
 
nd 
 
nd 
 
nd  
 
 
**** 
 
ns 
SB 203580 
(20 μM; p38 MAPK inhibitor) 
 
ns 
 
ns 
 
ns 
 
ns 
 
nd 
 
nd 
 
nd 
 
nd  
 
 
ns 
 
** 
Table 4.1 The overall ability of different treatments to inhibit PACAP-27-induced TG2 
activity assessed by different approaches 
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Figure 4.27  Schematic summary of PAC1 receptor-induced TG2 activation. 
Activation of PAC1 receptor by PACAP-27 trigger activation of various targets. (A) 
In differentiating mouse N2a cells, PACAP-27 induced TG2 activity and TG2 
phosphorylation by triggering the activation of protein kinases (ERK1/2, PKA, 
Akt/PKB, PKC and JNK1/2) and Ca2+ influx. (B) In differentiating human SH-SY5Y 
cells, TG2 activity and TG2 phosphorylation induced by PACAP-27 occurs as a result 
of activation of protein kinases (ERK1/2, PKA, Akt/PKB and p38 MAPK) and Ca2+ 
influx. Solid black arrows represent findings of the current study, dashed arrows 
represent findings from other studies. 
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5 Modulation of TG2 activity by nerve growth factor 
NGF in differentiating neuroblastoma cells 
 Introduction 
Nerve growth factor (NGF) was the first neurotrophin to be characterised (Levi-Montalcini & 
Hamburger, 1951). NGF modulates a wide range of biological functions and signalling in the 
nervous system; it regulates cell proliferation, differentiation and survival (Kawamoto and 
Matsuda 2004; Chao et al., 2006). It triggers its functions via the high affinity tyrosine kinase 
receptor A (TrkA; Wang et al., 2014). A substantial body of evidence indicates that NGF-
induced activation of TrkA evokes neurite outgrowth and survival in neuronal cells (Lavenius 
et al., 1995; Eggert et al., 2000; Schramm et al., 2005). Receptor tyrosine kinases represent a 
large family of receptors; this family’s prominent members include receptors for epidermal 
growth factor (EGF), platelet-derived growth factor (PDGF) and vascular endothelial growth 
factor (VEGF). Transglutaminase 2, the most widely expressed form of TG in the nervous 
system, as well as the most ubiquitous and studied transglutaminase isoform, has been found to 
mediate transamidase activity and participate in EGF receptor signalling, whereas the 
interaction of extracellular TG2 with PDGF and VEGF receptors promotes their activation 
(Dardik & Inbal, 2006; Zemskov et al., 2009; Li et al., 2010). These observations suggest a 
major role for TG2 in the modulation of receptor tyrosine kinases. However, at present, it is not 
known whether receptor tyrosine kinase activation by NGF promotes intracellular TG2 
activation. NGF’s activation of TrkA leads to a multitude of signalling pathways, including the 
ERK1/2, PI-3K/PKB and PLC-γ/PKC cascades (Wang et al., 2014). As some of these pathways 
are associated with the modulation of intracellular TG2 activity (PKC, ERK1/2 and Ca2+), it is 
conceivable that NGF directly regulates TG2 activity.  
Considering that mouse N2a and human SH-SY5Y neuroblastoma cells are responsive to NGF 
(Eggert et al., 2000; Price et al., 2003; Dwan et al., 2013), as well as the already established 
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interplay between NGF and TG2 in neuroblastoma cells (Condello et al., 2008), the current 
study sought to determine whether short-term treatment with NGF (<4 h) could modulate TG2-
mediated transamidase activity in these cells and identify the possible signalling pathways 
involved. To achieve this aim, NGF’s effect on the modulation of TG2 activity was investigated 
using TG2 transamidase activity assays and immunofluorescence visualisation. In addition, the 
possible molecular mechanisms underlying this modulation were investigated by assessing the 
protein kinases involved. 
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 Results 
5.2.1 The eﬀect of NGF on TG2 activity 
Although it has been determined that long-term exposure to NGF has neurotrophic effects, its 
possible potential actions as a fast-acting neurotrophin have not been investigated as thoroughly. 
The initial experiments in this study assessed the effects of short-term exposure of 
differentiating neuroblastoma cells to NGF. Following NGF exposure, cell lysates were initially 
subjected to biotin cadaverine amine–incorporated and biotin-labelled peptide (biotin-
TVQQEL) crosslinking assay. From the results, NGF (100 ng/ml) was shown to rapidly (1 h) 
and robustly enhance biotin–cadaverine incorporation and protein crosslinking activity at a 
significant level in diﬀerentiating N2a (Figure 5.1 A and B) and SH-SY5Y (Figure 5.2 A and 
B) cells. Furthermore, NGF also stimulated concentration-dependent increases in biotin–amine 
incorporation activity and peptide crosslinking activity in N2a (Figure 5.1 C and D) and SH-
SY5Y (Figure 5.2 C and D) cells.  
To conﬁrm that the observed increase in NGF-induced TG2 activation was not simply a 
consequence of increased levels of TG2 protein expression, the level of TG2 protein expression 
was monitored by Western blotting. The data obtained indicated no signiﬁcant change in the 
level of TG2 protein expression during the time course (up to 4 h) of NGF treatment in 
differentiated N2a and SH-SY5Y cells (Figure 5.3), confirming that NGF increased TG2 
activity but not TG2 protein expression during the indicated times. 
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Figure 5.1  Effects of NGF on TG2 activity in differentiating mouse N2a cells. 
Differentiating N2a cells were either incubated with 100 ng/ml NGF for the indicated 
times or for 1 h with the indicated concentrations of NGF. The cell lysates were then 
subjected to the biotin–cadaverine incorporation (A and C) or peptide crosslinking assay 
(B and D). The data points represent the mean TG2-speciﬁc activity ± S.E.M. from four 
independent experiments. *P < 0.05, **P <0.01, ***P < 0.001 and ****P < 0.0001 
versus the control response. 
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Figure 5.2  Effects of NGF on TG2 activity in differentiating human SH-SY5Y cells. 
Differentiating SH-SY5Y cells were either incubated with 100 ng/ml NGF for the 
indicated times or for 1 h with the indicated concentrations of NGF. The cell lysates 
were then subjected to the biotin–cadaverine incorporation (A and C) or peptide 
crosslinking assay (B and D). Data points represent the mean TG2 speciﬁc activity ± 
S.E.M. from four independent experiments. *p < 0.05, **P <0.01 and, ***P < 0.001 
versus control response. 
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Figure 5.3  Eﬀect of acute NGF-treatment on TG2 protein expression in diﬀerentiating 
N2a and SH-SY5Y cells. 
Differentiating N2a (A) and SH-SY5Y (B) cells were incubated with 100 ng/ml NGF for the 
indicated times. Cell lysates (20 µg protein) were analysed for TG2 expression by Western 
blotting with anti-TG2 antibody. Levels of GAPDH are included for comparison. Quantiﬁed 
data are expressed as the percentage of TG2 expression in control cells (100%) and represent 
the mean ± S.E.M. of four independent experiments. 
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To conﬁrm that TG2 was responsible for NGF-mediated transglutaminase activity, TG2-
speciﬁc inhibitors were tested, namely R283 and Z-DON. Cells were pre-treated for 1 h with Z-
DON (150 µM) or R283 (200 µM) prior to stimulation with NGF (100 ng/ml) for 1 h. Both 
inhibitors completely blocked NGF-induced TG-mediated amine incorporation (Figure 5.4A 
and C) and peptide crosslinking activity (Figure 5.4B and D) in N2a and SH-SY5Y cells. The 
data from these experiments revealed that TG2 was the transglutaminase form involved in these 
responses. It is important to note that, although the TG2 inhibitors are cell permeable, the 
inhibition of cellular TG2 is only achieved at concentrations signiﬁcantly above their IC50 
values versus puriﬁed enzymes (Freund et al., 1994; Schaertl et al., 2010). Overall, these data 
indicate that NGF stimulates robust TG2-mediated transamidase activity in diﬀerentiating N2a 
and SH-SY5Y cells. 
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Figure 5.4  Effects of TG2 inhibitors on NGF-induced TG activity. 
Differentiating N2a (A and B) and SH-SY5Y (C and D) cells were pre-treated for 1 h 
with the TG2 inhibitors Z-DON (150 µM) and R283 (200 µM) prior to 1 h of stimulation 
with NGF (100 ng/ml). The cell lysates were then subjected to the biotin-cadaverine 
incorporation (A and C) or peptide crosslinking assay (B and D). The data points 
represent the mean TG-specific activity ± S.E.M. from four independent experiments. 
**P <0.01, ***P<0.001, and ****P<0.0001, (a) versus control and (b) versus NGF alone.   
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5.2.2 The eﬀects of ERK1/2, PI-3K/PKB and PKC inhibitors on NGF-
induced TG2 activity 
The roles of ERK1/2 and PI-3K/PKB 
Several signalling proteins are known to act downstream of NGF, including ERK1/2, PI-
3K/PKB and PKC (Wang et al., 2014). In the current study, initial experiments assessed NGF 
induced ERK1/2 and PKB activation via Western blotting using phospho-speciﬁc antibodies 
that recognise phosphorylated motifs in activated ERK1/2 (pT202EpY204) and PKB (S473). As 
expected, NGF (100 ng/ml) stimulated robust increases in ERK1/2 and PKB phosphorylation 
in diﬀerentiating N2a (Figure 5.5 A and B) and SH-SY5Y cells (Figure 5.5 C and D). NGF-
mediated increases in ERK1/2 and PKB were inhibited by PD 98059 (50 µM; MEK1/2 
inhibitor) and Akt Inhibitor XI (100 nM; PKB inhibitor), respectively (Figure 5.5). Furthermore, 
inhibiting of PKB using Akt Inhibitor XI did not influence the NGF-induced increase in ERK1/2 
phosphorylation, and inhibition of MEK1/2 using PD 98059 had no effect on the PKB 
phosphorylation induced by NGF in N2a or SH-SY5Y cells (Fig. 5.6). The data from these 
experiments suggest inhibitor selectivity and a lack of ‘crosstalk’ between the two kinase 
pathways. 
Turning to the next experimental evidence on whether ERK1/2 and PKB were involved in NGF-
induced TG2 activation, the pharmacological inhibitors of these protein kinases were used prior 
to stimulating the cells with NGF and subjected to biotin-cadaverine incorporation and biotin-
labelled peptide (biotin-TVQQEL) crosslinking assay. As depicted in Figure 5.7, NGF-
induced TG-mediated amine incorporation activity and peptide crosslinking activity were 
significantly inhibited by PD 98950 (MEK1/2 inhibitor (50 µM) and Akt inhibitor XI (100 nM), 
suggesting the involvement of ERK1/2 and PKB, respectively.  
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Figure 5.5  Eﬀects of PD 98959 and Akt inhibitor XI on NGF-induced ERK1/2 and 
PKB activation in diﬀerentiating N2a and SH-SY5Y cells. 
Where indicated, differentiating cells were pre-treated for 30 min with (A and C) PD 98059 
(50 µM) or (B and D) Akt Inhibitor XI (100 nM) prior to stimulation with NGF (100 ng/ml) 
for 1 h. The cell lysates were analysed by Western blotting for activation of ERK1/2 and 
PKB using phospho-speciﬁc antibodies. The samples were subsequently analysed on 
separate blots using an antibody that recognises total ERK1/2 and PKB. Quantiﬁed data are 
expressed as the percentage of the value for control cells (= 100%) in the absence of protein 
kinase inhibitor and represent the mean ± S.E.M. of four independent experiments. *P<0.05, 
**P<0.01, *** P<0.001 and ****P<0.0001, (a) versus control and (b) versus NGF. 
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Figure 5.6  Eﬀects of Akt inhibitor XI and PD 98959 on NGF-induced ERK1/2 and 
PKB activation in diﬀerentiating N2a and SH-SY5Y cells. 
Where indicated, differentiating cells were pre-treated for 30 min with (A and C) Akt 
Inhibitor XI (100 nM) or (B and D) PD 98059 (50 µM) prior to stimulation with NGF 
(100 ng/ml) for 1 h. The cell lysates were analysed by Western blotting for ERK1/2 and 
PKB activation using phospho-speciﬁc antibodies. The samples were subsequently 
analysed on separate blots using antibodies that recognise total ERK1/2 and PKB. The 
quantiﬁed data are expressed as the percentage of the value for control cells (= 100%) 
in the absence of protein kinase inhibitor and represent the mean ± S.E.M. of four 
independent experiments. *** P<0.001 and ****P<0.0001, (a) versus control. 
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Figure 5.7  Eﬀects of ERK1/2 and PKB inhibition on NGF induced TG2 activity. 
Diﬀerentiating N2a and SHSY5Y cells were pre-treated for 30 min with PD 98059 (50 
µM) or Akt inhibitor XI (100 nM) prior to 1 h stimulation with NGF (100 ng/ml). The 
cell lysates were subjected to biotin–cadaverine incorporation (A and C) or biotin-
peptide crosslinking assay (B and D). The data points represent the mean TG-speciﬁc 
activity ± S.E.M. from four independent experiments. *P<0.05, ** P<0.01, *** P<0.001 
and **** P<0.0001, (a) versus control and (b) versus NGF alone. 
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The role of PKC 
Previous studies have reported an upstream role of PKC in NGF-induced ERK1/2 activation 
(Lloyd & Wooten, 1992; Wooten et al., 2000). Hence, in the present study, the effects of the 
pharmacological inhibition of PKC with Ro 31-8220 in modulating NGF-induced ERK1/2 and 
PKB activation in N2a and SH-SY5Y cells were determined. Treatment with Ro 31-8220 (10 
µM) attenuated NGF-induced ERK1/2 activation in both cell lines (Figure 5.8A and C). 
Conversely, Ro 31-8220 did not block NGF-induced PKB activation in N2a or SH-SY5Y cells 
(Figure 5.8 B and D). These findings suggest an upstream role of PKC in NGF induced ERK1/2 
activation. Subsequent experiments assessed the effects of the pharmacological inhibition of 
PKC on TG2 activity. Differentiated neuroblastoma cells were treated with the PKC inhibitor 
Ro 31-8220 (10 µM) for 30 min prior to stimulation with NGF (100 ng/ml) for 1 h. Cell lysates 
were then subjected to biotin-cadaverine incorporation and biotin-labelled peptide (biotin-
TVQQEL) crosslinking assay. Interestingly, in this case, the inhibition of PKC abolished 
NGF-induced TG2-mediated amine incorporation and peptide crosslinking activity in both N2a 
and SH-SY5Y cells (Figure 5.9), suggesting that PKC may play a mediator role in NGF-induced 
TG2 activity. Taken together, the data presented in this section suggest that NGF stimulates 
TG2 activity in diﬀerentiating N2a and SHSY5Y cells via a multi–protein kinase–dependent 
pathway involving ERK1/2, PKB and the upstream role of PKC.  
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Figure 5.8  Eﬀects of the protein kinase C inhibitor Ro 318220 on NGF-induced 
ERK1/2 and PKB activation in diﬀerentiating N2a and SH-SY5Y cells. 
Where indicated, differentiating cells were pre-treated for 30 min with Ro 318220 (10 
µM) prior to stimulation with NGF (100 ng/ml) for 1 h. The cell lysates were analysed 
by Western blotting for activation of ERK1/2 (A and C) and PKB (B and D) using 
phospho-speciﬁc antibodies. The samples were subsequently analysed on separate blots 
using antibodies recognising total ERK1/2 and PKB. The quantiﬁed data are expressed 
as the percentage of the value for control cells (= 100%) in the absence of protein kinase 
inhibitor and represent the mean ± S.E.M. of four independent experiments. *P<0.05, 
**P<0.01, *** P<0.001 and ****P<0.0001, (a) versus control and (b) versus NGF. 
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Figure 5.9  Eﬀects of PKC inhibition on NGF-induced TG2 activity. 
Diﬀerentiating N2a and SHSY5Y cells were pre-treated for 30 min with Ro 318220 (10 
µM) prior to 1 h of stimulation with NGF (100 ng/ml). The cell lysates were subjected 
to biotin-cadaverine incorporation (A and C) or biotin-peptide crosslinking assay (B and 
D). The data points represent the mean TG-speciﬁc activity ± S.E.M. from four 
independent experiments. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001, (a) 
versus control, (b) versus NGF alone. 
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It was important to assess the effect of the compounds used in this study; NGF and protein 
kinase inhibitors on purified guinea pig liver TG2 activity. TG2 amine incorporating and peptide 
crosslinking assays were carried out using purified guinea pig liver TG2 (50 ng/ well) after 
incubated with the indicated concentrations of the compounds for 30 min then, subjected to the 
biotin-cadaverine incorporation or peptide cross-linking assays. As shown in Figure 5.10 NGF 
and Figure 4.17 (in Chapter 4), protein kinase inhibitors used in this study had no significant 
effect on purified guinea pig liver TG2 activity. Overall, these data suggest that NGF stimulates 
TG2 activity in differentiating N2a and SH-SY5Y cells via a multi protein kinase-dependent 
pathway. 
 
 
Figure 5.10  Effect of compounds used in this study on purified guinea pig liver TG2 
activity. 
TG2 amine incorporating (A) and peptide crosslinking (B) assays were carried out using 
purified guinea pig liver TG2 (50 ng/ well). Briefly, 50 ng of purified guinea pig liver 
TG2 was incubated with NGF (100 ng/ml) for 1 h prior to incubation in presence of either 
6.67 mM calcium chloride or 13.3 mM EDTA containing 225 μM biotin-cadaverine and 
2mM 2-mercaptoethanol for 1 h. Following incubation, the plates were processed as 
described in section 2.2.4 of chapter 2. Data points represent the mean ± S.E.M. TG2 
specific activity from 4 independent experiments at basal level of purified guinea pig 
liver TG2 (control 100%). 
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5.2.3 The role of Ca2+ in NGF-induced TG2 activation 
The transamidating activity of TG2 is Ca2+ dependent (Nurminskaya & Belkin, 2013; Eckert et 
al., 2014); hence, it was important to determine the possible involvement of extracellular Ca2+ 
in the NGF-induced increases in TG2 activity. The involvement of extracellular Ca2+ was 
determined by measuring TG2 stimulation in the absence of extracellular Ca2+ using Ca2+-free 
Hanks/HEPES buﬀer containing 0.1 mM EGTA. Removal of extracellular Ca2+ moderately 
inhibited NGF-induced TG2 transamidation activity in N2a and SH-SY5Y cells (Figure 5.11). 
To ascertain the role of intracellular Ca2+, measurements of TG2 activation were also 
implemented using cells loaded with the intracellular Ca2+ chelator BAPTA-AM (50 µM for 30 
min) in the absence of extracellular Ca2+. Loading cells with BAPTA, in the continued absence 
of extracellular Ca2+, did not lead to further attenuation of NGF-induced TG2 activation (Figure 
5.11). These data indicate that NGF-induced TG2 activation partially depends on the influx of 
extracellular Ca2+.  
 
 
 
 
 
 
Modulation of TG2 activity by NGF in neuroblastoma cells Chapter 5 
140 
 
 
 
  
 
Figure 5.11  The role of Ca2+ in NGF-induced TG2 activity. 
Diﬀerentiating N2a and SH-SY5Y cells were stimulated with NGF (100 ng/ml) for 1 h, 
either in the presence (1.8 mM CaCl2) or absence of extracellular Ca2+ (nominally Ca2+-
free Hanks/HEPES buﬀer containing 0.1 mM EGTA). Experiments were also performed 
using cells pre-incubated for 30 min with 50 µM BAPTA/AM and in the absence of 
extracellular Ca2+ (nominally Ca2+-free Hanks/HEPES buﬀer containing 0.1 mM EGTA) 
to chelate intracellular Ca2+.Cell lysates were subjected to biotin-cadaverine 
incorporation assay (A and C) or protein crosslinking assay (B and D). Data points 
represent the mean TG speciﬁc activity ± S.E.M. from four independent experiments. 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001, (a) versus control, (b) versus NGF 
in the presence of extracellular Ca2+. 
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5.2.4 Visualisation of in situ TG2 activity following NGF treatment 
Since NGF-induced TG2 activity was evident at 1 h with 100 ng/ml exposure and involved 
various protein kinases, the present study determined the effect of time- and concentration- 
dependent NGF-induced TG2 activity at these earlier time points via immunocytochemistry, as 
described in Chapter 2 (section 2.2.5). Cells cultured in chamber slides were incubated with 1 
mM biotin-X-cadaverine (BXC) for 4 h; following this, they were incubated with either NGF 
(100 ng/ml) for the indicated time or the indicated concentrations of NGF for 1 h. TG2-mediated 
BXC incorporation into intracellular proteins was visualised with Extravidin®-FITC (green). 
As shown in Figures 5.12 and 5.13, in N2a and SH-SY5Y cells, NGF stimulated the 
incorporation of BXC into endogenous protein substrates of TG2 in a time- and concentration- 
dependent manner. Furthermore, the in situ responses to NGF in both cell lines were attenuated 
by the TG2 inhibitors Z-DON and R283, as well as the protein kinase inhibitors PD 98059, Akt 
Inhibitor XI and Ro 31-8220 and following removal of extracellular Ca2+ (Figures 5.14 and 
5.15). Overall, these data indicate a similar pattern of TG2 activation observed in vitro. 
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Figure 5.12  Effect of NGF on in situ TG2 activity in differentiating N2a cells. 
The cells were incubated with 1 mM biotin-X-cadaverine (BXC) for 6 h, after which, 
they were incubated with (A) NGF (100 ng/ml) for the indicated time or (B) the indicated 
concentration of NGF for 1 h. TG2-mediated BXC incorporation into intracellular 
proteins was visualised using FITC-conjugated ExtrAvidin® (green). Nuclei were 
stained with DAPI (blue) and viewed using a Leica TCS SP5 II confocal microscope (20x 
objective magnification). The images presented are from one experiment and 
representative of three assays. Quantified data points for (C) time course and (D) 
concentration response represent the mean ± S.E.M. of fluorescence intensity relative to 
DAPI stain for five fields of view each from at least three independent experiments. 
*P<0.05 and **P<0.01 versus the control response. 
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Figure 5.13  Effects of NGF on in situ TG2 activity in differentiating SH-SY5Y cells. 
The cells were incubated with 1 mM biotin-X-cadaverine (BXC) for 6 h, after which, they 
were incubated with (A) NGF (100 ng/ml) for indicated time or (B) the indicated 
concentration of NGF for 1 h. The TG2-mediated BXC incorporation into intracellular 
proteins was visualised using FITC-conjugated ExtrAvidin® (green). Nuclei were stained 
with DAPI (blue) and viewed using a Leica TCS SP5 II confocal microscope (20x 
objective magnification). The images presented are from one experiment and 
representative of three assays. Quantified data points for (C) time course and (D) 
concentration response represent the mean ± S.E.M. of fluorescence intensity relative to 
DAPI staining for five fields of view each from at least three independent experiments. 
*P<0.05 and **P<0.01 versus the control response. 
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Figure 5.14  NGF-induced in situ TG activity in diﬀerentiating N2a cells. 
The cells were incubated with 1 mM biotin-X-cadaverine (BXC) for 6 h, after which, 
they were incubated with (A) TG2 inhibitors Z-DON (150 µM) and R283 (200 µM) for 
1 h, (B) PD 98059 (50 µM) and Akt Inhibitor XI (100 nM) for 30 min, or (C) Ro 31-
8220 (10 µM) for 30 min or the absence of extracellular Ca2+ (nominally Ca2+-free 
Hanks/HEPES buﬀer containing 0.1 mM EGTA) prior to stimulation with NGF (100 
ng/ml) for 1 h. TG2-mediated BXC incorporation into intracellular proteins was 
visualised using FITC-conjugated ExtrAvidin® (green). Nuclei were stained with DAPI 
(blue) and viewed using a Leica TCS SP5 II confocal microscope (20× objective 
magniﬁcation). Scale bar = 20 µm. The images presented are from one experiment and 
representative of three assays. Quantiﬁed data represent the mean ± S.E.M. of 
ﬂuorescence intensity relative to DAPI staining for ﬁve ﬁelds of view each from at least 
three independent experiments. *P<0.05, ** P<0.01, *** P<0.001 and ****P<0.0001 
versus the control response. 
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Figure 5.15  NGF-induced in situ TG activity in diﬀerentiating SH-SY5Y cells. 
The cells were incubated with 1 mM biotin-X-cadaverine (BXC) for 6 h, after which, 
they were incubated with (A) TG2 inhibitors Z-DON (150 µM) and R283 (200 µM) for 
1 h, (B) PD 98059 (50 µM) and Akt Inhibitor XI (100 nM) for 30 min, or (C) Ro 31-8220 
(10 µM) for 30 min or the absence of extracellular Ca2+ (nominally  Ca2+-free 
Hanks/HEPES buﬀer containing 0.1 mM EGTA) prior to stimulation with NGF (100 
ng/ml) for 1 h. TG2-mediated BXC incorporation into intracellular proteins was 
visualised using FITC-conjugated ExtrAvidin® (green). Nuclei were stained with DAPI 
(blue) and viewed using a Leica TCS SP5 II confocal microscope (20× objective 
magniﬁcation). Scale bar = 20 µm. The images presented are from one experiment and 
representative of three assays. Quantiﬁed data represent the mean ± S.E.M. of 
ﬂuorescence intensity relative to DAPI stain for ﬁve ﬁelds of view each from at least 
three independent experiments. *P<0.05, ** P<0.01, *** P<0.001 and ****P<0.0001 
versus the control response. 
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5.2.5. Phosphorylation of TG2 in response to NGF 
Based on previous observations, NGF-induced TG2 activity involved various signalling 
proteins; it can be speculated that NGF could phosphorylate TG2 via those protein kinases. 
Therefore, the effect of NGF on the phosphorylation status of TG2 was next examined via the 
immunoprecipitation of TG2, followed by SDS-PAGE and Western blot analysis, using anti-
phosphoserine and anti-phosphothreonine antibodies, as described in Chapter 2 (section 2.2.10). 
The observation from these experiments clearly revealed that NGF (100 ng/ml) enhanced TG2-
bound phosphoserine and phosphothreonine in differentiating N2a (Figures 5.16 and 5.18) and 
SH-SY5Y cells (Figures 5.17 and 5.19). In addition, pre-treatment with PD 98059 (50 µM), Akt 
Inhibitor XI (100 nM) and Ro 31-8220 (10 µM) significantly inhibited NGF-mediated TG2 
phosphorylation in differentiating N2a (Figures 5.16 and 5.18) and SH-SY5Y cells (Figures 
5.17 and 5.19). In marked contrast, removal of extracellular Ca2+ had no significant influence 
on NGF-induced TG2 phosphorylation, and this result was similar in both cell lines (Figures 
5.18 and 5.19). These data indicate that NGF promotes robust increases in TG2 
phosphorylation, and this process is mainly ERK1/2, PKB and PKC dependent.  
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Figure 5.16  Effects of the ERK1/2 inhibitor PD 98059 and Akt inhibitor XI on NGF-
induced phosphorylation of TG2 in differentiating N2a cells. 
Where indicated, differentiating N2a cells were pre-treated for 30 min with PD 98059 (50 µM) 
or Akt Inhibitor XI (100 nM) prior to stimulation with NGF (100 ng/ml) for 1 h. Following 
stimulation with NGF, the cell lysates were subjected to immunoprecipitation using anti-TG2 
monoclonal antibody as described in section 2.2.10. The resultant immunoprecipitated protein(s) 
were subjected to SDS-PAGE and Western blot analysis using (A) anti-phosphoserine and (B) 
anti-phosphothreonine antibodies. One-tenth of the total input was applied to the first lane to 
show the presence of phosphorylated proteins prior to immunoprecipitation, and negative 
controls with the immunoprecipitation performed with immunobeads only were included to 
demonstrate the specificity of the band shown. Quantified data for NGF-induced increases in 
TG2-bound serine and threonine phosphorylation are expressed as a percentage of the TG2 
phosphorylation observed in control cells (= 100%). Data points represent the mean    S.E.M. 
from three independent experiments. ** P<0.01 and *** P<0.001 (a) versus control and (b) 
versus NGF alone. 
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Figure 5.17  Effects of the ERK1/2 inhibitor PD 98059 and Akt inhibitor XI on 
NGF-induced phosphorylation of TG2 in differentiating SH-SY5Y cells. 
Where indicated, differentiating SH-SY5Y cells were pre-treated for 30 min with PD 
98059 (50 µM) or Akt Inhibitor XI (100 nM) prior to stimulation with NGF (100 ng/ml) 
for 1 h. Following stimulation with NGF, cell lysates were subjected to 
immunoprecipitation using anti-TG2 monoclonal antibody, as described in section 
2.2.10. The resultant immunoprecipitated protein(s) were subjected to SDS-PAGE and 
Western blot analysis using (A) anti-phosphoserine and (B) anti-phosphothreonine 
antibodies. One-tenth of the total input was applied to the first lane to show the presence 
of phosphorylated proteins prior to immunoprecipitation and negative controls with the 
immunoprecipitation performed with immunobeads only were included to demonstrate 
the specificity of the band shown. Quantified data for NGF-induced increases in TG2-
bound serine and threonine phosphorylation are expressed as a percentage of the TG2 
phosphorylation observed in control cells (= 100%). Data points represent the mean    
S.E.M. from three independent experiments. *P<0.05, ** P<0.01 and *** P<0.001 (a) 
versus control and (b) versus NGF alone. 
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Figure 5.18  Effect of the Ca2+ and PKC inhibitor Ro 31-8220 on NGF-induced 
phosphorylation of TG2 in differentiating N2a cells. 
Where indicated, differentiating N2a cells were subjected to the absence of extracellular 
Ca2+ (nominally Ca2+-free Hanks/HEPES buffer containing 0.1 mM EGTA) or pre-
treated for 30 min with Ro 31-8220 (10 µM) prior to stimulation with NGF (100 ng/ml) 
for 1 h. Following stimulation with NGF, the cell lysates were subjected to 
immunoprecipitation using anti-TG2 monoclonal antibody, as described in section 
2.2.10. The resultant immunoprecipitated protein(s) were subjected to SDS-PAGE and 
Western blot analysis using (A) anti-phosphoserine and (B) and anti-phosphothreonine 
antibodies. One-tenth of the total input was applied to the first lane to show the presence 
of phosphorylated proteins prior to immunoprecipitation, and negative controls with the 
immunoprecipitation performed with immunobeads only were included to demonstrate 
the specificity of the band shown. Quantified data for NGF-induced increases in TG2-
bound serine and threonine phosphorylation are expressed as a percentage of the TG2 
phosphorylation observed in control cells (= 100%). Data points represent the mean ± 
S.E.M. from three independent experiments. *P<0.05, ** P<0.01 and *** P<0.001 (a) 
versus control and (b) versus NGF alone. 
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Figure 5.19  Effect of the Ca2+ and PKC inhibitor Ro 31-8220 on NGF-induced 
phosphorylation of TG2 in differentiating SH-SY5Y cells. 
Where indicated, differentiating SH-SY5Y cells were subjected to the absence of 
extracellular Ca2+ (nominally Ca2+-free Hanks/HEPES buffer containing 0.1 mM 
EGTA) or pre-treated for 30 min with Ro 31-8220 (10 µM) prior to stimulation with 
NGF (100 ng/ml) for 1 h. Following stimulation with NGF, cell lysates were subjected 
to immunoprecipitation using anti-TG2 monoclonal antibody, as described in section 
2.2.10. The resultant immunoprecipitated protein(s) were subjected to SDS-PAGE and 
Western blot analysis using (A) anti-phosphoserine and (B) and anti-phosphothreonine 
antibodies. One-tenth of the total input was applied to the first lane to show the presence 
of phosphorylated proteins prior to immunoprecipitation, and negative controls with the 
immunoprecipitation performed with immunobeads only were included to demonstrate 
the specificity of the band shown. Quantified data for NGF-induced increases in TG2-
bound serine and threonine phosphorylation are expressed as a percentage of the TG2 
phosphorylation observed in the control cells (= 100%). Data points represent the mean 
± S.E.M. from three independent experiments. ** P<0.01 and *** P<0.001 (a) versus 
control and (b) versus NGF alone. 
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 Discussion 
As the neurotrophic factor PACAP-27 induces TG2 activity via multiple protein kinase 
pathways (Chapter 4), determining the role of NGF – another member of the neurotrophin 
family – will provide insight into the molecular mechanisms underlying the correlation of these 
neurotrophic factors and the multifunctional enzyme TG2. This will also aid in studying the 
possible neuroprotective effect associated with this activation. The present study focussed on 
identifying whether TG2 is modulated by NGF in mouse and human neuroblastoma cells and 
determining the molecular mechanisms underlying such modulation. The data in this study 
provide sufficient evidence to support the notion that TG2 activity is modulated by NGF in 
differentiated neuroblastoma cells via ERK1/2, PKB and PKC-dependent pathways.  
5.3.1 Modulation of TG2 transamidation activity by NGF 
Over the years, NGF has been demonstrated to mediate neurite outgrowth and neuroprotection 
(Howe, & Mobley, 2001; Huang & Reichardt, 2001; Oe et al., 2005; Tang et al., 2005). TG2 
has been shown to be necessary for enhancing neurite outgrowth (Tucholski et al., 2001). 
However, it is not known whether TG2 has a role in the growth-promoting action of NGF. In a 
previous study, the interplay between NGF and TG2 in neuroblastoma cells was established; it 
was found that exposure of RA-differentiated N2a cells to NGF (4 days) caused a higher level 
of TG2 activity compared with that shown in cells treated with NGF alone (Condello et al., 
2008). This suggests that NGF and RA act synergistically to promote TG2 activation (Condello 
et al., 2008). However, to date, there is no evidence concerning crosstalk between short-term 
treatment with NGF, which is not carried out for differentiation purposes, and TG2 activity in 
neuroblastoma cells. In the current study, it appears that short-term treatment with NGF (<4 h) 
triggered time- and concentration-dependent increases in in vitro TG2-mediated biotin-
cadaverine incorporation and protein crosslinking activity in diﬀerentiating N2a (Figure 5.1) 
and SH-SY5Y (Figure 5.2) cells. This peaked at 1 h and a concentration of 100 ng/ml. The 
findings were further confirmed by quantitative analysis of ﬂuorescence microscopy of the in 
situ intracellular TG2 activity following NGF stimulation, which indicated a time- and 
concentration-dependent NGF induction of in situ TG2-mediated polyamine incorporation into 
the protein substrate activity in both differentiating neuroblastoma cell lines (Figures 5.12 and 
5.13). The results were comparable to those concerning the NGF-induced amine incorporation 
activity observed in vitro. Overall, these initial observations suggest that NGF has a direct 
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stimulation effect on inducing TG2 activity. Since the main aim of this study was to investigate 
NGF-induced TG2 activity and its possible involvement in neuroprotection and cell survival 
effects, in this context, the data obtained here are in line with previous observations suggesting 
that NGF exerts rapid neuroprotective effects (30 min treatment) and maximum protection 
within 1 h; this research also showed that 100 ng/ml of NGF is efficient in inducing sufficient 
neuroprotective action (Nguyen et al., 2010). This protective effect has been sustained up to 24 
h through the downstream signalling cascade (Nguyen et al., 2010). 
A previous study revealed that exposure of N2a cells to NGF (50 ng/ml) for 4 days mediated 
the induction of TG2 expression (Condello et al., 2008). However, from the findings of the 
current study, it is important to note that the levels of TG2 protein expression did not change 
during a short time period (<4 h), emphasising that the enhancement of TG2 activity induced 
by NGF is not a consequence of increased levels of TG2 expression. The possible explanation 
for this variation is that, in neuroblastoma cells, the optimum incubation time for NGF to 
enhance TG2 protein expression is up to 4 days, while a shorter time would be sufficient to 
induce TG2 enzymatic activity. Although diﬀerentiating N2a and SH-SY5Y cells also express 
TG1 and TG3 isoforms, NGF-induced increases in TG activity were inhibited by R283 and Z-
DON, conﬁrming that the observed increases in TG activity occurred selectively via TG2 
(Figure 5.4). This observation was also confirmed by assessing TG2’s in situ activity, and the 
findings revealed an equivalent pattern to reverse the NGF-induced in situ TG2 activity by the 
TG2 inhibitors R283 and Z-DON in both neuroblastoma cell lines (Figures 5.14 A and 5.15 A). 
5.3.2 The role of protein kinases  
It has recently been shown that the stimulation of intracellular TG2-mediated transamidase 
activity by the A1 adenosine receptor depends on ERK1/2, PKC, and TG2 phosphorylation 
(Vyas et al., 2016). There is increasing evidence for NGF-induced activation of the 
MAPK/ERK, phospholipase C (PLC)-γ1 and (PI3K/Akt) signalling cascades via the TrkA 
receptor, which are required for neuronal survival (Patapoutian and Reichardt 2001; Lemmon 
et al., 2010). These NGF signalling networks, which are initiated and controlled by Ras, 
represent a precise cascade of events that directly regulate protein–protein interactions. Since 
the crosslinking activity of TG1 is regulated via ERK1/2 and PKC, it is conceivable that NGF 
may modulate the activity of multiple TG isoforms through the induced kinases (Bollag et al., 
2005). Moreover, as the data in the previous section 5.3.1 showed that NGF significantly 
enhanced TG2 activity, it is presumed that NGF-induced activation of MAPKs (especially 
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ERK1/2, PKC and PKB/Akt) would be involved in enhancing of TG2 activity. The roles of 
protein kinases in NGF-induced TG2 activity and TG2 phosphorylation are discussed in the 
following sections.   
The role of protein kinases in NGF-mediated TG2 activation 
Since NGF via the TrkA receptor stimulates protein kinase cascades involving ERK1/2, PKB 
and PKC (Wang et al., 2014), the current study explored the roles of these kinases in NGF-
induced TG2 activation. Initially, the protein kinases activated by NGF in differentiating N2a 
and SH-SY5Y were characterised, and the effects of the appropriate protein kinase 
pharmacological inhibitors were assessed. The findings confirmed that NGF stimulates the 
phosphorylation of ERK1/2 and PKB; these findings are broadly comparable to those of 
previous studies, which have reported the activation pattern of ERK1/2 and PKB by NGF 
(Wang et al., 2014). As depicted in Figure 5.5, the induced activation of ERK1/2 and PKB was 
attenuated by the MEK1/2 inhibitor PD 98059 and Akt Inhibitor XI, respectively, in both 
neuroblastoma cell lines. ERK1/2 and Akt/PKB are independent signalling programs that 
generate compensatory mechanisms, which are especially important and sufficient for 
controlling cell survival and the differentiation process. Moreover, they have been found to be 
essential for NGF to induce the cell survival of different neuronal cell types (Yao & Cooper, 
1995; Philpott et al., 1997; Nguyen et al., 2010). In addition, there is extensive crosstalk 
between those pathways for regulating each other (Yu et al., 200; Moelling et al., 2002; 
Lemmon et al., 2010; Mendoza et al.,2011). For example, in various cancer models, the 
inhibition of both pathways conjointly has been found to effectively minimise tumour growth 
(Engelman et al., 2008; Kinkade et al., 2008). Thus, in this project, it was of interest to 
determine whether they could have a negative cross-inhibition effect on each other. As shown 
in Figure 5.6, inhibiting of PKB using Akt Inhibitor XI did not influence the NGF-induced 
increase in ERK1/2 phosphorylation; in addition, inhibition of MEK1/2 using PD 98059 had no 
effect on the PKB phosphorylation induced by NGF in N2a and SH-SY5Y cells. The data from 
these experiments suggest inhibitor selectivity and a lack of ‘crosstalk’ between the two kinase 
pathways in differentiating N2a and SH-SY5Y cells. 
Increasing evidence suggests that TG2 is regulated by phosphorylation. As in the previously 
mentioned example, phosphorylation of TG2 by PKA inhibits its transamidating activity, but 
augments its kinase activity (Mishra et al., 2007), whereas PTEN-induced putative kinase 1 
(PINK1) mediated phosphorylation of TG2 inhibits its proteasomal degradation (Min et al., 
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2015). As mentioned previously, TG2 activity could be modulated by ERK1/2, PKB and PKC 
induced by GPCRs, such as the A1 adenosine receptor (Vyas et al., 2016) or receptor tyrosine 
kinases (Sivaramakrishan et al., 2013). Thus, it was necessary to assess their role in NGF-
induced TG2 activity. The observation that pharmacological inhibition of ERK1/2, PKB and 
PKC attenuated NGF-induced TG2 transamidase activity in N2a and SH-SY5Y cells suggests 
prominent roles for these protein kinases in NGF-modulating TG2 activity (Figures 5.7 and 
5.9). These observations agree with previous research, which has revealed roles for ERK1/2, 
PKB and PKC in TG2 activation triggered by members of the GPCR family (Vyas et al., 2016, 
2017). Furthermore, NGF-induced in situ TG2 responses were also sensitive to the 
pharmacological inhibition of ERK1/2, PKB and PKC, confirming the role of these kinase 
pathways. Finally, it is important to note that the attenuation of NGF-induced TG2 activation 
by the inhibition of PKC reﬂected the reported upstream role of PKC isozymes in NGF-induced 
ERK1/2 activation (Lloyd & Wooten, 1992; Wooten et al., 2000). Clearly, further assessment 
is required to establish whether NGF activation promotes TG2 phosphorylation and, if so, 
identify the protein kinases involved. These targets are discussed in the next section. Such 
assessment would provide a better understanding of how the NGF-modulated TG2 activity may 
induce neuronal survival and neurite outgrowth.   
The role of protein kinases in NGF-mediated TG2 phosphorylation 
Considering the evident roles of ERK1/2, PKB and PKC in modulating TG2 activity (described 
in the previous section), it was of interest to investigate the role of these kinases in the 
phosphorylation status of TG2 following NGF stimulation. TG2 phosphorylation was 
monitored by immunoprecipitation, and the data demonstrated that TG2 was phosphorylated in 
response to NGF (Figures 5.16, 5.17, 5.18 and 5.19) in both neuroblastoma cell lines. Therefore, 
it is conceivable that the modulation of TG2 phosphorylation represents a downstream target of 
NGF-induced signalling. In this context, several studies have previously outlined the role of 
protein kinases in the regulation of TG2 activity. For example, a previous study reported that 
TG2 is phosphorylated by PKA at Ser215 and Ser216 which promotes its interaction with the 
scaﬀolding protein 14-3-3, leading to the attenuation of TG2 kinase activity (Mishra & Murphy, 
2006). Furthermore, TG2 is phosphorylated at an unknown site(s) by PINK1 (Min et al., 2015). 
It is also known that phosphorylation of TG2 by PKA at Ser216 inhibits its transamidase activity 
and enhances its kinase activity (Mishra et al., 2007; Wang et al., 2012). In the current study, it 
was also reasonable to investigate the influence of the inhibition of the involved protein kinases 
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on NGF-induced TG2 phosphorylation. From the findings in this chapter, it is quite clear that 
pharmacological inhibition of ERK 1/2 (PD 98059), PKB (Akt inhibitor XI) or PKC (Ro 31-
8220) significantly attenuated the NGF-induced promotion of TG2 serine and threonine 
phosphorylation. This suggests similar roles to those reported in earlier work, which showed 
that inhibition of ERK 1/2 and PKC reversed the TG2 phosphorylation induced by the activation 
of the A1 receptor in a cardiomyocyte model (Vyas et al., 2016). However, it is not known 
whether ERK1/2, PKB and PKC directly phosphorylate TG2, leading to direct enhancement of 
enzymic activity, or whether these kinases may phosphorylate downstream targets that 
subsequently interact with TG2, resulting in enhanced activity. Furthermore, as TG2 possesses 
kinase activity, the process possibly involves auto-phosphorylation; thus, further work to 
determine the possible auto-phosphorylation site, if it exists, in response to NGF would be 
worthwhile for improving the understanding of the signalling mechanism of the induced 
response. 
The role of Ca2+ in NGF-induced TG2 activation 
Previous studies have shown that NGF triggers intracellular Ca2+ release in C6-2B glioma cells 
(De Bernardi et al., 1996) and extracellular Ca2+ inﬂux in PC12 and bovine chromaﬃn cells 
(Pandiella Alonso et al., 1986). Moreover, since TG2 transamidase activity is Ca2+ dependent, 
it was of interest to investigate the potential involvement of extracellular and intracellular Ca2+ 
in NGF-induced TG2 activation. The data presented indicate that NGF-induced TG2-mediated 
in vitro (Figure 5.11) and in situ (Figures 5.14 C and 5.15 C) transamidase activity partially 
depends on extracellular Ca2+, suggesting that NGF triggers Ca2+ inﬂux in N2a and SH-SY5Y 
cells. However, no measurable increases in intracellular Ca2+ were observed following 
stimulation of these cells with NGF. The reason(s) for this are not currently known, but may 
reﬂect localised NGF-induced increases in [Ca2+]i that were not detectable using the technique 
employed. While the levels of Ca2+ required for TG2 activation are typically in the order of 3–
100 µM, there is evidence that [Ca2+]i can reach levels suﬃcient to activate intracellular TG2 
(Király et al., 2011). Alternatively, the participation of Ca2+ in NGF-induced TG2 activation 
may necessitate the sensitisation of TG2 to low levels of [Ca2+]i. It has been suggested that the 
interaction of TG2 with protein binding partners and/or membrane lipids promotes a 
conformational change that enables activation at low levels of intracellular [Ca2+] (Király et al., 
2011). It is also important to note that removal of extracellular Ca2+ has no effect on NGF-
induced TG2 phosphorylation (Figures 5.18 and 5.19). It has been reported that conformational 
changes in TG2 triggered by Ca2+ facilitate its subsequent phosphorylation by PKA and/or 
Modulation of TG2 activity by NGF in neuroblastoma cells Chapter 5 
156 
 
ERK1/2. However, in the current study, the removal of extracellular Ca2+ showed no effect on 
TG2 phosphorylation induced by NGF. It could be that TG2 phosphorylation induced by NGF 
sensitises TG2 to activate, and this reaction exists even in the presence of low Ca2+ levels. It 
would be of interest to study the effects of Ca2+ removal and either of the protein kinases 
simultaneously on TG2 phosphorylation to further understand the selective role of Ca2+ on this 
process. Clearly, further studies are required to determine how NGF-induced TG2 activation 
occurs in the absence of detectable increases in [Ca2+]i, but the kinase-dependent pathways 
outlined in the present study could be central to these novel aspects of TG2 regulation. 
 Conclusion 
The data presented in this chapter indicate that the neurotrophic factor NGF (100 ng/ml, 1 h) 
induces TG2 transamidase activity and TG2 phosphorylation in differentiating N2a and SH-
SY5Y neuroblastoma cells. Furthermore, the findings demonstrate that this modulation is 
carried out at the molecular level via ERK1/2-, PKB/Akt- and PKC-dependent pathways; 
summarised in Figure 5.20. The results in this chapter highlight the existence of crosstalk 
between neurotrophic NGF and TG2 activity in neuroblastoma cells, and this discussion may 
provide the basic components of the novel modulation of neuronal cell function (Table 5.1) 
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Results of the range of treatments used in this study to investigate the role of NGF in 
modulating of TG2 activity. Differentiated N2a or SH-SY5Y neuroblastoma cells were 
treated with the compounds in the table; then, the cells were stimulated with NGF, 
and the TG2 activity was assessed by different approaches, as follows: in vitro amine 
incorporation and peptide crosslinking assays, visualisation of in situ amine 
incorporation activity, protein expression by Western blotting (WB) and 
immunoprecipitation (IP). ns= no significant decrease, nd= not determined, *P0.05, 
**P<0.01, ***P<0.001, and ****P<0.0001, compared to the control  
 
 
 
 
 
 
 
Treatment 
Assessment following NGF treatment 
Amine 
incorporation 
Peptide 
crosslinking 
 
In-situ 
 
IP 
 
WB 
N2a SH-SY5Y N2a SH-SY5Y N2a SH-SY5Y N2a SH-SY5Y N2a SH-SY5Y 
Z-DON 
(150 μM; TG2 inhibitors) 
 
**** 
 
**** 
 
**** 
 
** 
 
*** 
 
***  
 
nd 
 
nd 
 
nd 
 
nd 
R283 
(200 μM; TG2 inhibitors) 
 
*** 
 
** 
 
**** 
 
** 
 
** 
 
** 
 
nd 
 
nd 
 
nd 
 
nd 
PD 98059 
(50 μM; MEK1/2 inhibitor) 
 
** 
 
*** 
 
*** 
 
** 
 
** 
 
*** 
 
** 
 
** 
 *  vs ERK1/2                      
ns vs PKB 
                       
***  vs ERK1/2                      
ns vs PKB  
 
Akt inhibitor XI 
(0.1 μM; PKB inhibitor) 
 
 
* 
 
** 
 
** 
 
* 
 
*** 
 
*** 
 
** 
 
* 
ns vs ERK1/2                      
** vs PKB 
ns vs ERK1/2                      
** vs PKB  
Ro 31-8220 
(10 μM; PKC inhibitor) 
 
** 
 
* 
 
 
*** 
 
** 
 
** 
 
** 
 
 
 
 
** vs ERK1/2                      
ns vs PKB 
* vs ERK1/2                      
ns vs PKB 
Nominally Ca2+-free 
Hanks/HEPES buffer containing 
0.1 mM EGTA 
 
* 
 
* 
 
** 
 
* 
 
** 
 
* 
 
 ns  
 
ns 
 
 
nd 
 
nd 
50 μM BAPTA-AM in nominally 
Ca2+-free Hanks/HEPES buffer 
containing 0.1 mM EGTA 
 
** 
 
* 
 
*** 
 
** 
 
** 
 
nd 
 
nd 
 
nd 
 
nd 
 
nd 
Table 5.1  The overall ability of different treatments to inhibit NGF-induced TG2 
activity assessed by different approaches 
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Figure 5.20  Schematic summary of the NGF-induced TG2 activation. 
NGF triggers activation of various downstream targets in differentiated mouse N2a and 
SH-SY5Y cells. NGF induces TG2 activity and phosphorylation by triggering the 
activation of protein kinases (ERK1/2, Akt/PKB and PKC). Solid black arrows represent 
the findings of the current study; dashed arrows represent findings from other research 
(Sivaramakrishan et al., 2013). 
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Chapter 6 
 
 
 
6 The role of TG2 in PACAP-27- and NGF-induced 
neuroblastoma cell survival and neurite outgrowth 
 Introduction 
A substantial body of evidence indicates that one of the key roles of neurotrophic factors is 
protecting neuronal cells from cell death after cerebral ischaemia and inducing neurite 
outgrowth (Kromer, 1987; Wang et al., 1993; Gonzalez et al., 1997; Erhardt & Sherwood, 2004; 
Oliveira et al., 2013). Both NGF and PACAP have neurotrophic effects, which have been 
studied extensively; they promote differentiation, maturation, neurite outgrowth and survival of 
neurons in vivo and in vitro (Williams et al., 1986; Hatanaka et al., 1988; akei et al., 2000; 
Yuhara et al., 2001). In addition, the intracellular transduction pathways involved in their 
neurotrophic effects are now well established (Kaplan & Miller, 2000; Ravni et al., 2006). For 
example, in the PC12 cell line, PACAP prevents cell apoptosis by activating the PKA signalling 
cascade (Reglodi et al., 2004), whereas NGF inhibits apoptosis and induces neuroprotection 
through the PI-3K/PKB pathway (Shimoke & Chiba, 2001; Salinas et al. 2003; Wu & Wong, 
2005). In agreement with the previous studies outlined above, the two trophic factors exerted 
similar effects in the present study, especially neurite outgrowth and neuronal survival; thus, it 
can be speculated that they may be protecting neuronal cell death via a similar modulator. It 
was recently suggested that TG2 has a neuronal cell protection and differentiation role 
(Tatsukawa et al., 2016). In addition, it has been reported that TG2 is activated via protein 
kinases, such as ERK1/2, PKB and PKC (Vyas et al., 2016, 2017). It is conceivable that these 
trophic factors could modulate TG2 activity to play a role in neuronal cell survival and neurite 
outgrowth. Hence, the aims of the work presented in this chapter were to assess the possible 
role of the multifunctional enzyme TG2 in the following: i) PACAP- and NGF-induced 
neuroprotection, which were determined after hypoxia exposure by assessing the cell viability 
and activation of caspase-3, and ii) their neurite outgrowth, as examined by high-throughput 
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screening for quantitatively analysing multiple parameters of neurite outgrowth in 
neuroblastoma cells. It was of interest to investigate whether the neurotrophic factor-induced 
TG2 activity has a protective role against hypoxia-induced neuronal cell injury, as well as 
whether it is involved in the neurite outgrowth process; such findings could reveal a new 
therapeutic target for neurodegenerative and hypoxia-associated neuronal injury.  
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 Results 
6.2.1 The role of TG2 in cell survival 
Determination of the time course for hypoxia-induced cell death 
Initially, the time course of simulated hypoxia (5% CO2/1% O2 in glucose- and serum-free 
medium at 37°C)-induced cell death was examined. Differentiating N2a and SH-SY5Y cells 
were exposed to hypoxia for different durations (0, 1, 2, 4, 6, 8 and 24 h). Then, cell viability 
was monitored by MTT reduction assay, cytotoxicity was measured by LDH activity assay 
(section 2.2.11), and the activation of caspase-3; an enzyme involved in programmed cell death 
(apoptosis), which was monitored via Western blotting (section 2.2.9). In both N2a and SH-
SY5Y cells, exposure to simulated hypoxia (1% O2) resulted in a time-dependent decrease in 
MTT reduction, increase in LDH release and gradual increase in caspase-3 activation. As shown 
in Figures 6.1 A and 6.2 A, cell viability was significantly decreased at 8 h of exposure to 
hypoxia in both cell lines, with a decrease in MTT reduction to about 60% of the control value. 
Notably, the release of LDH release was highly statistically significant (p < 0.001) at 8 h of 
hypoxia exposure compared with the control (at 0 h of hypoxia) in both cell lines (Figures 6.1B 
and 6.2B). Exposing neuroblastoma cells to 8 h of hypoxia triggered a significant increase (p < 
0.001) in caspase-3 activation (Figures 6.1 C-D and 6.2 C-D). Furthermore, to determine the 
timescale of the morphological changes induced by hypoxia in differentiated N2a and SH-SY5Y 
cells, the cells were stained with Coomassie Blue, and changes in cell morphology were 
assessed microscopically. As shown in Figure 6.3, about 25% of the neurites retracted in the 
first 2 h after hypoxia exposure. At 8 h of hypoxia, both N2a and SH-SY5Y cell images showed 
cell body shape and size alterations; these observations provided evidence of neuroblastoma 
cell deterioration occurring after 8 h of exposure to hypoxia. The previous cell viability and 
morphology findings were clearly comparable in both the mouse and human neuroblastoma cell 
lines, and they showed that exposing the cells to 8 h of hypoxia is sufficient to induce cell death; 
hence, an 8-h duration was chosen for the subsequent experiments. 
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Figure 6.1  Effect of simulated hypoxia on cell viability in terms of MTT reduction, 
LDH release and caspase-3 activity in differentiating N2a cells. 
Cells in glucose- and serum-free DMEM were exposed to hypoxia (1% O2) for the 
indicated times. Cell viability was assessed by measuring (A) the metabolic reduction of 
MTT by cellular dehydrogenases, (B) release of LDH into the culture medium and (C) 
caspase-3 activity via Western blot analysis using the anti-active caspase-3 antibody. 
Levels of GAPDH are shown for comparison. (D) Quantified caspase-3 activity data. Data 
are expressed as the percentage of the normoxic control (=100%) and represent the mean 
± SEM of four independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p 
< 0.0001 versus normoxic control. 
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Figure 6.2  Effect of simulated hypoxia on cell viability MTT reduction, LDH release 
and caspase-3 activity in differentiating SH-SY5Y cells. 
Cells in glucose- and serum-free DMEM were exposed to hypoxia (1% O2) for the 
indicated times. Cell viability was assessed by measuring (A) the metabolic reduction of 
MTT by cellular dehydrogenases, (B) release of LDH into the culture medium and (C) 
caspase-3 activity via Western blot analysis using the anti-active caspase-3 antibody. 
Levels of GAPDH are shown for comparison. (D) Quantified caspase-3 activity data. 
Data are expressed as the percentage of the normoxic control (=100%) and represent the 
mean ± SEM from four independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 
and ****p < 0.0001. 
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Figure 6.3  Effect of simulated hypoxia on differentiating N2a and SH-SY5Y cell 
morphology. 
Morphological evidence of injury and death in neurons exposed to hypoxia for 0, 2, 8 
and 24 h in differentiating N2a and SH-SY5Y cells. Cells were exposed to hypoxia (1% 
O2) for the indicated times. Cells were fixed with 90% (v/v) methanol and stained with 
Coomassie Brilliant Blue; the changes in neuronal cell morphology following hypoxia 
exposure were then visualised using light microscopy (20× objective lens). Arrows 
indicate the changes in neurite length and cell disintegration. The images presented are 
from one experiment and representative of three independent experiments. Scale bar = 
100 µm. 
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Role of TG2 in PACAP-27-induced cell survival against hypoxia-induced cell death 
Initially, the identification of PACAP-27’s cytoprotective role against hypoxia injury was 
assessed. Differentiating N2a and SH-SY5Y cells were pre-treated with PACAP-27 (100 nM) 
for 10 min and 30 min, respectively, prior to 8 h of hypoxia exposure. Following hypoxia 
incubation, cell viability was assessed. As shown in Figures 6.4, 6.5, 6.6 and 6.7, the findings 
revealed that pre-treatment with PACAP-27 significantly attenuated the hypoxia-induced 
decrease in MTT reduction, release of LDH and activation of caspase-3, thereby indicating the 
protective role of PACAP-27. This protection was abolished when cells were pre-treated with 
the PAC1 receptor antagonist PACAP 6-38 (100 nM; 30 min), confirming that the induced 
cytoprotection was modulated via the PAC1 receptor (Figure 6.4 and Figure 6.5). Finally, to 
determine if TG2 was involved in the PACAP-27-induced cell survival in neuroblastoma cells, 
the TG2 inhibitors R283 and Z-DON were used. Differentiating neuroblastoma cells were pre-
treated for 1 h with Z-DON (150 μM) or R283 (200 μM) prior to stimulation with PACAP-27 
(100 nM) and exposed to hypoxia. Both TG2 inhibitors attenuated PACAP-27-induced cell 
survival (Figures 6.6 and 6.7).  Overall, these results demonstrate a role of TG2 in PACAP-27-
induced cell survival and protection against hypoxia via the PAC1 receptor in both mouse N2a 
and human SH-SY5Y cells. 
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Figure 6.4  Effect of PACAP-27 on hypoxia-induced cell death in N2a cells. 
Differentiating N2a cells were pre-treated with the PAC1 receptor antagonist PACAP 6-
38 (100 nM) for 30 min before the addition of PACAP-27 (100 nM) for 10 min prior to 
8 h of hypoxia (1% O2) or normoxia. Cell viability was assessed by measuring (A) the 
metabolic reduction of MTT by cellular dehydrogenases, (B) release of LDH into the 
culture medium and (C) caspase-3 activity via Western blot analysis using the anti-active 
caspase 3 antibody. (D) Quantified caspase-3 activity data. Data are expressed as a 
percentage of normoxia control cell values (=100%) and represent the mean ± SEM from 
four independent experiments.  ****p < 0.0001 versus (a) normoxic control, (b) hypoxic 
control, (c) 100 nM PACAP-27 in the presence of hypoxia. 
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Figure 6.5  Effect of PACAP-27 on hypoxia-induced cell death in SH-SY5Y cells. 
Differentiating SH-SY5Y cells were pre-treated with the PAC1 receptor antagonist 
PACAP 6-38 (100 nM) for 30 min before the addition of PACAP-27 (100 nM) for 30 
min prior to 8 h of hypoxia (1% O2) or normoxia. Cell viability was assessed by 
measuring (A) the metabolic reduction of MTT by cellular dehydrogenases, (B) release 
of LDH into the culture medium and (C) caspase-3 activity via Western blot analysis 
using anti-active caspase-3 antibody. (D) Quantified caspase-3 activity data. Data are 
expressed as a percentage of normoxia control cell values (=100%) and represent the 
mean ± SEM from four independent experiments. ****p < 0.0001 versus (a) normoxic 
control, (b) hypoxic control, (c) 100 nM PACAP-27 in the presence of hypoxia. 
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Figure 6.6  Effects of the TG2 inhibitors Z-DON and R283 on PACAP-27 induced 
cell survival in N2a cells. 
Differentiating N2a cells were pre-treated for 1 h with the TG2 inhibitor Z-DON (150 
µM) or R283 (200 µM) before the addition of PACAP-27 (100 nM) for 10 min prior to 
8 h of hypoxia (1% O2) or normoxia. Cell viability was assessed by measuring (A) the 
metabolic reduction of MTT by cellular dehydrogenases, (B) release of LDH into the 
culture medium and (C) caspase-3 activity via Western blot analysis using the anti-
active caspase-3 antibody. (D) Quantified caspase-3 activity data. Data are expressed 
as a percentage of normoxia control cell values (=100%) and represent the mean ± SEM 
from four independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 
0.0001 versus (a) normoxic control, (b) hypoxic control, (c) 100 nM PACAP-27 in the 
presence of hypoxia. 
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Figure 6.7  The effects of the TG2 inhibitors Z-DON and R283 on PACAP-27-induced 
cell survival in SH-SY5Y cells. 
Differentiating SH-SY5Y cells were pre-treated for 1 h with the TG2 inhibitors Z-DON 
(150 µM) or R283 (200 µM) before the addition of PACAP-27 (100 nM) for 30 min prior 
to 8 h of hypoxia (1% O2) or normoxia. Cell viability was assessed by measuring (A) the 
metabolic reduction of MTT by cellular dehydrogenases, (B) release of LDH into the 
culture medium and (C) caspase-3 activity via Western blot analysis using the anti-active 
caspase 3 antibody. (D) Quantified caspase-3 activity data. Data are expressed as a 
percentage of normoxia control cell values (=100%) and represent the mean ± SEM from 
four independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 
versus (a) normoxic control, (b) hypoxic control, (c) 100 nM PACAP-27 in the presence 
of hypoxia. 
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Role of TG2 in NGF-induced cell survival against hypoxia-induced cell death 
To determine the role of TG2 in NGF-induced cell survival, differentiating neuroblastoma cells 
were treated with NGF (100 ng/ml; 1 h) prior to exposure to 8 h of hypoxia. After this, cell 
viability was assessed by measuring the metabolic reduction of MTT, release of LDH and 
activation of caspase-3. As expected, NGF significantly attenuated hypoxia-induced reduction 
in MTT, release of LDH and activation of caspase-3 in both N2a and SH-SY5Y neuroblastoma 
cells (Figures 6.8 and 6.9). Then, to determine the role of TG2 in this protection activity, the 
TG2-specific inhibitors Z-DON and R283 were implemented. Both differentiating 
neuroblastoma cells were pre-treated with Z-DON (150 μM) or R283 (200 μM) prior to 
stimulation with NGF 100 ng/ml and exposure to hypoxia. The TG2 inhibitors Z-DON and 
R283 attenuated NGF-induced neuronal cell protection in both cell lines (Figures 6.8 and 6.9). 
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Figure 6.8  Effects of the TG2 inhibitors Z-DON and R283 on NGF-induced cell 
survival in N2a cells. 
Differentiating N2a cells were pre-treated for 1 h with the TG2 inhibitors Z-DON (150 
µM) or R283 (200 µM) before the addition of NGF (100 ng/ml) for 1 h prior to 8 h of 
hypoxia (1% O2) or normoxia. Cell viability was assessed by measuring (A) the metabolic 
reduction of MTT by cellular dehydrogenases, (B) release of LDH into the culture 
medium and (C) caspase-3 activity via Western blot analysis using anti-active caspase 3 
antibody. (D) Quantified caspase-3 activity data. Data are expressed as a percentage of 
normoxia control cell values (=100%) and represent the mean ± SEM from four 
independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 versus 
(a) normoxic control, (b) hypoxic control, (c) NGF in the presence of hypoxia. 
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Figure 6.9  Effects of the TG2 inhibitors Z-DON and R283 on NGF induced cell 
survival in SH-SY5Y cells. 
Differentiating SH-SY5Y cells were pre-treated for 1 h with the TG2 inhibitors Z-DON 
(150 µM) or R283 (200 µM) before the addition of NGF (100 ng/ml) for 1 h prior to 8 
h of hypoxia (1% O2) or normoxia. Cell viability was assessed by measuring (A) the 
metabolic reduction of MTT by cellular dehydrogenases, (B) release of LDH into the 
culture medium and (C) caspase-3 activity via Western blot analysis using anti-active 
caspase 3 antibody. (D) Quantified caspase-3 activity data. Data are expressed as a 
percentage of normoxic control cell values (=100%) and represent the mean ± SEM from 
four independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 
versus (a) normoxic control, (b) hypoxic control, (c) NGF in the presence of hypoxia. 
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6.2.2 The role of TG2 in neurite outgrowth 
Neurite outgrowth is the extension of axonal processes (axons and dendrites) from the cell body; 
it is the main morphological characteristic of neuronal development (reviewed by Craig and 
Banker, 1994; Szu-Yu Ho and Rasband, 2011). Variation in neurite outgrowth processing is 
implicated in neuronal disorders or injury, such as ischaemic stroke/hypoxia (Qian et al., 2001). 
The role of TG2 in the neuroprotective effects of neurotrophic factors, PACAP-27 and NGF, 
on multiple-parameters of neurite outgrowth in differentiated N2a and SH-SY5Y were assessed 
in this section using high-throughput analysis. 
Development of high-throughput analysis of neurite outgrowth 
The main aim of this study was to develop an accurate high-throughput approach to investigate 
the role TG2 in neurotrophic factor–induced neurite outgrowth. To accomplish this, initially, 
multiple parameters of neurite outgrowth were quantitatively analysed in differentiating N2a 
and SH-SY5Y cells following PACAP-27 and NGF treatment for 48 h in serum-free medium 
to induce neurite outgrowth. Cells were then fixed and stained using indirect 
immunofluorescence with a monoclonal antibody against α-tubulin (clone B512), which 
enabled staining of the microtubules in axons, dendrites and cell bodies. B512 was used because 
tubulin is an abundant cytoskeletal protein that is found in both cell bodies and neurites, 
permitting examination of the PACAP-27 and NGF-induced effects on different parameters of 
neurite outgrowth in differentiating neuroblastoma cells. The stained cell monolayers were 
examined using a fluorescence microscope with the ImageXpress Micro Widefield High 
Content Screening System. The images were analysed with high-content image processing 
software MetaXpress for neurite outgrowth parameters, and the obtained outputs were given in 
a mathematical algorithm, as explained in section 2.2.12. 
Image segmentation of the acquired images was carried out using ImageXpress. Examples of 
image segmentation from PACAP-27- and NGF-treated N2a and SH-SY5Y neuroblastoma 
cells probed with B512 are depicted in Figure 6.10. Two wavelengths were used, namely FITC 
green to detect the cell body and neurites and DAPI blue for nuclei. Multicoloured mask images 
show segmentation tracing neurites and cell bodies, which were identified by setting up the 
MetaXpress imaging and analysis software segmentation parameters. The analysis settings were 
optimised and configured to identify the maximum relevant neuronal outgrowth processing 
details and minimum background noise until the most accurate image segmentation was 
obtained, as shown in Figure 6.10. Since this study was conducted to assess the neurite 
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outgrowth under different treatment conditions, the cell-by-cell neurite outgrowth parameters 
were selected accordingly, as follows: 
 Average number of cells per field (total number of neural cell bodies averaged by 
the number of fields); 
 Average cell body area per cell (total area of cell bodies in square micron averaged 
by the number of cell); 
 Average number of neurites (total number of neurites produced from the cell bodies 
averaged by the number of fields); 
 Significant outgrowth (neurites longer than 10 µm in length); 
 Maximum neurite length per cell (length in microns of the longest neurite from the 
neuronal cell body to an extreme segment per cell); 
 Average neurite length per cell (total length in microns of all significant outgrowths 
averaged by the number of cells); 
 Mean processes per cell (average number of neurites longer than 10 µm in length); 
and 
 Mean branches per cell (average number of branches originating from neurites 
produced by each cell). 
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Figure 6.10  Image segmentation of stained N2a and SH-SY5Y cells using the high-
throughput screening system. 
Segmentation of stained N2a and SH-SY5Y cells using high-throughput screening 
assays. Cells were fixed and stained with an antibody recognising α-tubulin (B512), 
followed by Alexa Fluor® –conjugated anti-IgG secondary antibody. All images shown 
are from PACAP-27- and NGF-treated controls from a single field of view. Acquired 
images were obtained using the ImageXpress Micro system (10× objective) with two 
wavelengths, namely FITC for cell body and neurite detection and DAPI for nucleus 
counting. Segmented images with multicoloured tracing masks on neurites and cell 
bodies were generated using the Neurite Outgrowth Module in the MetaXpress imaging 
and analysis software for monitoring different parameters of neurite outgrowth. 
TG2 cell survival and neurite outgrowth role Chapter 6 
176 
 
Role of TG2 in PACAP-27-induced neurite outgrowth 
The neurotrophic effects of PACAP-27 (100 nM, 48 h) on inducing neurite outgrowth in N2a 
and SH-SY5Y cells were monitored using high-throughput assay. Figure 6.11 shows the 
initial, automated images for the eﬀect of TG2 inhibitors on PACAP-27-induced neurite 
outgrowth in diﬀerentiating N2a and SH-SY5Y cells. In the absence of TG2 inhibitors, the 
cells had the typical neuronal cell morphology – round cell bodies with long extending 
axons for N2a and flat, extensive with elongated neuritic projections for  SH-SY5Y cells. 
After pre-treatment with TG2 inhibitors prior to stimulation with PACAP-27, smaller neurite 
projections were apparent in comparison with the cells treated with PACAP-27 alone.  
The high-throughput quantitative data analysis obtained show that PACAP-27 had no effects 
on the average neuronal cell number per field or on the measurement of cell body area of N2a 
and SH-SY5Y by analysis of B512 staining (Figure 6.12). Treatment with the TG2 inhibitor Z-
DON (150 μM) or R283 (200 μM) prior to stimulation with PACAP-27 (100 nM) caused 
no significant changes in neuronal cell number or cell body area measurements (Figure 
6.12). The quantitative analysis of B512 staining for the average number of neurites per 
field and the percentage of cells with a neurite of length above 10 μm (i.e. significant 
outgrowth) were also assessed, as shown in Figure 6.13. The presented data show that 
PACAP-27 caused a significant increase in the average number of neurites and number of 
cells with neurites compared with control untreated cells (Figure 6.13). In addition, 
exposing the cells to the TG2 inhibitors prior to stimulation with PACAP-27 significantly 
inhibited the average neurite number per field and the percentage of cells with significant 
outgrowth that stimulated with PACAP-27 in N2a and SH-SY5Y cells (Figure 6.13).  
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Figure 6.11  Representative, automated images for the eﬀect of TG2 inhibitors on 
PACAP-27-induced neurite outgrowth in diﬀerentiating N2a and SH-SY5Y cells. 
(A) N2a and (B) SH-SY5Y cells were incubated for 1 h with the TG2 inhibitor Z-DON 
(150 µM) or R283 (200 µM) before treatment with PACAP-27 (100 nM) in serum-free 
DMEM for 48 h. Following stimulation, high-throughput immunocytochemistry was 
performed using the anti-tubulin antibody and visualised using Alexa Fluor® 488–
labelled goat anti-mouse IgG secondary antibody (green). Nuclei were visualised using 
DAPI counterstain (blue). Images are from one experiment and representative of four. 
White arrows indicate typical neurite outgrowths. 
 
20 µm 
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Figure 6.12  Eﬀects of TG2 inhibitors on PACAP-27-induced neurite outgrowth 
(average cell number and cell body area) in diﬀerentiating N2a and SH-SY5Y cells. 
N2a (panels A and B) and SH-SY5Y (panels C and D) cells were incubated for 1 h with 
the TG2 inhibitors Z-DON (150 µM) or R283 (200 µM) before treatment with PACAP-
27 (100 nM) in serum-free DMEM for 48 h. Following stimulation, high-throughput 
immunocytochemistry was performed using the anti-tubulin antibody (B512). Data were 
acquired using the ImageXpress Micro system, and the cell number (A and C) and cell 
body area (B and D) were measured using MetaXpress imaging and analysis software. 
High-throughput data are expressed as a mean value ± SEM from four independent 
experiments. 
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Figure 6.13  Eﬀects of TG2 inhibitors on PACAP-27 induced neurite outgrowth 
(average number of neurites and significant outgrowth) in diﬀerentiating N2a and 
SH-SY5Y cells.   
N2a (panels A and B) and SH-SY5Y (panels C and D) cells were incubated for 1 h with 
the TG2 inhibitors Z-DON (150 µM) or R283 (200 µM) before treatment with PACAP-
27 (100 nM) in serum-free DMEM for 48 h. Following stimulation, high-throughput 
immunocytochemistry was performed using the anti-tubulin antibody (B512). Data were 
acquired using the ImageXpress Micro system, and the average number of neurites (A 
and C) and significant outgrowth (B and D) were measured using MetaXpress imaging 
and analysis software. High-throughput data are expressed as a mean value ± SEM from 
four independent experiments *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 
versus (a) control, (b) PACAP-27 alone. 
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The maximum and average neurite length per neuronal cell were also assessed (Figure 6.14). 
Quantitation of B512 staining showed significant increases in the maximum and the average 
neurite length per cell in response to PACAP-27. It revealed that the maximum neurite lengths 
per cell in PACAP-27-treated cells were 60 μm for N2a and 45 μm for SH-SY5Y cells. 
Exposure to the TG2 inhibitors significantly decreased the maximum length of B512-
positive neurite per cell by about 60% (p < 0.0001). 
B512 is expected to detect the neurite outgrowth–related processes and branches; thus, the 
measurement of the mean number of cell processes and branches per neuronal cell were 
considered. As shown in Figure 6.15, B512 staining detected that PACAP-27 significantly 
increased the average number of neuronal cell processes and branches in both N2a and SH-
SY5Y cells. A significant attenuation in the cell processes and branches per neuronal cell 
(p < 0.01) was observed when the cells were pre-treated with the TG2 inhibitors prior to 
stimulation with PACAP-27 (Figure 6.15). 
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Figure 6.14  Eﬀects of TG2 inhibitors on PACAP-27-induced neurite outgrowth 
(maximum neurite length and average neurite length) in diﬀerentiating N2a and 
SH-SY5Y cells.   
N2a (panels A and B) and SH-SY5Y (panels C and D) cells were pre-treated for 1 h with 
the TG2 inhibitors Z-DON (150 µM) or R283 (200 µM) before treatment with PACAP-
27 (100 nM) in serum-free DMEM for 48 h. Following stimulation, high-throughput 
immunocytochemistry was performed using the anti-tubulin antibody (B512). Data were 
acquired using the ImageXpress Micro system, and maximum neurite length (A and C) 
and average neurite length (B and D) were measured using MetaXpress imaging and 
analysis software. High-throughput data are expressed as mean values ± SEM from four 
independent experiments *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 versus 
(a) control, (b) PACAP-27 alone. 
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Figure 6.15  Eﬀects of TG2 inhibitors on PACAP-27-induced neurite outgrowth 
(mean processes and mean branches in diﬀerentiating N2a and SH-SY5Y cells. 
N2a (panels A and B) and SH-SY5Y (panels C and D) cells were pre-treated for 1 h with 
the TG2 inhibitors Z-DON (150 µM) or R283 (200 µM) before treatment with PACAP-
27 (100 nM) in serum-free DMEM for 48 h. Following stimulation, high-throughput 
immunocytochemistry was performed using anti-tubulin antibody (B512). Data were 
acquired using the ImageXpress Micro system, and mean processes (A and C) and mean 
branches (B and D) were measured using MetaXpress imaging and analysis software. 
High-throughput data are expressed as mean values ± SEM from four independent 
experiments. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 versus (a) control, 
(b) PACAP-27 alone. 
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Role of TG2 in NGF-induced neurite outgrowth 
The role of TG2 in NGF-induced neurite outgrowth was assessed by high-throughput 
monitoring of different neurite outgrowth related parameters following 48 h treatment with NGF 
(100 ng/ml) in N2a and SH-SY5Y cells. The effect of TG2 inhibitors on the neuronal cell 
morphology were assessed. As shown in Figure 6.16, the presented automated images 
illustrate that treatment with TG2 inhibitors resulted in retraction of the neurites and axons 
extending in both neuroblastoma cell lines.  
Like PACAP-27, NGF showed no significant changes in the average neuronal cell number per 
field of N2a and SH-SY5Y cells (Figure 6.17). In addition, no changes were observed in the 
measurement of cell body area per field in N2a cells; however, a slight increase in the SH-SY5Y 
cell body area per field in response to NGF was observed. Treatment with TG2 inhibitors Z-
DON (150 µM) and R283 (200 µM) caused no changes in the observed responses of the average 
neuronal cell number and body area (Figure 6.17). Furthermore, the quantification of the 
average number of neurites per field and number of cells with a neurite length above 10 
μm (i.e. significant outgrowth) in N2a and SH-SY5Y cells treated with NGF in the presence 
or absence of the TG2 inhibitors was performed. The findings indicated that NGF induced 
a significant enhancement effect on the neurite number per field and significant outgrowth, 
and these responses were reversed by TG2 inhibitors (Figure 6.18). 
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Figure 6.16  Representative automated images for the eﬀect of TG2 inhibitors on 
NGF induced neurite outgrowth in diﬀerentiating N2a and SH-SY5Y cells. 
(A) N2a and (B) SH-SY5Y cells were incubated for 1 h with the TG2 inhibitors Z-DON 
(150 µM) or R283 (200 µM) before treatment with NGF (100 ng/ml) in serum-free 
DMEM for 48 h. Following stimulation, high-throughput immunocytochemistry was 
performed using the anti-tubulin antibody and visualised using Alexa Fluor® 488–
labelled goat anti-mouse IgG secondary antibody (green). Nuclei were visualised using 
DAPI counterstain (blue). Images are from one experiment and representative of four. 
White arrows indicate typical neurite outgrowths. 
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Figure 6.17  Eﬀects of TG2 inhibitors on NGF-induced neurite outgrowth (average cell 
number and cell body area) in diﬀerentiating N2a and SH-SY5Y cells. 
N2a (panels A and B) and SH-SY5Y (panels C and D) cells were incubated for 1 h with 
the TG2 inhibitors Z-DON (150 µM) or R283 (200 µM) before treatment with NGF (100 
ng/ml) in serum-free DMEM for 48 h. Following stimulation, high-throughput 
immunocytochemistry was performed using the anti-tubulin antibody (B512). Data were 
acquired using the ImageXpress Micro system, and the cell number (A and C) and cell 
body area (B and D) were measured using MetaXpress imaging and analysis software. 
High-throughput data are expressed as mean values ± SEM from four independent 
experiments. 
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Figure 6.18  Eﬀects of TG2 inhibitors on NGF-induced neurite outgrowth (average 
number of neurites and significant outgrowth) in diﬀerentiating N2a and SH-SY5Y 
cells. 
N2a (panels A and B) and SH-SY5Y (panels C and D) cells were pre-treated for 1 h with 
the TG2 inhibitors Z-DON (150 µM) or R283 (200 µM) before treatment with NGF (100 
ng/ml) in serum-free DMEM for 48 h. Following stimulation, high-throughput 
immunocytochemistry was performed using the anti-tubulin antibody (B512). Data were 
acquired using the ImageXpress Micro system, and the average number of neurites (A 
and C) and significant outgrowth (B and D) were measured using MetaXpress imaging 
and analysis software. High-throughput data are expressed as mean values ± SEM from 
four independent experiments *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 
versus (a) control, (b) NGF alone. 
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Exposure to NGF was also shown to have a significant enhancement effect  on the average 
number of neurites per field and number of cells with a neurite length above 10 μm in 
length (i.e. significant outgrowth) in both neuroblastoma cell lines (Figure 6.19). To assess 
the role of TG2, cells were pre-treated with the TG2 inhibitors prior to exposure to NGF; 
both inhibitors significantly impaired NGF’s ability to stimulate the neurite number per 
field and percentage of cells with significant outgrowth.  Finally, measurements with B512 
staining showed that there was a significant increase in the mean number of processes and 
branches in N2a and SH-SY5Y cells in response to NGF (Figure 6.20). In addition, a significant 
reversal of these responses was observed with the TG2 inhibitors, suggesting a prominent role 
of TG2 in NGF-induced neurite outgrowth. Table 6.1 summarises the findings of this section. 
Overall, the high-throughput data presented in this section indicated a prominent role for TG2 
in PACAP-27- and NGF-mediated neurite outgrowth. 
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Figure 6.19  Eﬀects of TG2 inhibitors on NGF-induced neurite outgrowth 
(maximum and average neurite lengths) in diﬀerentiating N2a and SH-SY5Y cells. 
N2a (panels A and B) and SH-SY5Y (panels C and D) cells were pre-treated for 1 h with 
the TG2 inhibitors Z-DON (150 µM) or R283 (200 µM) before treatment with NGF (100 
ng/ml) in serum-free DMEM for 48 h. Following stimulation, high-throughput 
immunocytochemistry was performed using the anti-tubulin antibody (B512). Data were 
acquired using the ImageXpress Micro system, and the maximum neurite length (A and 
C) and average neurite length (B and D) were measured using MetaXpress imaging and 
analysis software. High-throughput data are expressed as mean values ± SEM from four 
independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 versus 
(a) control, (b) NGF alone. 
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Figure 6.20  Eﬀects of TG2 inhibitors on NGF-induced neurite outgrowth (mean 
processes and mean branches) in diﬀerentiating N2a and SH-SY5Y cells. 
N2a (panels A and B) and SH-SY5Y (panels C and D) cells were pre-treated for 1 h with 
the TG2 inhibitors Z-DON (150 µM) or R283 (200 µM) before treatment with NGF 
(100 ng/ml) in serum-free DMEM for 48 h. Following stimulation, high-throughput 
immunocytochemistry was performed using the anti-tubulin antibody (B512). Data were 
acquired using the ImageXpress Micro system, and mean branches (A and C) and mean 
processes (B and D) were measured using MetaXpress imaging and analysis software. 
High-throughput data are expressed as mean values ± SEM from four independent 
experiments. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 versus (a) control, 
(b) NGF alone. 
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Shown is a summary of the results of the range of treatments used in this study to 
investigate the role of TG2 in PACAP-27 and NGF in modulating of neurite outgrowth. 
Differentiating neuroblastoma N2a or SH-SY5Y cells were treated with the compounds 
indicated in the table, then the cells were stimulated with PACAP-27 or NGF with or 
without TG2 inhibitors. Results (average ± SEM) were calculated from the data 
generated from MetaXpress imaging and analysis software. 
 
 
 
 
 
 
 
 
 
Parameter 
N2a SH-SY5Y 
NGF NGF + Z-DON NGF + R283 NGF NGF + Z-DON NGF + R283 
Average ± SEM 
Average neurite number/field 81±8 35±6 42±3 72±9 36±3 45±4 
Cell with significant outgrowth % 85±8 43±6 32±8 80±7 34±10 42±6 
Maximum neurite length (μm)/cell  60±11 20±9 18±4 50±5 24±7 28±2 
Average neurite length(μm)/cell  40±15 18±7 16±4 29±7 132±2 17±6 
Mean branches/cell 8±0.5 2±0.9 2±0.9 3±0.2 0.9±0.2 2±0.3 
Table 6.1 Overall effect of TG2 inhibitors on PACAP-27 and NGF induced neurite 
outgrowth assessed by high throughput assay 
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 Discussion 
Several studies have investigated the neuronal protection and neurite outgrowth role of TG2 
(Tucholski et al., 2001; Singh et al., 2003; Filiano et al., 2008, 2010; Tatsukawa et al., 2016). 
However, little was known about the exact underlying cellular mechanism(s) involved. The 
main aim of the work presented in this chapter was to evaluate TG2’s role in the neuroprotective 
and neurite outgrowth potential of PACAP and NGF. In the present study, the pharmacological 
inhibition of TG2 resulted in attenuation of the neuronal protection and neurite outgrowth 
induced by the neurotrophic factors PACAP-27 and NGF in differentiating N2a and SH-SY5Y 
cells. These observations are in good agreement with previous findings on TG2’s neuronal 
survival (Tucholski et al., 2001; Filiano et al., 2008, 2010; Tatsukawa et al., 2016) and neurite 
outgrowth roles (Tucholski et al., 2001; Singh et al., 2003). For the first time, the current study 
has revealed the potential role of TG2 in neurotrophic factor–induced cell survival and neurite 
outgrowth.  
6.3.1 Role of TG2 in neurotrophic factor–induced cytoprotection 
There are currently conflicting data as to whether TG2 plays an anti-apoptotic or pro-apoptotic 
role in neuronal cell death (Tatsukawa et al., 2016). These opposing roles appear to depend on 
the cell type, trigger mechanism of cell death, intracellular location of TG2 and speciﬁc TG2 
enzymatic activity (Tatsukawa et al., 2016). One study, using a hippocampal ischaemic model, 
revealed that either TG2 knockout mice or mice treated with the TG2 inhibitor cystamine 
showed a smaller infarction size compared with control mice, suggesting that TG2 has a role in 
ischaemic cell death (Saiki et al., 2011). In contrast, increasing evidence indicates the neuronal 
protection role of TG2. For example, it has been found that TG2-mediated neuronal cell survival 
includes protection against heat shock-induced cell death in SH-SY5Y cells (Tucholski et al., 
2001), protection of rat primary cortical neurons against hypoxia and oxygen/glucose 
deprivation-induced cell death (Filiano et al., 2008) and in vivo protection against ischaemic 
stroke (Filiano et al., 2010). TG2 is considered to mediate protection of neuronal cells against 
hypoxia by attenuating the hypoxia inducible factor (HIF)-induced activation of pro-apoptotic 
genes (Filiano et al., 2008, 2010). Furthermore, the transamidating activity of TG2 appears to 
play a role in protection against oxygen/glucose deprivation-induced cell death (Filiano et al., 
2008). However, the precise cellular mechanism underlying the TG2 anti-apoptotic effect 
remains poorly understood.  
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The neurotrophic effects of PACAP-27 and NGF are widely recognised as activators of 
neuroprotective/cell survival mechanisms via reducing apoptosis, and they are considered 
potential therapeutic agents for the treatment of neuronal cell death associated with 
neurodegenerative disorders (Batistatou & Greene 1993; Tanaka et al., 1997; Allen et al., 2013). 
The complex cellular mechanisms and signal transduction pathways involved in this activity of 
either PACAP or NGF are well documented. The PACAP-induced neuronal survival and anti-
apoptotic effects have been reported to involve mainly PKA (Reglodi et al., 2004), as well as 
other signalling pathways, such as PKB, ERK1/2, NF-κB and Ca2+ mobilisation (May et al., 
2010; Manecka et al., 2013).  The neuroprotection and cell survival mechanisms associated with 
NGF are thought to involve the activation of PI-3K/ Akt cascade (Shimoke & Chiba, 2001; Koh 
et al., 2003; Salinas et al., 2003; Wu & Wong, 2005). Recent studies have shown that TG2 can 
be modulated by multi protein kinase dependent pathways, and it plays a role in cytoprotection 
in cardiomyoblasts (Almami et al., 2014; Vyas et al., 2016, 2017). Thus, it would be reasonable 
to assess the possible involvement of TG2 in neuronal cell survival induced by PACAP and 
NGF.  
In the current study, cell survival was assessed following exposure to hypoxia to investigate the 
neuronal protection effect of both neurotrophic factors and the possible involvement of TG2. 
Initially, hypoxia conditions were induced by incubating the differentiated N2a and SH-SY5Y 
cells in 5% CO2/1% O2 at 37°C in serum/glucose-free medium; then, different hypoxia exposure 
times were investigated for cell viability tests to determine which time exposures were sufficient 
for inducing cell death in differentiating N2a and SH-SY5Y cells. Cell viability was assessed 
by measuring the levels of MTT reduction and LDH release. As shown in Figure 6.1, Figure 
6.2 and Figure 6.3, an 8-h period was optimum for inducing significant MTT reduction and 
LDH release, and it was shown to induce morphological changes in differentiating N2a and SH-
SY5Y cells, with the degree of deterioration ranging from mild to severe. The question was 
asked whether the observed hypoxia-induced cell death was associated with apoptosis or 
necrosis; thus, activation of caspase-3 was assessed in differentiating N2a and SH-SY5Y cells 
exposed to hypoxia for various durations. The present findings showed that caspase-3 was 
gradually activated, suggesting that the cells were undergoing apoptosis, inducing cell death. 
Caspase-3 sensitivity in the early response to hypoxia exposure is comparable to that observed 
in a previous study, which identified a significant increase in caspase-3 expression 8h after 
exposure to hypoxia (Qian et al., 2001). 
The experiments performed in this part of the study were designed to relate the PACAP-27 and 
NGF modulation of TG2 activity observed in chapters 4 and 5, respectively, to the neuronal 
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protection/cell survival and associated regulatory proteins in differentiating N2a and SH-SY5Y 
cells. The present study identified that PACAP-27 and NGF significantly attenuated the 
hypoxia-induced decreases in MTT reduction and release of LDH. An apoptosis-induced cell 
death marker caspase-3 was also assessed, and the present findings showed that caspase-3 
activation induced by hypoxia was significantly decreased by PACAP-27 or NGF. These 
findings are in agreement with other studies that have reported the neuronal protection and anti-
apoptotic power of PACAP-27 and NGF against hypoxia (Masmoudi-Kouki et al., 2011; Mnich 
et al., 2014). It has been found that PACAP induces a transient intrinsic inhibition of caspase-3 
gene expression, providing additional evidence of PACAP’s anti-apoptotic properties (Douiri 
et al., 2016). Similarly, NGF has been reported to exert its neuronal protection function through 
mechanisms that also involve caspase-3. A recent study demonstrated that NGF-induced 
neuroprotection is through mechanisms that require lysosomes for the direct removal of active 
caspase-3 (Mnich et al., 2014). Furthermore, it has been reported that, in the PC12 model, NGF 
protects the neurons from apoptosis-induced death by down-regulation the expression of the 
pro-apoptotic factor Bcl-2 homology 3 [BH3] domain-only protein (BIM) via a MEK/ERK-
dependent pathway (Biswas & Greene, 2002). All of these previous literature findings provide 
evidence that the neuronal cell survival effects of PACAP and NGF are mostly carried out 
through anti-apoptotic activity. Based on the previous observations and the current data showing 
that PACAP and NGF potentially modulate TG2 activity in differentiating neuroblastoma cell 
lines, it can be speculated that TG2 has a role in the neuroprotection and in the anti-apoptotic 
effect of PACAP and NGF. Therefore, investigations into the intracellular protein targets 
involved in the cellular death process, such as the apoptosis biochemical markers caspase-3, 
and the mechanistic contribution of TG2 with the survival effect of PACAP and NGF, would 
be of interest. The noticeable differences in the activity of activated caspase-3 presented in this 
study suggested that the apoptotic cell death pathway was a major target to evaluate the role of 
TG2 in the cell survival induced by PACAP and NGF. 
To assess the role of TG2, differentiating neuroblastoma cells were pre-treated with the TG2 
inhibitors Z-DON (150 μM) or R283 (200 μM) prior to stimulation with PACAP-27 (100 
nM) or NGF (100 ng/ml) and exposed to hypoxic conditions. The obtained data revealed 
that inhibition of TG2 could significantly reverse the protection offered by PACAP-27 or NGF, 
providing the first suggestion for a key role of TG2 in PACAP-27- and NGF-induced 
cytoprotection in differentiating mouse N2a and human SH-SY5Y neuroblastoma cells. The 
signalling system involved in this process would be a fundamental area of research to consider 
for the development of new therapeutic approaches to cure various pathologies involving 
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hypoxic/ischaemic neurodegeneration. However, while it is not clear how PACAP/PAC1 
receptor-induced TG2 activation mediates cell survival, TG2 is known to regulate pathways 
associated with PACAP neuroprotection. For example, TG2 activates adenylyl cyclase and 
enhances cAMP/PKA-dependent CRE-reporter gene activity in SH-SY5Y neuroblastoma cells 
(Tucholski & Johnson, 2003) and promotes NF-κB signalling via crosslinking of IƘBα (Eckert 
et al., 2014). It is also unclear how NGF-induced TG2 activation mediates cell survival, 
although TG2 is known to regulate pathways associated with NGF neuroprotection. For 
example, TG2 mediates 5-HT-induced serotonylation of PKB in vascular smooth muscle cells 
(Penumatsa et al., 2014). While the data presented suggest that PKB is upstream of TG2 (i.e. 
NGF-induced TG2 activation is blocked by PKB inhibition) it is conceivable that NGF-induced 
TG2 activation functions to augment and sustain PKB activity. From the results obtained in 
chapters 4 and 5, PACAP-27 clearly induces TG2 enzymatic activity and phosphorylation in 
the PKA-dependent pathway, while NGF does so in the Akt/PKB dependent pathway. 
Accordingly, PACAP-27-induced PKA-dependent and NGF-induced Akt/PKB-dependent 
modulation of TG2 activity could be the possible cell survival and protection pathways under 
this study’s experimental conditions. 
In the current study, inhibition of TG2 blocked PACAP-27- and NGF-mediated attenuation of 
hypoxia-induced activation of caspase-3, which is indicative of an anti-apoptotic role of TG2. 
One potential anti-apoptotic mechanism is TG2’s inhibition of apoptosis via the downregulation 
of Bax expression and inhibition of caspase-3 and 9 (Cho et al., 2010). Furthermore, the reported 
effect of TG2 to act as a new type of apoptosis inhibitor by crosslinking caspase-3 and 
inactivating its enzymatic activity, resulting in the suppression of apoptosis (Yamaguchi & 
Wang, 2006), could be another possible mechanism. The findings indicate that TG2’s anti-
apoptotic role is involved in PACAP and NGF-induced neuronal cell protection; and this may 
provide a target for future attempts at modulating its anti-apoptotic potential for therapeutic 
benefit. Further work is required to determine the role and mechanisms of TG2 in PACAP- and 
NGF-induced cell survival. Taken together, these and the previous findings indicate that the 
PACAP- and NGF-induced TG2 activity have neuroprotective/anti-apoptotic potential against 
hypoxia-induced cell death in differentiating mouse and human neuroblastoma cells. Overall 
these data highlight the need to carefully consider the identification of the TG2 substrate(s) 
possibly involved in TG2-mediated neuroprotective activity. 
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6.3.2 The role of TG2 in neurotrophic factor-induced neurite outgrowth 
The data presented in this part of the study demonstrate for the first time that TG2 inhibition 
reverses the PACAP- and NGF-induced neurite outgrowth process, indicating the involvement 
of TG2 in the neurite outgrowth activity induced by PACAP and NGF. This conclusion is 
supported by three major pieces of evidence, as follows: i) PACAP-27 and NGF modulate TG2 
activity in neuroblastoma cell lines, ii) PACAP-27 and NGF induce neurite outgrowth in 
different neuronal cell models and iii) TG2 has been shown to be essential for the neurite 
outgrowth of neuronal cells. TG2 is a normal constituent found in the brain, spinal cord and 
neurons, and its expression and activation levels in different physiological and pathological 
conditions have been investigated. Previously, it was shown that TG activity was significantly 
elevated during the foetal stages when the axonal outgrowth process is occurring in rats and 
during the regeneration of the sciatic nerve following injury (Chakraborty et al., 1987). In 
addition, previous studies have shown that, in human neuroblastoma SH-SY5Y cells, TG2-
mediated neurite outgrowth depends on the transamidating activity (Tucholski et al., 2001; 
Singh et al., 2003). These studies provide confirmatory evidence that TG2 is essential for 
diﬀerentiation/neurite outgrowth in neuronal cells. Furthermore, modulation of TG2 
transamidation activity in neuroblastoma cells by the neurotrophic factors PACAP and NGF 
was confirmed in chapters 4 and 5. Although there is overwhelming evidence supporting the 
notion that PACAP and NGF have a potential role in inducing neurite outgrowth in 
neuronal cells (Grimes et al., 1996; Zhang et al. 2000; Monaghan et al., 2008; Kambe & 
Miyata, 2012), the TG2 functional implementation in this interaction has not been 
demonstrated. Accordingly, in this study, the role of TG2 in the PACAP-27 and NGF-induced 
neurite outgrowth of N2a and SH-SY5Y cells was investigated. The auto-quantified assay high-
throughput ImageXpress screening and analysis system was developed and applied for this 
purpose.  
The in vitro high-throughput analysis system permitted precise quantification of the changes in 
the different neurite parameters under different treatment conditions. This approach is a 
powerful, accurate, fast, reproducible tool that can provide homogenous detection and 
recognition of even fine neuronal cell processes and branches. In this part of the study, the 
primary aim was evaluating TG2’s role in the neurite outgrowth via multiparametric 
measurements of morphological changes induced by PACAP-27 and NGF in differentiating 
N2a and SH-SY5Y cells. Initially, the high-throughput quantification indicated that the 
inhibition of TG2 had no significant effect on the average number of cells per field or average 
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cell body area per field in mouse N2a or human SH-SY5Y neuroblastoma. Furthermore, the 
analysis provided valuable neurite outgrowth parameters data to interpret, namely the average 
number of neurites, significant outgrowth, maximum neurite length per cell, average neurite 
length per cell, mean processes per cell and mean number of processes and branches per cell. 
All these parameters were significantly enhanced in response to PACAP-27 and NGF in both 
cell lines, and this activity was attenuated by TG2 inhibition; these findings indicate a potential 
role of TG2 in the PACAP-27 and NGF modulation of neurite outgrowth. It is important to note 
that the lack of effect of the TG2 inhibitors Z-DON (150 µM) and R283 (200 µM) on the average 
cell number per field confirmed that the observed reductions in the neurite outgrowth 
parameters were mainly due to their inhibitory effect, and they were not because of any 
reduction in the average counting of the cell number. 
Several previous studies have found that PACAP has a triggering effect on different neurite 
outgrowth morphological characteristics, such as the neurite length or number (Shi et al., 2008; 
Kambe & Miyata, 2012; Ogata et al., 2015). For example, a morphological study on PC12 cells 
confirmed that PACAP enhances the neurite number per cell (Shi et al., 2008), and in cultured 
hippocampal neurons, PACAP increases neurite length in the first 2 days (Kambe & Miyata, 
2012). In SH-SY5Y human neuroblastoma cells, PACAP has been shown to induce neurite 
outgrowth and increase the expression of cytoskeletal proteins (Héraud et al., 2004). Reports 
from some researchers have addressed the underlying mechanism for this; one study showed 
that PACAP increases the total neurite length in human SH-SY5Y cells via a cAMP-dependent 
pathway requiring the activation of ERK1/2 and p38 MAPK (Monaghan et al., 2008). However, 
the mechanism by which TG2 involved in PACAP promotes neurite outgrowth in 
neuroblastoma cells has not yet been investigated. The PACAP/PAC1  receptors cause activation 
of adenylyl cyclase (May et al., 2014), and the available evidence seems to suggest that PACAP-
modulated neurite outgrowth is cAMP dependent and PKA-independent (Monaghan et al., 
2008). The present work also sheds light on the signalling cascade involved in the PACAP 
modulation of TG2 enzymatic activity and phosphorylation status, confirming that it is ERK1/2-
dependent modulation (chapter 4). Based on the currently available evidence, it seems 
reasonable to suggest that PACAP-mediated TG2 activation could promote neurite outgrowth 
via cAMP and ERK1/2 signalling.     
It is also prominent in the literature that the intracellular stream of the NGF-TrkA (a high-
affinity NGF receptor) complex is essential for an effective NGF signal transduction process to 
induce neurite outgrowth (Grimes et al., 1996; Zhang et al., 2000). Further research in this area 
indicated that PKC provides a positive signal for the neurite outgrowth response induced by 
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NGF via activation of ERK1/2 signalling  (Brodie et al., 1999). It has also been established that 
crosstalk between NGF and TG2 induces neurite outgrowth in neuroblastoma cells (Oe et al., 
2005; Condello et al., 2008). It is conceivable that this may involve modulation of the PKC 
signalling pathway, as earlier in the current study, the obtained findings confirmed that NGF 
modulation of TG2 activity was PKC dependent (chapter 5). It could also be one or more of the 
pathways described above, such as TG2-induced modulation of adenylyl cyclase/CREB 
signalling. Indeed, studies have shown that NGF can modulate cAMP levels in neuronal cells 
(Nikodijevic et al., 1975; Berg et al., 1995).  
Functional considerations 
TG2’s involvement in the stimulatory effect of PACAP and NGF on cell survival and neurite 
outgrowth strongly suggests a role for TG2 in their neurotrophic activity in mouse and human 
neuroblastoma cell lines. This conclusion leads to the suggestion that the observed response 
may share a common mechanism. Neurite branching has a fundamental role in connecting 
neuronal cells, and it is one of the sensitive parameters of neurite outgrowth. It has been reported 
that changes in axonal branching are associated with neurodegenerative disorders (Yu et al., 
1996). The current findings showed that neurite branching and processing were significantly 
increased in response to PACAP-27 and NGF, and this activity was reduced by the inhibition 
of TG2, suggesting that it has a key role in PACAP- and NGF-induced neurite branching. The 
observed reduction in the mean branches and mean processes per cell may indicate a disruption 
in the cytoskeletal proteins required for the development of neurite branching and enhanced 
microtubule stability, which is required for neurite stability. Accordingly, microtubule stability 
would be essential for preventing neurite deterioration associated with neurodegenerative 
disorders or neuronal hypoxia. Hence, TG2 could be neuroprotective due to its role in 
microtubule and neurite stability enhancement.  
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 Conclusion 
In conclusion, the results of this study indicate a role for TG2 as a useful neuroprotective/anti-
apoptotic agent involved in the modulation of neurite outgrowth and neuronal cell stability 
induced by PACAP and NGF. Thus, further studies are required to elucidate the downstream 
substrates of TG2 and signalling pathways associated with the role of TG2 in neuroprotection 
and neurite outgrowth induced by the neurotrophic factors PACAP and NGF.  
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7 Conclusion and future works 
 Summary of findings 
This study aimed to determine whether the neurotrophic factors, PACAP and NGF, could 
modulate tissue transglutaminase (TG2) transamidase activity in morphologically and 
biochemically characterised differentiating mouse N2a and human SH-SY5Y neuroblastoma 
cell lines. In addition, it was intended to assess the role of TG2 in PACAP- and NGF-induced 
neuroprotection and neurite outgrowth in mouse N2a and human SH-SY5Y neuroblastoma 
cells.  
7.1.1 Characterisation of differentiating neuroblastoma cell lines 
The differentiating mouse N2a and human SH-SY5Y neuroblastoma cell lines have been 
reported to be suitable for use in the study of cell signalling pathways, differentiation, neurite 
outgrowth and neuronal survival (Li et al., 2007; Kim et al., 2011; Sahu et al., 2013; Murillo et 
al., 2017; Pirou  et al., 2017). The SH-SY5Y cell line was used to validate the results observed 
in mouse N2a cells in a related human cell line. The findings were mostly comparable in both 
cell lines, except for minor variations that could be attributed to genetic drift and/or species- or 
cell line-related responses. Initially, both cell lines’ ability to differentiate into a neuron-like 
phenotype by all-trans retinoic acid RA was evaluated. The generation of neuron-like 
phenotype cells was confirmed by monitoring the morphological alterations following RA 
treatment and the expression of neuronal phenotype-specific markers, such as the cholinergic 
neuronal marker choline acetyltransferase (ChAT) and the dopaminergic neuronal marker 
tyrosine hydroxylase (TH). N2a cells became more cholinergic neuron–like, with developing 
axon-like processes and dendrites, whereas SH-SY5Y cells became more adrenergic neuron–
like with extended, long, and branched processes. Furthermore, Western blot analysis showed 
that differentiating N2a and SH-SY5Y cells expressed higher levels of TG2 compared with 
undifferentiated cells. In addition, the other transglutaminase members that are predominantly 
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expressed in neuronal tissue, TG1 and TG3, increased significantly in differentiating N2a cells 
and were present at comparable levels in differentiated and undifferentiated SH-SY5Y cells. 
Thus, the characterisation of differentiated N2a and SH-SY5Y cells could provide a potential 
aid for understanding the molecular mechanisms that contribute to the obtained responses.  
7.1.2 Modulation of TG2 activity by PACAP and NGF  
The neurotrophic effects of PACAP and NGF have been extensively studied; they both promote 
neurite outgrowth and neuronal survival (Williams et al., 1986; Hatanaka et al., 1988; Takei et 
al., 2000; Yuhara et al. 2001). However, it was essential to assess the possible modulation of 
TG2 activity by these neurotrophic factors prior to assessing its role in neuronal survival and 
neurite outgrowth. The first part of this thesis aimed to investigate the possible modulation of 
TG2 activity by the neurotrophic factors PACAP and NGF.  
The neurotrophic effect of PACAP and NGF mediates neurite outgrowth and neuroprotection 
(Allen and Dawbarn 2006; Monaghan et al., 2008; Lomb et al., 2009; Jóźwiak-Be¸benista et al., 
2015); however, it is not known whether these events involve modulation of TG2 activity. 
Therefore, initial experiments assessed the modulation of TG2 activity in response to PACAP 
and NGF. Modulation of TG2 was assessed by monitoring two types of transamidation activity, 
namely amine incorporation and crosslinking activity. The amine incorporating activity of TG2 
was measured via biotin-cadaverine incorporation into N, N’-dimethylcasein, as described by 
Slaughter et al. (1992), and the crosslinking activity of TG2 was measured via biotin-TVQQEL 
peptide incorporation into casein, as described by Trigwell et al. (2004). The results showed 
that the neuropeptide PACAP-27 (PAC1 receptor agonist) and NGF triggered transient time- 
and concentration-dependent increases in TG2-mediated biotin-cadaverine incorporation and 
peptide crosslinking activity in differentiating N2a and SH-SY5Y cells with no accompanying 
changes in TG2 expression level. In addition, the PAC1 receptor-induced increases in TG 
activity were attenuated by the PAC1 receptor antagonist PACAP 6-38, confirming that the 
activity is mediated through the PAC1 receptor. Furthermore, the TG2 inhibitors R283 and Z-
DON resulted in significant inhibition of the PACAP- and NGF-induced transamidation 
activity; on this basis, it can be confirmed that the observed increases in TG activity modulated 
by PACAP and NGF occurred via TG2. This was verified using in situ FITC-cadaverine 
incorporation and immunocytochemistry.   
TG2 enzymatic activity is tightly regulated by the allosteric regulators Ca2+ and guanine 
nucleotides (Király et al., 2009). The presence of Ca2+ is essential for TG2 catalytic activity, 
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which induces TG2 to develop an open and active conformational structure and exposes the 
active site to the substrates and produces its enzymatic activity (Pinkas et al., 2007). Previous 
studies have shown that the release of Ca2+ from intracellular stores or influx of extracellular 
Ca2+ is linked to TG activation in response to GPCR stimulation, such as muscarinic receptor, 
5-HT2A, A1 adenosine receptor and the β2-adrenoceptor (Zhang et al., 1998; Walther et al., 2003; 
Vyas et al., 2016). Cells were stimulated with PACAP-27/NGF in either the presence (1.8 mM 
CaCl2) or absence of extracellular Ca
2+ (nominally Ca2+-free Hanks/HEPES buffer containing 
0.1 mM EGTA) and cell lysates were subjected to biotin-cadaverine incorporation or peptide 
crosslinking assays. The data presented in the current work indicate that PAC1 receptor-induced 
transamidase activity was dependent on extracellular Ca2+. In contrast, the NGF modulation of 
TG2 activity was partially dependent on the extracellular Ca2+. 
Although TG2 activity is regulated by intracellular [Ca2+] changes, there is a growing and 
compelling body of evidence suggesting that TG activity can also be modulated by protein 
kinases and phosphorylation (Bollag et al, 2005; Mishra et al, 2007). For example, it has been 
shown that protein kinases, such as PKA and PKC, regulate the activity of TG2 (Almami et al. 
2014) and that phosphorylation of TG2 by protein kinase A (PKA), inhibits its transamidating 
activity but enhances its kinase activity (Mishra et al., 2007). Moreover, PACAP has long been 
known to activate PKA, ERK1/2 and p38 MAPK signalling cascades, which contribute to its 
neuroprotective eﬀect (Vaudry et al., 2009, 2000b), while NGF’s activation of TrkA leads to 
the up-regulation of a multitude of signalling pathways, including the ERK1/2, PI-3K/PKB and 
PLC-γ/PKC cascades (Wang et al., 2014). However, very little is known about the specific 
signal transduction pathways that mediate this neuroprotective activity. As some of these 
pathways are associated with the modulation of intracellular TG2 activity, it is conceivable that 
PACAP or NGF directly regulates TG2 activity.  Thus, the role of different protein kinases, 
which have been found to be more involved in the modulation of TG2 activity in the literature, 
was evaluated in this study. Accordingly, different protein kinase inhibitors were used to 
determine whether these signalling pathways are involved in PACAP-27- and NGF-induced 
TG2 activity. In brief, the observed inhibition in PACAP-27-induced TG2 activity in response 
to MEK1/2, PKB and PKA inhibition suggests that PACAP-27 modulates TG2 activity via these 
signalling proteins in both differentiating neuroblastoma cell lines. However, inhibition of PKC 
attenuated PACAP-27-induced TG2 activity in N2a, but not in SH-SY5Y, differentiating cells. 
As PACAP-27 has a significant activation effect on the central regulatory protein ERK1/2, it is 
conceivable that this phosphorylation of ERK1/2 would depend upon an up-stream role of other 
protein kinases and/or Ca2+ signalling. Therefore, the effect of protein kinase inhibitors and 
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removal of extracellular Ca2+ on PACAP-27-induced ERK1/2 phosphorylation were 
considered. The findings indicatethat PACAP-27 stimulation of the PAC1 receptor to induce 
ERK1/2 activation is independent on Ca2+ influx in both cell lines, partially sensitive to PKC 
inhibition in N2a cells but PKC independent in SH-SY5Y cells. Furthermore, as a previous 
study showed that PKA can activate ERK1/2 (Stork and Schmitt, 2002), in the current work, 
the inhibition effect of PKA inhibitor on PACAP-27 induced ERK1/2 activation indicated the 
upstream role of PKA in ERK1/2 activation. Hence, PKA-mediated inhibition of TG2 activation 
may indeed reflect the upstream role of PKA in ERK1/2 activation. In addition, NGF is known 
to activate different downstream signalling proteins, including ERK1/2, PI-3K/PKB and PKC 
(Wang et al., 2014); therefore, assessment of these kinases to understand the modulation of TG2 
activity by NGF was considered. The data elucidated that the NGF-induced TG2 activity was 
significantly attenuated by inhibiting ERK1/2, PKB and PKC, indicating their involvement in 
this modulation process and the lack of any ‘crosstalk’ between the ERK1/2 and PKB; however, 
PKC’s upstream role in ERK1/2 activation was identified. Figure 7.1 summarises the common 
identified kinase pathways in both N2a and SH-SY5Y cells. In regard to the protein kinases’ 
roles, the obtained data provide sufficient evidence to highlight the signalling pathways 
involved in the modulation of TG2 activity in neuron by neurotrophins which would be an initial 
platform to consider in future research in the field. 
The findings obtained from this study may also reflect the potential effect of both neurotrophic 
factors (PACAP and NGF) on TG2 phosphorylation. The robust increase in the levels of TG2 
phosphorylation after exposure to the PACAP or NGF was blocked by the inhibition of different 
protein kinases or removal of Ca2+; these findings suggested their involvement in the 
neurotrophic modulation of TG2 phosphorylation activity. The findings indicated a prominent 
role of PKA and ERK1/2 in PACAP-27-induced TG2 phosphorylation, and more interestingly, 
the removal of Ca2+ only blocked the PACAP-induced phosphorylation of TG2 in mouse N2a 
cells and showed no effect in human SH-SY5Y cells. In contrast, the TG2 phosphorylation 
modulated by NGF was mainly regulated by ERK1/2, PKB and PKC. 
 
 
 
 
Conclusion and Future works   Chapter 7 
203 
 
 
 
Figure 7.1  Schematic representation summarise the possible protein kinase 
pathways involved in PACAP- and NGF-induced TG2 activation in N2a and SH-
SY5Y cells. 
PACAP-27 promotes TG2 transamidase activity via a signalling pathway dependent 
upon PKC, ERK1/2, PKA and PKB along with influx of extracellular Ca2+ leading to 
increases in TG2 activity. The finding reflects the up- stream involvement of PKA in 
PACAP-induced ERK1/2 activation. NGF promotes TG2 transamidase activity in 
mouse N2a and human SH-SY5Y neuroblastoma cells via a signalling pathway 
dependent upon PKC, ERK1/2 and PKB. The role of PKC reflects the up- stream 
involvement of PKC in NGF-induced ERK1/2 activation. * represent signalling in N2a 
cells only, black lines represent this study’s findings and dashed lines represent effects 
that are not from the present study. 
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7.1.3 The role of TG2 in neurotrophic factor–induced cytoprotection 
The second part of this research evaluated the possible role of TG2 in the neuroprotection 
activity induced by PACAP or NGF in differentiating neuroblastoma cells after exposure to 
hypoxia conditions. Using the MTT and LDH assays and measuring the activity of caspase-3, 
decreased cell viability was observed within 8 h of hypoxia exposure in both N2a and SH-SY5Y 
cells. Treatment with PACAP and NGF prior to hypoxia exposure significantly attenuated the 
hypoxia-induced decrease in cell viability assessed by MTT reduction, LDH release and 
caspase-3 activation. The inhibition of TG2 attenuated the protective effect of PACAP and NGF 
under hypoxia condition and reversed their blocking effect on hypoxia-induced caspase-3 
activation. These findings suggested that TG2 has a prominent role in the neuroprotective and 
anti-apoptotic effect of PACAP and NGF under hypoxic conditions. 
7.1.4 The role of TG2 in neurotrophic factor-induced neurite outgrowth 
The last part of the current study involved the development of an automated, quantitative, high-
throughput imaging system for multiple-parameter measurement to evaluate the role of TG2 in 
the neurite outgrowth induced by PACAP and NGF in differentiating N2a and SH-SY5Y cells. 
Establishment of such automated measurement permitted quantitative evaluation of the 
morphological features of neurite outgrowth staining with the cytoskeleton-specific antibody 
B512 (which stained microtubules in the cell body, axons and dendrites). In brief, PACAP and 
NGF significantly enhanced the neurite number/field, cells with significant outgrowth, neurite 
length and branching, but with no effect on the cell number or cell body area. Inhibition of TG2 
significantly reversed the PACAP and NGF enhancement of the neurite outgrowth parameters, 
which suggests a role for TG2 in the neurite outgrowth induced by neurotrophic factors. Taken 
together, the findings indicate that TG2 is essential for neurite outgrowth process modulated by 
PACAP and NGF. 
Taking all of the results together, considering the role of TG2 in the stimulatory effect of 
PACAP and NGF for inducing neuronal cell survival/anti-apoptotic and neurite outgrowth, it 
may can be suggested that the observed response could share one mechanism. Based on the role 
of TG2 in PACAP- and NGF-enhanced neurite branching, which is required for neuronal 
stability and for preventing neuronal retrogradation associated with hypoxia, it can be 
hypothesised that TG2 could be neuroprotective due to its role in microtubule and neurite 
stability enhancement. The key findings of the current study are summarised in Figure 7.2. 
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Figure 7.2  Schematic diagram of the findings in this study 
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 Future work 
Based on the findings of the present study, recommendations can be made for future work. This 
study evaluated the modulation of TG2 activity by PACAP and NGF and the possible 
involvement of such phenomena in cell survival and neurite outgrowth. Assessment of TG2 
transamidase enzymatic activities were used in this study to evaluate this modulation response. 
Other TG2 biochemical activities, such as GTPase, kinase and/or isopeptidase are assigned for 
various TG2 cellular functions; therefore, it would be of interest in future work to investigate 
the potential of PACAP and NGF in modulation of these other TG2 activities. Due to the 
existence of other TG isoforms, for example TG1 and TG3 in the models used in this study, it 
would be of value to evaluate the possible modulation of these enzymes by the neurotrophic 
factors PACAP and NGF. 
The data presented in this thesis suggest that pharmacological inhibition of TG2 attenuates the 
neuroprotective and the neurite outgrowth function of PACAP and NGF. TG2 structure 
homogeneity with other transglutaminase family members could interfere with the selectivity 
profile of the applied TG2 inhibitors. Thus, it would be worthwhile to apply a method of 
eliminating the TG2 activity other than with pharmacological inhibition, such as siRNA, which 
allows selective reduction of the TG2 without using chemicals, to confirm the findings of this 
study. In addition, it would be of further interest to assess this modulation and the responses in 
TG2 null neuronal cell lines.  
The current study suggests the role of TG2 in PACAP- and NGF-induced cell survival and 
neurite outgrowth; extending this study to identify the downstream substrates of TG2 would be 
of value. One available approach could be using CaptAvidin™-agarose affinity 
chromatography to isolate TG2 substrates, followed by mass spectrometry and bioinformatics 
approaches to identify the labelled TG2 substrate and interacting proteins and relating them to 
the identified pathways. This would allow a better understanding of the signalling pathway(s) 
associated with the role of TG2 in PACAP and NGF neuroprotection. 
The findings revealed that TG2 was phosphorylated in response to the neurotrophic factors used, 
where TG2 and the protein kinases possibly involved in this process were identified. However, 
the precise TG2 phosphorylation site(s) under this experimental condition were not 
investigated. To extend this work, it would be beneficial to apply phosphoproteomic analysis to 
identify the site(s) on TG2 that are being phosphorylated in response to PACAP or NGF. Such 
a finding could conceivably provide sufficient knowledge to determine whether regulation of 
Conclusion and Future Works  Chapter 7 
207 
 
the TG2 phosphorylation site(s) has a neuroprotective, anti-apoptotic or neurite stabilisation 
effect that would be a therapeutic target in hypoxia or neurodegeneration-associated neuronal 
damage. 
Having confirmed the neuroprotective role of PACAP and NGF in differentiating N2a and SH-
SY5Y cells exposed to hypoxia and having shown the effect of TG2 inhibition on interfering 
with cell survival promoted by PACAP and NGF, the functional role of TG2 in the context of 
cell survival was addressed. The findings indicated the inhibition of TG2 blocked PACAP- and 
NGF-mediated reduction in hypoxia-induced activation of caspase-3, which is indicative of an 
anti-apoptotic role. Since it is known that TG2 inhibits apoptosis via the down-regulation of 
Bax expression and inhibition of caspases 3 and 9 (Cho et al., 2010), this regulation could 
account for the anti-apoptotic activity of TG2 under the current study conditions. In addition, 
TG2 cell survival studies highlighted the association of TG2 anti-apoptotic and growth-
stimulating functions with its GTPase activity, and this biochemical activity depends on its 
subcellular localisation (Antonyak et al., 2001). Thus, the detrimental effect on this signalling 
pathway could be further expanded by assessing the proteins associated with the apoptosis 
pathway and GTPase biochemical activity of TG2. Additional work could also examine TG2’s 
interaction with hypoxia inducible factor (HIF) signalling in differentiating mouse and human 
neuroblastoma cells, as it has been proven that, in neurons, TG2 binds to HIF, attenuating its 
activity under ischaemic conditions (Filiano et al., 2008). Also, it would be of interest assess 
the role of TG2 during the hypoxia and in hypoxia/reoxygenation condition. Thus, it is desirable 
to further characterise the mechanism by which this activity developed; thus, considering this 
in the future work would be of value. Taken together, such extensions in future works would 
further help in elucidating the exact mechanism of TG2’s role in neuroprotection and neurite 
outgrowth, modulated by PACAP and NGF, in differentiating N2a and SH-SY5Y cells. 
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 Concluding remarks 
The mechanism by which TG2 promotes anti-apoptotic and neurite outgrowth of neuronal cells 
remains a matter of speculation. The present study addressed the question of whether TG2 could 
be modulated by two neurotrophins, PACAP and NGF, and assessed the role of TG2 in neuronal 
survival under hypoxic conditions and neurite outgrowth in differentiating N2a and SH-SY5Y 
cells. Indeed, the findings demonstrate for the first time that the neurotrophins PACAP and NGF 
induce TG2 activity via multiple protein kinase-dependent pathways. Furthermore, PACAP and 
NGF-induced neuronal cell survival and neurite outgrowth depend on TG2 transamidation 
activity. These results highlight the importance of TG2 in the cellular functions of neurotrophins 
in neuronal cells. Continued research on these signalling mechanisms would be highly 
recommended to understand the precise role of TG2 in neuronal development and cell 
protection. This knowledge would provide valuable insight into how neurons behave under 
various conditions and development of therapeutic targets for pharmacological intervention to 
alleviate the neuronal damage associated with neurodegenerative disease, ischaemic stroke or 
apoptosis. 
 
 
 
 
 
 
 
 
 
 
 209 
 
8 References 
Achyuthan, K. E., & Greenberg, C. S. (1987). Identification of a guanosine triphosphate-binding site on 
guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity. Journal 
of Biological Chemistry, 262(4), 1901–06. 
Adem,  A., Mattsson, M. E., Nordberg,  a, & Påhlman, S. (1987). Muscarinic receptors in human SH-
SY5Y neuroblastoma cell line: regulation by phorbol ester and retinoic acid-induced 
differentiation. Brain Research, 430, 235–42. 
Aeschlimann, D., & Paulsson, M. (1991). Cross-linking of laminin-nidogen complexes by tissue 
transglutaminase: A novel mechanism for basement membrane stabilization. Journal of Biological 
Chemistry, 266(23), 15308–17. 
Aeschlimann, D., & Thomazy, V. (2000). Protein crosslinking in assembly and remodelling of 
extracellular matrices: the role of transglutaminases. Connective Tissue Research, 41(1), 1–27.  
Agerman, K., Baudet, C., Fundin, B., Willson, C., & Ernfors, P. (2000). Attenuation of a caspase-3 
dependent cell death in NT4- and p75-deficient embryonic sensory neurons. Molecular and 
Cellular Neurosciences, 16(3), 258–68.  
Ahn, J. S., Kim, M. kyung, Hahn, J. hee, Park, J. H., Park, K. H., Cho, B. R. & Kim, D. joong. (2008). 
Tissue transglutaminase-induced down-regulation of matrix metalloproteinase-9. Biochemical and 
Biophysical Research Communications, 376(4), 743–47.  
Akimov, S. S., & Belkin, A. M. (2001). Cell surface tissue transglutaminase is involved in adhesion and 
migration of monocytic cells on fibronectin. Blood, 98(5), 1567–76.  
Akimov, S. S., Krylov, D., Fleischmana, L. F., & Belkin, A. M. (2000). Tissue transglutaminase is an 
integrin-binding adhesion coreceptor for fibronectin. Journal of Cell Biology, 148(4), 825–38.  
Akpan, N., & Troy, C. M. (2013). Caspase inhibitors: prospective therapies for stroke. The 
Neuroscientist : A Review Journal Bringing Neurobiology, Neurology and Psychiatry, 19(2), 129–
36.  
Alessandrini, A., Namura, S., Moskowitz, M. A., & Bonventre, J. V. (1999). MEK1 protein kinase 
inhibition protects against damage resulting from focal cerebral ischemia. Proceedings of the 
National Academy of Sciences of the United States of America, 96(22), 12866–09.  
Allen, S. J., & Dawbarn, D. (2006). Clinical relevance of the neurotrophins and their receptors. Clinical 
Science, 110(2), 175–91. 
Allen, S. J.,Watson J. J., Shoemark D. K., Barua N. U., Patel N. K. (2013). GDNF, NGF and BDNF as 
therapeutic options for neurodegeneration. Pharmacology & Therapeutics,138(2), 155–75. 
Almami, I., Dickenson, J. M., Hargreaves, A. J., & Bonner, P. L. R. (2014). Modulation of 
transglutaminase 2 activity in H9c2 cells by PKC and PKA signalling: A role for transglutaminase 
2 in cytoprotection. British Journal of Pharmacology 171(16), 3946–60. 
Aloe, L., Rocco, M. L., Bianchi, P., & Manni, L. (2012). Nerve growth factor: from the early discoveries 
to the potential clinical use. Journal of Translational Medicine, 10(1), 239.  
Andringa, G., Lam, K. Y., Chegary, M., Wang, X., Chase, T. N., & Bennett, M. C. (2004). Tissue 
transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson’s disease. The 
FASEB Journal : Official Publication of the Federation of American Societies for Experimental 
Biology, 18(7), 932–34.  
 
 210 
 
Antonyak, M. A., Singh, U. S., Lee, D. A., Boehm, J. E., Combs, C., Zgola, M. M. & Cerione, R. A. 
(2001). Effects of Tissue Transglutaminase on Retinoic Acid-induced Cellular Differentiation and 
Protection against Apoptosis. Journal of Biological Chemistry, 276(36), 33582–87.  
Atwal, J. K., Massie, B., Miller, F. D., & Kaplan, D. R. (2000). The TrkB-Shc site signals neuronal 
survival and local axon growth via MEK and PI3-Kinase. Neuron, 27(2), 265–77.  
Aubert, N., Falluel-Morel, A., Vaudry, D., Xifro, X., Rodriguez-Alvarez, J., Fisch, C. &  Gonzalez, B. 
J. (2006). PACAP and C2-ceramide generate different AP-1 complexes through a MAP-kinase-
dependent pathway: Involvement of c-Fos in PACAP-induced Bcl-2 expression. Journal of 
Neurochemistry, 99(4), 1237–50.  
Bai, Y., Dergham, P., Nedev, H., Xu, J., Galan, A., Rivera, J. C., & Saragovi, H. U. (2010). Chronic and 
acute models of retinal neurodegeneration TrkA activity are neuroprotective whereas p75NTR 
activity is neurotoxic through a paracrine mechanism. Journal of Biological Chemistry, 285(50), 
39392–39400.  
Bailey, C. D., Graham, R. M., Nanda, N., Davies, P. J., & Johnson, G. V. (2004). Validity of mouse 
models for the study of tissue transglutaminase in neurodegenerative diseases. Mol Cell Neurosci, 
25(3), 493–503.  
Bailey, C. D., & Johnson, G. (2005). Tissue transglutaminase contributes to disease progression in the 
R6/2 Huntington’s disease mouse model via aggregate-independent mechanisms. Journal of 
Neurochemistry, 92(1), 83–92.  
Bamji, S. X., Majdan, M., Pozniak, C. D., Belliveau, D. J., Aloyz, R., Kohn, J., & Miller, F. D. (1998). 
The p75 neurotrophin receptor mediates neuronal apoptosis and is essential for naturally occurring 
sympathetic neuron death. The Journal of Cell Biology, 140(4), 911–23.  
Barres, B. A., & Barde, Y. (2000). Neuronal and glial cell biology. Current Opinion in Neurobiology, 
10(5), 642–48.  
Basille-Dugay, M., Vaudry H., Fournier A., Gonzalez B., & Vaudry D. (2013). Activation of PAC1 
receptors in rat cerebellar granule cells stimulates both calcium mobilization from intracellular 
stores and calcium inﬂux through N-type calcium channels. Front Endocrinol (Lausanne) 10(4): 
56. 
Batistatou, A., & Greene L. A., (1993). Internucleosomal DNA cleavage and neuronal cell 
survival/death The Journal of Cell Biology, 122 (3), 523–32. 
Baxter, P. S., Martel, M. A., McMahon, A., Kind, P. C., & Hardingham, G. E. (2011). Pituitary adenylate 
cyclase-activating peptide induces long-lasting neuroprotection through the induction of activity-
dependent signaling via the cyclic AMP response element-binding protein-regulated transcription 
co-activator 1. Journal of Neurochemistry, 118(3), 365–78.  
Bayascas, J. R., & Alessi, D. R. (2005). Regulation of Akt/PKB Ser473 phosphorylation. Molecular 
Cell, 18(2), 143–45. 
Belkin, A. M. (2011). Extracellular TG2: Emerging functions and regulation. FEBS Journal., 278(24), 
4704–16. 
Bennett, B. L., Sasaki, D. T., Murray, B. W., O’Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., 
Motiwala, A., Pierce, S., Satoh, Y., Bhagwat, S. S., Manning, A. M., & Anderson, D. W. (2001) 
Proc. Natl. Acad. Sci. U. S. A., 98(24), 13681–86. 
Berg, K.A., Maayani, S., McKay, R., & Clarke, W.P. (1995). Nerve Growth Factor Amplifies Cyclic 
AMP Production in the HT4 Neuronal Cell Line. Journal of Neurochemistry, 64 (1), 220–28. 
Bergamini, C. M., & Signorini, M. (1993). Studies on tissue transglutaminases: interaction of erythrocyte 
type-2 transglutaminase with GTP. The Biochemical Journal, 291 ( Pt 1), 37–9.  
 211 
 
 
Berridge, M. J. (2006) Calcium microdomains: organization and function. Cell Calcium 40(5-6), 405-
412. 
Bezzi, P., & Volterra, A. (2001). A neuron-glia signalling network in the active brain. Current Opinion 
in Neurobiology, 11(1), 387–94. 
Bian, Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., Ye M., & Zou H. (2014). 
An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J 
Proteomics. 96:253-62. 
Bibel, M., & Barde, Y. (2000). vertebrate nervous system Neurotrophins : key regulators of cell fate and 
cell shape in the vertebrate nervous system. Genes & Development, (Bargmann 1998), 2919–2937.  
Biedler, J. L., Helson, L., & Spengler, B. A. (1973). Morphology and Growth, Tumorigenicity, and 
Cytogenetics of Human Neuroblastoma Cells in Continuous Culture. Cancer Research, 33(11), 
2643–52.  
Biernat, J., Wu, Y.-Z., Timm, T., Zheng-, Q. F., Mandelkow, E., Meijer, L., & Mandelkow. (2002). 
Protein Kinase MARK/PAR-1 Is Required for Neurite Outgrowth and Establishment of Neuronal 
Polarity. Molecular Biology of the Cell, 13, 4013–28.  
Bijur, G. N., & Jope, R. S. (2003). Rapid accumulation of Akt in mitochondria following 
phosphatidylinositol 3-kinase activation. Journal of Neurochemistry, 87(6), 1427–35.  
Björkblom, B., Vainio, J. C., Hongisto, V., Herdegen, T., Courtney, M. J., & Coffey, E. T. (2008). All 
JNKs can kill, but nuclear localization is critical for neuronal death. Journal of Biological 
Chemistry, 283(28), 19704–13. 
Biswas, S.C. & Greene, L.A. NGF down-regulates the BH3-only protein Bim and suppresses its pro-
apoptotic activity by phosphorylation. (2002). J. Biol. Chem. 277(51),49511–16.  
Blaskó, B., Mádi, A., & Fésüs, L. (2003). Thioredoxin motif of Caenorhabditis elegans PDI-3 provides 
Cys and His catalytic residues for transglutaminase activity. Biochemical and Biophysical 
Research Communications, 303(4), 1142–1147.  
Blechman, J., & Levkowitz, G. (2013). Alternative splicing of the pituitary adenylate cyclase-activating 
polypeptide receptor PAC1: Mechanisms of fine tuning of brain activity. Frontiers in 
Endocrinology, 4(MAY), 1–19.  
Bollag, W. B., Zhong, X., Dodd, M. E., Hardy, D. M., Zheng, X., & Allred, W. T. (2005). Phospholipase 
d signaling and extracellular signal-regulated kinase-1 and -2 phosphorylation (activation) are 
required for maximal phorbol ester-induced transglutaminase activity, a marker of keratinocyte 
differentiation. J.Pharmacol.Exp.Ther., 312(3), 1223–31.  
Botia, B., Basille, M., Allais, A., Raoult, E., Falluel-Morel, A., Galas, L., & Vaudry, D. (2007). 
Neurotrophic effects of PACAP in the cerebellar cortex. Peptides, 28(9), 1746–52.  
Bozyczko-Coyne, D., O’Kane, T. M., Wu, Z. L., Dobrzanski, P., Murthy, S., Vaught, J. L., & Scott, R. 
W. (2001). CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival 
and blocks multiple events associated with A??-induced cortical neuron apoptosis. Journal of 
Neurochemistry, 77(3), 849–63.  
Braithwaite, S. P., Schmid, R. S., He, D. N., Sung, M. L. A., Cho, S., Resnick, L., & Lo, D. C. (2010). 
Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer’s disease. 
Neurobiology of Disease, 39(3), 311–17.  
Brazil, D. P., & Hemmings, B. A. (2001). Ten years of protein kinase B signalling: A hard Akt to follow. 
Trends in Biochemical Sciences, 26(11), 657–64. 
 212 
 
Briani, C., Samaroo, D., & Alaedini, A. (2008). Celiac disease: From gluten to autoimmunity. 
Autoimmunity Reviews, 7(8), 644–50. 
Brodie, C., Bogi, K., Acs, P., Lazarovici, P., Petrovics, G., Anderson, W. B., & Blumberg, P. M. (1999). 
Protein kinase C-epsilon plays a role in neurite outgrowth in response to epidermal growth factor 
and nerve growth factor in PC12 cells. Cell Growth & Differentiation, 10(3), 183–91. 
Bruce, S. E., Bjarnason, I., & Peters, T. J. (1985). Human jejunal transglutaminase: demonstration of 
activity, enzyme kinetics and substrate specificity with special relation to gliadin and coeliac 
disease. Clinical Science (London, England : 1979), 68(5), 573–79.  
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., & Greenberg, M. E. (1999). Akt 
promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell, 
96(6), 857–68. 
Cabell, L., & Audesirk, G., (1993). Effects of selective inhibition of protein kinase C, cyclic AMP-
dependent protein kinase, and Ca2+-calmodulin-dependent protein kinase on neurite development 
in cultured rat hippocampal neurons. Int. J. Dev. Neurosci., 11(1993),357–368. 
Cabeza, C., Figueroa, A., Lazo, O. M., Galleguillos, C., Pissani, C., Klein, A., & Bronfman, F. C. (2012). 
Cholinergic abnormalities, endosomal alterations and up-regulation of nerve growth factor 
signaling in Niemann-Pick type C disease. Molecular Neurodegeneration, 7(1), 11.  
Caccamo, D., Curro, M., Ferlazzo, N., Condello, S., & Ientile, R. (2012). Monitoring of transglutaminase 
2 under different oxidative stress conditions. Amino Acids, 42(2–3), 1037–43.  
Cai, J., Hua, F., Yuan, L., Tang, W., Lu, J., Yu, S., & Hu, Y. (2014). Potential therapeutic effects of 
neurotrophins for acute and chronic neurological diseases. BioMed Research International.  
Carlsson, Y., Schwendimann, L., Vontell, R., Rousset, C. I., Wang, X., Lebon, S., & Jacotot, E. (2011). 
Genetic inhibition of caspase-2 reduces hypoxic-ischemic and excitotoxic neonatal brain injury. 
Annals of Neurology, 70(5), 781–789.  
Carracedo, A., & Pandolfi, P. P. (2008). The PTEN-PI3K pathway: Of feedbacks and cross-talks. 
Oncogene, 27(41), 5527–41. 
Carriere, A., Romeo, Y., Acosta-Jaquez, H. A., Moreau, J., Bonneil, E., Thibault, P., & Roux, P. P. 
(2011). ERK1/2 phosphorylate raptor to promote ras-dependent activation of mTOR complex 1 
(mTORC1). Journal of Biological Chemistry, 286(1), 567–77. 
Casaccia-Bonnefil, P., Carter, B. D., Dobrowsky, R. T., & Chao, M. V. (1996). Death of 
oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75. Nature, 
383(6602), 716–719. 
Castorina, A., Scuderi, S., D’Amico, A. G., Drago, F., & D’Agata, V. (2014). PACAP and VIP increase 
the expression of myelin-related proteins in rat schwannoma cells: Involvement of PAC1/VPAC2 
receptor-mediated activation of PI3K/Akt signaling pathways. Experimental Cell Research, 
322(1), 108–121.  
Chakraborty, G., Leach, T., Zanakis, M. F., Sturman, J. A., & Ingoglia, N. A. (1987). Posttranslational 
Protein Modification by Polyamines in Intact and Regenerating Nerves. Journal of 
Neurochemistry, 48(3), 669–675.  
Chao, M. V., Rajagopal, R., & Lee, F. S. (2006). Neurotrophin signalling in health and disease: Figure 
1. Clinical Science, 110(2), 167–173.  
Chao, M. V, Bothwell, M. A., Ross, A. H., Koprowski, H., Lanahan, A. A., Buck, C. R., & Sehgal, A. 
(1986). Gene transfer and molecular cloning of the human NGF receptor. Science, 232(4749), 518–
521.  
 
 213 
 
Chauvier, D., Renolleau, S., Holifanjaniaina, S., Ankri, S., Bezault, M., Schwendimann, L., & Jacotot, 
E. (2011). Targeting neonatal ischemic brain injury with a pentapeptide-based irreversible caspase 
inhibitor. Cell Death and Disease, 2(9), e203.  
Cheung, Y. T., Lau, W. K. W., Yu, M. S., Lai, C. S. W., Yeung, S. C., So, K. F., & Chang, R. C. C. 
(2009). Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in 
neurotoxicity research. NeuroToxicology, 30(1), 127–135.  
Chhabra, A., Verma, A., & Mehta, K. (2009). Tissue transglutaminase promotes or suppresses tumors 
depending on cell context. Anticancer Research, 29(6), 1909–19. 
Chik, C. L.,Inukai T., Ogiwara T., Boyd H., Li B., Karpinski E.  & Ho. A.K. (1996). Characterization 
of pituitary adenylate cyclase-activating polypeptide 38 (PACAP38)- PACAP27-, and vasoactive 
intestinal peptide-stimulated responses in N1E-115 neuroblastoma cells. J. Neurochem. 67: 1005–
1013. 
Chivet M., Javalet C., Laulagnier K., Blot B., Hemming F. J., & Sadoul R. (2014). Exosomes secreted 
by cortical neurons upon glutamatergic synapse activation specifically interact with neurons. J. 
Extracell. Vesicles 3, 24722. 
Cho, S.-Y., Lee, J.-H., Bae, H.-D., Jeong, E. M., Jang, G.-Y., Kim, C.-W., & Kim, I.-G. (2010). 
Transglutaminase 2 inhibits apoptosis induced by calcium- overload through down-regulation of 
Bax. Experimental & Molecular Medicine, 42(9), 639–650.  
Ciccocioppo, R., Finamore, A., Mengheri, E., Millimaggi, D., Esslinger, B., Dieterich, W., & Corazza, 
G. R. (2010). Isolation and characterization of circulating tissue transglutaminase-specific T cells 
in coeliac disease. Int J Immunopathol Pharmacol, 23(1), 179–191.  
Citron, B. A., SantaCruz, K. S., Davies, P. J. A., & Festoff, B. W. (2001). Intron-Exon Swapping of 
Transglutaminase mRNA and Neuronal Tau Aggregation in Alzheimer’s Disease. Journal of 
Biological Chemistry, 276(5), 3295–3301. 
Clarke, D. D., Mycek, M. J., Neidle,  a., & Waelsch, H. (1959). The incorporation of amines into protein. 
Archives of Biochemistry and Biophysics, 79(1959), 338–354. 
Clason, T. A., Girard B. M., May V., & Parsons R. L. (2016). Activation of MEK/ERK signaling by 
PACAP in guinea pig cardiac neurons. J. Mol. Neurosci. 59(2): 309-316. 
Colak, G., & Johnson, G. V. W. (2012). Complete transglutaminase 2 ablation results in reduced stroke 
volumes and astrocytes that exhibit increased survival in response to ischemia. Neurobiology of 
Disease, 45(3), 1042–1050.  
Collins, L. M., Downer, E. J., Toulouse, A., & Nolan, Y. M. (2015). Mitogen-Activated Protein Kinase 
Phosphatase (MKP)-1 in Nervous System Development and Disease. Molecular Neurobiology, 
51(3), 1158–1167.  
Compston,  A, Zajicek, J., Sussman, J., Webb,  a, Hall, G., Muir, D., & Scolding, N. (1997). Glial 
lineages and myelination in the central nervous system. Journal of Anatomy, 190 ( Pt 2), 161–200.  
Condello, S., Caccamo, D., Currò, M., Ferlazzo, N., Parisi, G., & Ientile, R. (2008). Transglutaminase 2 
and NF-κB interplay during NGF-induced differentiation of neuroblastoma cells. Brain Research, 
1207(2008), 1–8. 
Corrêa, S. A. L., & Eales, K. L. (2012). The Role of p38 MAPK and Its Substrates in Neuronal Plasticity 
and Neurodegenerative Disease. Journal of Signal Transduction, 2012, 1–12.  
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010). The PI3K pathway as drug target in human 
cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical 
Oncology, 28(6), 1075–83.  
Couvineau, A., Amiranoff, B., & Laburthe, M. (1986). Solubilization of the Liver Vasoactive Intestinal 
 214 
 
Peptide Receptor and evidence for an association with with a functional GTP regulatory 
protein.The Journal of Biological Chemistry, 261(31), 14482–89. 
 
Craig, A. M., & Banker, G. (1994). Neuronal Polarity. Annual Review of Neuroscience, 17(1), 267–310.  
Creedon, D. J., Johnson, E. M., & Lawrence, J. C. (1996). Mitogen-activated protein kinase-independent 
pathways mediate the effects of nerve growth factor and cAMP on neuronal survival. J Biol Chem, 
271(34), 20713–20718. 
Crowder, R. J., & Freeman, R. S. (1998). Phosphatidylinositol 3-kinase and Akt protein kinase are 
necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons. J 
Neurosci, 18(8), 2933–2943. 
Crowley, C., Spencer, S. D., Nishimura, M. C., Chen, K. S., Pitts-Meek, S., Armaninl, M. P., & Phillips, 
H. S. (1994). Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic 
neurons yet develop basal forebrain cholinergic neurons. Cell, 76(6), 1001–1011.  
Cuenda, A., & Rousseau, S. (2007). p38 MAP-Kinases pathway regulation, function and role in human 
diseases. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1773(8), 1358–1375.  
Currò, M., Condello, S., Caccamo, D., Ferlazzo, N., Parisi, G., & Ientile, R. (2009). Homocysteine-
induced toxicity increases TG2 expression in Neuro2a cells. Amino Acids, 36(4), 725–730.  
Dai, Y, Dudek N.L. , Patel T.B. , & Muma N. A. (2008). Transglutaminase-catalyzedtransamidation:a 
novel mechanism for Rac1 activation by 5-hydroxytryptamine 2 A receptor stimulation. J 
Pharmacol Exp Ther 326(1): 153–162. 
Dardik, R., & Inbal, A. (2006). Complex formation between tissue transglutaminase II (tTG) and 
vascular endothelial growth factor receptor 2 (VEGFR-2): Proposed mechanism for modulation of 
endothelial cell response to VEGF. Experimental Cell Research, 312(16), 2973–2982.  
Das, T., Baek, K. J., Gray, C., & Im, M. J. (1993). Evidence that the Gh protein is a signal mediator 
from α1-adrenoceptor to a phospholipase C: II. Purification and characterization of a Gh-coupled 
69-kDa phospholipase C and reconstitution of α1-adrenoceptor, Gh family, and phospholipase C. 
Journal of Biological Chemistry, 268(36), 27398–27405. 
Davies, S. P., Reddy, H., Caivano, M. & Cohen, P. (2000). Specificity and mechanism of action of 
some commonly used protein kinase inhibitors. Biochem. J. 351(pt 1), 95–105. 
De Bernardi M. A., Rabin S. J., Colangelo A. M., Brooker G., & Mocchetti I. (1996). TrkA mediates 
the nerve growth factor-induced intracellular calcium accumulation. J Biol Chem 271(11), 6092–
98. 
Dejda, A., Sokołowska, P., & Nowak, J. Z. (2005). Neuroprotective potential of three neuropeptides 
PACAP, VIP and PHI. Pharmacological Reports, 57(3), 307–320. 
Deppmann, C. D., Mihalas, S., Sharma, N., Lonze, B. E., Niebur, E., & Ginty, D. D. (2008). A Model 
for Neuronal Competition During Development. Science, 320(5874), 369–373.  
Derijard, B., Hibi, M., Wu, I. H., Barrett, T., Su, B., Deng, T. L., &  Davis, R. J. (1994). JNK1 - A 
protein-kinase stimulated by uv-light and ha-ras that binds and phosphorylates the c-jun activation 
domain. Cell, 76(6), 1025–1037. 
Descloux, C., Ginet, V., Clarke, P. G. H., Puyal, J., & Truttmann, A. C. (2015). Neuronal death after 
perinatal cerebral hypoxia-ischemia: Focus on autophagy-mediated cell death. International 
Journal of Developmental Neuroscience, 45(2015), 75–85.  
 
 
 215 
 
Deutsch, PJ & Su NY. (1992). The 38-amino acid form of pituitary adenylate cyclase-activating 
polypeptide stimulates dual signaling cascades in PC12 cells and promotes neurite outgrowth. J 
Biol Chem 267(8): 5108–13. 
Dhanasekaran, D. N., & Reddy, E. P. (2008). JNK signaling in apoptosis. Oncogene, 27(48), 6245–6251.  
Di Sabatino A., & Corazza G. R. (2009). Coeliac disease. Lancet,373(9673):1480–1493. 
Dickinson, T., Fleetwood-Walker, S. M., Mitchell, R., & Lutz, E. M. (1997). Evidence for roles of 
vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide 
(PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs. 
Neuropeptides, 31(2), 175–185.  
Dickson, L., & Finlayson, K. (2009). VPAC and PAC receptors: From ligands to function. 
Pharmacology and Therapeutics, 121(3), 294–316.  
Dillon, R. L., White, D. E., & Muller, W. J. (2007). The phosphatidyl inositol 3-kinase signaling 
network: Implications for human breast cancer. Oncogene, 26(9), 1338–45. 
Douiri, S., Bahdoudi, S., Hamdi, Y., Cubì, R., Basille, M., Fournier, A., & Masmoudi-Kouki, O. (2016). 
Involvement of endogenous antioxidant systems in the protective activity of pituitary adenylate 
cyclase-activating polypeptide against hydrogen peroxide-induced oxidative damages in cultured 
rat astrocytes. Journal of Neurochemistry, 137(6),  913–930.  
Dudley DT, Pang L, Decker SJ, Bridges AJ, & Saltiel AR (1995) A syntheticinhibitorofthemitogen-
activatedproteinkinasecascade. Proc Natl Acad Sci USA, 92(17):7686–7689 
Durukan, A., & Tatlisumak, T. (2007). Acute ischemic stroke: Overview of major experimental rodent 
models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacology Biochemistry and 
Behavior, 87(1), 179–197. 
Dwane, S., Durack, E., & Kiely, P. A. (2013). Optimising parameters for the differentiation of SH-SY5Y 
cells to study cell adhesion and cell migration. BMC Research Notes, 6(1), 366.  
Eckert, R. L., Kaartinen, M. T., Nurminskaya, M., Belkin, A. M., Colak, G., Johnson, G. V. W., & 
Mehta, K. (2014). Transglutaminase regulation of cell function. Physiological Reviews, 94(2), 
383–417. 
Eggert,  A.,  Ikegaki, N., Liu, X., Chou, T. T., Lee, V. M., Trojanowski, J. Q., & Brodeur, G. M. (2000). 
Molecular dissection of TrkA signal transduction pathways mediating differentiation in human 
neuroblastoma cells. Oncogene, 19(16), 2043–51. 
Elli, L., Bergamini, C. M., Bardella, M. T., & Schuppan, D. (2009). Transglutaminases in inflammation 
and fibrosis of the gastrointestinal tract and the liver. Digestive and Liver Disease. 41(8), 541–50. 
Elmore, S. (2007). Apoptosis: A Review of Programmed Cell Death. Toxicologic Pathology, 35(4), 495–
516. 
Emery, A. C., & Eiden, L. E. (2012). Signaling through the neuropeptide GPCR PAC1 induces 
neuritogenesis via a single linear cAMP- and ERK-dependent pathway using a novel cAMP sensor. 
The FASEB Journal, 26(8), 3199–3211. 
Encinas, M., Iglesias, M., Liu, Y., Wang, H., Muhaisen, A., Ceña, V., & Comella, J. X. (2000). 
Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor 
gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. Journal 
of Neurochemistry, 75(3), 991–1003.  
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., & Wong, K. K. (2008). 
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine 
lung cancers. Nature Medicine, 14(12), 1351–56. 
 216 
 
Erhardt, N. M., & Sherwood, N. M. (2004). PACAP maintains cell cycling and inhibits apoptosis in 
chick neuroblasts. Molecular and Cellular Endocrinology, 221(1–2), 121–134.  
Esposito, C. L., D’Alessio, A., de Franciscis, V., & Cerchia, L. (2008). A cross-talk between TrkB and 
ret tyrosine kinase receptors mediates neuroblastoma cells differentiation. PLoS ONE, 3(2), 1643 
Evangelopoulos, M. E., Weis, J., & Krüttgen, A. (2005). Signalling pathways leading to neuroblastoma 
differentiation after serum withdrawal: HDL blocks neuroblastoma differentiation by inhibition of 
EGFR. Oncogene, 24(20), 3309–3318.  
Facchiano, F., Benfenati, F., Valtorta, F., & Luini, A. (1993). Covalent modification of synapsin I by a 
tetanus toxin-activated transglutaminase. Journal of Biological Chemistry, 268(7), 4588–4591. 
Falluel-Morel, A., Aubert, N., Vaudry, D., Basille, M., Fontaine, M., Fournier, A., & Gonzalez, B. J. 
(2004). Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP 
through a MAP-kinase-dependent mechanism in cerebellar granule cells. Journal of 
Neurochemistry, 91(5), 1231–1243. 
Fantacci, C., Capozzi, D., Ferrara, P., & Chiaretti, A. (2013). Neuroprotective Role of Nerve Growth 
Factor in Hypoxic-Ischemic Brain Injury. Brain Sci. Brain Sci, 3(3), 1013–1022.  
Feng, Y., Fratkin, J. D., & LeBlanc, M. H. (2003). Inhibiting caspase-8 after injury reduces hypoxic-
ischemic brain injury in the newborn rat. European Journal of Pharmacology, 481(2–3), 169–173.  
Feriche, B., Delgado, M., Calderón, C., Lisbona, O., Chirosa, I. J., Miranda, M. T., & Alvarez, J. (2007). 
The effect of acute moderate hypoxia on accumulated oxygen deficit during intermittent exercise 
in nonacclimatized men. Journal of Strength and Conditioning Research, 21(2), 413–8.  
Fesus, L., & Piacentini, M. (2002). Transglutaminase 2: An enigmatic enzyme with diverse functions. 
Trends in Biochemical Sciences, 27(10), 534–9. 
Fesus, L., & Szondy, Z. (2005). Transglutaminase 2 in the balance of cell death and survival. FEBS 
Letters, 579(15), 3297–3302.  
Filiano, A. J., Bailey, C. D. C., Tucholski, J., Gundemir, S., & Johnson, G. V. W. (2008). 
Transglutaminase 2 protects against ischemic insult, interacts with HIF1 , and attenuates HIF1 
signaling. The FASEB Journal, 22(8), 2662–2675. 
Filiano, A. J., Bailey, C. D. C., Tucholski, J., Gundemir, S., & Johnson, G. V. W. (2008). 
Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 
signaling. The FASEB Journal : Official Publication of the Federation of American Societies for 
Experimental Biology, 22(8), 2662–2675. 
Filiano, A. J., Tucholski, J., Dolan, P. J., Colak, G., & Johnson, G. V. W. (2010). Transglutaminase 2 
protects against ischemic stroke. Neurobiology of Disease, 39(3), 334–343.  
Fink, K., Zhu, J., Namura, S., Shimizu-Sasamata, M., Endres, M., Ma, J., & Moskowitz, M. A. (1998). 
Prolonged therapeutic window for ischemic brain damage caused by delayed caspase activation. 
Journal of Cerebral Blood Flow and Metabolism, 18(10), 1071–1076.  
Flaskos, J. (2012). The developmental neurotoxicity of organophosphorus insecticides: A direct role for 
the oxon metabolites. Toxicology Letters, 209(1), 86–93. 
Folk, J. E. (1983). Mechanism and basis for specificity of transglutaminase-catalyzed ε-(γ-glutamyl) 
lysine bond formation. Advances in Enzymology and Related Areas of Molecular Biology, 54(83), 
1–56.  
Freund, K. F., Doshi, K. P., Gaul, S. L., Claremon, D. a, Remy, D. C., Baldwin, J. J.,& Stern,  a M. 
(1994). Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism 
of factor XIIIa inactivation. Biochemistry, 33(33), 10109–19.  
 217 
 
Friedlander, R. M. (2003). Apoptosis and Caspases in Neurodegenerative Diseases. New England 
Journal of Medicine, 348(14), 1365–1375. 
Galluzzi, L., & Kroemer, G. (2008). Necroptosis: A Specialized Pathway of Programmed Necrosis. Cell. 
135(7):1161-3.  
Gaudry, C. A., Verderio, E., Aeschlimann, D., Cox, A., Smith, C., & Griffin, M. (1999). Cell surface 
localization of tissue transglutaminase is dependent on a fibronectin-binding site in its N-terminal 
β-sandwich domain. Journal of Biological Chemistry, 274(43), 30707–30714.  
Gentile, V., Porta, R., Chiosi, E., Spina, A., Valente, F., Pezone, R., Davies, P.J.A., Alaadik, A., & 
Illiano, G. (1997). TGase/Gah protein expres- sion inhibits adenylate cyclase activity in Balb-C 
3T3 fibroblasts mem- branes. Biochim. Biophys. Acta, 1357(1), 115–122. 
Ghatei, M. a, Takahashi, K., Suzuki, Y., Gardiner, J., Jones, P. M., & Bloom, S. R. (1993). Distribution, 
molecular characterization of pituitary adenylate cyclase-activating polypeptide and its precursor 
encoding messenger RNA in human and rat tissues. The Journal of Endocrinology, 136(1), 159–
166. 
Gjertsen, B. T., Mellgren, G., Otten, A., Maronde, E., Genieser, H. G., Jastorff, B., Vintermyr, O. K., 
McKnight, G. S., &  Døskeland, S. O. (1995). Novel (Rp)-cAMPS Analogs as Tools for 
Inhibition of cAMP-kinase in Cell Culture basal cAMP-Kinase activity modulates interleukin-1β 
action J. Biol. Chem. 270(35), 20599–20607 
Gonzalez, B. J., Basille, M., Vaudry, D., Fournier, A., & Vaudry, H. (1997). Pituitary adenylate cyclase-
activating polypeptide promotes cell survival and neurite outgrowth in rat cerebellar neuroblasts. 
Neuroscience, 78(2), 419–430.  
Gordon, J., Amini, S., & White, M. K. (2013). General Overview of Neuronal Cell Culture. In Neuronal 
Cell Culture: Methods and Protocols 1078(2013), 1–8.  
Gorman, A. M. (2008). Neuronal cell death in neurodegenerative diseases: Recurring themes around 
protein handling: Apoptosis Review Series. Journal of Cellular and Molecular Medicine, 12(6A), 
2263–2280.  
Greenberg, C. S., Birckbichler, P. J., & Rice, R. H. (1991). Transglutaminases: multifunctional cross-
linking enzymes that stabilize tissues. FASEB Journal : Official Publication of the Federation of 
American Societies for Experimental Biology, 5(15), 3071–7.  
Grenard, P., Bates, M. K., & Aeschlimann, D. (2001). Evolution of transglutaminase genes: 
Identification of a transglutaminase gene cluster on human chromosome 15q15: Structure of the 
gene encoding transglutaminase X and a novel gene family member, transglutaminase Z. Journal 
of Biological Chemistry, 276(35), 33066–33078.  
Griffin, M., Casadio, R., & Bergamini, C. M. (2002). Transglutaminases : Nature’s biological glues. 
Biochem. J, 368, 377–396. 
Grimes, M. L., Zhou, J., Beattie, E. C., Yuen, E. C., Hall, D. E., Valletta, J. S.,& Mobley, W. C. (1996). 
Endocytosis of activated TrkA: evidence that nerve growth factor induces formation of signaling 
endosomes. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience, 
16(24), 7950–7964. 
Hamanoue, M., Middleton, G., Wyatt, S., Jaffray, E., Hay, R. T., & Davies, A. M. (1999). p75-mediated 
NF-κB activation enhances the survival response of developing sensory neurons to nerve growth 
factor. Mol Cell Neurosci, 14, 28–40. 
Hammack, S. E., Roman, C. W., Lezak, K. R., Kocho-Shellenberg, M., Grimmig, B., Falls, W. A., & 
May, V. (2010). Roles for pituitary adenylate cyclase-activating peptide (PACAP) expression and 
signaling in the bed nucleus of the stria terminalis (BNST) in mediating the behavioral 
consequences of chronic stress. Journal of Molecular Neuroscience, 42(3), 327–40. 
 218 
 
Han, Z., Pantazis P., Lange T. S., Wyche J. H., & Hendrickson E. A. (2000). The staurosporine analog, 
Ro-31-8220, induces apoptosis independently of its ability to inhibit protein kinase C. Cell Death 
Differ. 7(6):521–530. 
Hang, J., Zemskov, E. A., Lorand, L., & Belkin, A. M. (2005). Identification of a novel recognition 
sequence for fibronectin within the NH2-terminal β-sandwich domain of tissue transglutaminase. 
Journal of Biological Chemistry, 280(25), 23675–23683.  
Hara, M. R., & Snyder, S. H. (2007). Cell signaling and neuronal death. Annual Review of Pharmacology 
and Toxicology, 47(July 2006), 117–141.  
Harding, T. C., Xue, L., Bienemann, A., Haywood, D., Dickens, M., Tolkovsky, A. M., & Uney, J. B. 
(2001). Inhibition of JNK by Overexpression of the JNK Binding Domain of JIP-1 Prevents 
Apoptosis in Sympathetic Neurons. Journal of Biological Chemistry, 276(7), 4531–4534.  
Harmar, A. J., Fahrenkrug, J., Gozes, I., Laburthe, M., May, V., Pisegna, J. R., & Said, S. I. (2012). 
Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate 
cyclase-activating polypeptide: IUPHAR Review 1. British Journal of Pharmacology, 166(1), 4–
17.  
Haroon, Z. a, Hettasch, J. M., Lai, T. S., Dewhirst, M. W., & Greenberg, C. S. (1999). Tissue 
transglutaminase is expressed, active, and directly involved in rat dermal wound healing and 
angiogenesis. The FASEB Journal : Official Publication of the Federation of American Societies 
for Experimental Biology, 13(13), 1787–1795. 
Hasegawa, G., Suwa, M., Ichikawa, Y., Ohtsuka, T., Kumagai, S., Kikuchi, M., & Saito, Y. (2003). A 
novel function of tissue-type transglutaminase: protein disulphide isomerase. Biochem. J, 373, 
793–803. 
Hashimoto, H., Shintani, N., & Baba, A. (2006). New insights into the central PACAPergic system from 
the phenotypes in PACAP- and PACAP receptor-knockout mice. In Annals of the New York 
Academy of Sciences 1070(2006), 75–89.  
Hatanaka, H., Nihonmatsu, I., & Tsukui, H. (1988). Nerve growth factor promotes survival of cultured 
magnocellular cholinergic neurons from nucleus basalis of Meynert in postnatal rats. Neuroscience 
Letters, 90(1–2), 63–68.  
Hausott, B., Kurnaz, I., Gajovic, S., & Klimaschewski, L. (2009). Signaling by neuronal tyrosine kinase 
receptors: Relevance for development and regeneration. Anatomical Record, 292(12), 1976–1985.  
Hefti, F. F., Rosenthal, A., Walicke, P. A., Wyatt, S., Vergara, G., Shelton, D. L., & Davies, A. M. 
(2006). Novel class of pain drugs based on antagonism of NGF. Trends in Pharmacological 
Sciences, 27(2), 85–91. 
Héraud, C. , Hilairet, S. , Muller, J. , Leterrier, J. & Chadéneau, C. (2004), Neuritogenesis induced by 
vasoactive intestinal peptide, pituitary adenylate cyclase‐activating polypeptide, and peptide 
histidine methionine in SH‐SY5Y cells is associated with regulated expression of cytoskeleton 
mRNAs and proteins. J. Neurosci. Res., 75(3): 320–29. 
Hetman, M., Kanning, K., Cavanaugh, J. E., & Xia, Z. (1999). Neuroprotection by brain-derived 
neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 
3-kinase. J Biol Chem, 274(32), 22569–22580.  
Hitomi, K., Kitamura, M., Alea, M. P., Ceylan, I., Thomas, V., & El Alaoui, S. (2009). A specific 
colorimetric assay for measuring transglutaminase 1 and factor XIII activities. Analytical 
Biochemistry, 394(2), 281–283.  
Holtzman, D. M., Sheldon, R. A., Jaffe, W., Cheng, Y., & Ferriero, D. M. (1996). Nerve growth factor 
protects the neonatal brain against hypoxic-ischemic injury. Annals of Neurology, 39(1), 114–122.  
 
 219 
 
Horton, A., Laramee, G., Wyatt, S., Shih, A., Winslow, J., & Davies, A. M. (1997). NGF Binding to p75 
Enhances the Sensitivity of Sensory and Sympathetic Neurons to NGF at Different Stages of 
Development. Molecular and Cellular Neuroscience, 10(3–4), 162–172.  
Hu, Y., Qiao, L., Wang, S., Rong, S., Meuillet, E.J., Berggren, M., Gallegos, A., Powis, G., & 
Kozikowski, A.P. (2000). 3-(Hydroxymethyl)bearing phosphatidylinositol ether lipid analogues 
and carbonate surrogates block PI3-K, akt, and cancer cell growth. J. Med. Chem. 43(16), 3045–
51. 
Huang, E. J., & Reichardt, L. F. (2001). Neurotrophins: Roles in Neuronal Development and Function. 
Annual Review of Neuroscience, 24(1), 677–736. 
Ientile, R., Caccamo, D., Marciano, M. C., Currò, M., Mannucci, C., Campisi, A., & Calapai, G. (2004). 
Transglutaminase activity and transglutaminase mRNA transcripts in gerbil brain ischemia. 
Neuroscience Letters, 363(2), 173–177.  
Iismaa, S. E., Mearns, B. M., Lorand, L., & Graham, R. M. (2009). Transglutaminases and disease: 
lessons from genetically engineered mouse models and inherited disorders. Physiological Reviews, 
89(3), 991–1023. 
Im, M. J., Russell, M. a, & Feng, J. F. (1997). Transglutaminase II: a new class of GTP-binding protein 
with new biological functions. Cellular Signalling, 9(7), 477–82. 
Imami K., Sugiyama N., Kyono Y., Tomita M.,& Ishihama Y. (2008) Automated phosphoproteome 
analysis for cultured cancer cells by two-dimensional nanoLC-MS using a calcined titania/C18 
biphasic column. Anal Sci. 24(1):161-6. 
Ishii, I., & Ui, M. (1994). Retinoic acid-induced gene expression of tissue transglutaminase via protein 
kinase C-dependent pathway in mouse peritoneal macrophages. Journal of Biochemistry, 115(6), 
1197–202.  
Jang, G.-Y., Jeon, J.-H., Cho, S.-Y., Shin, D.-M., Kim, C.-W., Jeong, E. M., & Kim, I.-G. (2010). 
Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-κB activity in hypoxic 
tumor cells. Oncogene, 29(3), 356–367.  
Jaworski, D. M. (2000). Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) and 
the PACAP-selective receptor in cultured rat astrocytes, human brain tumors, and in response to 
acute intracranial injury. Cell and Tissue Research, 300(2), 219–30.   
Jin, Z., & El-Deiry, W. S. (2005). Overview of cell death signaling pathways. Cancer Biology and 
Therapy, 4(2), 147–71.   
Johnson, K., Hashimoto, S., Lotz, M., Pritzker, K., & Terkeltaub, R. (2001). Interleukin-1 induces pro-
mineralizing activity of cartilage tissue transglutaminase and factor XIIIa. The American Journal 
of Pathology, 159(1), 149–63. 
Johnson, G. V, Cox, T. M., Lockhart, J. P., Zinnerman, M. D., Miller, M. L., & Powers, R. E. (1997). 
Transglutaminase activity is increased in Alzheimer’s disease brain. Brain Research, 751(2), 323–
329. 
Jolivel, V., Basille, M., Aubert, N., de Jouffrey, S., Ancian, P., Le Bigot, J. F., & Vaudry, D. (2009). 
Distribution and functional characterization of pituitary adenylate cyclase-activating polypeptide 
receptors in the brain of non-human primates. Neuroscience, 160(2), 434–451.  
Joshi, S., Guleria, R., Pan, J., DiPette, D., & Singh, U. S. (2006). Retinoic acid receptors and tissue-
transglutaminase mediate short-term effect of retinoic acid on migration and invasion of 
neuroblastoma SH-SY5Y cells. Oncogene, 25(2), 240–247.  
Jóźwiak-Bębenista M, Kowalczyt E, & Nowak JZ (2015). The cyclic AMP effects and neuroprotective 
activities of PACAP and VIP in cultured astrocytes and neurons exposed to oxygen-glucose 
deprivation. Pharmacol. Reports, 67(2), 332-338. 
 220 
 
Kalani A., Tyagi A., & Tyagi N. (2014) Exosomes: mediators of neurodegeneration, neuroprotection 
and therapeutics.  Mol. Neurobiol. 49(1), 590-600.  
Kambe, Y., & Miyata, A. (2012). Role of mitochondrial activation in PACAP dependent neurite 
outgrowth. Journal of Molecular Neuroscience, 48(3), 550–557. 
Kang, S.-K., Lee, J.-Y., Chung, T.-W., & Kim, C.-H. (2004). Overexpression of transglutaminase 2 
accelerates the erythroid differentiation of human chronic myelogenous leukemia K562 cell line 
through PI3K/Akt signaling pathway. FEBS Letters, 577(3), 361–366.  
Kaplan, D. R., Matsumoto, K., Lucarelli, E., & Thielet, C. J. (1993). Induction of TrkB by retinoic acid 
mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells. 
Neuron, 11(2), 321–331. 
Kaplan, D. R., & Miller, F. D. (2000). Neurotrophin signal transduction in the nervous system. Current 
Opinion in Neurobiology, 10(3), 381–91. 
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., & Waterfield, M. D. (2001). Cellular 
Function of Phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, 
and Cancer. Annual Review of Cell and Developmental Biology, 17(1), 615–75.  
Kawamoto, K., & Matsuda, H. (2004). Nerve growth factor and wound healing. In Progress in Brain 
Research, 146(2004), 369–84. 
Kenchappa, R. S., Zampieri, N., Chao, M. V., Barker, P. A., Teng, H. K., Hempstead, B. L., & Carter, 
B. D. (2006). Ligand-Dependent Cleavage of the P75 Neurotrophin Receptor Is Necessary for 
NRIF Nuclear Translocation and Apoptosis in Sympathetic Neurons. Neuron, 50(2), 219–32.  
Kettenbach A. N., Schweppe D. K., Faherty B. K., Pechenick D., Pletnev A. A., & Gerber S. A. (2011) 
Quantitative phosphoproteomics identifies substrates and functional modules of Aurora and Polo-
like kinase activities in mitotic cells. Sci Signal. 4(179):rs5. 
Kim, J. K., Choi, J. W., Lim, S., Kwon, O., Seo, J. K., Ryu, S. H., & Suh, P.-G. (2011). Phospholipase 
C-η1 is activated by intracellular Ca 2+ mobilization and enhances GPCRs/PLC/Ca 2+ signaling. 
Cellular Signalling, 23(26), 1022–29.  
Kim, S.-Y., Grant, P., Lee, J.-H., Pant, H. C., & Steinert, P. M. (1999). Differential Expression of 
Multiple Transglutaminases in Human Brain. Journal of Biological Chemistry, 274(43), 30715–
30721. 
Kim, S. Y., Grant, P., Lee, J. H., Pant, H. C., & Steinert, P. M. (1999). Differential expression of multiple 
transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 
and 2 in Alzheimer’s disease. Journal of Biological Chemistry, 274(43), 30715–30721.  
Kimura, S., Uchiyama, S., Takahashi, H. E., & Shibuki, K. (1998). cAMP-dependent long-term 
potentiation of nitric oxide release from cerebellar parallel fibers in rats. The Journal of 
Neuroscience : The Official Journal of the Society for Neuroscience, 18(21), 8551–8. 
Kinkade, C. W., Castillo-Martin, M., Puzio-Kuter, A., Yan, J., Foster, T. H., Gao, H., & Abate-Shen, C. 
(2008). Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate 
cancer in a preclinical mouse model. Journal of Clinical Investigation, 118(9), 3051–64. 
Király, R., Cssz, É., Kurtán, T., Antus, S., Szigeti, K., Simon-Vecsei, Z., & Fésüs, L. (2009). Functional 
significance of five noncanonical Ca2+-binding sites of human transglutaminase 2 characterized by 
site-directed mutagenesis. FEBS Journal, 276(23), 7083–7096.  
Király, R, Demény MA, & Fésϋs L (2011) Protein transamidation by transglutaminase 2 in cells: a 
disputed Ca2+-dependent action of a multifunctional protein. FEBS J. 278(24), 4717-4739. 
Kito, K., Ito, T., & Sakaki, Y. (1997). Fluorescent differential display analysis of gene expression in 
differentiating neuroblastoma cells. Gene, 184(1), 73–81. 
 221 
 
Klebe, R. J. & Ruddle, F. H. (1969). Neuroblastoma: cell culture analysis of a differentiating stem cell 
system. Journal of Cell Biology, 43(69). 
Klöock, C., & Khosla, C. (2012). Regulation of the activities of the mammalian transglutaminase family 
of enzymes. Protein Science, 21(12), 1781–91. 
Knight, R. A., & Verkhratsky, A. (2010). Neurodegenerative diseases: failures in brain connectivity. 
Cell Death and Differentiation, 17(7), 1069–1070. 
Koh, S., Kim S. H., Kwon H., Park Y., Kim K. S., Song C. W., Kim J., Kim M., Yu H., Henkel J. S., & 
Jung H. K. (2003). Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells 
from oxidative-radical-stress-induced apoptosis through its effect on phosphoinositide 3-
kinase/Akt and glycogen synthase kinase-3. Molecular Brain Research, 118(1–2)72–81. 
Kong, L., & Korthuis, R. J. (1997). Melanoma cell adhesion to injured arterioles: Mechanisms of 
stabilized tethering. Clinical and Experimental Metastasis, 15(4), 426–431.  
Koning, F., Schuppan, D., Cerf-Bensussan, N., & Sollid, L. M. (2005). Pathomechanisms in celiac 
disease. Best Practice and Research: Clinical Gastroenterology, 19(3 SPEC. ISS.), 373–387.  
Korecka, J. A., van Kesteren, R. E., Blaas, E., Spitzer, S. O., Kamstra, J. H., Smit, A. B., & Bossers, K. 
(2013). Phenotypic Characterization of Retinoic Acid Differentiated SH-SY5Y Cells by 
Transcriptional Profiling. PLoS ONE, 8(5), 63862-79.  
Korsching, S., & Thoenen, H. (1983). Quantitative demonstration of the retrograde axonal transport of 
endogenous nerve growth factor. Neuroscience Letters, 39(1), 1–4.  
Kotsakis, P., & Griffin, M. (2007). Tissue transglutaminase in tumour progression: Friend or foe? Amino 
Acids, 33(2), 373–84. 
Krasnikov, B. F., Kim, S. Y., McConoughey, S. J., Ryu, H., Xu, H., Stavrovskaya, I., & Cooper, A. J. 
L. (2005). Transglutaminase activity Is present in highly purified nonsynaptosomal mouse brain 
and liver mitochondria. Biochemistry, 44(21), 7830–7843. 
Kromer, L. F. (1987). Nerve growth factor treatment after brain injury prevents neuronal death. Science, 
235(4785), 214–216. 
Kumar, V., & Mahal, B. A. (2012). NGF - The TrkA to successful pain treatment. Journal of Pain 
Research, 5(2012), 279–87.  
Kume, T., Kawato, Y., Osakada, F., Izumi, Y., Katsuki, H., Nakagawa, T., & Akaike, A. (2008). 
Dibutyryl cyclic AMP induces differentiation of human neuroblastoma SH-SY5Y cells into a 
noradrenergic phenotype. Neuroscience Letters, 443(3), 199–203.  
Kummer, J. L., Rao, P. K., & Heidenreich, K. A. (1997). Apoptosis induced by withdrawal of trophic 
factors is mediated by p38 mitogen-activated protein kinase. J Biol Chem, 272(33), 20490–20494.  
Kuramoto, T., Werrbach‐Perez, K., Perez‐Polo, J. R., & Haber, B. (1981). Membrane properties of a 
human neuroblastoma II: Effects of differentiation. Journal of Neuroscience Research, 6(4), 441–
449. 
Laburthe, M., Couvineau, A., & Tan, V. (2007). Class II G protein-coupled receptors for VIP and 
PACAP: Structure, models of activation and pharmacology. Peptides, 144(1-3), 91–100. 
Laemmli, U. K., Mölbert E., Showe M., & Kellenberger E. (1970). Form-determining function of the 
genes required for the assembly of the head of bacteriophage T4. J Mol Biol. 49(1):99-113. 
Lallemend, F., Hadjab, S., Hans, G., Moonen, G., Lefebvre, P. P., & Malgrange, B. (2005). Activation 
of protein kinase CbetaI constitutes a new neurotrophic pathway for deafferented spiral ganglion 
neurons. Journal of Cell Science, 118(19), 4511–25. 
Lane, N. E., Schnitzer, T. J., Birbara, C. a, Mokhtarani, M., Shelton, D. L., Smith, M. D., & Brown, M. 
 222 
 
T. (2010). Tanezumab for the treatment of pain from osteoarthritis of the knee. The New England 
Journal of Medicine, 363(16), 1521–1531. 
Lavenius, E., Gestblom, C., Johansson, I., Nånberg, E., & Påhlman, S. (1995). Transfection of TRK-A 
into human neuroblastoma cells restores their ability to differentiate in response to nerve growth 
factor. Cell Growth & Differentiation : The Molecular Biology Journal of the American 
Association for Cancer Research, 6(6), 727–736. 
Le-Niculescu, H., Bonfoco, E., Kasuya, Y., Claret, F. X., Green, D. R., & Karin, M. (1999). Withdrawal 
of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand 
induction and cell death. Molecular and Cellular Biology, 19(1), 751–63. 
Lee, E. H., & Seo, S. R. (2014). Neuroprotective roles of pituitary adenylate cyclase-activating 
polypeptide in neurodegenerative diseases. BMB Reports, 47(7), 369–375.  
Lee, J., Kim, Y.-S., Choi, D.-H., Bang, M. S., Han, T. R., Joh, T. H., & Kim, S.-Y. (2004). 
Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 
microglia. The Journal of Biological Chemistry, 279(51), 53725–35.  
Lee, J. M., Grabb, M. C., Zipfel, G. J., & Choi, D. W. (2000). Brain tissue responses to ischemia. The 
Journal of Clinical Investigation, 106(6), 723–31. 
Lee K. N., Arnold S. A., Birckbichler P. J., Patterson M. K Jr, Fraij B. M., Takeuchi Y., & Carter H. A. 
(1993) Site-directed mutagenesis of human tissue transglutaminase: Cys-277 is essential for 
transglutaminase activity but not for GTPase activity. Biochim Biophys Acta. 1202(1):1-6. 
Lee, K. H., Lee, N., Lim, S., Jung, H., Ko, Y. G., Park, H. Y., & Hwang, K. C. (2003). Calreticulin 
inhibits the MEK1,2-ERK1,2 pathway in α1-adrenergic receptor/Gh-stimulated hypertrophy of 
neonatal rat cardiomyocytes. Journal of Steroid Biochemistry and Molecular Biology, 84(1), 101–
107.  
Lee, K. N., Birckbichler, P. J., & Patterson, M. K. (1989). GTP hydrolysis by guinea pig liver 
transglutaminase. Biochemical and Biophysical Research Communications, 162(3), 1370–1375.  
Lelièvre, V., Pineau, N., Du, J., Wen, C. H., Nguyen, T., Janet, T., & Waschek, J. A. (1998). Differential 
effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of 
neuroblastoma cell proliferation. A novel VIP-independent action of PHI via MAP kinase. Journal 
of Biological Chemistry, 273(31), 19685–90.  
Lemmon, M. A., & Schlessinger J. (2010). Cell signaling by receptor tyrosine kinases. Cell, 141(7), 
1117–34. 
Lerner, E. A., Ribeiro, J. M. C., Nelson, R. J., & Lerner, M. R. (1991). Isolation of maxadilan, a potent 
vasodilatory peptide from the salivary glands of the sand fly Lutzomyia longipalpis. Journal of 
Biological Chemistry, 266(17), 11234–11236. 
Lesort, M., Tucholski, J., Ml, M., & Gvw, J. (2000). Tissue transglutaminase: a possible role in 
neurodegenerative diseases. Progress in Neurobiology, 61(5), 439–463.  
Levi-Montalcini, R., & Hamburger, V. (1951). Selective growth stimulating effects of mouse sarcoma 
on the sensory and sympathetic nervous system of the chick embryo. Journal of Experimental 
Zoology, 116(2), 321–361. 
Li, B., Antonyak, M. A., Druso, J. E., Cheng, L., Nikitin, A. Y., & Cerione, R. A. (2010). EGF 
potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to 
Src activation. Proceedings of the National Academy of Sciences, 107(4), 1408–1413.  
Li, M. (2000). Functional Role of Caspase-1 and Caspase-3 in an ALS Transgenic Mouse Model. 
Science, 288(5464), 335–339.  
 
 223 
 
Li, X. H., Long, D. X., Li, W., & Wu, Y. J. (2007). Different mechanisms of lysophosphatidylcholine-
induced Ca2+mobilization in N2a mouse and SH-SY5Y human neuroblastoma cells. Neuroscience 
Letters, 424(1), 22–26. 
Li, Y., Liu, L., Barger, S. W., & Griffin, W. S. (2003). Interleukin-1 mediates pathological effects of 
microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a 
p38-MAPK pathway. J Neurosci, 23(5), 1605–1611.  
Lilley, G. R., Skill, J., Griffin, M., Bonner, P. L.. (1998) Detection of Ca2+-dependent transglutaminase 
activity in root and leaf tissue of monocotyledonous and dicotyledonous plants. Plant Physiol. 
117(3):1115–23. 
Lloyd, E. D. & Wooten, M. W. (1992), pp42/44MAP Kinase Is a Component of the Neurogenic Pathway 
Utilized by Nerve Growth Factor in PC12 Cells. Journal of Neurochemistry, 59  1099–109. 
Lizcano, J. M., Morrice, N., & Cohen, P. (2000). Regulation of BAD by cAMP-dependent protein kinase 
is mediated via phosphorylation of a novel site, Ser155. The Biochemical Journal, 349(2), 547–57.  
Lomb, D. J., Desouza, L. A., Franklin, J. L., & Freeman, R. S. (2009). Prolyl Hydroxylase Inhibitors 
Depend on Extracellular Glucose and Hypoxia-Inducible Factor (HIF)-2  to Inhibit Cell Death 
Caused by Nerve Growth Factor (NGF) Deprivation: Evidence that HIF-2  Has a Role in NGF-
Promoted Survival of Sympathetic Neurons. Molecular Pharmacology, 75(5), 1198–1209.  
Lopes, F. M., Schröder, R., Júnior, M. L. C. da F., Zanotto-Filho, A., Müller, C. B., Pires, A. S., & 
Klamt, F. (2010). Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro 
model for Parkinson disease studies. Brain Research, 1337(6), 85–94.  
Lorand, L., & Graham, R. M. (2003). Transglutaminases: crosslinking enzymes with pleiotropic 
functions. Nature Reviews Molecular Cell Biology, 4(2), 140–156.  
Lutz, E. M., Ronaldson, E., Shaw, P., Johnson, M. S., Holland, P. J., & Mitchell, R. (2006). 
Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: 
Consequences for signaling by VIP and PACAP. Molecular and Cellular Neuroscience, 31(2), 
193–209.  
Lutz-Bucher B., Monnier D., & Koch B. (1996). Evidence for the presence of receptors for pituitary 
adenylate cyclase-activating polypeptide in the neurohypophysis that are positively coupled to 
cyclic AMP formation and neurohypophyseal hormone secretion. Neuroendocrinology 64(2):153–
161. 
Maccioni, R. B., & Seeds, N. W. (1986). Transglutaminase and neuronal differentiation. Molecular and 
Cellular Biochemistry, 69(2), 161–68.  
Mahura, I. S. (2003). Cerebral ischemia-hypoxia and biophysical mechanisms of neurodegeneration and 
neuroprotection effects. Fiziol Zh, 49(2), 7–12.  
Malorni, W., Farrace, M. G., Matarrese, P., Tinari, A., Ciarlo, L., Mousavi-Shafaei, P., & Piacentini, M. 
(2009). The adenine nucleotide translocator 1 acts as a type 2 transglutaminase substrate: 
implications for mitochondrial-dependent apoptosis. Cell Death and Differentiation, 16(11), 1480–
1492. 
Manabe, T., Tatsumi, K., Inoue, M., Matsuyoshi, H., Makinodan, M., Yokoyama, S., & Wanaka, A. 
(2005). L3/Lhx8 is involved in the determination of cholinergic or GABAergic cell fate. Journal 
of Neurochemistry, 94(3), 723–730. 
Manecka, D. L., Mahmood, S. F., Grumolato, L., Lihrmann, I., & Anouar, Y. (2013). Pituitary Adenylate 
Cyclase-activating Polypeptide ( PACAP ) Promotes Both Survival and Neuritogenesis in PC12 
Cells through Activation of Nuclear Factor-kB ( NF-kB ) Pathway. The Journal of Biological 
Chemistry, 288(21), 14936–48. 
 
 224 
 
Mann, A. P., Verma, A., Sethi, G., Manavathi, B., Wang, H., Fok, J. Y., & Mehta, K. (2006). 
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB 
in cancer cells: delineation of a novel pathway. Cancer Res, 66(17), 8788–8795.  
Mao, A. J., Bechberger, J., Lidington, D., Galipeau, J., Laird, D. W., & Naus, C. C. (2000). Neuronal 
differentiation and growth control of neuro-2a cells after retroviral gene delivery of connexin43. 
The Journal of Biological Chemistry, 275(44), 34407–34414.  
María Frade, J., Rodríguez-Tébar, A., & Barde, Y.-A. (1996). Induction of cell death by endogenous 
nerve growth factor through its p75 receptor. Nature, 383(6596), 166–168.  
Martinez, J., Chalupowicz, D. G., Roush, R. K., Sheth, A., & Barsigian, C. (1994). Transglutaminase-
Mediated Processing of Fibronectin by Endothelial Cell Monolayers. Biochemistry, 33(9), 2538–
2545.  
Masmoudi-Kouki, O., Douiri, S., Hamdi, Y., Kaddour, H., Bahdoudi, S., Vaudry, D., & Amri, M. (2011). 
Pituitary adenylate cyclase-activating polypeptide protects astroglial cells against oxidative stress-
induced apoptosis. Journal of Neurochemistry, 117(3), 403–411.  
Mastroberardino, P. G., Iannicola, C., Nardacci, R., Bernassola, F., De Laurenzi, V., Melino, G., & 
Piacentini, M. (2002). “Tissue” transglutaminase ablation reduces neuronal death and prolongs 
survival in a mouse model of Huntington’s disease. Cell Death and Differentiation, 9(9), 873–80.  
Matysiak-Budnik, T., Moura, I. C., Arcos-Fajardo, M., Lebreton, C., Ménard, S., Candalh, C., & 
Heyman, M. (2008). Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the 
transferrin receptor in celiac disease. The Journal of Experimental Medicine, 205(1), 143–154.  
May, V., Buttolph, T. R., Girard, B. M., Clason, T. A., & Parsons, R. L. (2014). PACAP-induced ERK 
activation in HEK cells expressing PAC1 receptors involves both receptor internalization and PKC 
signaling. AJP: Cell Physiology, 306(11), 1068–1079.  
May, V., Lutz, E., MacKenzie, C., Schutz, K. C., Dozark, K., & Braas, K. M. (2010). Pituitary Adenylate 
Cyclase-activating Polypeptide (PACAP)/PAC1HOP1 Receptor Activation Coordinates Multiple 
Neurotrophic Signaling Pathways: Akt activation through phosphatidylinositol 3-kinase   and 
vesicle endocytosis for neuronal survival. Journal of Biological Chemistry, 285(13), 9749–9761.  
McConoughey, S. J., Basso, M., Niatsetskaya, Z. V., Sleiman, S. F., Smirnova, N. A., Langley, B. C., 
& Ratan, R. R. (2010). Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in 
models of Huntington’s disease. EMBO Molecular Medicine, 2(9), 349–370.  
McCulloch, D. a, Lutz, E. M., Johnson, M. S., Robertson, D. N., MacKenzie, C. J., Holland, P. J., & 
Mitchell, R. (2001). ADP-ribosylation factor-dependent phospholipase D activation by VPAC 
receptors and a PAC(1) receptor splice variant. Molecular Pharmacology, 59(6), 1523–32.  
Mehta, K., Fok, J. Y., & Mangala, L. S. (2006). Tissue transglutaminase: from biological glue to cell 
survival cues. Frontiers in Bioscience : A Journal and Virtual Library, 11(3), 173–185.  
Mehta, K., & Han, A. (2011). Tissue Transglutaminase (TG2)-induced inflammation in initiation, 
progression, and pathogenesis of pancreatic cancer. Cancers, 3(1), 897–912.  
Meloni, B. P. (2017). Pathophysiology and Neuroprotective Strategies in Hypoxic-Ischemic Brain Injury 
and Stroke. Brain Sciences, 7(8), 11–14. 
Mendoza, M. C., Er, E. E., & Blenis, J. (2011). The Ras-ERK and PI3K-mTOR pathways: Cross-talk 
and compensation. Trends in Biochemical Sciences, 36(6), 320–8. 
Mhaouty-Kodja, S. (2004). Ghα/tissue transglutaminase 2: An emerging G protein in signal 
transduction. Biology of the Cell, 96(5), 363–367. 
 
 225 
 
Mian, S., El Alaoui, S., Lawry, J., Gentile, V., Davies, P. J. A., & Griffin, M. (1995). The importance of 
the GTP-binding protein tissue transglutaminase in the regulation of cell cycle progression. FEBS 
Letters, 370(1–2), 27–31.  
Milakovic, T., Tucholski, J., McCoy, E., & Johnson, G. V. W. (2004). Intracellular Localization and 
Activity State of Tissue Transglutaminase Differentially Impacts Cell Death. Journal of Biological 
Chemistry, 279(10), 8715–8722.  
Milligan, G., & Kostenis, E. (2006). Heterotrimeric G-proteins: A short history. British Journal of 
Pharmacology, 147(1), 64–55. 
Min B., Kwon Y. C., Choe K. M., & Chung K. C. (2015) PINK1 phosphorylates transglutaminase 2 and 
blocks its proteasomal degradation. J Neurosci Res. 93(5):722-35. 
Mishra, S., Melino, G., & Murphy, L. J. (2007). Transglutaminase 2 kinase activity facilitates protein 
kinase A-induced phosphorylation of retinoblastoma protein. Journal of Biological Chemistry, 
282(25), 18108–18115.  
Mishra, S., & Murphy, L. J. (2004). Tissue transglutaminase has intrinsic kinase activity. Identification 
of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. Journal of 
Biological Chemistry, 279(23), 23863–23868.  
Mishra, S., & Murphy, L. J. (2006). Phosphorylation of transglutaminase 2 by PKA at Ser216 creates 
14-3-3 binding sites. Biochemical and Biophysical Research Communications, 347(4), 1166–1170.  
Miura, A., Kambe, Y., Inoue, K., Tatsukawa, H., Kurihara, T., Griffin, M., & Miyata, A. (2013). Pituitary 
adenylate cyclase-activating polypeptide type 1 receptor (PAC1) gene is suppressed by 
transglutaminase 2 activation. The Journal of Biological Chemistry, 288(45), 32720–30.  
Miyata, A., Arimura, A., Dahl, R. R., Minamino, N., Uehara, A., Jiang, L., & Coy, D. H. (1989). Isolation 
of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary 
cells. Biochemical and Biophysical Research Communications, 164(1), 567–574.  
Mnich, K., Carleton, L. A., Kavanagh, E. T., Doyle, K. M., Samali, A., & Gorman, A. M. (2014). Nerve 
growth factor-mediated inhibition of apoptosis post-caspase activation is due to removal of active 
caspase-3 in a lysosome-dependent manner. Cell Death and Disease, 5(5),1202–15. 
Moelling, K., Schad, K., Bosse, M., Zimmermann, S., & Schweneker, M. (2002). Regulation of Raf-Akt 
cross-talk. Journal of Biological Chemistry, 277(34),31099–106. 
Monaghan, T. K., MacKenzie, C. J., Plevin, R., & Lutz, E. M. (2008). PACAP-38 induces neuronal 
differentiation of human SH-SY5Y neuroblastoma cells via cAMP-mediated activation of ERK 
and p38 MAP kinases. Journal of Neurochemistry, 104(1), 74–88. 
Mookherjee, P., Quintanilla, R., Roh, M. S., Zmijewska, A. A., Jope, R. S., & Johnson, G. V. W. (2007). 
Mitochondrial-targeted active Akt protects SH-SY5Y neuroblastoma cells from staurosporine-
induced apoptotic cell death. Journal of Cellular Biochemistry, 102(1), 196–210.  
Morooka, T., & Nishida, E. (1998). Requirement of p38 mitogen-activated protein kinase for neuronal 
differentiation in PC12 cells. The Journal of Biological Chemistry, 273(38), 24285–24288.  
Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays. J Immunol Methods, 65(1-2), 55-63. 
Murad, F. (2011). Nitric oxide: the coming of the second messenger. Rambam Maimonides Medical 
Journal, 2(2), 38–44. 
Murillo, J. R., Goto-Silva, L., Sánchez, A., Nogueira, F. C. S., Domont, G. B., & Junqueira, M. (2017). 
Quantitative proteomic analysis identifies proteins and pathways related to neuronal development 
in differentiated SH-SY5Y neuroblastoma cells. EuPA Open Proteomics, 16(2017), 1–11.  
 226 
 
Nakaoka, H., Perez, D. M., Baek, K. J., Das, T., Husain,  A., Misono, K., & Graham, R. M. (1994). Gh: 
a GTP-binding protein with transglutaminase activity and receptor signaling function. Science 
(New York, N.Y.), 264(5165), 1593–1596. 
Nanda, N., Iismaa, S. E., Owens, W. A., Husain, A., Mackay, F., & Graham, R. M. (2001). Targeted 
Inactivation of Gh/Tissue Transglutaminase II. Journal of Biological Chemistry, 276(23), 20673–
78. 
Napoli, I., Noon, L. A., Ribeiro, S., Kerai, A. P., Parrinello, S., Rosenberg, L. H., & Lloyd, A. C. (2012). 
A Central Role for the ERK-Signaling Pathway in Controlling Schwann Cell Plasticity and 
Peripheral Nerve Regeneration In Vivo. Neuron, 73(4), 729–42.  
Neary, J. T. (2005). Protein kinase signaling cascades in CNS trauma. IUBMB Life, 57(11), 711–8. 
Nguyen, T. L., Kim, C. K., Cho, J.-H., Lee, K.-H., & Ahn, J.-Y. (2010). Neuroprotection signaling 
pathway of nerve growth factor and brain-derived neurotrophic factor against staurosporine 
induced apoptosis in hippocampal H19-7 cells. Experimental and molecular medicine, 42(8), 583–
595. 
Nikodijevic B., Nikodijevic O.,Yu M. Y., Pollard H., & Guroff G. (1975). The effect of nerve growth 
factor on cycle AMP levels in superior cerival ganglia of the rat. Proceedings of the National 
Academy of Sciences, 72 (12) 4769–71. 
Nicole, P., Lins, L., Rouyer-Fessard, C., Drouot, C., Fulcrand, P., Thomas, A., & Laburthe, M. (2000). 
Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 
and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist: Alanine 
scanning and molecular modeling of the peptide. Journal of Biological Chemistry, 275(31), 24003–
24012. 
Nikoletopoulou, V., Markaki, M., Palikaras, K., & Tavernarakis, N. (2013). Crosstalk between 
apoptosis, necrosis and autophagy. Biochimica et Biophysica Acta - Molecular Cell Research, 
1833(12), 3448–59.  
Northington, F. J., Chavez-Valdez, R., & Martin, L. J. (2011). Neuronal cell death in neonatal hypoxia-
ischemia. Annals of Neurology, 69(5), 743–758. 
Nozaki, K., Nishimura, M., & Hashimoto, N. (2001). Mitogen-activated protein kinases and cerebral 
ischemia. Molecular Neurobiology, 23(1), 1–19. 
Nurminskaya, M. V., & Belkin, A. M. (2013). Cellular functions of tissue transglutaminase. 
International Review of Cell and Molecular Biology, 294(2012), 1–9. 
Odii, B. O., & Coussons, P. (2014). Biological functionalities of transglutaminase 2 and the possibility 
of its compensation by other members of the transglutaminase family. The Scientific World 
Journal, 2014(3), 1–13. 
Oe, T., Sasayama, T., Nagashima, T., Muramoto, M., Yamazaki, T., Morikawa, N., & Kita, Y. (2005). 
Differences in gene expression profile among SH-SY5Y neuroblastoma subclones with different 
neurite outgrowth responses to nerve growth factor. Journal of Neurochemistry, 94(5), 1264–1276.  
Ogata, K., Shintani, N., Hayata-Takano, A., Kamo, T., Higashi, S., Seiriki, K., & Hashimoto, H. (2015). 
PACAP enhances axon outgrowth in cultured hippocampal neurons to a comparable extent as 
BDNF. PLoS ONE, 10(3), 1–13. 
Oh, J. E., Bae, G. U., Yang, Y. J., Yi, M. J., Lee, H. J., Kim, B. G., & Kang, J. S. (2009). Cdo promotes 
neuronal differentiation via activation of the p38 mitogen-activated protein kinase pathway. 
FASEB Journal, 23(7), 2088–2099.  
Ohnou, T., Yokai, M., Kurihara, T., Hasegawa-Moriyama, M., Shimizu, T., Inoue, K., & Miyata, A. 
(2016). Pituitary adenylate cyclase-activating polypeptide type 1 receptor signaling evokes long-
lasting nociceptive behaviors through the activation of spinal astrocytes in mice. Journal of 
 227 
 
Pharmacological Sciences, 130(4), 194–203.   
Oliveira, S. L. B., Pillat, M. M., Cheffer, A., Lameu, C., Schwindt, T. T., & Ulrich, H. (2013). Functions 
of neurotrophins and growth factors in neurogenesis and brain repair. Cytometry Part A, 83(1), 76–
89.   
Orrenius, S., Zhivotovsky, B., & Nicotera, P. (2003). Regulation of cell death: The calcium-apoptosis 
link. Nature Reviews Molecular Cell Biology, 4(7), 552–65.    
Otten, U., Ehrhard, P., & Peck, R. (1989). Nerve growth factor induces growth and differentiation of 
human B lymphocytes. Proceedings of the National Academy of Sciences, 86(24), 10059–10063.  
Pahlman, S., Ruusala, A. I., Abrahamsson, L., Mattsson, M. E., & Esscher, T. (1984). Retinoic acid-
induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-
induced differentiation. Cell Differ, 14(2), 135–144.  
Pandiella-Alonso A.,Malgaroli A.,Vicentini L. M. & Meldolesi J. (1986). Early rise of cytosolic Ca2+ 
induced by NGF in PC12 and chromaffin cells, FEBS Letters, 208(1),48–51. 
Patapoutian, A., & Reichardt, L. F. (2001). Trk receptors: Mediators of neurotrophin action. Current 
Opinion in Neurobiology, 11(3), 272–80. 
Paulmann, N., Grohmann, M., Voigt, J. P., Bert, B., Vowinckel, J., Bader, M., & Walther, D. J. (2009). 
Intracellular serotonin modulates insulin secretion from pancreatic β-cells by protein 
serotonylation. PLoS Biology, 7(10), 1–10. 
Payet, M. D., Bilodeau, L., Breault, L., Fournier, A., Yon, L., Vaudry, H., & Gallo-Payet, N. (2003). 
PAC1 receptor activation by PACAP-38 mediates Ca2+ release from a cAMP-dependent pool in 
human fetal adrenal gland chromaffin cells. The Journal of Biological Chemistry, 278(3), 1663–
70. 
Penumatsa K., Abualkhair S., Wei L., Warburton R., Preston I., Hill N., Watts S., Fanburg B., & 
Toksoz D. (2014). Tissue transglutaminase promotes serotonin-induced AKT signaling and 
mitogenesis in pulmonary vascular smooth muscle cells. Cellular Signalling, 26(12) 2818–25. 
Perron, J. C. & Bixby, J. L. (1999). Distinct neurite outgrowth signaling pathways converge on ERK 
activation. Mol Cell Neurosci, 13(5), 362-78. 
Perry MJ, Mahoney SA, & Haynes LW. (1995). Transglutaminase C in cerebellar granule neurons: 
regulation and localization of substrate cross-linking. Neuroscience. 65(4):1063-76. 
Philpott, K. L., McCarthy, M. J., Klippel, A., & Rubin, L. L. (1997). Activated phosphatidylinositol 3-
kinase and Akt kinase promote survival of superior cervical neurons. J Cell Biol, 139(3), 809–815.  
Picarelli, A., Di Tola, M., Sabbatella, L., Vetrano, S., Anania, M. C., Spadaro, A., & Taccari, E. (2003). 
Anti-Tissue Transglutaminase Antibodies in Arthritic Patients: A Disease-specific Finding. 
Clinical Chemistry, 49(12), 2091–2094.  
Pierchala, B. A., Ahrens, R. C., Paden, A. J., & Johnson, E. M. (2004). Nerve growth factor promotes 
the survival of sympathetic neurons through the cooperative function of the protein kinase C and 
phosphatidylinositol 3-kinase pathways. Journal of Biological Chemistry, 279(27), 27986–27993.  
Pinkas DM, Strop P, Brunger AT, & Khosla C (2007). Transglutaminase 2 Undergoes a Large 
Conformational Change upon Activation . PLOS Biology 5(12): e327. 
Pirou, C., Montazer-Torbati, F., Jah, N., Delmas, E., Lasbleiz, C., Mignotte, B., & Renaud, F. (2017). 
FGF1 protects neuroblastoma SH-SY5Y cells from p53-dependent apoptosis through an intracrine 
pathway regulated by FGF1 phosphorylation. Cell Death and Disease, 8(8), 1–10.  
 
 
 228 
 
Pisano, J. J., Finlayson, J. S., & Peyton, M. P. (1969). Chemical and Enzymic Detection of Protein Cross-
Links. Measurement of ϵ-(γ-Glutamyl)Lysine in Fibrin Polymerized by Factor Iii. Biochemistry, 
8(3), 871–876. 
Pisegna, J., & Wanks, S. (1996). Cloning and Characterization of the Signal Transduction of Four Splice 
Variants of the Human Pituitary Adenylate Cyclase Activating Polypeptide Receptor. The Journal 
of Biological Chemistry, 271(29), 17267–17274. 
Pozuelo-Rubio, M., Leslie, N. R., Murphy, J., & MacKintosh, C. (2010). Mechanism of Activation of 
PKB/Akt by the Protein Phosphatase Inhibitor Calyculin A. Cell Biochemistry and Biophysics, 
58(3), 147–156. 
Presgraves, S. P., Ahmed, T., Borwege, S., & Joyce, J. N. (2004). Terminally differentiated SH-SY5Y 
cells provide a model system for studying neuroprotective effects of dopamine agonists. 
Neurotoxicity Research, 5(8), 579–598. 
Price, R. D., Yamaji, T., & Matsuoka, N. (2003). FK506 potentiates NGF-induced neurite outgrowth via 
the Ras/Raf/MAP kinase pathway. British Journal of Pharmacology, 140(5), 825–9.  
Pun, P. B. L., Lu, J., & Moochhala, S. (2009). Involvement of ROS in BBB dysfunction. Free Radical 
Research, 43(4), 348–364. 
Putney, J. W., & Tomita, T. (2011). Phospholipase C Signaling and Calcium Influx. Advances in 
Biological Regulation, 52(1), 152–164.  
Qian, J., Ramroop, K., McLeod,  A., Bandari, P., Livingston, D. H., Harrison, J. S., & Rameshwar, P. 
(2001). Induction of hypoxia-inducible factor-1alpha and activation of caspase-3 in hypoxia-
reoxygenated bone marrow stroma is negatively regulated by the delayed production of substance 
P. Journal of Immunology (Baltimore, Md : 1950), 167(8), 4600–4608.  
Qiao, J., Paul, P., Lee, S., Qiao, L., Josifi, E., Tiao, J. R., & Chung, D. H. (2012). PI3K/AKT and ERK 
regulate retinoic acid-induced neuroblastoma cellular differentiation. Biochemical and Biophysical 
Research Communications, 424(3), 421–6. 
Quan, G., Choi, J. Y., Lee, D. S., & Lee, S. C. (2005). TGF-b1 up-regulates transglutaminase two and 
fibronectin in dermal fibroblasts: A possible mechanism for the stabilization of tissue 
inflammation. Archives of Dermatological Research, 297(2), 84–90.  
Radio, N. M., & Mundy, W. R. (2008). Developmental neurotoxicity testing in vitro: Models for 
assessing chemical effects on neurite outgrowth. NeuroToxicology, 297(3),361–76. 
Ramos-A`lvarez, I., Mantey, S. A., Nakamura, T., Nuche-Berenguer, B., Moreno, P., Moody, T. W., & 
Jensen, R. T. (2015). A structure-function study of PACAP using conformationally restricted 
analogs: Identification of PAC1 receptor-selective PACAP agonists. Peptides, 66(4), 26–42.  
Ravni, A., Bourgault, S., Lebon, A., Chan, P., Galas, L., Fournier, A., & Vaudry, D. (2006). The 
neurotrophic effects of PACAP in PC12 cells: Control by multiple transduction pathways. Journal 
of Neurochemistry, 98(2), 321–9. 
Reglodi, D., Fábián, Z., Tamás, A., Lubics, A., Szeberényi, J., Alexy, T., & Lengvári, I. (2004). Effects 
of PACAP on in vitro and in vivo neuronal cell death, platelet aggregation, and production of 
reactive oxygen radicals. Regulatory Peptides, 123(1–3), 51–59.  
Reglodi, D., Somogyvari-vigh, A., Vigh, S., Maderdrut, J. L., & Arimura, A. (2000). Neuroprotective 
Effects of PACAP38 in a Rat Model of Transient Focal Ischemia under Various Experimental 
Conditions. Biomedical Research, 31(2000), 1411–17. 
Reglodi, D., Tamás, A., Somogyvári-Vigh, A., Szántó, Z., Kertes, E., Lénárd, L., & Lengvári, I. (2002). 
Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent 
focal cerebral ischemia. Peptides, 23(12), 2227–34. 
 229 
 
Reichardt, L. F. (2006). Neurotrophin-regulated signalling pathways. Philosophical Transactions of the 
Royal Society B: Biological Sciences, 361(1473), 1545–1564.  
Reichelt, K. L., & Poulsen, E. (1992). gamma-Glutamylaminotransferase and transglutaminase in 
subcellular fractions of rat cortex and in cultured astrocytes. J.Neurochem., 59(2), 500–4. 
Rice, D., & Barone, S. (2000). Critical periods of vulnerability for the developing nervous system: 
Evidence from humans and animal models. Environmental Health Perspectives, 108(3), 511–33. 
Riedl, S. J., & Shi, Y. (2004). Molecular mechanisms of caspase regulation during apoptosis. Nature 
Reviews Molecular Cell Biology, 5(11), 897–907. 
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., & Comb, M. J. (2007). Global Survey 
of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer. Cell, 131(6), 1190–
1203.  
Robberecht P., Gourlet P., De Neef P., Woussen-Colle M. C., Vandermeers-Piret M. C., Vandermeers 
A., & Christophe J. (1992). Structural requirements for the occupancy of pituitary adenylate 
cyclase activating polypeptide (PACAP) receptors and adenylate cyclase activation in human 
neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist. Eur. 
J. Biochem. 207(1), 239-246. 
Roskoski, R. (2012). ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacological 
Research, 66(2), 105–143. 
Ross, R. A., Spengler, B. A., & Biedler, J. L. (1983). Coordinate Morphological and Biochemical 
Interconversion of Human Neuroblastoma Cells. Journal of the National Cancer Institute, 71(4), 
741–747. 
Ruan, Q., Tucholski, J., Gundemir, S., & Johnson Voll, G. V. W. (2008). The Differential Effects of 
R580A Mutation on Transamidation and GTP Binding Activity of Rat and Human Type 2 
Transglutaminase. International Journal of Clinical and Experimental Medicine, 1(3), 248–59.  
Ruberti, F., Capsoni, S., Comparini,  A, Di Daniel, E., Franzot, J., Gonfloni, S., & Cattaneo,  A. (2000). 
Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal 
forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. The Journal 
of Neuroscience : Journal of the Society for Neuroscience, 20(7), 2589–601.  
Sahu, U., Sidhar, H., Ghate, P. S., Advirao, G. M., Raghavan, S. C., & Giri, R. K. (2013). A Novel 
Anticancer Agent, 8-Methoxypyrimido[4′,5′:4,5]thieno(2,3-b) Quinoline-4(3H)-One Induces 
Neuro 2a Neuroblastoma Cell Death through p53-Dependent, Caspase-Dependent and -
Independent Apoptotic Pathways. PLoS ONE, 8(6), 1–18. 
Saiki, R., Park, H., Ishii, I., Yoshida, M., Nishimura, K., & Toida, T. (2011). Brain infarction correlates 
more closely with acrolein than with reactive oxygen species. Biochem Biophys Res Commun 2011; 
404(4),1044–49. 
Saito, A., Hayashi, T., Okuno, S., Ferrand-Drake, M., & Chan, P. H. (2003). Overexpression of 
copper/zinc superoxide dismutase in transgenic mice protects against neuronal cell death after 
transient focal ischemia by blocking activation of the Bad cell death signaling pathway. J Neurosci, 
23(5), 1710–1718.  
Sajithlal, G., Huttunen, H., Rauvala, H., & Münch, G. (2002). Receptor for advanced glycation end 
products plays a more important role in cellular survival than in neurite outgrowth during retinoic 
acid-induced differentiation of neuroblastoma cells. Journal of Biological Chemistry, 277(9), 
6888–6897. 
Salinas, M., Diaz, R., Abraham, N. G., De Galarreta, C. M. R., & Cuadrado, A. (2003). Nerve growth 
factor protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of 
heme oxygenase-1 in a phosphatidylinositol 3-kinase-dependent manner. Journal of Biological 
 230 
 
Chemistry, 278(16), 13898–13904.  
Sarang, Z., Molnár, P., Németh, T., Gomba, S., Kardon, T., Melino, G., & Szondy, Z. (2005). Tissue 
transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death 
in mice. Hepatology, 42(3), 578–587.  
Sarkar, N. K., Clarke, D. D., & Waelsch, H. (1957). An enzymically catalyzed incorporation of amines 
into proteins. Biochimica et Biophysica Acta, 25(2), 451–52.  
Satpathy, M., Cao, L., Pincheira, R., Emerson, R., Bigsby, R., Nakshatri, H., & Matei, D. (2007). 
Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Research, 
67(15), 7194–7202.  
Schaertl, S., Prime, M., Wityak, J., Dominguez, C., Munoz-Sanjuan, I., Pacifici, R. E., & Macdonald, 
D. (2010). A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors. 
Journal of Biomolecular Screening : The Official Journal of the Society for Biomolecular 
Screening, 15(5), 478–487.  
Schramm, A., Schulte, J. H., Astrahantseff, K., Apostolov, O., Van Limpt, V., Sieverts, H., & Eggert, 
A. (2005). Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer 
Letters, 228(1-2), 143–53. 
Seaborn, T., Ravni, A., Au, R., Chow, B. K. C., Fournier, A., Wurtz, O., & Vaudry, D. (2014). Induction 
of serpinb1a by PACAP or NGF is required for PC12 cells survival after serum withdrawal. Journal 
of Neurochemistry, 131(1), 21–32.  
Semenza, G. L. (2011). Oxygen Sensing, Homeostasis, and Disease. New England Journal of Medicine, 
365(6), 537–547. 
Shao, N., Wang, H., Zhou, T., & Liu, C. (1993). 7S nerve growth factor has different biological activity 
from 2.5S nerve growth factor in vitro. Brain Res, 609(1–2), 338–340. 
Sharp, F. R., & Bernaudin, M. (2004). HIF1 and oxygen sensing in the brain. Nature Reviews 
Neuroscience, 5(6), 437–448.  
Shaw, R. J., & Cantley, L. C. (2006). Ras, PI(3)K and mTOR signalling controls tumour cell growth. 
Nature, 441(7092), 424–30. 
Shi, G.-X., Jin, L., & Andres, D. A. (2008). Pituitary Adenylate Cyclase-Activating Polypeptide 38-
Mediated Rin Activation Requires Src and Contributes to the Regulation of Hsp27 Signaling during 
Neuronal Differentiation. Molecular and Cellular Biology, 28(16), 4940–4951.  
Shimoke, K., & Chiba, H. (2001). Nerve growth factor prevents 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity 
using PC12 cells: Relevance to therapeutical application for Parkinson’s disease. Journal of 
Neuroscience Research, 63(5), 402–409. 
Shioda, S., & Arimura, A. (1995). Pituitary adenylate cyclase activating polypeptide (PACAP) and its 
receptors: neuroendocrine and endocrine interaction. Front Neuroendocrinol, 16(1), 53–88. 
Shipley, M. M., Mangold, C. A., & Szpara, M. L. (2016). Differentiation of the SH-SY5Y Human 
Neuroblastoma Cell Line. Journal of Visualized Experiments : JoVE,  2016(108), 1–11. 
Siegel, M., & Khosla, C. (2007). Transglutaminase 2 inhibitors and their therapeutic role in disease 
states. Pharmacology & Therapeutics, 115(2), 232–45.  
Singh, U. S., Pan, J., Kao, Y. L., Joshi, S., Young, K. L., & Baker, K. M. (2003). Tissue transglutaminase 
mediates activation of RhoA and MAP kinase pathways during retinoic acid-induced neuronal 
differentiation of SH-SY5Y cells. Journal of Biological Chemistry, 278(1), 391–399. 
 
 231 
 
Sivaramakrishnan, M., Croll T. I., Gupta R., Stupar D., Van Lonkhuyzen D. R., Upton Z., & Shooter 
G. (2013). Lysine residues of IGF-I are substrates for transglutaminases and modulate 
downstream IGF-I signalling. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 
1833(12) 12, 3176–85. 
Slaughter, T. F., Achyuthan, K. E., Lai, T. S., & Greenberg, C..S. (1992). A microtiter plate 
transglutaminase assay utilizing 5-(biotinamido)pentylamine as substrate. Anal Biochem. 
205(1):166–71. 
Smith, C. & Eisenstein, M. (2005). Automated imaging: data as far as the eye can see. Nature methods, 
2, 547–55.   
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, 
E. K., Goeke, N. M., Olson, B. J., Klenk, D. C. (1985). Measurement of protein using bicinchoninic 
acid. Anal Biochem. 150(1):76–85.  
Sofroniew, M. V, Howe, C. L., & Mobley, W. C. (2001). Nerve growth factor signaling, neuroprotection, 
and neural repair. Annual Review of Neuroscience, 24, 1217–81.  
Stamnaes J., Fleckenstein B., Sollid L.M. (2008) The propensity for deamidation and transamidation of 
peptides by transglutaminase 2 is dependent on substrate affinity and reaction conditions. Biochim 
Biophys Acta. 1784(11):1804-11. 
Stork, P. J. & Schmitt, J. M. Crosstalk between cAMP and MAP kinase signaling in the regulation of 
cell proliferation. (2002).Trends Cell Biol. 12(6), 258–266.  
Suda, K., Smith, D. M., Ghatei, M. A., & Bloom, S. R. (1992) Investigation of the interaction of VIP 
binding sites with VIP and PACAP in human brain. Neurosci Lett 137(1):19– 23.  
Suda, K., Smith, D. M., Ghatei, M. A., & Bloom, S. R. (1991) Investigation and characterization of 
receptors for pituitary adenylate cyclase-activating polypeptide in human brain by radioligand 
bind- ing and chemical cross-linking. J Clin Endocrinol Metab, 72(5), 958–964. 
Sugawara, T., Fujimura, M., Noshita, N., Kim, G. W., Saito, A., Hayashi, T., & Chan, P. H. (2004). 
Neuronal Death/Survival Signaling Pathways in Cerebral Ischemia. NeuroRx, 1(1), 17–25.  
Suto, N., Ikura, K., & Sasaki, R. (1993). Expression induced by interleukin-6 of tissue-type 
transglutaminase in human hepatoblastoma HepG2 cells. Journal of Biological Chemistry, 
268(10), 7469–7473. 
Suzuki, R., Arata, S., Nakajo, S., Ikenaka, K., Kikuyama, S., & Shioda, S. (2003). Expression of the 
receptor for pituitary adenylate cyclase-activating polypeptide (PAC1-R) in reactive astrocytes. 
Brain Research. Molecular Brain Research, 115(1), 10–20. 
Szondy, Z., Mastroberardino, P. G., Váradi, J., Farrace, M. G., Nagy, N., Bak, I., & Piacentini, M. 
(2006). Tissue transglutaminase (TG2) protects cardiomyocytes against ischemia/reperfusion 
injury by regulating ATP synthesis. Cell Death and Differentiation, 13(10), 1827–1829.  
Szu-Yu Ho, T., & Rasband, M. N. (2011). Maintenance of neuronal polarity. Developmental 
Neurobiology, 71(6), 474–482. 
Tabakman, R., Jiang, H., Schaefer, E., Levine, R. A., & Lazarovici, P. (2004). Nerve growth factor 
pretreatment attenuates oxygen and glucose deprivation-induced c-Jun amino-terminal kinase 1 
and stress-activated kinases p38alpha and p38beta activation and confers neuroprotection in the 
pheochromocytoma PC12 Model. J Mol Neurosci, 22(3), 237–250.  
Tabakman, R., Jiang, H., Shahar, I., Arien-Zakay, H., Levine, R. A., & Lazarovici, P. (2005). 
Neuroprotection by NGF in the PC12 in vitro OGD model: Involvement of mitogen-activated 
protein kinases and gene expression. In Annals of the New York Academy of Sciences, 1053(8), 84–
96.   
 232 
 
Takeda, K., & Ichiijo, H. (2002). Neuronal p38 MAPK signalling: An emerging regulator of cell fate 
and function in the nervous system. Genes to Cells, 7(11), 1099–1111.  
Takei, N., Torres, E., Yuhara, A., Jongsma, H., Otto, C., Korhonen, L., & Lindholm, D. (2000). Pituitary 
adenylate cyclase-activating polypeptide promotes the survival of basal forebrain cholinergic 
neurons in vitro and in vivo: comparison with effects of nerve growth factor. European Journal of 
Neurosci, 12(7), 2273–2280.  
Tanaka, K., & Tsukahara, T., Hashimoto, N., Ogata, N., Yonekawa, Y., Kimura, T., & Taniguchi, T. 
(1994). Effect of nerve growth factor on delayed neuronal death after cerebral ischaemia. Acta 
Neurochir (Wien), 129(1–2), 64–71.  
Tanaka T., Knapp D., Nasmyth K.(1997). Loading of an Mcm protein onto DNA replication origins is 
regulated by Cdc6p and CDKs. Cell, 90(4): 649–60. 
Tang, L. L., Wang, R., & Tang, X. C. (2005). Huperzine A protects SHSY5Y neuroblastoma cells against 
oxidative stress damage via nerve growth factor production. European Journal of Pharmacology, 
519(1–2), 9–15. 
Tatsukawa, H., Fukaya, Y., Frampton, G., Martinez-Fuentes, A., Suzuki, K., Kuo, T. F., & Kojima, S. 
(2009). Role of Transglutaminase 2 in Liver Injury via Cross-linking and Silencing of 
Transcription Factor Sp1. Gastroenterology, 136(5), 1783–95. 
Tatsukawa, H., Furutani, Y., Hitomi, K., & Kojima, S. (2016). Transglutaminase 2 has opposing roles 
in the regulation of cellular functions as well as cell growth and death. Cell Death and Disease.  
Tee, A. E. L., Marshall, G. M., Liu, P. Y., Xu, N., Haber, M., Norris, M. D., & Liu, T. (2010). Opposing 
effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation. The 
Journal of Biological Chemistry, 285(6), 3561–3567.  
Ter Horst, G. J. & Korf, H. J. (1997). Clinical Pharmacology of Cerebral Ischemia. Journal of 
Neurochemistry, 69(6), 2624. 
Thomázy, V., & Fésüs, L. (1989). Differential expression of tissue transglutaminase in human cells. An 
immunohistochemical study. Cell and Tissue Research, 255(1), 215–24.  
Thornton, C., Leaw, B., Mallard, C., Nair, S., Jinnai, M., & Hagberg, H. (2017). Cell Death in the 
Developing Brain after Hypoxia-Ischemia. Frontiers in Cellular Neuroscience, 11(8), 1–19. 
Thorpe, L. W., & Perez-Polo, J. R. (1987). The influence of nerve growth factor on the in vitro 
proliferative response of rat spleen lymphocytes. J Neurosci Res, 18(1), 134–139.  
Tolentino, P. J., Waghray, A., Wang, K. K. W., & Hayes, R. L. (2004). Increased expression of tissue-
type transglutaminase following middle cerebral artery occlusion in rats. Journal of 
Neurochemistry, 89(5), 1301–1307. 
Tomaselli, B., Podhraski, V., Heftberger, V., Böck, G., & Baier-Bitterlich, G. (2005). Purine nucleoside-
mediated protection of chemical hypoxia-induced neuronal injuries involves p42/44 MAPK 
activation. Neurochemistry International, 46(7), 513–521.  
Tremblay, R. G., Sikorska, M., Sandhu, J. K., Lanthier, P., Ribecco-Lutkiewicz, M., & Bani-Yaghoub, 
M. (2010). Differentiation of mouse Neuro 2A cells into dopamine neurons. Journal of 
Neuroscience Methods, 186, 60–67. 
Trigwell SM, Lynch PT, Griffin M, Hargreaves AJ, Bonner PL. (2004). An improved colorimetric assay 
for the measurement of transglutaminase (type II)-(gammaglutamyl) lysine cross-linking activity. 
Anal Biochem. 330(1):164-6. 
Tucholski, J., & Johnson, G. V. W. (2002). Tissue transglutaminase differentially modulates apoptosis 
in a stimuli-dependent manner. Journal of Neurochemistry, 81(4), 780–791.  
 233 
 
Tucholski, J., & Johnson, G. V. W. (2003). Tissue transglutaminase directly regulates adenylyl cyclase 
resulting in enhanced cAMP-response element-binding protein (CREB) activation. Journal of 
Biological Chemistry, 278(29), 26838–26843.  
Tucholski, J., Lesort, M., & Johnson, G. V. (2001). Tissue transglutaminase is essential for neurite 
outgrowth in human neuroblastoma SH-SY5Y cells. Neuroscience, 102(2), 481–491.  
Tuszynski, M. H., Yang, J. H., Barba, D., U, H. S., Bakay, R., Pay, M. M. & Nagahara, A. H. (2015). 
Nerve Growth Factor Gene Therapy Activates Neuronal Responses in Alzheimer’s Disease. JAMA 
Neurology, 72(10), 1139–1147.  
Uchida, D., Tatsuno, I., Tanaka, T., Hirai, A., Saito, Y., Moro, O., & Tajima, M. (1998). Maxadilan is a 
specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type 1 receptor. 
In Annals of the New York Academy of Sciences 865(1), (253–258).  
Uings, I. J., & Farrow, S. N. (2000). Cell receptors and cell signalling. Molecular Pathology : MP, 53(6), 
295–9.  
Van der Zee, C. E. E. M., Ross, G. M., Riopelle, R. J., & Hagg, T. (1996). Survival of Cholinergic 
Forebrain Neurons in Developing p75NGFR-Deficient Mice. Science, 274(5293), 1729–1732.  
Vanhaesebroeck, B., & Alessi, D. R. (2000). The PI3K–PDK1 connection : more than just a road to 
PKB. Biochem. J, 346(3), 561–76. 
Vanhaesebroeck, B., Stephens, L., & Hawkins, P. (2012). PI3K signalling: the path to discovery and 
understanding. Nature Reviews Molecular Cell Biology, 13(3), 195–203.  
Vaudry, D., Gonzalez, B. J., Basille, M., Yon, L., Fournier, A., & Vaudry, H. (2000a). Pituitary adenylate 
cyclase-activating polypeptide and its receptors: From structure to functions. Pharmacological 
Reviews, 52(2), 269–324.  
Vaudry, D., Falluel-morel, A., Bourgault, S., Basille, M., Burel, D., Wurtz, O., & Sante, D. (2009). 
Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors : 20 Years after the 
Discovery. Peptide Research, 61(3), 283–357. 
Vaudry, D., Gonzalez, B. J., Basille, M., Pamantung, T. F., Fontaine, M., Fournier,  A, & Vaudry, H. 
(2000b). The neuroprotective effect of pituitary adenylate cyclase-activating polypeptide on 
cerebellar granule cells is mediated through inhibition of the CED3-related cysteine protease 
caspase-3/CPP32. Proceedings of the National Academy of Sciences of the United States of 
America, 97(24), 13390–5. 
Verbeke, S., Meignan, S., Lagadec, C., Germain, E., Hondermarck, H., Adriaenssens, E., & Le Bourhis, 
X. (2010). Overexpression of p75NTR increases survival of breast cancer cells through p21waf1. 
Cellular Signalling, 22(12), 1864–1873.  
Verma, A., & Mehta, K. (2007). Tissue transglutaminase-mediated chemoresistance in cancer cells. 
Drug Resistance Updates, 10(4–5), 144–151. 
Villalba, M., Bockaert, J., & Journot, L. (1997). Pituitary adenylate cyclase-activating polypeptide 
(PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-
activated protein kinase (MAP kinase) pathway. The Journal of Neuroscience : The Official 
Journal of the Society for Neuroscience, 17(1), 83–90. 
Vyas, F. S. , Hargreaves, A. J. , Bonner, P. L., Boocock, D. J., Coveney, C., & Dickenson, J. M. (2016) 
A1 adenosine receptor-induced phosphorylation and modulation of transglutaminase 2 activity in 
H9c2 cells: A role in cell survival. Biochem Pharmacol 107:41-58.   
Vyas, F. S., Nelson, C. P., Freeman, F., Boocock, D. J., Hargreaves, A. J., & Dickenson, J. M. (2017) 
β2adrenoceptor-induced modulation of transglutaminase 2 transamidase activity in 
cardiomyoblasts. Eur J Pharmacol 813:105-121. 
 234 
 
Walther D. J., Peter J-U., Winter S., Höltje M., Paulmann N., & Grohmann M. (2003) Serotonylation of 
small GTPases is a signal transduction pathway that triggers platelet α-granule release. Cell 115(7), 
851-862. 
Wang, F. (2006). Culture of animal cells: a manual of basic technique, fifth edition. In Vitro Cellular & 
Developmental Biology - Animal, 42(5), 169–86.  
Wang H., Wang R., Thrimawithana T., Little P. J., Xu J., Feng Z. P., & Zheng W. (2014) The nerve 
growth factor signaling and its potential as therapeutic target for glaucoma. Biomed Res Int, 
759473,1–10. 
Wang, Y., Ande, S. R., & Mishra, S. (2012). Phosphorylation of transglutaminase 2 (TG2) at serine-216 
has a role in TG2 mediated activation of nuclear factor-kappa B and in the downregulation of 
PTEN. BMC Cancer, 12(277), 1–12.  
Wang, Z., & Griffin, M. (2011). TG2, a novel extracellular protein with multiple functions. Amino Acids. 
42(2-3),939-49  
Waschek, J. A. (2002). Multiple actions of pituitary adenylyl cyclase activating peptide in nervous 
system development and regeneration. Developmental Neuroscience, 24(1), 14–23. 
Williams, L. R., Varon, S., Peterson, G. M., Wictorin, K., Fischer, W., Bjorklund, A., & Gage, F. H. 
(1986). Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after 
fimbria fornix transection. Proceedings of the National Academy of Sciences of the United States 
of America, 83(23), 9231–5. 
Wooten, M. W., Seibenhener, M. L., Neidigh, K. B. W., & Vandenplas, M. L. (2000). Mapping of 
atypical protein kinase C within the nerve growth factor signaling cascade: Relationship to 
differentiation and survival of PC12 cells. Molecular and Cellular Biology, 20(13), 4494–4504. 
Wortzel, I., & Seger, R. (2011). The ERK Cascade: Distinct Functions within Various Subcellular 
Organelles. Genes & Cancer, 2(3), 195–209. 
Wu, E. H. T., & Wong, Y. H. (2005). Pertussis toxin-sensitive Gi/o proteins are involved in nerve growth 
factor-induced pro-survival Akt signaling cascade in PC12 cells. Cellular Signalling, 17(7), 881–
890.  
Wu, P.Y., Lin, Y.C., Chang, C.L., Lu, H.T., Chin, C.H., Hsu, T.T., & Sun, S. H. (2009). Functional 
decreases in P2X 7 receptors are associated with retinoic acid-induced neuronal differentiation of 
Neuro-2a neuroblastoma cells. Cellular Signalling, 21(6), 881–91. 
Wyatt, S., & Davies, A. M. (1993). Regulation of expression of mRNAs encoding the nerve growth 
factor receptors p75 and trkA in developing sensory neurons. Development, 119(3), 635–648. 
Wyatt, S., & Davies, A. M. (1995). Regulation of nerve growth factor receptor gene expression in 
sympathetic neurons during development. J Cell Biol, 130(6), 1435–1446.  
Xie, H., Hu, L., & Li, G. (2010). SH-SY5Y human neuroblastoma cell line: in vitro cell model of 
dopaminergic neurons in Parkinson’s disease. Chinese Medical Journal, 123(8), 1086–1092.  
Yamaguchi, H., & Wang, H.-G. (2006). Tissue Transglutaminase Serves as an Inhibitor of Apoptosis by 
Cross-Linking Caspase 3 in Thapsigargin-Treated Cells. Molecular and Cellular Biology, 26(2), 
569–579. 
Yamaguchi, H., & Wang, H. G. (2001). The protein kinase PKB/Akt regulates cell survival and apoptosis 
by inhibiting Bax conformational change. Oncogene, 20(53), 7779–86.  
Yao, R., & Cooper, G. M. (1995). Requirement for phosphatidylinositol-3 kinase in the prevention of 
apoptosis by nerve growth factor. Science, 267(5206), 2003–6.  
Yeo, T. T., Chua-Couzens, J., Butcher, L. L., Bredesen, D. E., Cooper, J. D., Valletta, J. S., & Longo, F. 
 235 
 
M. (1997). Absence of p75NTR causes increased basal forebrain cholinergic neuron size, choline 
acetyltransferase activity, and target innervation. The Journal of Neuroscience : The Official 
Journal of the Society for Neuroscience, 17(20), 7594–605.  
Yu, S. P., Canzoniero, L. M. T., & Choi, D. W. (2001). Ion homeostasis and apoptosis. Current Opinion 
in Cell Biology, 13(4), 405–411.  
Yu, W., Schwei, M. J., & Baas, P. W. (1996). Microtubule transport and assembly during axon growth. 
Journal of Cell Biology, 133(1), 151–157. 
Yuan, J., Lipinski, M., & Degterev, A. (2003). Diversity in the mechanisms of neuronal cell death. 
Neuron, 40(2), 401–13. 
Yuhara, A., Ishii, K., Nishio, C., Abiru, Y., Yamada, M., Nawa, H., & Takei, N. (2003). PACAP and 
NGF cooperatively enhance choline acetyltransferase activity in postnatal basal forebrain neurons 
by complementary induction of its different mRNA species. Biochemical and Biophysical 
Research Communications, 301(2), 344–349.  
Yuhara, A., Nishio, C., Abiru, Y., Hatanaka, H., & Takei, N. (2001). PACAP has a neurotrophic effect 
on cultured basal forebrain cholinergic neurons from adult rats. Developmental Brain Research, 
131(1–2), 41–45.  
Zarubin, T., & Han, J. (2005). Activation and signaling of the p38 MAP kinase pathway. Cell Research, 
15(1), 11–18. 
Zemskov, E. A., Loukinova, E., Mikhailenko, I., Coleman, R. a, Strickland, D. K., & Belkin, A. M. 
(2009). Regulation of platelet-derived growth factor receptor function by integrin-associated cell 
surface transglutaminase. The Journal of Biological Chemistry, 284(24), 16693–703.  
Zhang, J., Lesort, M., Guttmann, R. P., & Johnson, G. V. W. (1998). Modulation of the in situ activity 
of tissue transglutaminase by calcium and GTP. Journal of Biological Chemistry, 273(4), 2288–
2295.  
Zhang, J., Qian, H., Zhao, P., Hong, S. S., & Xia, Y. (2006). Rapid hypoxia preconditioning protects 
cortical neurons from glutamate toxicity through ᵟ-opioid receptor. Stroke, 37(4), 1094–1099.  
Zhang, W., Liu, H. T., & Tu LIU, H. (2002). MAPK signal pathways in the regulation of cell 
proliferation in mammalian cells. Cell Research, 12(1), 9–18.  
Zhang, Y.-Z., Moheban, D. B., Conway, B. R., Bhattacharyya, A., & Segal, R. A. (2000). Cell surface 
Trk receptors mediate NGF-induced survival while internalized receptors regulate NGF-induced 
differentiation. The Journal of Neuroscience, 20(15), 5671–5678.  
Zhou, C. J., Yada, T., Kohno, D., Kikuyama, S., Suzuki, R., Mizushima, H., & Shioda, S. (2001). 
PACAP activates PKA, PKC and Ca2+ signaling cascades in rat neuroepithelial cells. Peptides, 
22(7), 1111–1117.  
Zhu, Y., Yang, G. Y., Ahlemeyer, B., Pang, L., Che, X. M., Culmsee, C., & Krieglstein, J. (2002). 
Transforming growth factor-beta 1 increases bad phosphorylation and protects neurons against 
damage. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience, 
22(10), 3898–3909.  
Zimmermann, M., Gardoni, F., Marcello, E., Colciaghi, F., Borroni, B., Padovani, A., & Di Luca, M. 
(2004). Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in 
neuroblastoma cell lines. Journal of Neurochemistry, 90(6), 1489–1499.  
 
 
 
 236 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contents lists available at ScienceDirect
European Journal of Pharmacology
journal homepage: www.elsevier.com/locate/ejphar
Neuropharmacology and analgesia
Activation of transglutaminase 2 by nerve growth factor in diﬀerentiating
neuroblastoma cells: A role in cell survival and neurite outgrowth
Alanood S. Algarni, Alan J. Hargreaves, John M. Dickenson⁎
School of Science and Technology, Nottingham Trent University, Clifton Lane, Nottingham NG11 8NS, United Kingdom
A R T I C L E I N F O
Keywords:
Cell survival
Hypoxia
Neuroblastoma cells
Neurite outgrowth
NGF
Transglutaminase 2
A B S T R A C T
NGF (nerve growth factor) and tissue transglutaminase (TG2) play important roles in neurite outgrowth and
modulation of neuronal cell survival. In this study, we investigated the regulation of TG2 transamidase activity
by NGF in retinoic acid-induced diﬀerentiating mouse N2a and human SH-SY5Y neuroblastoma cells. TG2
transamidase activity was determined using an amine incorporation and a peptide cross linking assay. In situ
TG2 activity was assessed by visualising the incorporation of biotin-X-cadaverine using confocal microscopy. The
role of TG2 in NGF-induced cytoprotection and neurite outgrowth was investigated by monitoring hypoxia-
induced cell death and appearance of axonal-like processes, respectively. The amine incorporation and protein
crosslinking activity of TG2 increased in a time and concentration-dependent manner following stimulation with
NGF in N2a and SH-SY5Y cells. NGF mediated increases in TG2 activity were abolished by the TG2 inhibitors Z-
DON (Z-ZON-Val-Pro-Leu-OMe; Benzyloxycarbonyl-(6-Diazo-5-oxonorleucinyl)-L-valinyl-L-prolinyl-L-leu-
cinmethylester) and R283 (1,3,dimethyl-2[2-oxo-propyl]thio)imidazole chloride) and by pharmacological in-
hibition of extracellular signal-regulated kinases 1 and 2 (ERK1/2), protein kinase B (PKB) and protein kinase C
(PKC), and removal of extracellular Ca2+. Fluorescence microscopy demonstrated NGF induced in situ TG2
activity. TG2 inhibition blocked NGF-induced attenuation of hypoxia-induced cell death and neurite outgrowth
in both cell lines. Together, these results demonstrate that NGF stimulates TG2 transamidase activity via a ERK1/
2, PKB and PKC-dependent pathway in diﬀerentiating mouse N2a and human SH-SY5Y neuroblastoma cells.
Furthermore, NGF-induced cytoprotection and neurite outgrowth are dependent upon TG2. These results suggest
a novel and important role of TG2 in the cellular functions of NGF.
1. Introduction
Transglutaminases (TGs) are a family of Ca2+-dependent enzymes
that catalyse the post-translational modiﬁcation of proteins
(Nurminskaya and Belkin, 2012; Eckert et al., 2014). There are eight
distinct catalytically active members of the TG family which exhibit
diﬀerential expression (Factor XIIIa and TGs 1–7).
The ubiquitously expressed TG2, which is the most widely studied
member of the TG family, is involved in the regulation of numerous
cellular processes, including cell adhesion, migration, growth, survival,
apoptosis, diﬀerentiation, and extracellular matrix organization
(Nurminskaya and Belkin, 2012; Eckert et al., 2014). In neuronal cells,
TG2 is involved in neurite outgrowth during diﬀerentiation and in
neuroprotection following cerebral ischaemia (Tucholski et al., 2001;
Filiano et al., 2010; Vanella et al., 2015).
Transglutaminase 2 possesses multiple enzymic functions that in-
clude transamidation, protein disulphide isomerase and protein kinase
activity (Gundemir et al., 2012). Furthermore, TG2 also has non-
enzymatic functions which can modulate signal transduction pathways
(Nurminskaya and Belkin, 2012).
Receptor tyrosine kinases represent a large family of receptors
whose prominent members include receptors for epidermal growth
factor (EGF), platelet-derived growth factor (PDGF) and vascular en-
dothelial growth factor (VEGF). It is notable that cytoplasmic TG2-
mediated transamidase activity participates in EGF receptor signalling,
whereas the interaction of extracellular TG2 with PDGF and VEGF re-
ceptors promotes their activation (Dardik and Inbal, 2006; Zemskov
et al., 2009; Li et al., 2010). These observations suggest a major role for
TG2 in the modulation of receptor tyrosine kinases. However, at pre-
sent, it is not known if receptor tyrosine kinase activation promotes
intracellular TG2 activation. A study has shown that prolonged ex-
posure (3–6 days) of mouse N2a neuroblastoma cells to nerve growth
factor (NGF) promoted increased TG2 protein expression and TG2-
mediated transamidase activity (Condello et al., 2008). However, it is
conceivable that the increased levels of transamidase activity may re-
ﬂect increased levels of TG2 expression rather than direct activation of
https://doi.org/10.1016/j.ejphar.2017.12.023
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the enzyme itself by NGF-induced signalling. NGF triggers its biological
eﬀects via the tyrosine kinase receptor TrkA (Wang et al., 2014), which
when activated stimulates a multitude of signalling pathways including
ERK1/2 (extracellular signal-regulated kinases 1 and 2), PI-3K (phos-
phatidylinositol 3-kinase)/PKB (protein kinase B) and PLC-γ (phos-
pholipase C-γ)/PKC (protein kinase C) cascades (Wang et al., 2014). As
some of these pathways are associated with modulation of intracellular
TG2 activity (PKC, ERK1/2 and Ca2+) it is conceivable that NGF di-
rectly regulates TG2 activity. Since mouse N2a and human SH-SY5Y
neuroblastoma cells are responsive to NGF (Price et al., 2003; Condello
et al., 2008; Dwane et al., 2013), the primary aims of this study were (i)
to determine whether short term treatment with NGF (< 4 h) could
modulate TG2-mediated transamidase activity in these cells and (ii) to
assess the role of TG2 in NGF-induced neuroprotection and neurite
outgrowth. The results obtained indicate that NGF triggers robust TG2-
mediated amine incorporation and protein cross-linking activity in
mouse N2a and human SH-SY5Y cells. Furthermore, inhibition of TG2
attenuated NGF-induced cytoprotection and neurite outgrowth.
Overall, these results suggest a novel and prominent role for TG2 in
NGF function and signalling.
2. Materials and methods
2.1. Materials
Nerve growth factor (NGF) was obtained from Merck Millipore
(Watford, UK). Akt inhibitor XI was purchased from Calbiochem (San
Diego, CA). BAPTA/AM (1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'-
tetraacetic acid tetrakis acetoxymethyl ester), PD 98059 (2’-amino-3′-
methoxyﬂavone) and Ro 31-8220 (3-[3-[2,5-Dihydro-4-(1-methyl-1H-
indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl carbamimi-
dothioic acid ester mesylate) were obtained from Tocris Bioscience
(Bristol, UK). All-trans retinoic acid, casein, Protease Inhibitor Cocktail
(for use with mammalian cell and tissue extracts), Phosphatase
Inhibitor Cocktail 2 and 3, hordereadish peroxidase conjugated-
ExtrAvidin® (ExtrAvidin®-HRP) and ﬂuorescein isothiocyanate con-
jugated ExtrAvidin® (ExtrAvidin®-FITC) were obtained from Sigma-
Aldrich Co. Ltd. (Gillingham, UK). The TG2 inhibitors Z-DON (Z-ZON-
Val-Pro-Leu-OMe; Benzyloxycarbonyl-(6-Diazo-5-oxonorleucinyl)-L-va-
linyl-L-prolinyl-L-leucinmethylester) and R283 (1,3,dimethyl-2[2-oxo-
propyl]thio)imidazole chloride), together with puriﬁed guinea-pig liver
TG2 were obtained from Zedira GmbH (Darmstadt, Germany). DAPI
(4′,6-diamidino-2-phenylindole) was from Vector Laboratories Inc
(Peterborough, UK). Biotin-TVQQEL was purchased from Pepceuticals
(Enderby, UK). Biotin cadaverine (N-(5-aminopentyl)biotinamide) and
biotin-X-cadaverine (5-([(N-(biotinoyl)amino)hexanoyl]amino)penty-
lamine) were purchased from Invitrogen (Loughborough, UK).
Dulbecco's modiﬁed Eagle's medium (DMEM), foetal bovine serum,
trypsin (10×), L-glutamine (200 mM), penicillin (10,000 U/ml)/strep-
tomycin (10,000 μg/ml) were purchased from Scientiﬁc Laboratory
Supplies (Nottingham, UK. All other reagents were purchased from
Sigma-Aldrich Co. Ltd. (Gillingham, UK) and were of analytical grade.
Antibodies were obtained from the following suppliers: monoclonal
anti-phospho ERK1/2 (Thr202/Tyr204) from Sigma-Aldrich Co. Ltd.
(Gillingham, UK); polyclonal anti-phospho PKB (Ser473), polyclonal
anti-total PKB, monoclonal anti-total ERK1/2, and polyclonal anti-
cleaved caspase 3 from New England Biolabs Ltd. (Hitchin, UK);
monoclonal anti-TG2 (CUB 7402) from Thermo Scientiﬁc
(Loughborough, UK); polyclonal anti-human keratinocyte TG1 and
polyclonal anti-human epidermal TG3 from Zedira GmbH (Darmstadt,
Germany); monoclonal anti-GAPDH from Santa Cruz Biotechnology Inc
(Heidelberg, Germany); Alexa Fluor® 488 goat anti-mouse IgG labelled
secondary antibody from Thermo Scientiﬁc (Loughborough, UK).
2.2. Cell culture
Murine N2a and human SH-SY5Y neuroblastoma cells were obtained
from the European Collection of Animal Cell Cultures (Porton Down,
Salisbury, UK). Cells were cultured in DMEM supplemented with 2 mM L-
glutamine, 10% (v/v) foetal bovine serum, penicillin (100 U/ml) and
streptomycin (100 μg/ml). Cells were maintained in a humidiﬁed in-
cubator (95% air/5% CO2 at 37 °C) until 70–80% conﬂuent and sub-cul-
tured (1:5 split ratio) every 3–4 days. SH-SY5Y cells were sub-cultured
using trypsin (0.05% w/v)/EDTA (0.02% w/v). Diﬀerentiation of N2a
cells was induced by culturing cells in serum-free DMEM containing 1 µM
all-trans retinoic acid for 48 h, unless otherwise speciﬁed. Diﬀerentiation
of SH-SY5Y cells was induced by culturing cells in serum-free DMEM
containing 10 µM all-trans retinoic acid for 5 days. Experiments were
performed on passage numbers 8–20 for N2a and 18–25 for SH-SY5Y.
2.3. Cell extraction for measurement of TG2 activity
Following prior diﬀerentiation with retinoic acid as described above
time course proﬁles and concentration-response curves were obtained
for NGF. Where appropriate, cells were also pre-incubated for 30 min in
medium with or without the protein kinase inhibitors Akt inhibitor XI
(PKB/Akt, 100 nM; Barve et al., 2006), PD 98059 (MEK1/2, 50 µM;
Dudley et al., 1995), and Ro 31-8220 (PKC, 10 µM; Davis et al., 1989)
prior to treatment with 100 ng/ml NGF. The concentrations of protein
kinase inhibitors employed in this study were in the range of values in
the literature that are used to inhibit the cellular activity of these ki-
nases: PD 98059 (10–50 µM; Sutter et al., 2004; Kim et al., 2008), Akt
inhibitor XI (1 µM; Frampton et al., 2012; Rybchyn et al., 2011) and Ro
31-8220 (1–10 µM; Lee et al., 2013; Montejo-López et al., 2016). In the
case of less well known Akt inhibitor XI, eﬀects on PKB inhibition were
veriﬁed by Western blot analysis.
Following stimulation with NGF, N2a and SH-SY5Y cells were rinsed
twice with 2.0 ml of chilled PBS, lysed with 500 μl of ice-cold lysis
buﬀer ((50 mM Tris-HCl pH 8.0, 0.5% (w/v) sodium deoxycholate,
0.1% (v/v) Protease Inhibitor Cocktail, and 1% (v/v) Phosphatase
Inhibitor Cocktail 2)). Cell lysates were clariﬁed by centrifugation at
4 °C for 10 min at 14,000 × g prior to being assayed for TG transami-
dase activity. Supernatants were collected and stored at − 80 °C.
Protein levels were determined by the bicinchoninic acid (BCA)
protein assay, based on the method of Smith et al. (1985), which was
performed using a commercially available kit (Sigma-Aldrich Co. Ltd,
UK) using bovine serum albumin (BSA) as the standard. Transgluta-
minase activity was subsequently monitored by two diﬀerent transa-
midase assays; amine incorporation and protein cross-linking.
2.4. Biotin-labelled cadaverine incorporation assay
The assay was performed as per the method described by Slaughter
et al. (1992) with the modiﬁcations of Lilley et al. (1998). Brieﬂy, 96-
well microtitre plates were coated overnight at 4 °C with 250 μl of
N′,N′-dimethylcasein (10 mg/ml in 100 mM Tris-HCl, pH 8.0). The
plate was washed twice with distilled water and blocked with 250 μl of
3% (w/v) BSA in 100 mM Tris-HCl, pH 8.0 and incubated for 1 h at
room temperature. The plate was washed twice before the application
of 150 μl of either 6.67 mM calcium chloride and or 13.3 mM EDTA
(used to deplete calcium and suppress TG activity) assay buﬀer con-
taining 225 µM biotin cadaverine (a widely used substrate to monitor
TG amine incorporating activity) and 2 mM 2-mercaptoethanol. The
reaction was started by the addition of 50 μl of samples or positive
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control (50 ng/well of guinea-pig liver TG2) and negative control
(100 mM Tris-HCl, pH 8.0). After incubation for 1 h at 37 °C plates were
washed as before. Then, 200 μl of 100 mM Tris-HCl pH 8.0 containing
1% (w/v) BSA and ExtrAvidin®-HRP (1:5000 dilution) were added to
each well and the plate incubated at 37 °C for 45 min then washed as
before. The plate was developed with 200 μl of freshly made developing
buﬀer (7.5 µg/ml 3,3′,5,5′-tetramethylbenzidine (TMB) and 0.0005%
(v/v) H2O2 in 100 mM sodium acetate, pH 6.0) and incubated at room
temperature for 15 min. The reaction was terminated by adding 50 μl of
5 M sulphuric acid and the absorbance read at 450 nm. One unit of
transglutaminase activity was deﬁned as a change in A450 of 1.0 per h.
Each experiment was performed in triplicate.
2.5. Biotin-labelled peptide cross-linking assay
The assay was performed according to the method of Trigwell et al.
(2004) with minor modiﬁcations. Microtitre plates (96-well) were
coated and incubated overnight at 4 °C with casein at 1.0 mg/ml in
100 mM Tris-HCl pH 8.0 (250 μl per well). The wells were washed
twice with distilled water, before incubation at room temperature for
1 h with 250 μl of blocking solution (100 mM Tris-HCl pH 8.0 con-
taining 3% (w/v) BSA). The plate was washed twice before the appli-
cation of 150 μl of either 6.67 mM calcium chloride and or 13.3 mM
EDTA assay buﬀer containing 5 μM biotin-TVQQEL and 2 mM 2-mer-
captoethanol. The reaction was started by the addition of 50 μl of
Fig. 1. Protein expression of TG isoforms in mitotic and diﬀer-
entiating SH-SY5Y cells. (A) Cell lysates (20 µg protein) from
mitotic (M) and diﬀerentiating (D) SH-SY5Y cells (10 µM retinoic
acid; for 5 days) were analysed for TG1, TG2 and TG3 expression
by Western blotting using TG isoform speciﬁc antibodies. Puriﬁed
TG1, TG2 and TG3 were used as positive controls. Levels of
GAPDH are included for comparison. (B) Quantiﬁed data are ex-
pressed as the ratio of TG isoform to GAPDH and represent the
mean± S.E.M. from four independent experiments.
****P<0.0001 versus mitotic cells.
Fig. 2. Eﬀect of NGF on transglutaminase activity in
diﬀerentiating mouse N2a cells. Cells were either
incubated with 100 ng/ml NGF for the indicated
time periods or for 1 h with the indicated con-
centrations of NGF. Cell lysates were then subjected
to the biotin-cadaverine incorporation (A and C) or
protein cross-linking assay (B and D). Data points
represent the mean TG speciﬁc activity± S.E.M.
from four independent experiments. *P<0.05,
**P<0.01, ***P<0.001, and ****P<0.0001
versus control response.
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samples or positive control (50 ng/well of guinea-pig liver TG2) and
negative control (100 mM Tris-HCl, pH 8.0) and allowed to proceed for
1 h at 37 °C. Reaction development and termination were performed as
described for biotin-cadaverine assays. One unit of transglutaminase
activity was deﬁned as a change in A450 of 1.0 per h. Each experiment
was performed in triplicate.
2.6. Hypoxia-induced cell death
Diﬀerentiating N2a and SH-SY5Y cells in glucose-free and serum-
free DMEM (Gibco™, Life Technologies Ltd, Paisley, UK) were exposed
to 8 h hypoxia using a hypoxic incubator (5% CO2/1% O2 at 37 °C) in
which O2 was replaced by N2.
Fig. 3. Eﬀect of NGF on transglutaminase activity in
diﬀerentiating human SH-SY5Y cells. Cells were ei-
ther incubated with 100 ng/ml NGF for the indicated
time periods or for 1 h with the indicated con-
centrations of NGF. Cell lysates were then subjected
to the biotin-cadaverine incorporation (A and C) or
protein cross-linking assay (B and D). Data points
represent the mean TG speciﬁc activity± S.E.M.
from four independent experiments. *P<0.05,
**P<0.01, and ***P<0.001 versus control re-
sponse.
Fig. 4. Eﬀect of acute NGF-treatment on TG2 protein ex-
pression in diﬀerentiating N2a and SH-SY5Y cells. (A) N2a
and (B) SH-SY5Y cells were incubated with 100 ng/ml NGF
for the indicated time periods. Cell lysates (20 µg protein)
were analysed for TG2 expression by Western blotting using
anti TG2 antibody. Levels of GAPDH are included for com-
parison. Quantiﬁed data are expressed as the percentage of
TG2 expression in control cells (100%) and represent the
mean± S.E.M. of four independent experiments.
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2.7. Cell viability assays
N2a (25,000 cells/well) and SH-SY5Y (50,000 cells/well) cells were
plated in 24-well ﬂat bottomed plates and diﬀerentiated for 48 h using
retinoic acid, as described above, before cell viability was determined
by measuring the reduction of MTT (Mosmann, 1983). The amount of
DMSO-solubilised reduced formazan product was determined by mea-
surement of absorbance at a wavelength 570 nm. Alternatively, N2a
(5,000 cells/well) and SH-SY5Y (10,000 cells/well) cells were plated in
96-well ﬂat bottomed plates and diﬀerentiated for 48 h. Following
normoxia/hypoxia exposure, the activity of lactate dehydrogenase
(LDH) released into the culture medium was detected using the CytoTox
96® non-radioactive cytotoxicity assay (Promega, Southampton, UK)
with measurement of absorbance at 490 nm.
2.8. High-throughput analysis of NGF-induced neurite outgrowth
Cells were seeded on 8-well Ibidi μ-slides: 15,000 cells/well for N2a
and 30,000 cells/well for SH-SY5Y and cultured for 24 h in fully sup-
plemented DMEM. Where appropriate, cells were treated for 1 h with
TG2 inhibitors Z-DON (150 μM) or R283 (200 μM). The medium con-
taining the TG2 inhibitors was removed and replaced with fresh
medium before the addition of 100 ng/ml NGF for 48 h. Following
stimulation, cells were ﬁxed with 3.7% (w/v) paraformaldehyde and
permeabilised with 0.1% (v/v) Triton-X100 (both in PBS) for 15 min at
room temperature. After washing, cells were blocked with 3% (w/v)
BSA in PBS for 1 h at room temperature. They were then stained
overnight at 4 °C with monoclonal antibodies to total α-tubulin (B512),
followed by Alexa Fluor® 488 goat anti-mouse IgG labelled secondary
antibody for 2 h at room temperature. The slides were subsequently
washed three times for 5 min with PBS and incubated for 1 min with
Vectashield® medium (Vector Laboratories Ltd, Peterborough, UK)
containing DAPI counterstain for nuclei visualisation. Slides were
preserved in PBS containing 0.01% (w/v) sodium azide as a pre-
servative and stored at 4 °C prior to image acquisition and analysis.
Neurite outgrowth was monitored using an ImageXpress® Micro
Wideﬁeld High Content Screening (HCS) System (Molecular Devices,
Wokingham, UK). Fluorescence images were acquired using a 10×
objective lens and analysed by MetaXpress software, using Neurite
Outgrowth analysis settings to measure a number of morphological
parameters including average neurite length per cell and maximum
neurite length per cell. Analysis was performed on a total of four ﬁelds
and at least 200 cells per well from four independent experiments.
2.9. Western blot analysis
Protein extracts (15–20 μg per lane) were separated by SDS-PAGE
(10% w/v polyacrylamide gel) using a Bio-Rad Mini-Protean III system.
Proteins were transferred to nitrocellulose membranes in a Bio-Rad Trans-
Blot system using transfer buﬀer comprising 25 mM Tris, 192 mM glycine
pH 8.3 and 20% (v/v) MeOH). Following transfer, the membranes were
washed with Tris-buﬀered saline (TBS) and blocked for 1 h at room
temperature with 3% (w/v) skimmed milk powder in TBS containing
0.1% (v/v) Tween-20. Blots were then incubated overnight at 4 °C in
blocking buﬀer with primary antibodies to the following targets (1:1000
dilutions unless otherwise indicated): phospho-speciﬁc ERK1/2, phospho-
speciﬁc PKB (1:500), cleaved active caspase-3 (1:500), GAPDH, TG1, TG2
or TG3. The primary antibodies were removed and blots washed three
times for 5 min in TBS/Tween 20. Blots were then incubated for 2 h at
room temperature with the appropriate secondary antibody (1:1000)
coupled to horseradish peroxidase (New England Biolabs Ltd; UK) in
blocking buﬀer. Following removal of the secondary antibody, blots were
extensively washed as above and developed using the Enhanced
Chemiluminescence Detection System (Uptima, Interchim, France) and
quantiﬁed by densitometry using Advanced Image Data Analysis Software
(Fuji; version 3.52). The uniform transfer of proteins to the nitrocellulose
Fig. 5. Eﬀect of TG2 inhibitors on NGF-induced TG2
activity. N2a (A and B) and SH-SY5Y (C and D) cells
were pretreated for 1 h with the TG2 inhibitors Z-
DON (150 µM) and R283 (200 µM) prior to 1 h sti-
mulation with NGF (100 ng/ml). Cell lysates were
then subjected to the biotin-cadaverine incorpora-
tion (A and C) or protein cross-linking assay (B and
D). Data points represent the mean TG speciﬁc
activity± S.E.M. from four independent experi-
ments. **P<0.01, ***P<0.001, and
****P<0.0001, (a) versus control and (b) versus
NGF alone.
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membrane was routinely monitored by transiently staining the mem-
branes with Ponceau S stain prior to application of the primary antibody.
When assessing protein kinase phosphorylation samples from each ex-
periment were also analysed on separate blots using primary antibodies
that recognize total ERK1/2 and PKB, (both at 1:1000 dilution) in order to
conﬁrm the uniformity of protein loading.
2.10. Visualisation of in situ TG2 activity
N2a (15,000 cells/well) and SH-SY5Y (30,000 cells/well) cells were
seeded on 8-well chamber slides and diﬀerentiated using retinoic acid as
described above. For the visualisation of in situ TG2 activity, the medium
was then removed, monolayer gently washed with PBS and slides in-
cubated for 6 h with 1 mM biotin-X-cadaverine (a cell permeable TG2
substrate; Perry et al., 1995) in serum-free DMEM before experimenta-
tion. Where appropriate, cells were treated for 1 h with TG2 inhibitors
Z-DON (150 µM) or R283 (200 µM) before the addition of NGF (100 ng/
ml). Following stimulation with NGF, cells were ﬁxed with 3.7% (w/v)
paraformaldehyde and permeabilised with 0.1% (v/v) Triton-X100 both
in PBS for 15 min at room temperature. After washing, cells were blocked
with 3% (w/v) BSA for 1 h at room temperature and the transglutaminase
mediated biotin-X-cadaverine labelled protein substrates detected by
(1:200 v/v) FITC-conjugated ExtrAvidin® (Sigma-Aldrich Co. Ltd., UK).
The chamber slide was subsequently washed three times for 5 min with
PBS, air-dried and mounted with Vectashield® medium (Vector Labora-
tories Ltd, Peterborough, UK) containing DAPI counterstain for nuclei
visualisation. Finally slides were sealed using clear, colourless nail varnish
and stained cells visualised using a Leica TCS SP5 II confocal microscope
(Leica Microsystems, GmbH, Manheim, Germany) equipped with a 20×
air objective. Optical sections were typically 1–2 µm and the highest
ﬂuorescence intensity values were acquired and ﬂuorescence intensity
relative to DAPI stain quantiﬁed for each ﬁeld of view. Saturation was
Fig. 6. Eﬀect of PD 98959 and Akt inhibitor XI on
NGF-induced ERK1/2 and PKB activation in diﬀer-
entiating N2a and SH-SY5Y cells. Where indicated,
cells were pre-treated for 30 min with (A, C) PD
98059 (50 µM) or (B, D) Akt Inhibitor XI (100 nM)
prior to stimulation with NGF (100 ng/ml) for 1 h.
Cell lysates were analysed by Western blotting for
activation of ERK1/2 and PKB using phospho-spe-
ciﬁc antibodies. Samples were subsequently analysed
on separate blots using an antibodies that recognize
total ERK1/2 and PKB. Quantiﬁed data are expressed
as the percentage of the value for control cells (=
100%) in the absence of protein kinase inhibitor and
represent the mean± S.E.M. of four independent
experiments. *P<0.05, **P<0.01, *** P<0.001
and ****P<0.0001, (a) versus control and (b)
versus NGF.
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avoided using the look-up Table overlay provided by the software. Image
analysis and quantiﬁcation were carried out using Leica LAS AF software.
2.11. Statistical analysis
All graphs and statistics (one-way ANOVA followed by Dunnet's
multiple comparison test and two-way ANOVA for group comparison)
were performed using GraphPad Prism® software (GraphPad Software,
Inc., USA). Results represent mean± S.E.M. and P values< 0.05 were
considered statistically signiﬁcant.
3. Results
3.1. Eﬀect of NGF on TG2 activity
We have recently reported that TG1, TG2 and TG3 protein expres-
sion increased signiﬁcantly in N2a cells induced to diﬀerentiate with
retinoic acid (Algarni et al., 2017). In this study, Western blot analysis
revealed that mitotic SH-SY5Y cells expressed comparable levels of
TG1, TG2 and TG3, and only TG2 expression signiﬁcantly increased
following retinoic acid induced diﬀerentiation (Fig. 1).
TG2 catalyses two types of transamidation, namely (i) intra-, and/or
inter-molecular covalent cross-links between protein-bound glutamine
and protein-bound lysine residues, and (ii) cross-links between primary
amines and protein-bound glutamine (Nurminskaya and Belkin, 2012).
NGF treatment of diﬀerentiating N2a cells produced transient increases
in TG2-catalysed biotin-cadaverine incorporation and protein cross-
linking activity, peaking at 1 h (Fig. 2A and B). Furthermore, NGF also
stimulated concentration-dependent increases in biotin-amine in-
corporation activity (Fig. 2C) and protein cross-linking activity
(Fig. 2D). It is important to demonstrate in vitro changes in more than
one cell model, because in cell culture studies there is always a risk that
recorded eﬀects may be unique to a speciﬁc cell line or due to genetic
drift or clonal/species related eﬀects. In order to conﬁrm these ob-
servations in another cell model, the ability of NGF to stimulate TG2
activation in diﬀerentiating human SH-SY5Y neuroblastoma cells was
Fig. 7. Eﬀect of Akt inhibitor XI and PD 98959 on
NGF-induced ERK1/2 and PKB activation in diﬀer-
entiating N2a and SH-SY5Y cells. Where indicated,
cells were pre-treated for 30 min with (A, C) Akt
Inhibitor XI (100 nM) or (B, D) PD 98059 (50 µM)
prior to stimulation with NGF (100 ng/ml) for 1 h.
Cell lysates were analysed by Western blotting for
activation of ERK1/2 and PKB using phospho-spe-
ciﬁc antibodies. Samples were subsequently analysed
on separate blots using an antibodies that recognize
total ERK1/2 and PKB. Quantiﬁed data are expressed
as the percentage of the value for control cells (=
100%) in the absence of protein kinase inhibitor and
represent the mean± S.E.M. of four independent
experiments. *** P<0.001 and ****P<0.0001, (a)
versus control. NS = not signiﬁcant.
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also investigated. NGF treatment of SH-SY5Y cells produced transient
increases in TG2 catalysed biotin-cadaverine incorporation and protein
cross-linking activity, peaking at 1 h (Fig. 3A and B). Furthermore, NGF
also stimulated concentration-dependent increases in biotin-amine in-
corporation activity (Fig. 3C) and protein cross-linking activity
(Fig. 3D) in SH-SY5Y cells. To conﬁrm that the observed increase in
NGF-induced TG2 activation is not simply a consequence of increased
levels of TG2 protein expression, the level of TG2 protein was mon-
itored by Western blotting. The data obtained indicate no signiﬁcant
change in the level of TG2 protein expression during the time course
(up to 4 h) of NGF treatment in N2a and SH-SY5Y cells (Fig. 4). Overall,
these data indicate that NGF stimulates robust TG2-mediated transa-
midase activity in diﬀerentiating N2a and SH-SY5Y cells.
3.2. Eﬀect of TG2 inhibitors on NGF induced TG2 activity
To conﬁrm that TG2 was responsible for NGF-mediated transglu-
taminase activity, two structurally diﬀerent cell permeable TG2 speciﬁc
inhibitors were tested; R283 (a small molecule; Freund et al., 1994) and
Z-DON (peptide-based; Schaertl et al., 2010). Cells were pre-treated for
1 h with Z-DON (150 µM) or R283 (200 µM) prior to stimulation with
NGF (100 ng/ml) for 1 h. Both inhibitors completely blocked NGF-in-
duced TG-mediated amine incorporation (Fig. 5A and C) and protein
cross-linking activity (Fig. 5B and D). It is important to note that despite
these TG2 inhibitors being cell-permeable, inhibition of cellular TG2 is
only achieved at concentrations signiﬁcantly above their IC50 value
versus puriﬁed enzyme (Schaertl et al., 2010; Freund et al., 1994).
3.3. The eﬀect of ERK1/2, PKB and PKC inhibitors on NGF-induced TG2
activity
NGF triggers the activation of multiple signalling pathways in-
cluding PI-3K/PKB, ERK1/2, and PKC (Wang et al., 2014). In this study,
NGF-induced ERK1/2 and PKB activation was assessed by Western
blotting using phospho-speciﬁc antibodies that recognize phosphory-
lated motifs within activated ERK1/2 (pTEpY) and PKB (S473). As
Fig. 8. Eﬀect of the protein kinase C inhibitor Ro 31-
8220 on NGF-induced ERK1/2 and PKB activation in
diﬀerentiating N2a and SH-SY5Y cells. Where in-
dicated, cells were pre-treated for 30 min Ro 31-
8220 (10 µM) prior to stimulation with NGF
(100 ng/ml) for 1 h. Cell lysates were analysed by
Western blotting for activation of ERK1/2 (panels A
and C) and PKB (panels B and D) using phospho-
speciﬁc antibodies. Samples were subsequently ana-
lysed on separate blots using an antibodies that re-
cognize total ERK1/2 and PKB. Quantiﬁed data are
expressed as the percentage of the value for control
cells (= 100%) in the absence of protein kinase in-
hibitor and represent the mean± S.E.M. of four in-
dependent experiments. *P<0.05, **P<0.01, ***
P<0.001 and ****P<0.0001, (a) versus control
and (b) versus NGF. NS = not signiﬁcant.
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expected, NGF (100 ng/ml) stimulated robust increases in ERK1/2 and
PKB phosphorylation in diﬀerentiating N2a (Fig. 6A and B) and SH-
SY5Y cells (Fig. 6C and D). NGF-mediated increases in ERK1/2 and PKB
were inhibited by PD 98059 (50 µM; MEK1/2 inhibitor) and Akt In-
hibitor XI (100 nM; PKB inhibitor) respectively (Fig. 6). Furthermore,
NGF-induced increases in ERK1/2 and PKB were insensitive to Akt In-
hibitor XI (Fig. 7A and C) and PD 98059 (Fig. 7B and D), respectively
suggesting inhibitor selectivity and lack of “cross-talk” between the two
kinase pathways. Previous studies have reported an up-stream role of
PKC isozymes in NGF-induced ERK1/2 activation (Lloyd and Wooten,
1992; Wooten et al., 2000). Hence in this study we determined if
pharmacological inhibition of PKC with Ro 31-8220 modulates NGF-
induced ERK1/2 activation in N2a and SH-SY5Y cells. Treatment with
Ro 31-8220 (10 µM) attenuated NGF-induced ERK1/2 activation in
both cell lines (Fig. 8A and C) suggesting that NGF activates PKC in N2a
and SH-SY5Y cells. Finally, Ro 31-8220 did not block NGF-induced PKB
activation (Fig. 8B and D).
The role of ERK1/2, PKB and PKC in NGF-induced TG2 activation
was determined using pharmacological inhibitors of these protein ki-
nases. NGF-induced transglutaminase-mediated amine incorporation
activity and protein cross-linking activity were inhibited by PD 98950
(MEK1 inhibitor; 50 µM; Fig. 9), Akt inhibitor XI (100 nM; Fig. 9), and
PKC inhibitor Ro 31-8220 (10 µM; Fig. 10A–D) suggesting the in-
volvement of ERK1/2, PKB and PKC, respectively. Overall, these data
suggest that NGF stimulates TG2 activity in diﬀerentiating N2a and SH-
SY5Y cells via a multi protein kinase-dependent pathway.
3.4. The role of Ca2+ in NGF-induced TG2 activation
The transamidating activity of TG2 is a Ca2+-dependent
(Nurminskaya and Belkin, 2012; Eckert et al., 2014). Hence we ex-
amined the role of Ca2+ in NGF-induced TG2 activation. The involve-
ment of extracellular Ca2+ was determined by measuring TG2 stimu-
lation in the absence of extracellular Ca2+ using Ca2+-free Hanks/
HEPES buﬀer containing 0.1 mM EGTA. Removal of extracellular Ca2+
moderately inhibited NGF-induced TG2 transamidation activity in N2a
and SH-SY5Y cells (Fig. 10E–H). To ascertain the role of intracellular
Ca2+, measurements of TG2 activation were also implemented using
cells loaded with the Ca2+ chelator BAPTA-AM (50 µM for 30 min) in
the absence of extracellular Ca2+. Loading cells with BAPTA, in the
continued absence of extracellular Ca2+, did not lead to further at-
tenuation of NGF-induced TG2 activation (Fig. 10E–H). These data in-
dicate that NGF-induced TG2 activation is partially dependent upon
extracellular Ca2+. Finally, we assessed whether NGF triggers changes
in intracellular Ca2+ using the ﬂuorescent Ca2+ indicator Fluo-8. NGF
did not trigger measurable increases in intracellular Ca2+ in N2a and
SH-SY5Y cells loaded with Fluo-8AM (data not shown).
3.5. Visualisation of in situ TG2 activity following NGF treatment
Biotin-X-cadaverine, is a cell penetrating primary amine, which
enables the in situ visualisation of endogenous protein substrates of
TG2, when combined with FITC-ExtrAvidin® (Lee et al., 1993). In N2a
and SH-SY5Y cells, NGF (100 ng/ml) stimulated the incorporation of
Fig. 9. Eﬀect of ERK1/2 and PKB inhibition on NGF-
induced TG activity. Diﬀerentiating N2a and SH-
SY5Y cells were pretreated for 30 min with PD 98059
(50 µM) or Akt inhibitor XI (100 nM) prior to 1 h
stimulation with NGF (100 ng/ml). Cell lysates sub-
jected to biotin-cadaverine incorporation (A, C, E) or
protein cross-linking assay (B, D, F). Data points re-
present the mean TG speciﬁc activity± S.E.M. from
four independent experiments. *P<0.05, **
P<0.01, *** P<0.001 and **** P<0.0001, (a)
versus control and (b) versus NGF alone.
A.S. Algarni et al. European Journal of Pharmacology 820 (2018) 113–129
121
biotin-X-cadaverine into endogenous protein substrates of TG2 (Figs. 11
and 12). Furthermore, the in situ responses to NGF in both cell lines
were attenuated by the TG2 inhibitors Z-DON and R283, the protein
kinase inhibitors PD 98059, Akt Inhibitor XI and Ro 31-8220 and fol-
lowing removal of extracellular Ca2+ (Figs. 11 and 12). Overall, these
data indicate a similar pattern of TG2 activation in live cells.
Fig. 10. Eﬀect of PKC inhibition and role of Ca2+ in NGF-in-
duced TG2 activation in diﬀerentiating N2a and SH-SY5Y cells.
In panels (A)–(D) cells were pretreated for 30 min with Ro 31-
8220 (10 µM) prior to 1 h stimulation with NGF (100 ng/ml). In
panels (E)–(H) cells were stimulated for 1 h with NGF (100 ng/
nml) either in the presence (1.8 mM CaCl2) or absence of ex-
tracellular Ca2+ (nominally Ca2+-free Hanks/HEPES buﬀer
containing 0.1 mM EGTA). Experiments were also performed
using cells pre-incubated for 30 min with 50 µM BAPTA/AM
and in the absence of extracellular Ca2+ (nominally Ca2+-free
Hanks/HEPES buﬀer containing 0.1 mM EGTA) to chelate in-
tracellular Ca2+. Cell lysates were subjected to biotin-cada-
verine incorporation assay (A, C, E, G) or protein cross-linking
assay (B, D, F, H). Data points represent the mean TG speciﬁc
activity± S.E.M. from four independent experiments.
*P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001, (a)
versus control, (b) versus NGF alone and in the presence of
extracellular Ca2+. Not signiﬁcant (NS) versus NGF in the ab-
sence of extracellular Ca2+.
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3.6. Role of TG2 in NGF-induced cell survival and neurite outgrowth
The role of TG2 in NGF-induced cell survival was determined in
retinoic acid induced diﬀerentiating N2a cells and SH-SY5Y cells fol-
lowing exposure of cells to 8 h simulated hypoxia (1% O2 in glucose-
free and serum-free medium; Algarni et al., 2017). Pre-treatment with
NGF (100 ng/ml; 1 h) signiﬁcantly attenuated hypoxia-induced de-
crease in MTT reduction, release of LDH and activation of caspase-3 in
N2a (Fig. 13) and SH-SY5Y (Fig. 14) cells. Furthermore, the TG2 in-
hibitors R283 and Z-DON attenuated NGF induced cell survival in both
Fig. 11. NGF-induced in situ TG activity in diﬀerentiating N2a cells. Cells were incubated with 1 mM biotin-X-cadaverine (BTC) for 6 h, after which they were incubated with (A) TG2
inhibitors Z-DON (150 µM) and R283 (200 µM) for 1 h, (B) PD 98059 (50 µM) and Akt Inhibitor XI (100 nM) for 30 min, or (C) Ro 31-8220 (10 µM) for 30 min or the absence of
extracellular Ca2+ (nominally Ca2+-free Hanks/HEPES buﬀer containing 0.1 mM EGTA) prior to stimulation with NGF (100 ng/ml) for 1 h. TG2-mediated biotin-X-cadaverine in-
corporation into intracellular proteins was visualised using FITC-conjugated ExtrAvidin® (green). Nuclei were stained with DAPI (blue) and viewed using a Leica TCS SP5 II confocal
microscope (20× objective magniﬁcation). Scale bar = 20 µm. Images presented are from one experiment and representative of three. Quantiﬁed data represent the mean±S.E.M. of
ﬂuorescence intensity relative to DAPI stain for ﬁve ﬁelds of view each from at least three independent experiments. *P<0.05, ** P<0.01, *** P<0.001 and ****P<0.0001 versus
control response.
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Fig. 12. NGF-induced in situ TG activity in diﬀerentiating SH-SY5Y cells. Cells were incubated with 1 mM biotin-X-cadaverine (BTC) for 6 h, after which they were incubated with (A)
TG2 inhibitors Z-DON (150 µM) and R283 (200 µM) for 1 h, (B) PD 98059 (50 µM) and Akt Inhibitor XI (100 nM) for 30 min, or (C) Ro 31-8220 (10 µM) for 30 min or the absence of
extracellular Ca2+ (nominally Ca2+-free Hanks/HEPES buﬀer containing 0.1 mM EGTA) prior to stimulation with NGF (100 ng/ml) for 1 h. TG2-mediated biotin-X-cadaverine in-
corporation into intracellular proteins was visualised using FITC-conjugated ExtrAvidin® (green). Nuclei were stained with DAPI (blue) and viewed using a Leica TCS SP5 II confocal
microscope (20× objective magniﬁcation). Scale bar = 20 µm. Images presented are from one experiment and representative of three. Quantiﬁed data represent the mean±S.E.M. of
ﬂuorescence intensity relative to DAPI stain for ﬁve ﬁelds of view each from at least three independent experiments. *P<0.05, ** P<0.01, *** P<0.001 and ****P<0.0001 versus
control response.
A.S. Algarni et al. European Journal of Pharmacology 820 (2018) 113–129
124
cell lines (Figs. 13 and 14).
The role of TG2 in NGF-induced neurite outgrowth was assessed by
high-throughput monitoring of neurite outgrowth following 48 h
treatment with NGF (100 ng/ml) in N2a and SH-SY5Y cells. The TG2
inhibitors Z-DON (150 µM) and R283 (200 µM) attenuated maximum
neurite outgrowth per cell and average neurite length per cell following
treatment with NGF, conﬁrming the involvement of TG2 in N2a
(Fig. 15) and SH-SY5Y (Fig. 16) cells. Overall, these data indicate a
prominent role for TG2 in NGF-mediated neurite outgrowth.
4. Discussion
The data in this report reveal for the ﬁrst time that NGF-mediated
cell survival and neurite outgrowth are dependent on TG2-mediated
transamidase activity.
4.1. In vitro and in situ modulation of TG2 transamidation activity by NGF
NGF mediates neurite outgrowth and neuroprotection; however, it
is not known if these events involve NGF-induced TG2 activation
(Sofroniew et al., 2001; Huang and Reichardt, 2001; Oe et al., 2005;
Condello et al., 2008; Tang et al., 2005). In this study we have shown
that short term treatment with NGF (< 4 h) triggered time- and
concentration-dependent increases in TG2-mediated biotin-cadaverine
incorporation and protein cross-linking activity in diﬀerentiating N2a
and SH-SY5Y cells. These observations suggest a direct stimulation of
TG2 following activation of the TrkA receptor with NGF. It is important
to note that levels of TG2 protein expression did not change during this
time period (< 4 h). Furthermore, although diﬀerentiating N2a and SH-
SY5Y cells also express TG1 and TG3 isoforms, NGF-induced increases
in TG activity were inhibited by R283 and Z-DON, conﬁrming that the
observed increases in TG activity were via TG2. Finally, ﬂuorescence
microscopy revealed in situ intracellular TG2 activity following NGF
stimulation. The results were comparable to NGF-induced amine in-
corporation activity observed in vitro. Since the cross-linking activity
TG1 is regulated via ERK1/2 and PKC it is conceivable that NGF may
modulate the activity of multiple TG isoforms (Bollag et al., 2005).
As detailed in the Introduction, very little is known regarding the
regulation of TG2 enzymic activity following receptor tyrosine kinase
activation. However, since TG2 transamidase activity modulates pro-
tein function by cross-linking and incorporation of small molecule
mono- and polyamines into protein substrates, it is likely that activation
of TG2 by tyrosine kinase receptors (and in particular other members of
the neurotrophin family) plays a major role in the regulation of neu-
ronal cell function (Nurminskaya and Belkin, 2012; Eckert et al., 2014).
Fig. 13. The eﬀects of the TG2 inhibitors Z-DON and
R283 on NGF-induced cell survival against hypoxia-
induced cell death in N2a cells. Diﬀerentiating N2a
cells were pre-treated with NGF (100 ng/ml) for 1 h
prior to 8 h hypoxia (1% O2) or 8 h normoxia. Where
indicated cells were pretreated for 1 h with the TG2
inhibitors Z-DON (150 µM) and R283 (200 µM) prior
to stimulation with NGF. Cell viability was assessed
by measuring (A) the metabolic reduction of MTT by
cellular dehydrogenases, (B) release of LDH into the
culture medium and (C and D) caspase-3 activity via
Western blot analysis using anti-active caspase 3
antibody. Representative Western blots for caspase
activation are shown in panels (E) and (F). Levels of
GAPDH are shown for comparison. Data are ex-
pressed as a percentage of normoxia control cell
values (= 100%) and represent the mean±S.E.M.
from four independent experiments, each performed
in (a) quadruplicate or (b) sextuplicate. *P<0.05,
** P<0.01, *** P<0.001 and ****P<0.0001, (a)
versus normoxia control, (b) versus hypoxia control
(c) versus NGF in the presence of hypoxia.
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4.2. Role of protein kinases in NGF-mediated TG2 activation
Increasing evidence suggests that TG2 is regulated by phosphor-
ylation. For example, phosphorylation of TG2 by PKA inhibits its
transamidating activity but augments its kinase activity (Mishra et al.,
2007), whereas PTEN-induced putative kinase 1 (PINK1) phosphor-
ylation of TG2 inhibits its proteasomal degradation (Min et al., 2015).
Furthermore, we have recently shown that stimulation of intracellular
TG2 transamidase activity by the A1 adenosine receptor and PAC1 re-
ceptor is dependent upon ERK1/2, PKC and TG2 phosphorylation (Vyas
et al., 2016; Algarni et al., 2017). Since the TrkA receptor stimulates
protein kinase cascades involving ERK1/2, PKB and PKC (Wang et al.,
2014) we explored the roles of these kinases in NGF-induced TG2 ac-
tivation. The observation that pharmacological inhibition of ERK1/2,
PKB and PKC attenuated NGF-induced TG2 transamidase activity in
N2a and SH-SY5Y cells, suggests prominent roles for these protein ki-
nases. These observations are in agreement with our previous studies
which have revealed roles for ERK1/2, PKB and PKC in TG2 activation
triggered by members of the GPCR family (Vyas et al., 2016, 2017;
Algarni et al., 2017). At present it is not known if ERK1/2, PKB and PKC
directly phosphorylate TG2, leading to direct enhancement of enzymic
activity or whether TG2 phoshorylation promotes its association with
interacting proteins. For example, TG2 phosphorylation by PKA
promotes its interaction with the scaﬀolding protein 14-3-3 which leads
to the attenuation of TG2 kinase activity (Mishra and Murphy, 2006).
Alternatively, these kinases may phosphorylate downstream targets
that subsequently interact with TG2, resulting in enhanced activity.
Finally, it is important to note that the attenuation of NGF-induced TG2
activation by inhibition of PKC reﬂects the reported up-stream role of
PKC isozymes in NGF-induced ERK1/2 activation (Lloyd and Wooten,
1992; Wooten et al., 2000). Clearly, further studies are required, to
establish if NGF activation promotes TG2 phosphorylation and, if so, to
subsequently identify the speciﬁc site(s).
4.3. Role of Ca2+ in NGF-induced TG2 activation
Previous studies have shown that NGF triggers intracellular Ca2+
release in C6-2B glioma cells (De Bernardi et al., 1996) and extra-
cellular Ca2+ inﬂux in PC12 and bovine chromaﬃn cells (Pandiella-
Alonso et al., 1986). Since TG2 transamidase activity is Ca2+ depen-
dent, we investigated the potential involvement of extracellular and
intracellular Ca2+ in NGF-induced TG2 activation. The data presented
indicate that NGF-induced TG2-mediated transamidase activity is par-
tially dependent upon extracellular Ca2+, suggesting that NGF triggers
Ca2+ inﬂux in N2a and SH-SY5Y cells. However, no measureable in-
creases in intracellular Ca2+ were observed following stimulation of
Fig. 14. The eﬀects of the TG2 inhibitors Z-DON and
R283 on NGF-induced cell survival against hypoxia-
induced cell death in SH-SY5Y cells. Diﬀerentiating
SH-SY5Y cells were pre-treated with NGF (100 ng/
ml) for 1 h prior to 8 h hypoxia (1% O2) or 8 h nor-
moxia. Where indicated cells were pretreated for 1 h
with the TG2 inhibitors Z-DON (150 µM) and R283
(200 µM) prior to stimulation with NGF. Cell viabi-
lity was assessed by measuring (A) the metabolic
reduction of MTT by cellular dehydrogenases, (B)
release of LDH into the culture medium and (C and
D) caspase-3 activity via Western blot analysis using
anti-active caspase 3 antibody. Representative
Western blots for caspase activation are shown in
panels (E) and (F). Levels of GAPDH are shown for
comparison. Data are expressed as a percentage of
normoxia control cell values (= 100%) and re-
present the mean±S.E.M. from four independent
experiments, each performed in (a) quadruplicate or
(b) sextuplicate. *P<0.05, ** P<0.01, ***
P<0.001 and ****P<0.0001, (a) versus normoxia
control, (b) versus hypoxia control (c) versus NGF in
the presence of hypoxia.
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these cells with NGF. The reason(s) for this are not currently known but
it may reﬂect localized NGF-induced increases in [Ca2+]i that were not
detectable using the technique employed. Whilst levels of Ca2+ re-
quired for TG2 activation are typically in the order 3–100 µM, there is
evidence that [Ca2+]i can reach levels suﬃcient to activate intracellular
TG2 (Király et al., 2011). Alternatively, the participation of Ca2+ in
NGF-induced TG2 activation may necessitate the sensitization of TG2 to
low levels of [Ca2+]i. It has been suggested that the interaction of TG2
with protein binding partners and/or membrane lipids promotes a
conformational change that enables activation at low levels of in-
tracellular [Ca2+] (Király et al., 2011). Clearly, further studies are re-
quired to determine how NGF-induced TG2 activation occurs in the
absence of detectable increases in [Ca2+]i, but the kinase-dependent
pathways outlined in the present study could be central to these novel
aspects of TG2 regulation.
4.4. Role of TG2 in NGF-induced cytoprotection
The role of TG2 in neuronal cell death is controversial with both
anti-apoptotic and pro-apoptoric roles reported (Tatsukawa et al.,
2016). These opposing roles appear to be dependent upon cell type,
trigger mechanism of cell death, intracellular location of TG2 and
speciﬁc TG2 enzymic activity (Tatsukawa et al., 2016). Examples of
TG2-mediated neuronal cell survival include; protection against heat
shock–induced cell death in SH-SY5Y cells (Tucholski et al., 2001),
protection of rat primary cortical neurons against hypoxia and oxygen/
glucose deprivation–induced cell death (Filiano et al., 2008) and in vivo
protection against ischaemic stroke (Filiano et al., 2010). TG2 is be-
lieved to mediate protection against hypoxia by attenuating HIF-in-
duced activation of pro-apoptotic genes (Filiano et al., 2008, 2010).
Furthermore, transamidating activity of TG2 does appear to play a role
in protection against oxygen/glucose deprivation–induced cell death
(Filiano et al., 2008). Likewise, NGF is widely recognized as a neuro-
protective agent and potential therapeutic agent for the treatment of
neurodegenerative disorders (Allen et al., 2013). The mechanisms of
NGF-induced neuroprotection are complex and involve activation of PI-
3K/PKB mediated cell survival signalling (Nguyen et al., 2010). In this
study we have shown for the ﬁrst time a role for TG2 in NGF-induced
cytoprotection in diﬀerentiating mouse N2a and human SH-SY5Y
neuroblastoma cells. However, whilst it is not clear how NGF-induced
TG2 activation mediates cell survival, TG2 is known to regulate path-
ways associated with NGF neuroprotection. For example, TG2 mediates
5-HT induced (serotonylation) of PKB in vascular smooth muscle cells
(Penumatsa et al., 2014). However, although the data presented suggest
that PKB is up-stream of TG2 (i.e. NGF-induced TG2 activation is
blocked by PKB inhibition) it is conceivable that NGF-induced TG2
activation functions to augment and sustain PKB activity. Finally, TG2
inhibition blocked NGF-mediated reduction in hypoxia-induced acti-
vation of caspase-3, which is indicative of an anti-apoptotic role. Recent
studies have shown that under conditions of Ca2+ overload, TG2 in-
hibits apoptosis via the down-regulation of Bax expression and inhibi-
tion of caspase 3 and 9 (Cho et al., 2010). Further work is required
to determine the role and mechanisms of TG2 in NGF-induced cell
survival.
4.5. Role of TG2 in NGF-induced neurite outgrowth
Previous studies have shown that TG2 is essential for diﬀerentia-
tion/neurite outgrowth in human neuroblastoma SH-SY5Y cells
(Tucholski et al., 2001; Singh et al., 2003). Furthermore, TG2-mediated
neurite outgrowth is dependent upon the transamidating role of TG2
(Tucholski et al., 2001). Postulated mechanisms include the following;
Fig. 15. The eﬀect of TG2 inhibitors on
NGF-induced neurite outgrowth in diﬀer-
entiating N2a cells. Cells were incubated for
1 h with the TG2 inhibitors Z-DON (150 µM)
or R283 (200 µM) before treatment with
NGF (100 ng/ml) in serum-free DMEM for
48 h. (A) Following stimulation high-
throughput immunocytochemistry was per-
formed using anti-tubulin antibody and vi-
sualised using Alexa Fluor® 488 labelled
goat anti-mouse IgG secondary antibody
(green). Nuclei were visualised using DAPI
counterstain (blue). Images presented are
from one experiment and representative of
four. High-throughout quantiﬁcation of (B)
the maximum neurite length per cell and (C)
the average neurite length per cell as de-
scribed in Section 2. White arrows indicate
typical neurite outgrowths. Data points re-
present the mean± S.E.M. from four in-
dependent experiments. *P<0.05,
**P<0.01 and *** P<0.001 (a) versus
mitotic control and (b) versus NGF alone.
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transamidation of RhoA and subsequent activation of ERK1/2, p38
MAPK and JNK (Singh et al., 2003), activation of adenylyl cyclase ac-
tivity and enhanced phosphorylation of cyclic AMP-response element
(CRE) binding protein (CREB; Tucholski and Johnson, 2003), and
polyamination of tubulin (Song et al., 2013). Although it is well es-
tablished that NGF triggers neurite outgrowth in N2a and SH-SY5Y
cells, it is not known whether TG2 plays a role in NGF-induced neuronal
diﬀerentiation (Condello et al., 2008; Oe et al., 2005). In the current
study we have shown that pharmacological inhibition of TG2 attenuates
NGF-induced neurite outgrowth, suggesting the participation of TG2 in
NGF-induced neurite outgrowth. At present it is not known how NGF-
mediated TG2 activation promotes neurite outgrowth, but it is con-
ceivable that it may involve modulation of one or more of the pathways
described above e.g. TG2-induced modulation of adenylyl cyclase/
CREB signalling. Indeed, studies have shown that NGF can modulate
cAMP levels in neuronal cells (Nikodijevic et al., 1975; Berg et al.,
1995). However, further studies are required to identify the down-
stream substrates of TG2 and signalling pathways associated with the
role of TG2 in NGF-induced neuronal diﬀerentiation.
In conclusion, our data show for the ﬁrst time that TG2 transami-
dase activity is regulated by NGF in diﬀerentiating N2a and SH-SY5Y
cells via a ERK1/2, PKB and PKC-dependent pathway (summarised in
Fig. 17). Work is currently underway to understand more fully the role
of TG2 in NGF signalling and modulation of neuronal cell function.
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The PAC1 receptor and tissue transglutaminase (TG2) play important roles in neurite outgrowth and mod-
ulation of neuronal cell survival. In this study, we investigated the regulation of TG2 activity by the PAC1
receptor in retinoic acid-induced differentiating N2a neuroblastoma cells. TG2 transamidase activity was
determined using an amine incorporation and a peptide cross linking assay. In situ TG2 activity was
assessed by visualising the incorporation of biotin-X-cadaverine using confocal microscopy. TG2 phos-
phorylation was monitored via immunoprecipitation and Western blotting. The role of TG2 in PAC1
receptor-induced cytoprotection and neurite outgrowth was investigated by monitoring hypoxia-
induced cell death and appearance of axonal-like processes, respectively. The amine incorporation and
protein crosslinking activity of TG2 increased in a time and concentration-dependent manner following
stimulation with pituitary adenylate cyclase-activating polypeptide-27 (PACAP-27). PACAP-27 mediated
increases in TG2 activity were abolished by the TG2 inhibitors Z-DON and R283 and by pharmacological
inhibition of protein kinase A (KT 5720 and Rp-cAMPs), protein kinase C (Ro 31-8220), MEK1/2 (PD
98059), and removal of extracellular Ca2+. Fluorescence microscopy demonstrated PACAP-27 induced
in situ TG2 activity. TG2 inhibition blocked PACAP-27 induced attenuation of hypoxia-induced cell death
and outgrowth of axon-like processes. TG2 activation and cytoprotection were also observed in human
SH-SY5Y cells. Together, these results demonstrate that TG2 activity was stimulated downstream of
the PAC1 receptor via a multi protein kinase dependent pathway. Furthermore, PAC1 receptor-induced
cytoprotection and neurite outgrowth are dependent upon TG2. These results highlight the importance
of TG2 in the cellular functions of the PAC1 receptor.
 2017 Elsevier Inc. All rights reserved.1. Introduction
Transglutaminases (TGs) are a family of Ca2+-dependent
enzymes that catalyse the post-translational modification of pro-
teins (for extensive reviews see [54,20]). There are eight distinctcatalytically active members of the TG family which exhibit differ-
ential expression (Factor XIIIa and TGs 1–7).
The ubiquitously expressed TG2 is the most widely studied
member of the TG family which is involved in the regulation of
numerous cellular processes, including cell adhesion, migration,
growth, survival, apoptosis, differentiation, and extracellular
matrix organization [54]. In neuronal cells, TG2 is involved in neu-
ral differentiation, neurite outgrowth and neuroprotection follow-
ing cerebral ischaemia [69,22,72].
Transglutaminase 2 (TG2) possesses multiple enzymic func-
tions that include transamidation, protein disulphide isomerase
and protein kinase activity [25]. The transamidase activity of TG2
is inhibited by GTP/GDP and evidence suggests that TG2 when
bound to GTP/GDP functions as a G-protein (known as Gh; [46]),
which is independent of its transamidase activity. Indeed, several
members of the G-protein coupled receptor (GPCR) family includ-
ing the a1B-adrenergic receptor, thromboxane A2 receptor and
56 A.S. Algarni et al. / Biochemical Pharmacology 128 (2017) 55–73oxytocin receptor couple to Gh when activated, promoting
exchange of GDP for GTP [25]. Activated Gh-GTP stimulates phos-
pholipase C d1 promoting phosphoinositide hydrolysis and stimu-
lating increases in intracellular Ca2+.
The activity of TG2 and other TG family members can be regu-
lated by protein kinases. For example, phosphorylation of TG2 by
protein kinase A (PKA) inhibits its transamidating activity but
enhances its kinase activity [49]. The transamidating activity of
TG1 (keratinocyte transglutaminase) is enhanced by phorbol
ester-induced stimulation of protein kinase C (PKC) and extracellu-
lar signal-regulated kinase 1/2 (ERK1/2; [7]. These findings suggest
that the activity of TG can be regulated by signalling pathways
associated with GPCRs. However, the regulation of intracellular
TG2 following stimulation of GPCRs is not well understood. Exam-
ples include muscarinic receptor-mediated increases in TG2 activ-
ity in SH-SY5Y cells [78], 5-HT2A receptor-mediated
transamidation of Rac1 in the rat A1A1v cortical cell line [13]
and A1 adenosine receptor-mediated increases in TG2 transami-
dase activity in rat H9c2 cardiomyoblasts [74].
Of particular interest to the current study is pituitary adenylate
cyclase-activating polypeptide (PACAP), which is widely dis-
tributed in the brain and peripheral organs and displays high affin-
ity for the PAC1 receptor [73]. The PAC1 receptor is a member of the
GPCR superfamily which activates adenylyl cyclase/cAMP/PKA (via
Gs-protein coupling) and phospholipase C/DAG/PKC (via Gq-
protein coupling) dependent signalling pathways [18,73]. The
PAC1 receptor also triggers the activation of several other protein
kinase cascades such as ERK1/2, JNK1/2, p38 MAPK and PKB
[51,44,8]. Since some of these protein kinase pathways are associ-
ated with modulation of TG activity (PKA, PKC and ERK1/2) it is
conceivable that the PAC1 receptor regulates TG activity. Since
mouse N2a neuroblastoma cells express PAC1 receptors [39,50]
the primary aims of this study were (i) to determine whether the
PAC1 receptor modulates TG2 activity in these cells and (ii) to
assess the role of TG2 in PAC1 receptor-induced neuroprotection
and neurite outgrowth. The results obtained indicate that PAC1
receptor stimulation triggers TG2-mediated amine incorporation
and protein cross-linking activity in differentiating N2a and SH-
SY5Y cells. Furthermore, inhibition of TG2 attenuates PAC1
receptor-induced cytoprotection and neurite outgrowth.2. Materials and methods
2.1. Materials
Akt inhibitor XI, KT 5720, Ro-31-8220 and Rp-8-Cl-cAMPS (ade-
nosine 30,50-cyclic monophosphorothioate, 8-chlro-, Rp-isomer)
were purchased from Calbiochem (San Diego, CA). [Ala11,22,28]-
VIP, Bay 55-9837, PACAP-27, PACAP 6-38, PD 98059, SB 203580,
and SP 600 125 were obtained from Tocris Bioscience (Bristol,
UK). All-trans retinoic acid, casein, Protease Inhibitor Cocktail (for
use with mammalian cell and tissue extracts), Phosphatase Inhibi-
tor Cocktail 2 and 3, ExtrAvidin-HRP and ExtrAvidin-FITC were
obtained from Sigma-Aldrich Co. Ltd. (Gillingham, UK). The TG2
inhibitors Z-DON (Z-DON-Val-Pro-Leu-OMe) and R283, together
with purified guinea-pig liver TG2 were obtained from Zedira
GmbH (Darmstadt, Germany). DAPI was from Vector Laboratories
Inc (Peterborough, UK). Fluo-8/AM was purchased from Stratech
Scientific Ltd (Newmarket, UK). Biotin-TVQQEL was purchased
from Pepceuticals (Enderby, UK). Biotin cadaverine (N-(5-
aminopentyl)biotinamide) and biotin-X-cadaverine (5-([(N-(bioti
noyl)amino)hexanoyl]amino)pentylamine) were purchased from
Invitrogen, UK. Dulbecco’s modified Eagle’s medium (DMEM), foe-
tal bovine serum, trypsin (10), L-glutamine (200 mM), penicillin
(10,000 U/ml)/streptomycin (10,000 lg/ml) were purchased fromBioWhittaker Ltd, UK. All other reagents were purchased from
Sigma-Aldrich Co. Ltd. (Gillingham, UK) and were of analytical
grade.
Antibodies were obtained from the following suppliers: mono-
clonal anti-phospho ERK1/2 (Thr202/Tyr204) and polyclonal anti-
tyrosine hydroxylase from Sigma-Aldrich; polyclonal anti-
phospho PKB (Ser473), polyclonal anti-total PKB, monoclonal anti-
total ERK1/2, monoclonal anti-phospho p38 MAPK, polyclonal
anti-total p38 MAPK, monoclonal anti-phospho JNK1/2, polyclonal
anti-total JNK1/2 and polyclonal anti-cleaved caspase 3 from New
England Biolabs Ltd (UK); polyclonal anti-human keratinocyte TG1
and polyclonal anti-human epidermal TG3 from Zedira GmbH
(Darmstadt, Germany); monoclonal anti-TG2 (CUB 7402) from
Thermo Scientific (Leicestershire, UK); monoclonal anti-GAPDH,
polyclonal anti-phosphoserine and polyclonal anti-
phosphothreonine from Abcam (Cambridge, UK); polyclonal
anti-choline acetyltransferase from Santa Cruz Biotechnology Inc
(Heidelberg, Germany).
2.2. Cell culture
Murine N2a and human SH-SY5Y neuroblastoma cells were
obtained from the European Collection of Animal Cell Cultures
(Porton Down, Salisbury, UK). Cells were cultured in DMEM sup-
plemented with 2 mM L-glutamine, 10% (v/v) foetal bovine serum,
penicillin (100 U/ml) and streptomycin (100 lg/ml). Cells were
maintained in a humidified incubator (95% air/5% CO2 at 37 C)
until 70–80% confluent and sub-cultured (1:5 split ratio) every
3–4 days. SH-SY5Y cells were sub-cultured using trypsin (0.05%
w/v)/EDTA (0.02% w/v). Differentiation of N2a cells was induced
by culturing cells in serum-free DMEM containing 1 lM all-trans
retinoic acid for 48 h, unless otherwise specified. Differentiation
of SH-SY5Y cells was induced by culturing cells in serum-free
DMEM containing 10 lM all-trans retinoic acid for 5 days. Experi-
ments were performed on passage numbers 8–20 for N2a and
18–25 for SH-SY5Y.
2.3. cAMP accumulation assay
N2a cells (5000 cells well1) were seeded on a white 96 well
microtitre plate, with clear bottomed wells (Corning; Fisher Scien-
tific, Loughborough, UK) and induced to differentiate as described
above. The medium was then removed and the monolayer treated
with a range of concentrations of PACAP-27 for 20 min in serum-
free DMEM (40 ll well1) in the presence of 20 mM MgCl2 and
500 lM 3-isobutyl-1-methylxanthine (IBMX). Following stimula-
tion, cAMP levels within cells were determined using the cAMP-
GloTM Max Assay kit (Promega; Southampton, UK). Briefly, 10 ll of
cAMP detection solution was added to all wells and incubated for
20 min at room temperature. After incubation, Kinase-Glo reagent
(50 ll well1) was added and incubated for 10 min at room tem-
perature, following which luminescence levels across the plate
were recorded using a plate-reading FLUOstar Optima luminome-
ter (BMG Labtech Ltd, UK,). Treatment with forskolin (10 lM)
was used as a positive control and the luminescence values were
converted to cAMP levels using a cAMP standard curve (0–
100 nM), according to the manufacturer’s instructions.
2.4. Cell extraction for measurement of TG2 activity
Time course profiles and concentration-response curves were
obtained for PACAP-27. Where appropriate, cells were also pre-
incubated for 30 min in medium with or without the protein
kinase inhibitors Rp-cAMPs (PKA, 50 lM; [15]), KT 5720 (PKA,
5 lM; [31]), Akt inhibitor XI (PKB/Akt, 100 nM; [2]), PD 98059
(MEK1/2, 50 lM; [19]), SP 600125 (JNK1/2, 20 lM; [5]), and Ro
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PACAP-27. The concentrations of protein kinase inhibitors
employed in this study were in the range of values in the literature
that are used to inhibit the cellular activity of these kinases: KT
5720 (2–10 lM; [77,43]); Rp-cAMPs (10–100 lM; [77]);
[43,76,56,71]; Ro 31-8220 1–10 lM; [37,52], PD 98059 (10–
50 lM; [66,33]), SP 600125 (20 lM; [26,32]) and Akt inhibitor XI
(1 lM; [23,59]). In the case of less well known Akt inhibitor XI
effects on PKB inhibition were verified by Western blot analysis.
Following stimulation, N2a and SH-SY5Y cells were rinsed twice
with 2.0 ml of chilled PBS, lysed with 500 ll of ice-cold lysis buffer
(50 mM Tris-HCl pH 8.0, 0.5% (w/v) sodium deoxycholate, 0.1% (v/
v) Protease Inhibitor Cocktail, and 1% (v/v) Phosphatase Inhibitor
Cocktail 2). Cell lysates were scraped and clarified by centrifuga-
tion at 4 C for 10 min at 14000g prior to being assayed for TG
activity using the biotin-labeled cadaverine incorporation assay
(see below). Supernatants were collected and stored at 80 C.
Protein levels were determined by the bicinchoninic acid (BCA)
protein assay, based on the method of Smith et al. [63], which was
performed using a commercially available kit (Sigma-Aldrich, UK)
using bovine serum albumin (BSA) as the standard. Transglutami-
nase activity was monitored by two different transamidase assays;
amine incorporation and protein cross-linking.
2.5. Biotin-labeled cadaverine incorporation assay
The assay was performed as per the method described by
Slaughter et al. [62] with the modifications of Lilley et al. [40].
Briefly, 96-well microtitre plates were coated overnight at 4 C
with 250 ll of N0,N0-dimethylcasein (10 mg ml1 in 100 mM Tris-
HCl, pH 8.0). The plate was washed twice with distilled water
and blocked with 250 ll of 3% (w/v) BSA in 100 mM Tris-HCl, pH
8.0 and incubated for 1 h at room temperature. The plate was
washed twice before the application of 150 ll of either 6.67 mM
calcium chloride and or 13.3 mM EDTA (used to deplete calcium
and suppress TG activity) assay buffer containing 225 lM biotin
cadaverine (a widely used substrate to monitor TG amine incorpo-
rating activity) and 2 mM 2-mercaptoethanol. The reaction was
started by the addition of 50 ll of samples or positive control
(50 ng/well of guinea-pig liver TG2) and negative control
(100 mM Tris-HCl, pH 8.0). After incubation for 1 h at 37 C plates
were washed as before. Then, 200 ll of 100 mM Tris-HCl pH 8.0
containing 1% (w/v) BSA and ExtrAvidin-HRP (1:5000 dilution)
was added to each well and the plate incubated at 37 C for
45 min then washed as before. The plate was developed with
200 ll of freshly made developing buffer (7.5 lg ml1 3,30,5,50-tet
ramethylbenzidine (TMB) and 0.0005% (v/v) H2O2 in 100 mM
sodium acetate, pH 6.0) and incubated at room temperature for
15 min. The reaction was terminated by adding 50 ll of 5 M sul-
phuric acid and the absorbance read at 450 nm. One unit of TG2
was defined as a change in absorbance of one unit h1. Each exper-
iment was performed in triplicate.
2.6. Biotin-labeled peptide-cross-linking assay
The assay was performed according to the method of Trigwell
et al. [70] with minor modifications. Microtitre plates (96-well)
were coated and incubated overnight at 4 C with casein at
1.0 mg ml1 in 100 mM Tris-HCl pH 8.0 (250 ll per well). The wells
were washed twice with distilled water, before incubation at room
temperature for 1 h with 250 ll of blocking solution (100 mM Tris-
HCl pH 8.0 containing 3% (w/v) BSA). The plate was washed twice
before the application of 150 ll of either 6.67 mM calcium chloride
and or 13.3 mM EDTA assay buffer containing 5 lM biotin-TVQQEL
and 2 mM 2-mercaptoethanol. The reaction was started by the
addition of 50 ll of samples or positive control (50 ng/well ofguinea-pig liver TG2) and negative control (100 mM Tris-HCl, pH
8.0) and allowed to proceed for 1 h at 37 C. Reaction development
and termination were performed as described for biotin-
cadaverine assays. One unit of TG2 was defined as a change in
absorbance of one unit h1. Each experiment was performed in
triplicate.
2.7. Hypoxia-induced cell death
Differentiating N2a and SH-SY5Y cells in glucose-free and
serum-free DMEM (GibcoTM, Life Technologies Ltd, Paisley, UK)
were exposed to hypoxia using a hypoxic incubator (5% CO2/1%
O2 at 37 C) in which O2 was replaced by N2.
2.8. Cell viability assays
N2a and SH-SY5Y cells were plated in 24-well flat bottomed
plates (15,000 cells/well) and differentiated for 48 h, before cell
viability was determined by measuring the reduction of MTT
[53]. The amount of DMSO-solubilised reduced formazan product
was determined by measurement of absorbance at a wavelength
of 570 nm. Alternatively, cells were plated in 96-well flat bottomed
plates (5000 cells per well) and differentiated for 48 h. Following
normoxia/hypoxia exposure, the activity of lactate dehydrogenase
(LDH) released into the culture medium was detected using the
CytoTox 96 non-radioactive cytotoxicity assay (Promega,
Southampton, UK) with measurement of absorbance at 490 nm.
2.9. Outgrowth of axon-like processes
The outgrowth of axon-like processes in N2a cells was assessed
as described previously [27]. N2a cells were seeded in 24-well
plates (25,000 cells/well) and incubated for 24 h in growth med-
ium prior to treatment with PACAP-27 (100 nM) in serum-free
DMEM for 24 or 48 h. After stimulation, the cells were washed with
ice cold phosphate buffered saline (PBS) then fixed in 90% (v/v)
methanol in PBS at 20 C for 15 min. After washing, the cells were
stained for 1 min at room temperature with Coomassie brilliant
blue, washed with PBS then with distilled water. The outgrowth
of axon-like processes was morphologically assessed using an
inverted light microscope. Five randomly selected fields, contain-
ing at least 200 cells, were examined in each well. The total num-
ber of cells and the number of axon-like processes, defined as
extensions greater than two cell body diameters in length with
an extension foot [35] were recorded.
2.10. Western blot analysis
Protein extracts (15–20 lg per lane) were separated by SDS-
PAGE (10% w/v polyacrylamide gel) using a Bio-Rad Mini-Protean
III system. Proteins were transferred to nitrocellulose membranes
in a Bio-Rad trans-Blot system using 25 mM Tris, 192 mM glycine
pH 8.3 and 20% (v/v) MeOH). Following transfer, the membranes
were washed with Tris-buffered saline (TBS) and blocked for 1 h
at room temperature with 3% (w/v) skimmed milk powder in TBS
containing 0.1% (v/v) Tween-20. Blots were then incubated over-
night at 4 C in blocking buffer with primary antibodies to the fol-
lowing targets (1:1000 dilutions unless otherwise indicated):
phospho-specific ERK1/2, phospho-specific PKB (1:500), phospho-
specific p38 MAPK, phospho-specific JNK (1:500), cleaved active
caspase-3 (1:500), GAPDH, TG1, TG2 or TG3. The primary antibod-
ies were removed and blots washed three times for 5 min in TBS/
Tween 20. Blots were then incubated for 2 h at room temperature
with the appropriate secondary antibody (1:1000) coupled to
horseradish peroxidase (New England Biolabs Ltd; UK) in blocking
buffer. Following removal of the secondary antibody, blots were
Fig. 1. Protein expression of TG isoforms and neuronal markers in mitotic and differentiated N2a cells. Where indicated cells were differentiated with retinoic acid (1 lM) or
PACAP-27 (100 nM) for 48 h in serum-free medium. (A) Immunocytochemistry by fluorescence microscopy was performed using anti-choline acetyltransferase antibody
(ChAT; cholinergic neuronal marker; green) and anti-tyrosine hydroxylase antibody (TH; dopaminergic and noradrenergic neuronal marker) and DAPI counterstain for nuclei
visualisation (blue). Images presented are from one experiment and representative of three. (B) Quantified immunocytochemistry data represent the mean ± S.E.M. of
fluorescence intensity relative to DAPI stain for five fields of view each from three independent experiments. (C) Cell lysates (20 lg protein) from mitotic (M) and
differentiating (D) N2a cells were analysed for TG1, TG2 and TG3 expression by Western blotting using TG isoform specific antibodies. Levels of GAPDH are included for
comparison. (D) Quantified data are expressed as the ratio of TG isoform to GAPDH and represent the mean ± S.E.M. from four independent experiments. **P < 0.01,
***P < 0.001, and ****P < 0.0001 versus mitotic cells. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Chemiluminescence Detection System (Uptima, Interchim, France)
and quantified by densitometry using Advanced Image Data Anal-
ysis Software (Fuji; version 3.52). The uniform transfer of proteins
to the nitrocellulose membrane was routinely monitored by tran-
siently staining the membranes with Ponceau S stain prior to appli-
cation of the primary antibody. When assessing protein kinase
phosphorylation samples from each experiment were also anal-
ysed on separate blots using primary antibodies that recognisetotal ERK1/2, PKB, p38 MAPK and JNK1/2 (all 1:1000 dilution) in
order to confirm the uniformity of protein loading.
2.11. Visualisation of in situ TG2 activity and neuronal markers
N2a cells were seeded on 8-well chamber slides
(15,000 cells well1) and differentiated for 48 h in serum-free
DMEM containing retinoic acid or PACAP-27 (100 nM). The med-
ium was then removed, monolayer gently washed with PBS and
Fig. 2. PACAP-27-induced cAMP accumulation in differentiating N2a cells. Differ-
entiating N2a cells were treated with the indicated concentrations of PACAP-27 for
10 min. The bar represents control. Levels of cAMP were determined as described in
Section 2. The results represent the mean ± S.E.M. of three experiments each
performed in triplicate. *P < 0.05, **P < 0.01, and ****P < 0.0001 versus control
response.
A.S. Algarni et al. / Biochemical Pharmacology 128 (2017) 55–73 59slides were incubated for 6 h with 1 mM biotin-X-cadaverine
(a cell permeable TG2 substrate; [55]) in serum-free DMEM exper-
imentation. Where appropriate, cells were treated for 1 h with TG2
inhibitors Z-DON (150 lM) or R283 (200 lM) before the addition
of 100 nM PACAP-27. Following stimulation, cells were fixed with
3.7 % (w/v) paraformaldehyde and permeabilised with 0.1% (v/v)
Triton-X100 both in PBS for 15 min at room temperature. After
washing, cells were blocked with 3% (w/v) BSA for 1 h at room tem-
perature and the transglutaminase mediated biotin-X-cadaverineFig. 3. Effect of PACAP-27 on transglutaminase activity in N2a cells. Differentiating N2a c
for 10 min with the indicated concentrations of PACAP-27. Cell lysates were then subject
and D). Data points represent the mean TG specific activity ± S.E.M. from four (A and C
****P < 0.0001 versus control response.labeled protein substrates detected by (1:200 v/v) FITC-
conjugated ExtrAvidin (Sigma-Aldrich). For the visualisation of
neuronal markers fixed cell monolayers were incubated overnight
at 4 C with rabbit anti-choline acetyltransferase antibody (1:200)
or mouse anti-tyrosine hydroxylase antibody (1:200) in 3% (w/v)
BSA. Unbound primary antibody was then removed, and the cells
washed three times for 5 min with PBS. Cells were then incubated
for 2 h at 37 C in a humidified chamber with either goat anti-
mouse or anti-rabbit FITC-conjugated immunoglobulin G (Abcam,
Cambridge, UK) diluted 1:1000 in 3% (w/v) BSA. The chamber slide
was subsequently washed three times for 5 min with PBS, air-dried
and mounted with Vectashield medium (Vector Laboratories Ltd,
Peterborough, UK) containing DAPI counterstain for nuclei visuali-
sation. Finally slides were sealed using clear, colourless nail var-
nish and stained cells visualised using a Leica TCS SP5 II confocal
microscope (Leica Microsystems, GmbH, Manheim, Germany)
equipped with a 20 air objective. Optical sections were typically
1–2 lm and the highest fluorescence intensity values were
acquired and fluorescence intensity relative to DAPI stain quanti-
fied for each field of view. Saturation was avoided using the
look-up Table overlay provided by the software. Image analysis
and quantification were carried out using Leica LAS AF software.2.12. Measurement of intracellular calcium
N2a cells were plated in 24-well flat-bottomed plates (15,000
cells well1) and differentiated for 48 h. Cells were loaded with
Fluo-8 AM (5 lM, 30–40 min) before mounting on the stage of an
Leica TCS SP5 II confocal microscope (Leica Microsystems, GmbH,ells were either incubated with 100 nM PACAP-27 for the indicated time periods or
ed to the biotin-cadaverine incorporation (A and B) or peptide cross-linking assay (C
), five (B) or six (D) independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, and
Fig. 4. Effect of the selective PAC1 receptor antagonist PACAP 6-38 and inhibitors of TG2 and PKA in on PACAP-27 induced TG2 activity in differentiating N2a cells. Cells were
pretreated for 1 h with the TG2 inhibitors Z-DON (150 lM) and R283 (200 lM) or for 30 min with the selective PAC1 receptor antagonist PACAP 6-38 (100 nM) or the PKA
inhibitors KT 5720 (5 lM) or Rp-30 ,50-cAMPs (50 lM) prior to 10 min stimulation with PACAP-27 (100 nM). Cell lysates were then subjected to the biotin-cadaverine
incorporation (A,C,E) or peptide cross-linking assay (B,D,F). Data points represent the mean TG specific activity ± S.E.M. from four independent experiments. *P < 0.05,
***P < 0.001, and ****P < 0.0001, (a) versus control and (b) versus 100 nM PACAP-27 alone.
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incubated at 37 C using a temperature controller and micro incu-
bator (The Cube, Life Imaging Services, Basel, Switzerland) in the
presence of imaging buffer (134 mM NaCl, 6 mM KCl, 1.3 mM
CaCl2, 1 mM MgCl2, 10 mM HEPES, and 10 mM glucose; pH 7.4).
Using an excitation wavelength of 490 nm, emissions over
514 nm were recorded. Images were collected every 1.7 s for
10 min. Relative increases in intracellular Ca2+ were defined as F/
F0 where F was the fluorescence at any given time, and F0 was
the initial basal level of Ca2+.
2.13. Determination of TG2 phosphorylation
Following stimulation, differentiated N2a cells were rinsed
twice with 2.0 ml of chilled PBS and lysed with 500 ll of ice-cold
lysis buffer (2 mM EDTA, 1.5 mM MgCl2, 10% (v/v) glycerol, 0.5%(v/v) IGEPAL, 0.1% (v/v) Protease Inhibitor Cocktail, and 1% (v/v)
Phosphatase Inhibitor Cocktail 2 and 3 in PBS). Cell lysates were
clarified by centrifugation (4 C for 10 min at 14000g), after which
500 lg of supernatant protein were incubated overnight at 4 C
with 2 lg of anti-TG2 monoclonal antibody or IgG control. Immune
complexes were precipitated using PierceTM Classic Magnetic IP/Co-
IP Kit (Loughborough, UK). The precipitates were resolved by SDS-
PAGE and Western blotting, then probed using anti-phosphoserine
or anti-phosphothreonine antibodies (1:1000). Antibody reactivity
was visualised by ECL and quantified densitometrically, as
described above.
2.14. Statistical analysis
All graphs and statistics (one-way ANOVA followed by Dunnet’s
multiple comparison test and two-way ANOVA for group compar-
Fig. 5. Effect of PACAP-27 on ERK1/2, PKB and JNK1/2 phosphorylation in differentiating N2a cells. Where indicated, N2a cells were pre-treated for 30 min with PD 98059
(50 lM), SP 600 125 (20 lM) or Akt inhibitor X1 (100 nM, 1 lM or 10 lM) prior to stimulation with PACAP-27 (100 nM) for 10 min. Cell lysates were analysed by Western
blotting for activation of (A) ERK1/2, (B) PKB and (C) JNK1/2 using phospho-specific antibodies. Samples were subsequently analysed on separate blots using antibodies that
recognise total ERK1/2, PKB and JNK1/2. Quantified data are expressed as the percentage of the value for control cells (=100%) in the absence of protein kinase inhibitor and
represent the mean ± S.E.M. of four independent experiments. ***P < 0.001 and ****P < 0.0001, (a) versus control and (b) versus 100 nM PACAP-27.
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Software, Inc., USA). Agonist EC50 values (concentration of agonist
producing 50% of the maximal stimulation) were obtained by
computer-assisted curve fitting using GraphPad Prism software.
Agonist p[EC50] values were subsequently calculated as the nega-
tive logarithm to base 10 of the EC50. Results represent mean ± S.
E.M. and p values <0.05 were considered statistically significant.3. Results
3.1. Characterisation of cholinergic neuronal phenotype and TG
expression pattern in N2a cells
Mouse N2a neuroblastoma cells can be differentiated into vari-
ous neuronal types dependent upon the method used [41,67]. For
example, serum withdrawal in the presence of retinoic acid
induces differentiation into cholinergic neurons, whereas dibutyryl
cAMP promotes the development of dopaminergic neurons [41,67].
In this study N2a cells were induced to differentiate using retinoic
acid in order to avoid potential problems using dibutyryl cAMP
when assessing functional responses mediated by the Gs-protein
coupled PAC1 receptor. Immunocytochemical staining indicated
that expression of the cholinergic neuronal marker, choline acetyl-transferase increased markedly after 48 h confirming that retinoic
acid promotes differentiation of N2a cells into cholinergic neurons
(Fig. 1A and B).
Western blot analysis was performed to compare the expres-
sion of TG isoforms in mitotic and differentiating N2a cells. TG1,
TG2 and TG3 expression increased significantly in N2a cells follow-
ing differentiation for 48 h with 1 lM all-trans retinoic acid
(Fig. 1C and D). These observations are in agreement with previous
studies [12].3.2. Effect of PAC1 receptor activation on TG2 activity
PACAP-27 induced a robust increase in cAMP accumulation
(EC50 = 4.0 ± 1.3 nM; p[EC]50 = 8.5 ± 0.2; n = 3) in retinoic acid-
induced differentiating N2a cells (Fig. 2). The selective VPAC1 and
VPAC2 agonists, [Ala11,22,28]-VIP (1 lM) and Bay 55-9837 (1 lM)
respectively, had no significant effect on cAMP accumulation (data
not shown). PACAP-27 treatment produced transient increases in
TG2 catalysed biotin-cadaverine incorporation and protein cross-
linking activity, peaking at 10 min (Fig. 3A and C). Furthermore,
as shown in Fig. 3, PACAP-27 stimulated concentration-
dependent increases in biotin-amine incorporation activity
(EC50 = 0.08 ± 0.01 nM; p[EC50] = 10.1 ± 0.1; n = 5) and protein
Fig. 6. Effect of protein kinase inhibitors (PKA, PKC) and Ca2+ on PACAP-27 induced ERK1/2 activation. Where indicated, differentiating N2a cells were pre-treated for 30 min
with (A) KT 5720 (5 lM) or (B) Ro 318220 (10 lM) prior to stimulation with PACAP-27 (100 nM) for 10 min. (C) Cells were stimulated for 10 min with PACAP-27 (100 nM)
either in the presence (1.8 mM CaCl2) or absence of extracellular Ca2+ (nominally Ca2+-free Hanks/HEPES buffer containing 0.1 mM EGTA). Cell lysates were analysed by
Western blotting for activation of ERK1/2 using a phospho-specific antibody. Samples were subsequently analysed on separate blots using an antibody that recognizes total
ERK1/2. Quantified data are expressed as the percentage of the value for control cells (=100%) in the absence of protein kinase inhibitor or presence of extracellular Ca2+ and
represent the mean ± S.E.M. of four independent experiments. ***P < 0.001 and ****P < 0.0001, (a) versus control and (b) versus 100 nM PACAP-27.
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n = 6). The selective PAC1 receptor antagonist PACAP 6-38 attenu-
ated PACAP-27 induced biotin-amine incorporation activity
(Fig. 4A) and protein cross-linking activity (Fig. 4B). The selective
VPAC1 and VPAC2 agonists, [Ala11,22,28]-VIP (1 lM) and Bay 55-
9837 (1 lM) respectively, had no significant effect on TG2 activity
(data not shown). Overall, these data indicate that the PAC1 recep-
tor is functionally expressed and stimulates TG2-mediated
transamidase activity in differentiated N2a cells.3.3. Effect of TG2 inhibitors on PAC1 receptor induced TG2 activity
To confirm that TG2 is responsible for PAC1 receptor-mediated
transglutaminase activity in differentiating N2a cells, two struc-
turally different cell permeable TG2 specific inhibitors were tested;
R283 (a small molecule; [24]) and Z-DON (peptide-based; [60]).
N2a cells were pre-treated for 1 h with Z-DON (150 lM) or R283
(200 lM) prior to stimulation with PACAP-27 for 10 min. Bothinhibitors completely blocked PACAP-27-induced TG-mediated
amine incorporation (Fig. 4C) and protein cross-linking activity
(Fig. 4D). It is important to note that despite these TG2 inhibitors
being cell-permeable, inhibition of cellular TG2 is only achieved
at concentrations significantly above their IC50 value versus puri-
fied enzyme [60,24]. Overall, these data indicate that TG2 is the
TG isoform activated by the PAC1 receptor.3.4. The effect of protein kinase inhibitors on PAC1 receptor-induced
TG2 activity
Pre-treatment with the PKA inhibitors KT 5720 (5 lM) and Rp-
cAMPs (50 lM) completely abolished PACAP-27-induced amine
incorporation (Fig. 4E) and protein cross-linking activity (Fig. 4F),
confirming the involvement of PKA in TG2 activation via the
PAC1 receptor.
Modulation of protein kinase activity following PAC1 receptor
activation was assessed by Western blotting using phospho-
Fig. 7. Effect of protein kinase inhibitors (ERK1/2, PKC, PKB, JNK1/2) on PAC1 receptor-induced TG activity. Differentiating N2a cells were pretreated for 30 min with PD 98059
(50 lM), Ro 31-8220 (10 lM), Akt inhibitor XI (100 nM) or SP 600125 (20 lM) prior to 10 min stimulation with PACAP-27 (100 nM). Cell lysates subjected to biotin-
cadaverine incorporation (A,C,E) or peptide cross-linking assay (B,D,F). Data points represent the mean ± S.E.M. TG specific activity from four independent experiments.
*P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001, (a) versus control and (b) versus 100 nM PACAP-27 alone.
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activated ERK1/2 (pTEpY), p38 MAPK (pTGpY), JNK (pTPpY) and
PKB (S473). PACAP-27 (100 nM) stimulated significant increases in
ERK1/2 (Fig. 5A), PKB (Fig. 5B) and JNK1/2 (Fig. 5C) phosphoryla-
tion in differentiating N2a cells. As expected PACAP-27-mediated
increases in ERK1/2, PKB and JNK1/2 phosphorylation were inhib-
ited by PD 98059 (50 lM; MEK1/2 inhibitor; Fig. 5A), Akt inhibitor
XI (0.1, 1 lM and 10 lM; PKB inhibitor; Fig. 5B) and SP 600125
(20 lM; JNK1/2 inhibitor; Fig. 5B), respectively. No significant
increases in p38 MAPK phosphorylation were observed following
PACAP-27 (100 nM for 10 min) treatment (data not shown).
PACAP-27-induced increases in ERK1/2 were also attenuated by
KT 5720 (5 lM; PKA inhibitor; Fig. 6A) and Ro 31-8220 (10 lM;PKC inhibitor; Fig. 6B), but not following removal of extracellular
Ca2+ (Fig. 6C). In summary, these data have shown that PAC1 recep-
tor activation in differentiating N2a cells triggers robust increases
in ERK1/2, PKB and JNK1/2 phosphorylation and that ERK1/2 acti-
vation is PKA and PKC dependent.
The role of ERK1/2, PKB, PKC and JNK1/2 in PAC1 receptor-
induced TG2 activation was determined using pharmacological
inhibitors of these protein kinases. PACAP-27-induced
transglutaminase-mediated amine incorporation activity and pro-
tein cross-linking activity were inhibited by PD 98950, Ro
318220, and Akt inhibitor XI, suggesting the involvement of
ERK1/2, PKC and PKB, respectively, in PAC1 receptor-mediated
TG2 responses (Fig. 7A–D). In contrast, SP 6000125 attenuated
Fig. 8. PACAP-27-induced in situ TG activity in differentiating N2a cells. Cells were incubated with 1 mM biotin-X-cadaverine (BTC) for 6 h, after which they were incubated
with (A) 100 nM PACAP-27 for 5, 10, 20, or 40 min, (B) the indicated concentrations of PACAP-27 for 10 min, or (C) with the PAC1 receptor antagonist PACAP 6-38 (100 nM) for
30 min or for 1 h with the TG2 inhibitors Z-DON (150 lM) and R283 (200 lM) prior to 10 min stimulation with PACAP-27 (100 nM). TG2-mediated biotin-X-cadaverine
incorporation into intracellular proteins was visualised using FITC-conjugated ExtrAvidin (green). Nuclei were stained with DAPI (blue) and viewed using a Leica TCS SP5 II
confocal microscope (20 objective magnification). Images presented are from one experiment and representative of three. Quantified data represent the mean ± S.E.M. of
fluorescence intensity relative to DAPI stain for five fields of view each from at least three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 versus
control response. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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without effect on TG2-mediated amine incorporation (Fig. 7E).
Finally, PD 98059, Ro 31-8220, Akt inhibitor XI, and SP 600125
had no significant effect on purified guinea pig liver TG2 activity
(data not shown). Overall, these data suggest that the PAC1 recep-
tor stimulates TG2 activity in differentiating N2a cells via a multi
protein kinase dependent pathway.3.5. Visualisation of in situ TG2 activity following PACAP treatment
Biotin-X-cadaverine, is a cell penetrating primary amine, which
enables the in situ visualisation of endogenous protein substrates
of TG2, when combined with FITC-ExtrAvidin [38]. PACAP-27(100 nM) induced a time dependent and concentration-
dependent (EC50 = 6.7 ± 3 nM; pEC50 = 8.3 ± 0.2; n = 3) increase in
the incorporation of biotin-X-cadaverine into endogenous protein
substrates of TG2 (Fig. 8). Finally, the in situ responses to PACAP-
27 were attenuated by the PAC1 antagonist PACAP 6-38 and the
TG2 inhibitors ZDON and R283 (Fig. 8). Overall, these data indicate
a similar pattern of TG2 activation in live cells.3.6. The role of Ca2+ in PAC1 receptor induced TG2 activity
PACAP-27 (100 nM) triggered a robust increase in intracellular
Ca2+ that was abolished in the absence of extracellular Ca2+
(Fig. 9A and B). The role of extracellular Ca2+ in TG2 activation
Fig. 9. Effect of PACAP-27 on [Ca2+]i and role of Ca2+ in PACAP-27-induced TG2 activation in differentiating N2a cells. Shown are A) PACAP-27 (100 nM) triggering a rapid and
transient rise in intracellular Ca2+ in the presence of extracellular Ca2+ (1.3 mM). B) The absence of Ca2+ responses induced by PACAP-27 during experiments performed in
nominally Ca2+-free buffer and 0.1 mM EGTA. In these experiments depletion of intracellular Ca2+ stores with thapsigargin (5 lM) was still evident. The panel letters (a–d)
correspond to the time points in the traces. Similar results were obtained in three other experiments. For TG2 activity, cells were stimulated for 10 min with PACAP-27
(100 nM) either in the presence (1.8 mM CaCl2) or absence of extracellular Ca2+ (nominally Ca2+-free Hanks/HEPES buffer containing 0.1 mM EGTA). Cell lysates were
subjected to biotin-cadaverine incorporation assay (C) or protein cross-linking assay (D). Data points represent the mean TG specific activity ± S.E.M. from four independent
experiments. **P < 0.01, ***P < 0.001 and ****P < 0.0001, (a) versus control in presence of extracellular Ca2+, (b) versus 100 nM PACAP-27 in presence of extracellular Ca2+.
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Ca2+-free Hanks/HEPES buffer containing 0.1 mM EGTA. Removal
of extracellular Ca2+ abolished PACAP-27-induced TG2 activation
(Fig. 9C and D). These observations suggest that PAC1 receptor-
induced TG2 activation is dependent upon extracellular Ca2+.3.7. Phosphorylation of TG2 following PAC1 receptor activation
The effect of PAC1 receptor activation on the phosphorylation
status of TG2 was monitored via immunoprecipitation of TG2 fol-
lowed by SDS-PAGE and Western blot analysis using anti-
phosphoserine and anti-phosphothreonine antibodies. PACAP-27
(100 nM) triggered a robust increase in the levels of TG2 phospho-
serine and phosphothreonine (Fig. 10). Pre-treatment with PD
98059 (50 lM; Fig. 10) and KT 5720 (5 lM; Fig. 11) attenuated
PACAP-27 mediated increases in TG2 phosphorylation. In contrast,
Ro 318220 (10 lM) had no significant effect (data not shown).
Finally, removal of extracellular Ca2+ partially attenuated PACAP-
27-induced TG2 phosphorylation (data not shown). These dataindicate that activation of the PAC1 receptor promotes robust
increases in TG2 phosphorylation.3.8. Role of TG2 in PAC1 receptor-induced cell survival and neurite
outgrowth
The role of TG2 in PAC1 receptor-induced cell survival was
determined in differentiating N2a cells following exposure of cells
to simulated hypoxia (1% O2 in glucose-free and serum-free med-
ium). Initial experiments determined the time course of simulated
hypoxia-induced cell death in differentiated N2a cells. Exposure of
cells to simulated hypoxia (1% O2) resulted in a time dependent
decrease in MTT reduction, an increase in LDH release and activa-
tion of caspase 3 (Fig. 12). A time period of 8 h hypoxia was used in
subsequent experiments. Pre-treatment with PACAP-27 (100 nM;
10 min) significantly attenuated hypoxia-induced decrease in
MTT reduction, release of LDH and activation of caspase-3
(Fig. 13). Treatment with PACAP 6-38 (100 nM; 30 min) reversed
PACAP-27 induced protection confirming the role of the PAC1
receptor. Finally, the TG2 inhibitors R283 and Z-DON attenuated
Fig. 10. Effect of the MEK1/2 inhibitor PD 98059 on PACAP-27-induced phospho-
rylation of TG2. Where indicated, differentiating N2a cells were pre-treated for
30 min with PD 98059 (50 lM) prior to stimulation with PACAP-27 (100 nM) for
10 min. Following stimulation with PACAP-27, cell lysates were subjected to
immunoprecipitation using anti-TG2 monoclonal antibody as described under
‘‘Section 2”. The resultant immunoprecipitated protein(s) were subjected to SDS-
PAGE and Western blot analysis using (A) anti-phosphoserine and (B) and anti-
phosphothreonine antibodies. One tenth of the total input was applied to the first
lane to show the presence of phosphorylated proteins prior to immunoprecipitation
and negative controls with the immunoprecipitation performed with immunobeads
only were included to demonstrate the specificity of the band shown. Quantified
data for PACAP-induced increases in TG2-bound serine and threonine phosphory-
lation are expressed as a percentage of the TG2 phosphorylation observed in control
cells (=100%). Data points represent the mean ± S.E.M. from three independent
experiments. *P < 0.05, **P < 0.01, and ***P < 0.001, (a) versus control and (b) versus
100 nM PACAP-27 alone.
Fig. 11. Effect of the PKA inhibitor KT 5720 on PACAP-27-induced phosphorylation
of TG2. Where indicated, differentiating N2a cells were pre-treated for 30 min with
KT 5720 (5 lM) prior to stimulation with PACAP-27 (100 nM) for 10 min. Following
stimulation with PACAP-27, cell lysates were subjected to immunoprecipitation
using anti-TG2 monoclonal antibody as described under ‘‘Materials and Methods”.
The resultant immunoprecipitated protein(s) were subjected to SDS-PAGE and
Western blot analysis using (A) anti-phosphoserine and (B) and anti-phosphothre-
onine antibodies. One tenth of the total input was applied to the first lane to show
the presence of phosphorylated proteins prior to immunoprecipitation and negative
controls with the immunoprecipitation performed with immunobeads only were
included to demonstrate the specificity of the band shown. Quantified data for
PACAP-induced increases in TG2-bound serine and threonine phosphorylation are
expressed as a percentage of the TG2 phosphorylation observed in control cells
(=100%). Data points represent the mean ± S.E.M. from three independent exper-
iments. *P < 0.05, **P < 0.01, and ***P < 0.001, (a) versus control and (b) versus
100 nM PACAP-27 alone.
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Fig. 12. Effect of simulated hypoxia on MTT reduction, LDH release and caspase 3 activity in differentiating N2a cells. Cells in glucose- and serum-free DMEMwere exposed to
hypoxia (1% O2) for the indicated periods of time. Cell viability was assessed by measuring (A) the metabolic reduction of MTT by cellular dehydrogenases, (B) release of LDH
into the culture medium and (C) caspase-3 activity via Western blot analysis using anti-active caspase 3 antibody. (D) Quantified caspase-3 activity data. Data are expressed
as the percentage of the normoxic control (=100%) and represent the mean ± S.E.M. from four independent experiments, each performed in (A) quadruplicate or (B)
sextuplicate. *P < 0.05, ***P < 0.0001 and ****p < 0.0001 versus normoxic control.
Fig. 13. The effect of PACAP-27 on hypoxia-induced cell death in N2a cells. Differentiating N2a cells were pre-treated with the PAC1 receptor antagonist PACAP 6-38 (100 nM)
for 30 min before the addition of PACAP-27 (100 nM) for 10 min prior to 8 h hypoxia (1% O2) or 8 h normoxia. Cell viability was assessed by measuring (A) the metabolic
reduction of MTT by cellular dehydrogenases, (B) release of LDH into the culture medium and (C) caspase-3 activity via Western blot analysis using anti-active caspase 3
antibody. (D) Quantified caspase-3 activity data. Data are expressed as a percentage of normoxia control cell values (=100%) and represent the mean ± S.E.M. from four
independent experiments, each performed in (A) quadruplicate or (B) sextuplicate. ****P < 0.0001, (a) versus normoxia control, (b) versus hypoxia control (c) versus 100 nM
PACAP-27 in the presence of hypoxia.
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Fig. 14. The effects of the TG2 inhibitors Z-DON and R283 on PACAP-27 induced cell survival in N2a cells. Differentiating N2a cells were pre-treated for 1 h with the TG2
inhibitors Z-DON (150 lM) or R283 (200 lM) before the addition of PACAP-27 (100 nM) for 10 min prior to 8 h hypoxia (1% O2) or 8 h normoxia. Cell viability was assessed by
measuring (A) the metabolic reduction of MTT by cellular dehydrogenases, (B) release of LDH into the culture medium and (C) caspase-3 activity via Western blot analysis
using anti-active caspase 3 antibody. (D) Quantified caspase-3 activity data. Data are expressed as a percentage of normoxia control cell values (=100%) and represent the
mean ± S.E.M. from four independent experiments each performed in (A) quadruplicate and (B) sextuplicate. *P < 0.05, **P < 0.01, ***P < 0.0001 and ****P < 0.0001, (a) versus
normoxia control, (b) versus hypoxia control (c) versus 100 nM PACAP-27 in the presence of hypoxia.
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tions in another cell model the role of TG2 in PAC1 receptor-
induced cell survival in human SH-SY5Y neuroblastoma cells was
also investigated. Initial experiments demonstrated that PACAP-
27 treatment produced transient increases in TG2 catalysed
biotin-cadaverine incorporation and protein cross-linking activity,
peaking at 30 min (Fig. 15A and C). Furthermore, as shown in
Fig. 15, PACAP-27 stimulated concentration-dependent increases
in biotin-amine incorporation activity (EC50 = 2.2 ± 1.0 nM; p
[EC50] = 8.9 ± 0.4; n = 3) and protein cross-linking activity
(EC50 = 1.3 ± 0.5 nM; p[EC50] = 9.0 ± 0.2; n = 3). Exposure of SH-
SY5Y cells to simulated hypoxia (1% O2) resulted in a time depen-
dent decrease in MTT reduction, an increase in LDH release and
activation of caspase 3 (data not shown), with 8 h used in subse-
quent experiments. As shown in Fig. 16, pre-treatment with
PACAP-27 (100 nM; 10 min) significantly attenuated hypoxia-
induced decrease in MTT reduction, release of LDH and activation
of caspase-3 in SH-SY5Y cells (Fig. 16). Furthermore, PACAP 6-38
(100 nM; 30 min) reversed PACAP-27 induced protection confirm-
ing the role of the PAC1 receptor in human SH-SY5Y cells (Fig. 16A–
D). Finally, the TG2 inhibitors R283 and Z-DON attenuated PACAP-
27 induced cell survival (Fig. 16E–G). Overall, these results demon-
strate a role of TG2 in PAC1 receptor-induced cell survival in both
mouse N2a and human SH-SY5Y cells.
The role of TG2 in PAC1 receptor induced neurite outgrowth was
assessed by monitoring the outgrowth of axon-like processes fol-
lowing 24 and 48 h treatment with PACAP-27 (100 nM). The TG2
inhibitors Z-DON (150 lM) and R283 (200 lM) attenuated out-
growth of axon-like processes following 24 h (data not shown)
and 48 h treatment with PACAP-27, confirming the involvementof TG2 (Fig. 17). These data confirm a role for TG2 in PAC1 receptor
mediated neurite outgrowth.4. Discussion
The data in this report collectively suggest that PAC1 receptor-
mediated cell survival and neurite outgrowth are mediated by
TG2, consistent with the view that TG2-mediated amine incorpora-
tion and protein cross-linking play important roles in these events.4.1. In vitro modulation of TG2 transamidation activity by the PAC1
receptor
Although the PAC1 receptor is expressed in mitotic N2a cells
[39,50] its functional expression in differentiating N2a cells has
to our knowledge not been reported. Hence, this study has demon-
strated for the first time functional expression of the PAC1 receptor
in N2a cells induced to differentiate with retinoic acid. The neu-
ropeptide PACAP mediates neurite outgrowth and neuroprotec-
tion; however, it is not known if these events involve PAC1
receptor-induced TG2 activation [51,42,29]. TG2 can catalyse two
types of transamidation, namely (i) intra-, and/or inter-molecular
covalent cross-links between protein-bound glutamine and
protein-bound lysine residues, and (ii) cross-links between pri-
mary amines and protein-bound glutamine [54]. In this study the
PAC1 receptor agonist PACAP-27 triggered time- and
concentration-dependent increases in TG2-mediated biotin-
cadaverine incorporation and protein cross-linking activity in dif-
ferentiating N2a cells. The EC50 values for PACAP-27 mediated
Fig. 15. Effect of PACAP-27 on transglutaminase activity in human SH-SY5Y neuroblastoma cells. Differentiating SH-SY5Y cells were either incubated with 100 nM PACAP-27
for the indicated time periods or for 30 min with the indicated concentrations of PACAP-27. Cell lysates were then subjected to the biotin-cadaverine incorporation (A and B)
or protein cross-linking assay (C and D). Data points represent the mean TG specific activity ± S.E.M. from four (A and C) or three (B and D) independent experiments. *P < 0.05,
**P < 0.01, ***P < 0.001, and ****P < 0.0001 versus control response.
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protein cross-linking activity (0.4 nM) are in-line with the affinity
of PACAP-27 for the PAC1 receptor [17,18,28]. Furthermore,
PACAP-27-induced TG2 activity was blocked by the PAC1 receptor
antagonist PACAP 6-38 [58]. Overall these data suggest that activa-
tion of TG2 by PACAP-27 is mediated via the PAC1 receptor. It is
important to note that PACAP 6-38 also displays high affinity for
the VPAC2 receptor [16]; however, since the VPAC2 agonist Bay
55-9837 did not trigger TG2 activity the effects of PACAP 6-38
are mediated entirely via the PAC1 receptor. Finally, the PAC1
receptor-induced increases in TG activity were inhibited by R283
and Z-DON, confirming that the observed increases in TG activity
were via TG2.
At present, very little is known regarding the regulation of TG2
enzymic activity by GPCRs. Examples in the literature include mus-
carinic receptor-mediated increases in TG2 activity in SH-SY5Y
cells [78] and 5-HT2A receptor-mediated transamidation (TG-
catalysed) of the small G-protein Rac1 in the rat cortical cell line
A1A1v [13]. The study by Zhang et al. [78] measured in situ TG2
activity (polyamine incorporation) triggered by the non-selective
muscarinic agonist carbachol, whereas, Dai et al. [13] reported
TG2 catalysed incorporation of 5-hydroxytryptamine into Rac1.
5-HT2A receptor-mediated incorporation of 5-HT into the small
GTPases RhoA and Rab4 has also been observed in platelets [75].
It was suggested that 5-HT2A and muscarinic receptor-mediated
release of Ca2+ from intracellular Ca2+ stores may be responsible
for triggering TG transamidating activity [78,75]. Our recent stud-
ies have shown that the Gi/o-protein coupled A1 adenosine receptor
stimulates TG2 activation in H9c2 cardiomyocyte-like cells [74].
Since TG2 transamidase activity modulates protein function bycross-linking and incorporation of small molecule mono- and
polyamines into protein substrates, it is likely that activation of
TG2 by GPCRs plays a major role in the regulation of cellular func-
tion [54,20].
4.2. Role of Ca2+ in PAC1 receptor-mediated TG2 activation
The transamidating activity of TG2 is dependent upon Ca2+,
which promotes the ‘‘open” form of TG2 and negates the inhibitory
actions of the nucleotides GTP, GDP and ATP [34]. Previous studies
have shown that release of Ca2+ from intracellular Ca2+ stores or
influx of extracellular Ca2+ is linked to TG activation in response
to GPCR stimulation [78,75,74]. The data presented in the current
work indicate that PAC1 receptor-induced transamidase activity
is dependent upon extracellular Ca2+. Previous studies have shown
that the PAC1 receptor promotes Ca2+ mobilization from intracellu-
lar stores and Ca2+ influx via N-type calcium channels [3] in rat
cerebellar granule cells. In this study, PACAP-27-triggered Ca2+
responses were abolished in the absence of extracellular Ca2+,
which is indicative of Ca2+ influx. Clearly, further studies are
required to determine the mechanism(s) of PAC1 receptor-
induced Ca2+ influx in differentiated N2a cells and its role in TG2
activation. It is interesting to note that changes in intracellular
[Ca2+] required for TG2 transamidating activity are typically in
the order 3–100 lM [34]. However, there is growing evidence that
intracellular [Ca2+] can reach levels sufficient to activate TG2, for
example in calcium microdomains that occur near the cell mem-
brane following the opening of voltage gated Ca2+ channels or near
internal stores [6,34]. Alternatively, the role of Ca2+ in PAC1
receptor-induced TG2 activation may require the sensitization of
Fig. 16. The effect of PACAP-27 on hypoxia-induced cell death in human SH-SY5Y cells. Differentiating SH-SY5Y cells were pre-treated either with the PAC1 receptor
antagonist PACAP 6-38 (100 nM) for 30 min (panels A–D) or with the TG2 inhibitors Z-DON (150 lM) or R283 (200 lM) for 1 h (panels E–H) before the addition of PACAP-27
(100 nM) for 10 min prior to 8 h hypoxia (1% O2) or 8 h normoxia. Cell viability was assessed by measuring the metabolic reduction of MTT by cellular dehydrogenases (panels
A,E), release of LDH into the culture medium (panels B,F) and caspase-3 activity via Western blot analysis using anti-active caspase 3 antibody (panels C,G). Quantified
caspase-3 activity data are shown in panels D and H. Data are expressed as a percentage of normoxia control cell values (=100%) and represent the mean ± S.E.M. from four
independent experiments each performed in (A,E) quadruplicate and (B,F) sextuplicate. *P < 0.05, **P < 0.01, ***P < 0.0001 and ****P < 0.0001, (a) versus normoxia control, (b)
versus hypoxia control (c) versus 100 nM PACAP-27 in the presence of hypoxia.
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TG2 with protein binding partners and/or membrane lipids have
been proposed to induce a conformational change that promotes
activation at low levels of intracellular [Ca2+] [34].4.3. Role of protein kinases in PAC1 receptor-mediated TG2 activation
The phosphorylation of TG2 by PKA inhibits its transamidating
activity but augments its kinase activity [49]. These contrasting
Fig. 17. The effect of TG2 inhibitors on PACAP-27 induced outgrowth of axon-like
processes in differentiating N2a cells. (A) N2a cells were incubated for 1 h with the
TG2 inhibitors Z-DON (150 lM) or R283 (200 lM) before treatment with PACAP-27
(100 nM) in serum-free DMEM for 48 h. Following stimulation the cells were fixed
and stained with Coomassie blue. (B) Quantified data points represent the number
of axon-like processes determined as described in Materials and Methods. Shown
are the mean number of axons/100 cells ± S.E.M. from four independent experi-
ments each performed in quadruplicate. White arrows indicate typical axon-like
processes. ***P < 0.0001 and ****P < 0.0001, (a) versus mitotic control, (b) versus
100 nM PACAP-27 alone.
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immobilized on nickel-agarose and incubated with the catalytic
subunit of PKA. In this study the PKA inhibitors KT 5720 and Rp-
cAMPs completely blocked PACAP-27-induced TG2 transamidating
activity, which reflects PAC1 receptor signalling via cAMP/PKA. The
PAC1 receptor also activates PLC/DAG/PKC (via Gq-protein cou-
pling) signalling and hence we determined the role of PKC. The
broad spectrum PKC inhibitor Ro 318220 inhibited PACAP-27-
induced TG2 activity, indicating that Gq-protein coupling is
involved in PAC1 receptor-mediated TG2 activation. The PAC1
receptor also activates ERK1/2, JNK1/2, p38 MAPK and PKB
[51,44,8]. In this study we observed PACAP-27-induced activation
of ERK1/2, JNK1/2, and PKB but not p38 MAPK. The MEK1/2
(upstream activator of ERK1/2) inhibitor PD 98059 blocked
PACAP-27-induced TG2 activity, suggesting a prominent role for
ERK1/2. These observations are comparable to A1 adenosine
receptor-mediated activation of TG2 in H9c2 cells, which was also
sensitive to PKC and ERK1/2 inhibition [74]. In transfected HEK293
cells, PAC1 receptor-induced ERK1/2 is dependent upon calcium
influx and PLC/DAG/PKC [45] and hence the inhibition of PACAP-
27-induced TG2 by removal of extracellular Ca2+ and inhibition
of PKC may reflect their up-stream role(s) in ERK1/2 activation.
In the current study, PAC1 receptor-induced ERK1/2 activation is
independent of Ca2+ influx and partially sensitive to PKC inhibition.
Similarly, PKA can activate ERK1/2 [65] and therefore the effect ofPKA inhibitors on PAC1 receptor TG2 activation may also reflect the
up-stream role of PKA in ERK1/2 activation. In SH-SY5Y cells PAC1
receptor-induced ERK1/2 activation is cAMP-dependent but PKA-
independent [51]. However, in guinea-pig cardiac neurons [11]
and N2a cells (the current study) PAC1 receptor-induced ERK1/2
signalling is PKA-dependent. Hence, PKA-mediated inhibition of
TG2 activation may indeed reflect the up-stream role of PKA in
ERK1/2 activation. Finally, PACAP-27-induced TG2 activation was
also sensitive to inhibition of PKB and JNK1/2, suggesting a role
for these kinases in PAC1 receptor-induced TG2 activation.
We have previously shown that TG2 is phosphorylated follow-
ing activation of the A1 adenosine receptor in H9c2 cells [74].
The current data demonstrate that TG2 is also phosphorylated fol-
lowing PAC1 receptor activation. Furthermore, PAC1 receptor-
induced TG2 phosphorylation was attenuated by pharmacological
inhibition of MEK1/2, PKA and removal of extracellular Ca2+. It is
not clear how the absence of extracellular Ca2+ blocks TG2 phos-
phorylation since PAC1 receptor-induced ERK1/2 activation is inde-
pendent of Ca2+ influx. One possible explanation is that changes in
[Ca2+]i promote conformational changes in TG2 that facilitate its
phosphorylation by protein kinase(s). Alternatively, Ca2+ influx
may play a role in augmenting PAC1 receptor-induced PLC/PKC sig-
nalling. However, the fact that the PKC inhibitor Ro 31-8220 did
not block TG2 phosphorylation, suggests that PKC may regulate
other targets involved in TG2 activation. The next logical step
would be to identify the specific site(s) of TG2-associated serine
and threonine phosphorylation. Previous studies have shown that
TG2 is phosphorylated by PKA at Ser215 and Ser216 [48] and at an
unknown site(s) by PTEN-induced putative kinase 1 (PINK1;
[47]). At present the precise role of PAC1 receptor-induced TG2
phosphorylation is not known. However, PKA-mediated phospho-
rylation of TG2 enhances its interaction with the scaffolding pro-
tein 14-3-3 and increases TG2 kinase activity, whereas PINK1-
mediated phosphorylation of TG2 blocks its proteasomal degrada-
tion [48,49,47]. It is also conceivable that TG2 phosphorylation
sensitizes TG2 to low levels of intracellular [Ca2+] or alters its sub-
cellular location. Work underway will determine the functional
consequences of PAC1 receptor-induced TG2 phosphorylation.
4.4. In situ visualisation of TG2 activity
Fluorescence microscopy was used to visualise in situ TG2 activ-
ity following PAC1 receptor activation. The results were compara-
ble to PAC1 receptor-induced amine incorporation activity
observed in vitro. However, given the covalent nature of biotin-X-
cadaverine incorporation into protein substrates, it was surprising
to observe that in situ TG2 activity returned to basal levels after
40 min. Possible explanations for this include reversal of amine
incorporation by TG [64], targeting of modified proteins for degra-
dation or their rapid removal from the cell. Our previous studies
have reported the rapid expulsion of biotinylated proteins from
H9c2 cells following treatment with PMA or forskolin [1]. It could
be that the rapid expulsion of biotinylated proteins from N2a cells
occurs via exosomes [30]. Since N2a cells secrete exosomes it will
be of interest to determine whether amine-labeled proteins can be
detected in exosomes purified from cell culture supernatants
obtained from these cells following PACAP-27 treatment [9].
4.5. Role of TG2 in PAC1 receptor-induced cytoprotection
Previous studies have shown that TG2 protects human SH-SY5Y
neuroblastoma cells against heat shock-induced cell death [69].
Similarly, TG2 mediates protection of neuronal cells against
hypoxia and oxygen/glucose deprivation-induced cell death by
attenuating the HIF hypoxic response pathway [21]. Likewise,
PACAP is widely recognized as a neuroprotective peptide and
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and various neurodegenerative disorders [57,36]. The mechanisms
of PACAP/PAC1 receptor-induced neuroprotection are complex and
involve multiple signalling pathways that include PKA, PKB,
ERK1/2, NF-rB and Ca2+ mobilization [44,4,42]. In this study we
have shown for the first time a role for TG2 in PAC1 receptor-
induced cytoprotection in differentiating mouse N2a and human
SH-SY5Y neuroblastoma cells. However, whilst it is not clear how
PAC1 receptor-induced TG2 activation mediates cell survival, TG2
is known to regulate pathways associated with PACAP neuropro-
tection. For example, TG2 activates adenylyl cyclase and enhances
cAMP/PKA dependent CRE-reporter gene activity in SH-SY5Y neu-
roblastoma cells [68] and promotes NF-rB signalling via cross-
linking of IrBa [20]. In the current study inhibition of TG2 blocked
PACAP-27 mediated attenuation of hypoxia-induced activation of
caspase-3. Recent studies have shown that TG2 inhibits apoptosis
via the down-regulation of the Bax expression and inhibition of
caspase 3 and 9 [10]. Further work is required to determine the
role of TG2 in PAC1 receptor-induced cell survival.
4.6. Role of TG2 in PAC1 receptor-induced neurite outgrowth
Previous studies have shown that TG2 is essential for differen-
tiation/neurite outgrowth in human neuroblastoma SHSY5Y cells
[69,61]. Mechanisms associated with TG2-induced neurite out-
growth include transamidation of RhoA and subsequent activation
of ERK1/2 and p38 MAPK [61]. Similarly, PACAP triggers neuronal
differentiation of human SH-SY5Y cells via a cAMP-dependent
but PKA-independent pathway requiring activation of ERK1/2
and p38 MAPK [51]. The data presented in this study suggest that
pharmacological inhibition of TG2 blocks PACAP-27-induced out-
growth of axon-like processes, suggesting the involvement of
TG2 in PAC1 receptor neurite outgrowth. However, further studies
are required to identify the downstream substrates of TG2 and sig-
nalling pathways associated with the role of TG2 in PAC1 receptor
neuronal differentiation.
In conclusion, our data show for the first time that TG2 activity
is regulated by the PAC1 receptor in differentiating N2a and SH-
SY5Y cells. Work is currently underway to understand more fully
the role of TG2 in PAC1 receptor signalling and modulation of neu-
ronal cell function.
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